

# EAU Guidelines on Paediatric Urology

C. Radmayr (Chair), G. Bogaert, H.S. Dogan, R. Kočvara,  
J.M. Nijman (Vice-chair), R. Stein, S. Tekgül  
Guidelines Associates: L.A. 't Hoen, J. Quaedackers,  
M.S. Silay, S. Undre



European Society for Paediatric Urology © European Association of Urology 2019



# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	8
1.1	Aim	8
1.2	Panel composition	8
1.3	Available publications	8
1.4	Publication history	8
1.5	Summary of changes	8
1.5.1	New and changed recommendations	9
2.	METHODS	9
2.1	Introduction	9
2.2	Peer review	9
2.3	Future goals	9
3.	THE GUIDELINE	10
3.1	Phimosis	10
3.1.1	Epidemiology, aetiology and pathophysiology	10
3.1.2	Classification systems	10
3.1.3	Diagnostic evaluation	10
3.1.4	Management	10
3.1.5	Follow-up	11
3.1.6	Summary of evidence and recommendations for the management of phimosis	11
3.2	Management of undescended testes	11
3.2.1	Background	11
3.2.2	Classification	11
3.2.2.1	Palpable testes	12
3.2.2.2	Non-palpable testes	12
3.2.3	Diagnostic evaluation	13
3.2.3.1	History	13
3.2.3.2	Physical examination	13
3.2.3.3	Imaging studies	13
3.2.4	Management	13
3.2.4.1	Medical therapy	13
3.2.4.1.1	Medical therapy for testicular descent	13
3.2.4.1.2	Medical therapy for fertility potential	14
3.2.4.2	Surgical therapy	14
3.2.4.2.1	Palpable testes	14
3.2.4.2.1.1	Inguinal orchidopexy	14
3.2.4.2.1.2	Scrotal orchidopexy	15
3.2.4.2.2	Non-palpable testes	15
3.2.4.2.3	Complications of surgical therapy	15
3.2.4.2.4	Surgical therapy for undescended testes after puberty	15
3.2.5	Undescended testes and fertility	16
3.2.6	Undescended testes and malignancy	16
3.2.7	Summary of evidence and recommendations for the management of undescended testes	17
3.3	Hydrocele	17
3.3.1	Epidemiology, aetiology and pathophysiology	17
3.3.2	Diagnostic evaluation	17
3.3.3	Management	18
3.3.4	Summary of evidence and recommendations for the management of hydrocele	18
3.4	Acute scrotum	18
3.4.1	Epidemiology, aetiology and pathophysiology	18
3.4.2	Diagnostic evaluation	19
3.4.3	Management	19
3.4.3.1	Epididymitis	19
3.4.3.2	Testicular torsion	19
3.4.3.3	Surgical treatment	20
3.4.4	Follow-up	20

3.4.4.1	Fertility	20
3.4.4.2	Subfertility	20
3.4.4.3	Androgen levels	20
3.4.4.4	Unanswered questions	20
3.4.5	Summary of evidence and recommendations for the management of acute scrotum in children	21
3.5	Hypospadias	21
3.5.1	Epidemiology, aetiology and pathophysiology	21
3.5.1.1	Epidemiology	21
3.5.2	Risk factors	21
3.5.3	Classification systems	21
3.5.4	Diagnostic evaluation	22
3.5.5	Management	22
3.5.5.1	Indication for reconstruction and therapeutic objectives	22
3.5.5.2	Pre-operative hormonal treatment	22
3.5.5.3	Age at surgery	23
3.5.5.4	Penile curvature	23
3.5.5.5	Urethral reconstruction	23
3.5.5.6	Re-do hypospadias repairs	24
3.5.5.7	Penile reconstruction following formation of the neo-urethra	24
3.5.5.8	Urine drainage and wound dressing	24
3.5.5.9	Outcome	25
3.5.6	Follow-up	25
3.5.7	Summary of evidence and recommendations for the management of hypospadias	26
3.6	Congenital penile curvature	26
3.6.1	Epidemiology, aetiology and pathophysiology	26
3.6.2	Diagnostic evaluation	26
3.6.3	Management	26
3.6.4	Summary of evidence and recommendations for the management of congenital penile curvature	27
3.7	Varicocele in children and adolescents	27
3.7.1	Epidemiology, aetiology and pathophysiology	27
3.7.2	Classification systems	28
3.7.3	Diagnostic evaluation	28
3.7.4	Management	28
3.7.5	Summary of evidence and recommendations for the management of varicocele	29
3.8	Urinary tract infections in children	30
3.8.1	Epidemiology, aetiology and pathophysiology	30
3.8.2	Classification systems	30
3.8.2.1	Classification according to site	30
3.8.2.2	Classification according to episode	30
3.8.2.3	Classification according to severity	31
3.8.2.4	Classification according to symptoms	31
3.8.2.5	Classification according to complicating factors	31
3.8.3	Diagnostic evaluation	31
3.8.3.1	Medical history	31
3.8.3.2	Clinical signs and symptoms	31
3.8.3.3	Physical examination	31
3.8.3.4	Urine sampling, analysis and culture	31
3.8.3.4.1	Urine sampling	32
3.8.3.4.2	Urinalysis	32
3.8.3.4.3	Urine culture	33
3.8.3.5	Imaging	33
3.8.3.5.1	Ultrasound	33
3.8.3.5.2	Radionuclide scanning	33
3.8.3.5.3	Voiding cystourethrography	34
3.8.3.6	Bladder and bowel dysfunction	34
3.8.4	Management	34
3.8.4.1	Administration route	34

	3.8.4.2	Duration of therapy	34
	3.8.4.3	Chemoprophylaxis	37
	3.8.4.4	Monitoring of UTI	38
	3.8.5	Summary of evidence and recommendations for the management of UTI in children	38
3.9		Day-time lower urinary tract conditions	39
	3.9.1	Terminology, classification, epidemiology and pathophysiology	39
	3.9.1.1	Filling-phase (storage) dysfunctions	40
	3.9.1.2	Voiding-phase (emptying) dysfunctions	40
	3.9.2	Diagnostic evaluation	40
	3.9.3	Management	41
	3.9.3.1	Specific interventions	42
	3.9.4	Summary of evidence and recommendations for the management of day-time lower urinary tract conditions	42
3.10		Monosymptomatic nocturnal enuresis - bedwetting	43
	3.10.1	Epidemiology, aetiology and pathophysiology	43
	3.10.2	Diagnostic evaluation	43
	3.10.3	Management	44
	3.10.3.1	Supportive treatment measures	44
	3.10.3.2	Conservative wait and see approach	44
	3.10.3.3	Nocturnal enuresis wetting alarm treatment	44
	3.10.3.4	Medical therapy	44
	3.10.4	Summary of evidence and recommendations for the management of monosymptomatic enuresis	45
3.11		Management of neurogenic bladder	46
	3.11.1	Epidemiology, aetiology and pathophysiology	46
	3.11.2	Classification systems	46
	3.11.3	Diagnostic evaluation	47
	3.11.3.1	History and clinical evaluation	47
	3.11.3.2	Laboratory & urinalysis	47
	3.11.3.3	Ultrasound	47
	3.11.3.4	Urodynamic studies/videourodynamic	47
	3.11.3.4.1	Preparation before urodynamic studies	47
	3.11.3.4.2	Uroflowmetry	48
	3.11.3.5	Urodynamic studies	48
	3.11.3.6	Voiding cystourethrogram	48
	3.11.3.7	Renal scan	48
	3.11.4	Management	48
	3.11.4.1	Early management with intermittent catheterisation	48
	3.11.4.2	Medical therapy	49
	3.11.4.3	Management of faecal incontinence	50
	3.11.4.4	Urinary tract infection	50
	3.11.4.4.1	Urinary tract infection and clean intermittent catheterisation	50
	3.11.4.5	Sexuality	51
	3.11.4.6	Bladder augmentation	51
	3.11.4.7	Bladder outlet procedures	52
	3.11.4.8	Catheterisable cutaneous channel.	52
	3.11.4.9	Continent and incontinent cutaneous urinary diversion	53
	3.11.5	Follow-up	53
	3.11.6	Self-organisation of patients	53
	3.11.7	Summary of evidence and recommendations for the management of neurogenic bladder	55
3.12		Dilatation of the upper urinary tract (UPJ and UVJ obstruction)	55
	3.12.1	Epidemiology, aetiology and pathophysiology	55
	3.12.2	Diagnostic evaluation	56
	3.12.2.1	Antenatal ultrasound	56
	3.12.2.2	Postnatal ultrasound	56
	3.12.2.3	Voiding cystourethrogram	56
	3.12.2.4	Diuretic renography	56
	3.12.3	Management	57

3.12.3.1	Prenatal management	57
3.12.3.1.1	Antibiotic prophylaxis for antenatal hydronephrosis	57
3.12.3.2	UPJ obstruction	58
3.12.3.3	Megaureter	58
3.12.3.3.1	Non-operative management	58
3.12.4	Conclusion	58
3.12.5	Summary of evidence and recommendations for the management of UPJ-, UVJ-obstruction	59
3.13	Vesicoureteric reflux	59
3.13.1	Epidemiology, aetiology and pathophysiology	59
3.13.2	Diagnostic evaluation	60
3.13.2.1	Infants presenting because of prenatally diagnosed hydronephrosis	61
3.13.2.2	Siblings and offspring of reflux patients	61
3.13.2.3	Recommendations for paediatric screening of VUR	62
3.13.2.4	Children with febrile urinary tract infections	62
3.13.2.5	Children with lower urinary tract symptoms and vesicoureteric reflux	62
3.13.3	Disease management	62
3.13.3.1	Non-surgical therapy	62
3.13.3.1.1	Follow-up	63
3.13.3.1.2	Continuous antibiotic prophylaxis	63
3.13.3.2	Surgical treatment	63
3.13.3.2.1	Subureteric injection of bulking materials	63
3.13.3.2.2	Open surgical techniques	64
3.13.3.2.3	Laparoscopy and robot-assisted	64
3.13.4	Summary of evidence and recommendations for the management of vesicoureteric reflux in childhood	65
3.14	Urinary stone disease	67
3.14.1	Epidemiology, aetiology and pathophysiology	67
3.14.2	Classification systems	67
3.14.2.1	Calcium stones	67
3.14.2.2	Uric acid stones	68
3.14.2.3	Cystine stones	69
3.14.2.4	Infection stones (struvite stones)	69
3.14.3	Diagnostic evaluation	69
3.14.3.1	Imaging	69
3.14.3.2	Metabolic evaluation	69
3.14.4	Management	71
3.14.4.1	Extracorporeal shockwave lithotripsy	71
3.14.4.2	Percutaneous nephrolithotomy	72
3.14.4.3	Ureterorenoscopy	72
3.14.4.4	Open or laparoscopic stone surgery	73
3.14.5	Summary of evidence and recommendations for the management of urinary stones	74
3.15	Obstructive pathology of renal duplication: ureterocele and ectopic ureter	75
3.15.1	Epidemiology, aetiology and pathophysiology	75
3.15.1.1	Ureterocele	75
3.15.1.2	Ectopic ureter	75
3.15.2	Classification systems	75
3.15.2.1	Ureterocele	75
3.15.2.1.1	Ectopic (extravesical) ureterocele	75
3.15.2.1.2	Orthotopic (intravesical) ureterocele	75
3.15.2.2	Ectopic ureter	75
3.15.3	Diagnostic evaluation	76
3.15.3.1	Ureterocele	76
3.15.3.2	Ectopic ureter	76
3.15.4	Management	76
3.15.4.1	Ureterocele	76
3.15.4.1.1	Early treatment	76
3.15.4.1.2	Re-evaluation	77
3.15.4.2	Ectopic ureter	77

3.15.5	Summary of evidence and recommendations for the management of obstructive pathology of renal duplication: ureterocele and ectopic ureter	78
3.16	Disorders of sex development	78
3.16.1	Introduction	78
3.16.2	Current classification of DSD conditions	79
3.16.3	Diagnostic evaluation	80
3.16.3.1	The neonatal emergency	80
3.16.3.2	Family history and clinical examination	80
3.16.4	Gender assignment	81
3.16.5	Risk of tumor development	82
3.16.6	Recommendations for the management of disorders of sex development	82
3.17	Posterior urethral valves	82
3.17.1	Epidemiology, aetiology and pathophysiology	82
3.17.2	Classification systems	82
3.17.2.1	Urethral valve	82
3.17.3	Diagnostic evaluation	83
3.17.4	Management	83
3.17.4.1	Antenatal treatment	83
3.17.4.2	Postnatal treatment	84
3.17.5	Follow-up	84
3.17.6	Summary	86
3.17.7	Summary of evidence and recommendations for the management of posterior urethral valves	87
3.18	Paediatric urological trauma	87
3.18.1	Paediatric renal trauma	87
3.18.1.1	Epidemiology, aetiology and pathophysiology	87
3.18.1.2	Classification systems	87
3.18.1.3	Diagnostic evaluation	88
3.18.1.3.1	Haematuria	88
3.18.1.3.2	Blood pressure	88
3.18.1.3.3	Choice of imaging method	88
3.18.1.4	Disease management	88
3.18.1.5	Recommendations for the diagnosis and management of paediatric renal trauma	89
3.18.2	Paediatric ureteral trauma	89
3.18.2.1	Diagnostic evaluation	89
3.18.2.2	Management	89
3.18.2.3	Recommendations for the diagnosis and management of paediatric ureteral trauma	89
3.18.3	Paediatric bladder injuries	89
3.18.3.1	Diagnostic evaluation	90
3.18.3.2	Management	90
3.18.3.2.1	Intraperitoneal injuries	90
3.18.3.2.2	Extraperitoneal injuries	90
3.18.3.3	Recommendations for the diagnosis and management of paediatric bladder injuries	90
3.18.4	Paediatric urethral injuries	90
3.18.4.1	Diagnostic evaluation	90
3.18.4.2	Disease management	91
3.18.4.3	Recommendations for the diagnosis and management of paediatric trauma	91
3.19	Post-operative fluid management	91
3.19.1	Epidemiology, aetiology and pathophysiology	91
3.19.2	Disease management	92
3.19.2.1	Pre-operative fasting	92
3.19.2.2	Maintenance therapy and intra-operative fluid therapy	92
3.19.2.3	Post-operative fluid management	93
3.19.2.4	Post-operative fasting	94
3.19.3	Summary of evidence and recommendations for the management of post-operative fluid management	94

3.20	Post-operative pain management: general information	94
3.20.1	Epidemiology, aetiology and pathophysiology	94
3.20.2	Diagnostic evaluation	95
3.20.3	Disease management	95
3.20.3.1	Drugs and route of administration	95
3.20.3.2	Circumcision	95
3.20.3.2.1	Penile, inguinal and scrotal surgery	95
3.20.4	Summary of evidence and recommendations for the management of post-operative pain	98
4.	REFERENCES	98
5.	CONFLICT OF INTEREST	157
6.	CITATION INFORMATION	157

# 1. INTRODUCTION

## 1.1 Aim

A collaborative working group consisting of members representing the European Society for Paediatric Urology (ESPU) and the European Association of Urology (EAU) has prepared these Guidelines with the aim of increasing the quality of care for children with urological conditions. This Guideline document is limited to a number of common clinical pathologies in paediatric urological practice, as covering the entire field of paediatric urology in a single guideline document is unattainable.

The majority of urological clinical problems in children are specialised and in many ways differ to those in adults. This publication intends to outline a practical and preliminary approach to paediatric urological conditions. Complex and rare conditions that require special care with experienced doctors should be referred to designated centres where paediatric urology practice has been fully established and a multidisciplinary team is available.

Over time, paediatric urology has developed and matured, establishing its diverse body of knowledge and expertise and may now be ready to distinguish itself from its parent specialties. Thus, paediatric urology has recently emerged in many European countries as a distinct subspecialty of both urology and paediatric surgery and presents a unique challenge in the sense that it covers a large area with many different schools of thought and a huge diversity in management.

Knowledge gained by increasing experience, new technological advances and non-invasive diagnostic screening modalities has had a profound influence on treatment modalities in paediatric urology, a trend that is likely to continue in the years to come.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of children and their caregivers into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## 1.2 Panel composition

The EAU-ESPU Paediatric Urology Guidelines Panel consists of an international group of clinicians with particular expertise in this area. All experts involved in the production of this document have submitted potential conflict of interest statements, which can be viewed on the EAU Website: <http://uroweb.org/guideline/paediatric-urology/>.

## 1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version. A number of translated versions, alongside several scientific publications in European Urology, the Associations scientific journal are also available [1-3]. All documents can be viewed through the EAU website: <http://uroweb.org/guideline/paediatric-urology/>.

## 1.4 Publication history

The Paediatric Urology Guidelines were first published in 2001 [4]. This 2019 publication includes a number of updated chapters and sections as detailed below.

## 1.5 Summary of changes

The literature for the complete document has been assessed and updated, wherever relevant. Key changes in the 2019 publication:

- Section 3.5 – Hypospadias: Both the literature and the text have been updated;
- Section 3.7 - Varicocele in children and adolescents: The summary of evidence table and the level of evidence in a recommendation have been updated following the outcome of a systematic review by the Panel;
- Section 3.13 - Vesicoureteric reflux: Both the literature and text have been updated;
- Section 3.14 - Urinary stone disease: The literature has been updated resulting in minor amendments to the text;
- Section 3.16 - Disorders of sex development: The text has been revised extensively;
- Section 3.17 - Posterior urethral valves: Both the literature and the text have been updated.



### 1.5.1 **New and changed recommendations**

#### 3.16.6 **Recommendations for the management of disorders of sex development**

<b>Recommendations</b>	<b>Strength rating</b>
Newborns with DSD conditions warrant a multidisciplinary team approach.	Strong
Refer children to experienced centres where neonatology, paediatric endocrinology, paediatric urology, child psychology and transition to adult care are guaranteed.	Strong
Do not delay diagnosis and treatment of any neonate presenting with ambiguous genitalia since salt-loss in a 46XX CAH girl can be fatal.	Strong

## **2. METHODS**

### **2.1 Introduction**

These Guidelines were compiled based on current literature following a structured review. Databases covered by the searches included Pubmed, Ovid, EMBASE and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Application of a structured analysis of the literature was not possible in many conditions due to a lack of well-designed studies. The limited availability of large randomised controlled trials (RCTs) - influenced also by the fact that a considerable number of treatment options relate to surgical interventions on a large spectrum of different congenital problems - means this document is largely a consensus document. Clearly there is a need for continuous re-evaluation of the information presented in this document.

For each recommendation within the guidelines there is an accompanying online strength rating form, the basis of which is a modified GRADE methodology [5, 6]. Each strength rating form addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [7];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [8]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.

### **2.2 Peer review**

All chapters of the Paediatric Urology Guidelines were peer-reviewed in 2015.

### **2.3 Future goals**

The Paediatric Urology Guidelines Panel aim to systematically address the following key clinical topic in a future update of the Guidelines:

- Does using an inlay graft during primary hypospadias repair affect the outcomes?
- Is there any prognostic importance of diagnosing testicular microlithiasis in the paediatric population in predicting the risk of testicular malignancy and infertility?

## 3. THE GUIDELINE

### 3.1 Phimosis

#### 3.1.1 *Epidemiology, aetiology and pathophysiology*

At the end of the first year of life, retraction of the foreskin behind the glandular sulcus is possible in approximately 50% of boys; this rises to approximately 89% by the age of three years. The incidence of phimosis is 8% in six to seven year olds and just 1% in males aged sixteen to eighteen years [9].

#### 3.1.2 *Classification systems*

The phimosis is either primary with no sign of scarring, or secondary (pathological) to a scarring such as balanitis xerotica obliterans (BXO) [9]. Balanitis xerotica obliterans, also termed lichen sclerosis, has been recently found in 35% circumcised prepuce in children and adolescents and in 17% of boys younger than ten years presenting with phimosis. The clinical appearance of BXO in children may be confusing and does not correlate with the final histopathological results. Lymphocyte-mediated chronic inflammatory disease was the most common finding [10, 11] (LE: 2b).

Phimosis has to be distinguished from normal agglutination of the foreskin to the glans, which is a more or less lasting physiological phenomenon with clearly-visible meatus and free partial retraction [12]. Separation of the prepuce from the glans is based on accumulated epithelial debris and penile erections. Forceful preputial retraction should be discouraged to avoid cicatrix formation [13].

Paraphimosis must be regarded as an emergency situation: retraction of a too narrow prepuce behind the glans penis into the glanular sulcus may constrict the shaft and lead to oedema of the glans and retracted foreskin. It interferes with perfusion distally from the constrictive ring and brings a risk of preputial necrosis.

#### 3.1.3 *Diagnostic evaluation*

The diagnosis of phimosis and paraphimosis is made by physical examination. If the prepuce is not retractable, or only partly retractable, and shows a constrictive ring on drawing back over the glans penis, a disproportion between the width of the foreskin and the diameter of the glans penis has to be assumed. In addition to the constricted foreskin, there may be adhesions between the inner surface of the prepuce and the glanular epithelium and/or a fraenum breve. Paraphimosis is characterised by a retracted foreskin with the constrictive ring localised at the level of the sulcus, which prevents replacement of the foreskin over the glans.

#### 3.1.4 *Management*

Conservative treatment is an option for primary phimosis. The steroid therapies were more effective over placebo and manual stretching [14]. A corticoid ointment or cream (0.05-0.1%) can be administered twice a day over a period of 20-30 days with a success rate of > 90% [15-18] (LE: 1b). A recurrence rate of up to 17% can be expected [19]. This treatment has no side effects and the mean bloodspot cortisol levels are not significantly different from an untreated group of patients [20] (LE: 1b). The hypothalamic pituitary-adrenal axis was not influenced by local corticoid treatment [21]. Agglutination of the foreskin does not respond to steroid treatment [16] (LE: 2).

Operative treatment of phimosis in children is dependent on the caregivers' preferences and can be plastic or radical circumcision after completion of the second year of life. Alternatively, the Shang Ring may be used especially in developing countries [22]. Plastic circumcision has the objective of achieving a wide foreskin circumference with full retractability, while the foreskin is preserved (dorsal incision, partial circumcision, trident preputial plasty) [23]. However, this procedure carries the potential for recurrence of the phimosis [24]. In the same session, adhesions are released and an associated fraenum breve is corrected by fraenulotomy. Meatoplasty is added if necessary.

An absolute indication for circumcision is secondary phimosis. In primary phimosis, recurrent balanoposthitis and recurrent urinary tract infections (UTIs) in patients with urinary tract abnormalities are indications for intervention [25-28] (LE: 2b). Male circumcision significantly reduces the bacterial colonisation of the glans penis with regard to both non-uropathogenic and uropathogenic bacteria [29] (LE: 2b). Simple ballooning of the foreskin during micturition is not a strict indication for circumcision.

Routine neonatal circumcision to prevent penile carcinoma is not indicated. A recent meta-analysis could not find any risk in uncircumcised patients without a history of phimosis [30]. Contraindications for circumcision are: an acute local infection and congenital anomalies of the penis, particularly hypospadias or buried penis, as the foreskin may be required for a reconstructive procedure [31, 32]. Circumcision can be performed in children with coagulopathy with 1-5% suffering complications (bleeding), if haemostatic agents or a diathermic knife are used [33, 34]. Childhood circumcision has an appreciable morbidity and should not be recommended without a medical reason and also taking into account epidemiological and social aspects [35-39] (LE: 1b). Balanitis xerotica obliterans is associated with meatal pathology (stenosis) after circumcision in up

to 20% of boys and adjuvant local steroid treatment is advised [11, 40].

Treatment of paraphimosis consists of manual compression of the oedematous tissue with a subsequent attempt to retract the tightened foreskin over the glans penis. Injection of hyaluronidase beneath the narrow band or 20% mannitol may be helpful to release the foreskin [41, 42] (LE: 3-4). If this manoeuvre fails, a dorsal incision of the constrictive ring is required. Depending on the local findings, a circumcision is carried out immediately or can be performed in a second session.

### 3.1.5 **Follow-up**

Any surgery done on the prepuce requires an early follow-up of four to six weeks after surgery.

### 3.1.6 **Summary of evidence and recommendations for the management of phimosis**

Summary of evidence	LE
Treatment for phimosis usually starts after two years of age or according to caregivers' preference.	3
In primary phimosis, conservative treatment with a corticoid ointment or cream is a first line treatment with a success rate of more than 90%.	1b

Recommendations	LE	Strength rating
Offer corticoid ointment or cream to treat primary symptomatic phimosis. Circumcision will also solve the problem.	1b	Strong
Treat primary phimosis in patients with recurrent urinary tract infection and/or with urinary tract abnormalities.	2b	Strong
Circumcise in case of lichen sclerosus or scarred phimosis.	2b	Strong
Treat paraphimosis by manual reposition and proceed to surgery if it fails.	3	Strong
Avoid retraction of asymptomatic preputial adhesions.	2b	Weak

## 3.2 **Management of undescended testes**

### 3.2.1 **Background**


Cryptorchidism or undescended testis is one of the most common congenital malformations of male neonates. Incidence varies and depends on gestational age, affecting 1.0-4.6% of full-term and 1.1-45% of preterm neonates. Following spontaneous descent within the first months of life, nearly 1.0% of all full-term male infants still have undescended testes at one year of age [43]. This congenital malformation may affect both sides in up to 30% of cases [44]. In newborn cases with non-palpable or undescended testes on both sides and any sign of disorders of sex development (DSDs) like concomitant hypospadias, urgent endocrinological and genetic evaluation is required [45].

### 3.2.2 **Classification**

The term cryptorchidism is most often used synonymously for undescended testes. The most useful classification of undescended testes is distinguishing into palpable and non-palpable testes, and clinical management is decided by the location and presence of the testes (see Figure 1). Approximately 80% of all undescended testes are palpable [46]. Acquired undescended testes can be caused by entrapment after herniorrhaphy or spontaneously referred to as ascending testis.

Palpable testes include true undescended testes and ectopic testes. Non-palpable testes include intra-abdominal, inguinal, absent, and sometimes also some ectopic testes. Most importantly, the diagnosis of palpable or non-palpable testis needs to be confirmed once the child is under general anaesthesia, as this is the first step of any surgical procedure for undescended testes.

**Figure 1: Classification of undescended testes**



### 3.2.2.1 Palpable testes

#### Undescended testes

A true undescended testis is on its normal path of descent but is halted on its way down to the scrotum. Depending on the location, the testes may be palpable or not, as in the case of testes arrested in the inguinal canal.

#### Ectopic testes

If the position of a testis is outside its normal path of descent and outside the scrotum, the testis is considered to be ectopic. The most common aberrant position is in the superficial inguinal pouch. Sometimes an ectopic testis can be identified in a femoral, perineal, pubic, penile or even contralateral position. Usually, there is no possibility for an ectopic testis to descend spontaneously to the correct position; therefore, it requires surgical intervention. In addition, an ectopic testis might not be palpable due to its position.

#### Retractile testes

Retractile testes have completed their descent into a proper scrotal position but can be found again in a suprascrotal position along the path of their normal descent. This is due to an overactive cremasteric reflex [47]. Retractile testes can be easily manipulated down to the scrotum and remain there at least temporarily. They are typically normal in size and consistency. However, they may not be normal and should be monitored carefully since up to one-third can ascend and become undescended [48].

### 3.2.2.2 Non-palpable testes

Among the 20% of non-palpable testes, 50-60% are intra-abdominal, canalicular or peeping (right inside the internal inguinal ring). The remaining 20% are absent and 30% are atrophic or rudimentary.

#### Intra-abdominal testes

Intra-abdominal testes can be located in different positions, with most of them being found close to the internal inguinal ring. However, possible locations include the kidney, anterior abdominal wall, and retrovesical space. In the case of an open internal inguinal ring, the testis may be peeping into the inguinal canal.

### *Absent testes*

Monorchidism can be identified in up to 4% of boys with undescended testes, and anorchidism (bilateral absence) in < 1%. Possible pathogenic mechanisms include testicular agenesis and atrophy after intrauterine torsion with the latter one most probably due to an *in utero* infarction of a normal testis by gonadal vessel torsion. The term vanishing testis is commonly used for this condition [49].

### **3.2.3 Diagnostic evaluation**

History taking and physical examination are key in evaluating boys with undescended testes. Localisation studies using different imaging modalities are usually without any additional benefit.

#### **3.2.3.1 History**

Caregivers should be asked for maternal and paternal risk factors, including hormonal exposure and genetic or hormonal disorders. If the child has a history of previously descended testes this might be suggestive of testicular ascent [50]. Prior inguinal surgery is indicative of secondary undescended testes due to entrapment.

#### **3.2.3.2 Physical examination**

An undescended testis is pursued by carefully advancing the examining fingers along the inguinal canal towards the pubis region, perhaps with the help of lubricant. A possible inguinal testis can be felt to bounce under the fingers [51]. A non-palpable testis in the supine position may become palpable once the child is in a sitting or squatting position. If no testis can be identified along the normal path of descent, possible ectopic locations must be considered.

In case of unilateral non-palpable testis, the contralateral testis needs to be examined. Its size and location can have important prognostic implications. Any compensatory hypertrophy suggests testicular absence or atrophy [52]. Nevertheless, this does not preclude surgical exploration since the sign of compensatory hypertrophy is not specific enough [53].

In case of bilateral undescended testes and any evidence or sign of DSDs, such as genital ambiguity, or scrotal hyperpigmentation, further evaluation including endocrinological and genetic assessment becomes mandatory [54].

#### **3.2.3.3 Imaging studies**

Imaging studies cannot determine with certainty that a testis is present or not [55]. Ultrasound (US) lacks the diagnostic performance to detect the testis confidently or establish the absence of an intra-abdominal testis [56].

Consequently, the use of different imaging modalities, such as US or MRI [57], for undescended testes is limited and only recommended in specific and selected clinical scenarios (e.g. identification of Müllerian structures in cases with suspicion of DSDs) [56].

### **3.2.4 Management**

Treatment should be started at the age of six months. After that age, undescended testes rarely descend [58]. Any kind of treatment leading to a scrotally positioned testis should be finished by twelve months, or eighteen months at the latest, because histological examination of undescended testes at that age has already revealed a progressive loss of germ cells and Leydig cells [59]. The early timing of treatment is also driven by the final adult results on spermatogenesis and hormone production, as well as on the risk of tumour development [60].

#### **3.2.4.1 Medical therapy**

Unfortunately, most of the studies on hormonal treatment have been of poor quality, with heterogeneous and mixed patient populations, testis location, schedules and dosages of hormonal administration. Additionally, long-term data are almost completely lacking.

Short-term side effects of hormonal treatment include increased scrotal erythema and pigmentation, and induction of pubic hair and penile growth. Some boys experience pain after intramuscular injection of human chorionic gonadotropin (hCG). All of these tend to regress after treatment cessation [61, 62].

##### **3.2.4.1.1 Medical therapy for testicular descent**

Hormonal therapy using hCG or gonadotropin-releasing hormone (GnRH) is based on the hormonal dependence of testicular descent, but has a limited success rate of only 20% [63]. However, it must be taken into account that almost 20% of these descended testes have the risk of re-ascending later [64]. In general, success rates depend on testicular location. The higher the testis is located prior to therapy, the lower the success rate, suggesting that testicular position is an important determinant of success [61]. Some authors recommend combined hCG-GnRH treatment. Unfortunately, it is poorly documented and the treatment groups were diverse. Some studies reported successful descent in up to 38% of non-responders to monotherapy [65]. The Panel consensus is that endocrine treatment to achieve testicular descent is not recommended (LE: 4).

### *Human chorionic gonadotropin*

Human chorionic gonadotropin stimulates endogenous testosterone production and is administered by intramuscular injection. Several dose and administration schedules are reported. There is no proven difference between 1.5 IU and weight-based doses up to 3.0 IU every other day for fourteen days [66]. Similar response rates were achieved with 500 IU once weekly and 1.50 IU three times weekly [67]. However, there is evidence that dosing frequency might affect testicular descent rates. Fewer lower dose injections per week for five weeks seem to be superior to one higher dose every seven to ten days for three weeks with regard to testicular descent [68].

### *Gonadotropin-releasing hormone*

Gonadotropin-releasing hormone analogues (e.g., buserelin and gonadorelin) are available as nasal sprays, thus avoiding painful intramuscular injections. A typical dosage regimen consists of 1.2 mg per day in three divided doses, for four weeks. Success rates are wide ranging, from 9 to 60%, due to multiple treatment strategies and heterogeneous patient populations [69].

#### 3.2.4.1.2 Medical therapy for fertility potential

Hormonal treatment may improve fertility indices [69, 70] and therefore serve as an additional tool to orchidopexy. There is no difference in treatment with GnRH before (neo-adjuvant) or after (adjuvant) surgical orchidolysis and orchidopexy in terms of increasing fertility index, which may be a predictor for fertility later in life [71]. It is still unknown whether this effect on testicular histology persists into adulthood but it has been shown that men who were treated in childhood with buserelin had better semen analyses compared with men who had childhood orchidopexy alone or placebo treatment [69].

It is reported that hCG treatment may be harmful to future spermatogenesis through increased apoptosis of germ cells, including acute inflammatory changes in the testes and reduced testicular volume in adulthood [72].

Identification of specific subgroups of boys with undescended testes who would benefit from such an approach using hormones is difficult. Since these important data on specific groups as well as additional support on the long-term effects are still lacking, the Nordic consensus does not recommend hormonal therapy [73]. The consensus of the Panel recommends endocrine treatment with GnRH analogues in a dosage described above for boys with bilateral undescended testes to preserve the fertility potential (LE: 4).

#### 3.2.4.2 Surgical therapy

If a testis has not concluded its descent at the age of six months (corrected for gestational age), and since spontaneous testicular descent is unlikely to occur after that age, surgery should be performed within the subsequent year, and by age eighteen months at the latest [60]. In addition, early orchidopexy can be followed by partial catch-up testicular growth, which is not the case in delayed surgery [74]. All these findings recommend performing early orchidopexy between the ages of six and twelve months [58].

##### 3.2.4.2.1 Palpable testes

Surgery for palpable testes includes orchidofunicolysis and orchidopexy, either via an inguinal or scrotal approach. The latter approach is mainly reserved for low-positioned, undescended testes, with the pros and cons of each method being weighed against each other [75].

###### 3.2.4.2.1.1 Inguinal orchidopexy

Inguinal orchidopexy is a widely used technique with a high success rate of up to 92% [76]. Important steps include mobilisation of the testis and spermatic cord to the level of the internal inguinal ring, with dissection and division of all cremasteric fibres, to prevent secondary retraction and detachment of the gubernaculum testis. The patent processus vaginalis needs to be ligated proximally at the level of the internal ring, because an unidentified or inadequately repaired patent processus vaginalis is an important factor leading to failure of orchidopexy [77]. Any additional pathology has to be taken care of, such as removal of an appendix testis (hydatis of Morgagni). At this moment the size of the testis can be measured and the connection of the epididymis to the testis can be judged and described in the protocol. Some boys have a significant dissociation between testis and epididymis which is prognostically bad for fertility. Finally, the mobilised testicle needs to be placed in a sub-dartos pouch within the hemi-scrotum without any tension. In case the length achieved using the above-mentioned technique is still inadequate, the Prentiss manoeuvre, which consists of dividing the inferior epigastric vessels and transposing the spermatic cord medially, in order to provide a straight course to the scrotum, might be an option [78]. With regard to fixation sutures, if required, they should be made between the tunica vaginalis and the dartos musculature [79]. Lymph drainage of a testis that has undergone surgery for orchidopexy may have changed from high retroperitoneal drainage to iliac and inguinal drainage, which might become important in the event of later malignancy [80].

#### 3.2.4.2.1.2 Scrotal orchidopexy

Low-positioned, palpable undescended testis can be fixed through a scrotal incision including division of the gubernaculum, and the processus vaginalis needs to be probed to check for patency [81]. Otherwise, fixation in the scrotum is carried out correspondingly to the inguinal approach. In up to 20% of cases, an inguinal incision will be compulsory to correct an associated inguinal hernia [82]. Any testicular or epididymal appendages can be easily identified and removed. A systematic review shows that the overall success rates ranged from 88 to 100%, with rates of recurrence and post-operative testicular atrophy or hypotrophy < 1% [75].

#### 3.2.4.2.2 Non-palpable testes

For non-palpable testes, surgery must clearly determine whether a testis is present or not [83]. If a testis is found, the decision has to be made to remove it or bring it down to the scrotum. An important step in surgery is a thorough re-examination once the boy is under general anaesthesia, since a previously non-palpable testis might be identifiable and subsequently change the surgical approach to standard inguinal orchidopexy, as described above. Otherwise, the easiest and most accurate way to locate an intra-abdominal testis is diagnostic laparoscopy [84]. Subsequent removal or orchidolysis and orchidopexy can be carried out using the same approach to achieve the therapeutic aims [85]. Some tend to start with inguinal surgical exploration, with possible laparoscopy during the procedure [86]. If an ipsilateral scrotal nubbin is suspected, and contralateral compensatory testicular hypertrophy is present, a scrotal incision with removal of the nubbin, thus confirming the vanishing testis, is an option avoiding the need for laparoscopy [87].

During laparoscopy for non-palpable testes, possible anatomical findings include spermatic vessels entering the inguinal canal (40%), an intra-abdominal (40%) or peeping (10%) testis, or blind-ending spermatic vessels confirming vanishing testis (10%) [88].

In case of a vanishing testis, the procedure is finished once blind-ending spermatic vessels are clearly identified. If the vessels enter the inguinal canal, one may find an atrophic testis upon inguinal exploration or a healthy testis that needs to undergo standard orchidopexy [89]. A peeping testis can be placed down in the scrotum laparoscopically or via an inguinal incision [90]. Placement of an intra-abdominal testis can sometimes be a surgical challenge. Usually, testes lying > 2 cm above the internal inguinal ring may not reach the scrotum without division of the testicular vessels [91]. Under such circumstances, a Fowler-Stephens orchidopexy may be an option [92] (see Figure 2).

Proximal cutting and transection of the testicular vessels, with conservation of the collateral arterial blood supply, via the deferential artery and cremasteric vessels comprise the key features of the Fowler-Stephens procedure. Recently, a modification with low spermatic vessel ligation has gained popularity, allowing blood supply from the testicular artery to the deferential artery. An additional advantage is the position of the peritoneal incision, leading to a longer structure, to ease later scrotal placement [93]. Due to the nature of these approaches the testis is at risk of hypotrophy or atrophy if the collateral blood supply is insufficient [94]. The testicular survival rate in the one-stage Fowler-Stephens technique varies between 50 and 60%, with success rates increasing up to 90% for the two-stage procedure [95]. The advantages of two-stage orchidopexy, with the second part done usually six months after the first, are to allow for development of collateral blood supply and to create greater testicular mobility [96]. In addition, preservation of the gubernaculum may also decrease the chance of testicular atrophy [97]. An alternative might be microsurgical auto-transplantation, which has a success rate of up to 90%. However, this approach requires skilled and experienced surgeons and is performed in a limited number of centres [98].

#### 3.2.4.2.3 Complications of surgical therapy


Surgical complications are usually uncommon, with testicular atrophy being the most serious. A systematic review revealed an overall atrophy rate for primary orchidopexy of 1.83%, 28.1% for one-stage Fowler-Stephens procedure, and 8.2% for the two-stage approach [99]. Other rare complications comprise testicular ascent and vas deferens injury besides local wound infection, dehiscence, and haematoma.

#### 3.2.4.2.4 Surgical therapy for undescended testes after puberty

A recent study on 51 men diagnosed with inguinal unilateral undescended testis and a normal contralateral one, with no history of any previous therapy, demonstrated a wide range of changes upon histological evaluation. Nearly half of the study population still had significant germ cell activity at different maturation levels. Importantly, the incidence of intratubular germ cell neoplasia was 2% [100].

The Panel consensus recommends orchiectomy in post-pubertal boys with an undescended testis and a normal contralateral one in a scrotal position.

**Figure 2: Treatment of unilateral non-palpable undescended testes**



### 3.2.5 **Undescended testes and fertility**

The association of undescended testes with compromised fertility [101] is extensively discussed in the literature and seems to be a result of multiple factors, including germ cell loss, impaired germ cell maturation [102], Leydig cell diminution and testicular fibrosis [103].

Although boys with one undescended testis have a lower fertility rate, they have the same paternity rate as those with bilateral descended testes. Boys with bilateral undescended testes suffer both, lower fertility and paternity rates. Fertility rate is the number of offspring born per mating pair, individual of population, whereas paternity reflects the actual potential of fatherhood [104]. The age at which surgical intervention for an undescended testis occurs seems to be an important predictive factor for fertility later in life. Endocrinological studies revealed higher inhibin-B and lower follicle-stimulating hormone (FSH) levels in men who underwent orchidopexy at age two years compared to individuals who had surgery later, which is indicative of a benefit of earlier orchidopexy [105]. In addition, others demonstrated a relation between undescended testes and increased loss of germ cells and Leydig cells, which is also suggestive of prompt orchidopexy being a significant factor for fertility preservation [106].

Outcome studies for untreated bilateral undescended testes revealed that 100% are oligospermic and 75% azoospermic. Among those successfully treated for bilateral undescended testes, 75% still remain oligospermic and 42% azoospermic [103].

In summary, early surgical correction of undescended testes is highly recommended before twelve months of age, and by eighteen months at the latest for preservation of fertility potential [59].

### 3.2.6 **Undescended testes and malignancy**

Boys who are treated for an undescended testis have an increased risk of developing testicular malignancy. Screening and self-examination both during and after puberty is therefore recommended [107]. A Swedish study, with a cohort of almost 17,000 men (56 developed a testicular tumour) who were treated surgically for undescended testes and followed for 210,000 person-years, showed that management of undescended testes



before the onset of puberty decreased the risk of testicular cancer. The relative risk of testicular cancer among those who underwent orchidopexy before thirteen years of age was 2.2 compared to the Swedish general population; this increased to 5.4 for those treated after thirteen years of age [108].

A systematic review and meta-analysis of the literature have also concluded that pre-pubertal orchidopexy may reduce the risk of testicular cancer and that early surgical intervention is indicated in boys with undescended testes [109].

### 3.2.7 **Summary of evidence and recommendations for the management of undescended testes**

<b>Summary of evidence</b>	<b>LE</b>
An undescended testis justifies treatment early in life to avoid loss of spermatogenic potential.	2a
A failed or delayed orchidopexy may increase the risk of testicular malignancy later in life.	2a
The earlier the treatment, the lower the risk of impaired fertility and testicular cancer.	2a
In unilateral undescended testis, fertility rate is reduced whereas paternity rate is not.	1b
In bilateral undescended testes, fertility and paternity rates are impaired.	1b
The treatment of choice for undescended testis is surgical replacement in the scrotum.	1b
The palpable testis is usually treated surgically using an inguinal approach.	2b
The non-palpable testis is most commonly approached laparoscopically.	2b
There is no consensus on the use of hormonal treatment.	2b

<b>Recommendations</b>	<b>LE</b>	<b>Strength rating</b>
The Panel do not recommend medical or surgical treatment for retractile testes but recommend close follow-up on a yearly basis until puberty.	2a	Strong
Perform surgical orchidolysis and orchidopexy before the age of twelve months, and by eighteen months at the latest.	2b	Strong
Evaluate male neonates with bilateral non-palpable testes for possible disorders of sex development.	1b	Strong
Perform a diagnostic laparoscopy to locate an intra-abdominal testicle.	1a	Strong
Hormonal therapy in unilateral undescended testes is of no benefit for future paternity.	2a	Weak
Offer endocrine treatment in case of bilateral undescended testes.	4	Weak
Inform the patient/caregivers about the increased risk of a later malignancy with an undescended testis in a post-pubertal boy or older and discuss removal in case of a contralateral normal testis in a scrotal position.	3	Weak

## 3.3 **Hydrocele**

### 3.3.1 **Epidemiology, aetiology and pathophysiology**

Hydrocele is defined as a collection of fluid between the parietal and visceral layers of the tunica vaginalis [110]. Pathogenesis of primary hydrocele is based on patency of processus vaginalis in contrast with secondary hydrocele. Incomplete obliteration of the processus vaginalis peritonei results in formation of various types of communicating hydrocele; a large open processus vaginalis allowing passage of abdominal viscera results in clinical hernia [111]. The exact time of spontaneous closure of the processus vaginalis is not known. It persists in approximately 80-94% of newborns and in 20% of adults [112]. If complete obliteration of the processus vaginalis occurs with patency of mid-portion, a hydrocele of the cord occurs. Scrotal hydroceles without associated patency of the processus vaginalis are also encountered in newborns [113]. Non-communicating hydroceles, based on an imbalance between the secretion and re-absorption of this fluid, are found secondary to minor trauma, testicular torsion, epididymitis, varicocele operation or may appear as a recurrence after primary repair of a communicating or non-communicating hydrocele.

### 3.3.2 **Diagnostic evaluation**

The classic description of a communicating hydrocele is that of a hydrocele that vacillates in size, and is usually related to ambulation. It may be diagnosed by history and physical investigation. Transillumination of the scrotum provides the diagnosis in the majority of cases, keeping in mind that fluid-filled intestine and some pre-pubertal tumours may transilluminate as well [114, 115]. If the diagnosis is that of a hydrocele, there will be no history of reducibility and no associated symptoms; the swelling is translucent, smooth and usually not tender. If there are any doubts about the character of an intrascrotal mass, scrotal US should be performed and has nearly 100% sensitivity in detecting intrascrotal lesions. Doppler US studies help to distinguish hydroceles from varicocele and testicular torsion, although these conditions may also be accompanied by a hydrocele.

### 3.3.3 Management

In the majority of infants, surgical treatment of hydrocele is not indicated within the first twelve months because of the tendency for spontaneous resolution [116] (LE: 2). Little risk is taken by initial observation as progression to hernia is rare and does not result in incarceration [116]. Early surgery is indicated if there is suspicion of a concomitant inguinal hernia or underlying testicular pathology [117, 118] (LE: 2). Persistence of a simple scrotal hydrocele beyond twelve months of age may be an indication for surgical correction. There is no evidence that this type of hydrocele risks testicular damage. The natural history of hydrocele is poorly documented beyond the age of two years and according to a systematic review there is no good evidence to support current practice. Delaying surgery may reduce the number of procedures necessary without increasing morbidity [119].

The question of contralateral disease should be addressed by both history and physical examination at the time of initial consultation (LE: 2) [120]. In late-onset hydrocele, suggestive of a non-communicating hydrocele, there is a reasonable chance of spontaneous resolution (75%) and expectant management of six to nine months is recommended [121]. In the paediatric age group, the operation consists of ligation of patent processus vaginalis via inguinal incision and the distal stump is left open, whereas in hydrocele of the cord the cystic mass is excised or unroofed [115, 117] (LE: 4). In expert hands, the incidence of testicular damage during hydrocele or inguinal hernia repair is very low (0.3%) (LE: 3). Sclerosing agents should not be used because of the risk of chemical peritonitis in communicating processus vaginalis peritonei [115, 117] (LE: 4). The scrotal approach (Lord or Jaboulay technique) is used in the treatment of a secondary non-communicating hydrocele.

### 3.3.4 Summary of evidence and recommendations for the management of hydrocele

Summary of evidence	LE
In the majority of infants, surgical treatment of hydrocele is not indicated within the first twelve months due to the tendency for spontaneous resolution. Little risk is taken by initial observation as progression to hernia is rare.	2a
In the paediatric age group, an operation would generally involve ligation of the patent processus vaginalis via inguinal incision.	4

Recommendations	LE	Strength rating
In the majority of infants, observe hydrocele for twelve months prior to considering surgical treatment.	2a	Strong
Perform early surgery if there is suspicion of a concomitant inguinal hernia or underlying testicular pathology.	2b	Strong
Perform a scrotal ultrasound in case of doubt about the character of an intrascrotal mass.	4	Strong
Do not use sclerosing agents because of the risk for chemical peritonitis.	4	Strong

## 3.4 Acute scrotum

### 3.4.1 Epidemiology, aetiology and pathophysiology

Acute scrotum is a paediatric urological emergency, most commonly caused by torsion of the testis or appendix testis, or epididymitis/epididymo-orchitis [122-127]. Other causes of acute scrotal pain are idiopathic scrotal oedema, mumps orchitis, varicocele, scrotal haematoma, incarcerated hernia, appendicitis or systemic disease (e.g. Henoch-Schönlein purpura) [128-140]. Trauma can also be a cause of acute scrotum as it can relate to post-traumatic haematomas, testicular contusion, rupture dislocation or torsion [141-146]. Scrotal fat necrosis has also been reported to be an uncommon cause of mild-to-moderate scrotal pain in pre-pubertal overweight boys after exposure to cold [147].

In this chapter testicular torsion and epididymitis are discussed, while recurrent epididymitis is discussed in the chapter dealing with infections. Torsion of the testis occurs most often in the neonatal period and around puberty, whereas torsion of the appendix testes occurs over a wider age range.

Epididymitis affects two age groups: less than one year and twelve to fifteen years [148, 149]. One study predicted the annual incidence of epididymitis around 1.2 per 1,000 children [150]. Perinatal torsion of the testis most often occurs prenatally. Bilateral torsion comprises 11-21% of all perinatal cases [151]. Most cases are extravaginal in contrast to the usual intravaginal torsion, which occurs during puberty.

### 3.4.2 **Diagnostic evaluation**

Patients usually present with scrotal pain, except in neonatal torsion. The sudden onset of invalidating pain in combination with vomiting is typical for torsion of the testis or appendix testes [152, 153].

In general, the duration of symptoms is shorter in testicular torsion (69% present within twelve hours) and torsion of the appendix testes (62%) compared to epididymitis (31%) [124, 125, 149].

In the early phase, location of the pain can lead to diagnosis. Patients with acute epididymitis experience a tender epididymis, whereas patients with testicular torsion are more likely to have a tender testicle, and patients with torsion of the appendix testis feel isolated tenderness of the superior pole of the testis [149].

An abnormal (horizontal) position of the testis is more frequent in testicular torsion than epididymitis [124]. Looking for absence of the cremasteric reflex is a simple method with 100% sensitivity and 66% specificity for testicular torsion [148, 153] (LE: 3). Elevation of the scrotum may reduce complaints in epididymitis, but not in testicular torsion.

Fever occurs more often in epididymitis (11-19%). The classical sign of a “blue dot” was found only in 10-23% of patients with torsion of the appendix testis [123, 124, 148, 154]. In many cases, it is not easy to determine the cause of acute scrotum based on history and physical examination alone [122-127, 148, 154].

A positive urine culture is only found in a few patients with epididymitis [126, 148, 154, 155]. It should be remembered that a normal urinalysis does not exclude epididymitis. Similarly, an abnormal urinalysis does not exclude testicular torsion.

Doppler US is useful to evaluate acute scrotum, with 63.6-100% sensitivity and 97-100% specificity, a positive predictive value of 100% and negative predictive value of 97.5% [156-161] (LE: 3). The use of Doppler US may reduce the number of patients with acute scrotum undergoing scrotal exploration, but it is operator-dependent and can be difficult to perform in pre-pubertal patients [158, 162]. It may also show a misleading arterial flow in the early phases of torsion and in partial or intermittent torsion. Of key importance, persistent arterial flow does not exclude testicular torsion. In a multicentre study of 208 boys with torsion of the testis, 24% had normal or increased testicular vascularisation [158]. A comparison with the other side should always be done.

Better results were reported using high-resolution US (HRUS) for direct visualisation of the spermatic cord twist with a sensitivity of 97.3% and specificity of 99% [158, 163] (LE: 2).

Scintigraphy and, more recently, dynamic contrast-enhanced subtraction MRI of the scrotum also provide a comparable sensitivity and specificity to US [164-167]. These investigations may be used when diagnosis is less likely and if torsion of the testis still cannot be excluded from history and physical examination. This should be done without inordinate delays for emergency intervention [154].

The diagnosis of acute epididymitis in boys is mainly based on clinical judgement and adjunctive investigation. However, it should be remembered that findings of secondary inflammatory changes in the absence of evidence of an extra-testicular nodule by Doppler US might suggest an erroneous diagnosis of epididymitis in children with torsion of the appendix testes [168]. Pre-pubertal boys with acute epididymitis have an incidence of underlying urogenital anomalies of 25-27.6%. Complete urological evaluation in all children with acute epididymitis is still debatable [126, 148, 150].

### 3.4.3 **Management**

#### 3.4.3.1 *Epididymitis*

In pre-pubertal boys, the aetiology is usually unclear, with an underlying pathology in about 25%. A urine culture is usually negative, and unlike in older boys, a sexually transmitted disease is very rare.

Antibiotic treatment, although often started, is not indicated in most cases unless urinalysis and urine culture show a bacterial infection [150, 169]. Epididymitis is usually self-limiting and with supportive therapy (i.e. minimal physical activity and analgesics) heals without any sequelae (LE: 3). However, bacterial epididymitis can be complicated by abscess or necrotic testis and surgical exploration is required [170].

#### 3.4.3.2 *Testicular torsion*

Manual detorsion of the testis is done without anaesthesia. It should initially be done by outwards rotation of the testis unless the pain increases or if there is obvious resistance. Success is defined as the immediate relief of all symptoms and normal findings at physical examination [171] (LE: 3). Doppler US may be used for guidance [172]. Bilateral orchiopexy is still required after successful detorsion. This should not be done as an elective procedure, but rather immediately following detorsion. One study reported residual torsion during exploration in 17 out of 53 patients, including eleven patients who had reported pain relief after manual detorsion [171, 173].

Torsion of the appendix testis can be managed non-operatively with the use of anti-inflammatory

analgesics (LE: 4). During the six-week follow-up, clinically and with US, no testicular atrophy was revealed. Surgical exploration is done in equivocal cases and in patients with persistent pain [161].

#### 3.4.3.3 *Surgical treatment*

Testicular torsion is an urgent condition, which requires prompt surgical treatment. The two most important determinants of early salvage rate of the testis are the time between onset of symptoms and detorsion, and the degree of cord twisting [174]. Severe testicular atrophy occurred after torsion for as little as four hours when the turn was  $> 360^\circ$ . In cases of incomplete torsion ( $180-360^\circ$ ), with symptom duration up to twelve hours, no atrophy was observed. However, an absent or severely atrophied testis was found in all cases of torsion  $> 360^\circ$  and symptom duration  $> 24$  hours [175].

Early surgical intervention with detorsion (mean torsion time less than thirteen hours) was found to preserve fertility [176]. Urgent surgical exploration is mandatory in all cases of testicular torsion within 24 hours of symptom onset. In patients with testicular torsion  $> 24$  hours, semi-elective exploration is necessary [174, 175] (LE: 3). There is still controversy on whether to carry out detorsion and to preserve the ipsilateral testis, or to perform an orchiectomy, in order to preserve contralateral function and fertility after testicular torsion of long duration ( $> 24$  hours).

A study found that sperm quality was preserved after orchiectomy and orchidopexy in comparison to normal control men, although orchiectomy resulted in better sperm morphology [177].

During exploration, fixation of the contralateral testis is also performed. Recurrence after orchidopexy is rare (4.5%) and may occur several years later. There is no consensus recommendation about the preferred type of fixation and suture material [178]. Incision of the tunica albuginea with tunica vaginalis graft to prevent or treat compartment syndrome has also been suggested [179].

External cooling before exploration and multiple medical treatments seem effective in reducing ischaemia-reperfusion injury and preserving the viability of the torsed and the contralateral testis [180-184]. It is good clinical practice to also perform fixation of the contralateral testis in prenatal and neonatal torsion, (although there is no literature to support this) and to remove an atrophied testicle.

#### 3.4.4 *Follow-up*

Patients require follow-up mainly for fertility issues and hormonal consequences. Despite timely and adequate detorsion and fixation of the testicle, up to half of the patients may develop testicular atrophy, even when intraoperatively assessed as viable, and should be counselled accordingly [185].

##### 3.4.4.1 *Fertility*

The results vary and are conflicting. In one study, unilateral torsion of the testis seriously intervened with subsequent spermatogenesis in about 50% of the patients and produced borderline impairment in another 20% [166]. Although, 30% of affected testicles with mumps orchitis show a degree of atrophy, long-term outcome in terms of fertility is not conclusive [186].

A recent study showed a normal pregnancy rate after unilateral testicular torsion, with no difference between the patients undergoing orchidopexy and those after orchidectomy [187].

##### 3.4.4.2 *Subfertility*

Subfertility is found in 36-39% of patients after torsion. Semen analysis may be normal in only 5-50% in long-term follow-up [174]. Early surgical intervention (mean torsion time less than thirteen hours) with detorsion was found to preserve fertility, but a prolonged torsion period (mean 70 hours) followed by orchiectomy jeopardised fertility [176].

Subfertility and infertility are consequences of direct injury to the testis after the torsion. This is caused by the cut-off of blood supply, but also by post-ischaemia-reperfusion injury that is caused after the detorsion when oxygen-derived free radicals are rapidly circulated within the testicular parenchyma [174].

##### 3.4.4.3 *Androgen levels*

Even though the levels of FSH, luteinising hormone (LH) and testosterone are higher in patients after testicular torsion compared to normal controls, endocrine testicular function remains in the normal range after testicular torsion [177].

##### 3.4.4.4 *Unanswered questions*

Although testicular torsion is a common problem the mechanism of neonatal and prenatal torsion is still not exactly known, as well as whether fixation of the contralateral testicle in these cases is really necessary. The influence of an atrophied testicle on fertility is also unclear.

### 3.4.5 **Summary of evidence and recommendations for the management of acute scrotum in children**

Summary of evidence	LE
Diagnosis of testicular torsion is based on presentation and physical exam.	
Doppler US is an effective imaging tool to evaluate acute scrotum and comparable to scintigraphy and dynamic contrast-enhanced subtraction MRI.	2a
Neonates with acute scrotum should be treated as surgical emergencies.	3

Recommendations	LE	Strength rating
Testicular torsion is a paediatric urological emergency and requires immediate treatment.	3	Strong
In neonates with testicular torsion perform orchidopexy of the contralateral testicle. In prenatal torsion the timing of surgery is usually dictated by clinical findings.	3	Weak
Base the clinical decision on physical examination. The use of Doppler ultrasound to evaluate acute scrotum is useful, but this should not delay the intervention.	2a	Strong
Manage torsion of the appendix testis conservatively. Perform surgical exploration in equivocal cases and in patients with persistent pain.	3	Strong
Perform urgent surgical exploration in all cases of testicular torsion within 24 hours of symptom onset. In prenatal torsion the timing of surgery is usually dictated by clinical findings.	3	Strong

## 3.5 **Hypospadias**

### 3.5.1 **Epidemiology, aetiology and pathophysiology**

#### 3.5.1.1 **Epidemiology**

The total prevalence of hypospadias in Europe is 18.6 new cases per 10,000 births (5.1-36.8) according to the recent EUROCAT registry-based study. This incidence was stable over the period of 2001 to 2010 [188, 189]. The mean worldwide prevalence of hypospadias according to an extended systematic literature review varies: Europe 19.9 (range: 1-464), North America 34.2 (6-129.8), South America 5.2 (2.8-110), Asia 0.6-69, Africa 5.9 (1.9-110), and Australia 17.1-34.8. There are conflicting data on the recent trends of prevalence – different trends in Europe and an increasing trend in the USA [190, 191].

#### 3.5.2 **Risk factors**

Risk factors associated with hypospadias are likely to be genetic, placental and/or environmental [188, 189] (LE: 2b). Interactions between genetic and environmental factors may help explain non-replication in genetic studies of hypospadias. Single nucleotide polymorphisms seemed to influence hypospadias risk only in exposed cases [189, 192] (LE: 2b).

- An additional family member with hypospadias is found in 7% of families, but this is more predominant in anterior and middle forms [192-195].
- Endocrine disorders can be detected in rare cases.
- Babies with a low birth weight have a higher risk of hypospadias [192-195].
- Over the last 25 years, a significant increase in the incidence of hypospadias has been found.
- Endocrines disruptors are one component of a multi-factorial model for hypospadias.
- The use of oral contraceptives prior to pregnancy has not been associated with an increased risk of hypospadias in offspring, but their use after conception increased the risk of middle and posterior hypospadias [193-196] (LE: 2a).

#### 3.5.3 **Classification systems**

Hypospadias are usually classified based on the anatomical location of the proximally displaced urethral orifice:

- distal-anterior hypospadias (located on the glans or distal shaft of the penis and the most common type of hypospadias);
- intermediate-middle (penile);
- proximal-posterior (penoscrotal, scrotal, perineal).

The pathology may be different after skin release and should be reclassified accordingly. Anatomical location of meatus may not always be enough to explain the severity and the complex nature of this pathology. Therefore, a simple classification related to severity of the problem, which considers penile length, glans size, shape, urethral plate quality and penile curvature is commonly used. In that classification there are two

types: mild hypospadias (glanular or penile isolated hypospadias without associated chordee, micropenis or scrotal anomaly); severe hypospadias (penoscrotal, perineal hypospadias with associated chordee and scrotal anomalies).

#### 3.5.4 **Diagnostic evaluation**

Most hypospadias patients are easily diagnosed at birth (except for the megameatus intact prepuce variant which can only be seen after retraction of foreskin). Diagnosis includes a description of the local findings:

- position, shape and width of the orifice;
- presence of atretic urethra and division of corpus spongiosum;
- appearance of the preputial hood and scrotum;
- size of the penis;
- curvature of the penis on erection.

The diagnostic evaluation also includes an assessment of associated anomalies, which are:

- cryptorchidism (in up to 10% of cases of hypospadias);
- open processus vaginalis or inguinal hernia (in 9-15%).

Severe hypospadias with unilaterally or bilaterally impalpable testis, or with ambiguous genitalia, requires a complete genetic and endocrine work-up immediately after birth to exclude DSD, especially congenital adrenal hyperplasia.

Urine trickling and ballooning of the urethra requires exclusion of meatal stenosis. The relationship between the severity of the hypospadias and associated anomalies of the upper- or lower urinary tract were not confirmed [197] (LE: 3).

#### 3.5.5 **Management**

##### 3.5.5.1 *Indication for reconstruction and therapeutic objectives*

Differentiation between functionally necessary and aesthetically feasible operative procedures is important for therapeutic decision making.

The indications for surgery are:

- proximally located (ectopic) meatus causing ventrally deflected or spraying urinary stream;
- meatal stenosis;
- anterior curvature of the penis;
- cleft glans;
- rotated penis with abnormal cutaneous raphe;
- preputial hood;
- penoscrotal transposition;
- split scrotum.

Physical examination should check all anatomic components of the penis and evaluate the degree and nature of abnormality in each component. The examination should evaluate location of the meatus, the degree of proximal spongiosal hypoplasia, presence and degree of penile curvature, width and depth of the urethral plate, size of the glans, degree of ventral skin deficiency, availability of the foreskin and scrotal abnormalities like penoscrotal transposition and bifid scrotum.

As all surgical procedures carry the risk of complications, thorough pre-operative counselling of the caregiver is crucial.

To achieve an overall acceptable functional and cosmetic outcome, the penile curvature must be corrected and a neo-urethra of an adequate size with opening on the glans formed with proper skin coverage of the penile shaft [198] (LE: 4) (Figure 3). The use of magnifying spectacles and fine synthetic absorbable suture materials (6.0-7.0) are required. As in any penile surgery, exceptional prudence should be adopted with the use of cautery. Bipolar cautery is recommended. Knowledge of a variety of surgical reconstructive techniques, wound care and post-operative treatment are essential for a satisfactory outcome.

##### 3.5.5.2 *Pre-operative hormonal treatment*

There is a lack of high-quality evidence to support that pre-operative hormonal treatment with androgen stimulation improves surgical outcomes. Yet, this treatment in the form of systemic testosterone, topical testosterone, and derivatives like dihydrotestosterone (DHT) and hCG are commonly being used to increase glans size pre-operatively to allow better tubularisation of the urethral plate and decrease the incidence of

glans dehiscence. This treatment is usually limited to patients with proximal hypospadias, a small appearing penis, reduced glans circumference or reduced urethral plate [196, 199, 200]. Studies have shown that it leads to significant enlargement of the glans and shaft of the penis (LE: 1b) [201, 202].

Moderate quality evidence from three randomised studies demonstrate significantly lower rates of urethra-cutaneous fistulae and reoperation rates in patients who received pre-operative hormonal treatment [203].

Pre-operative testosterone administration is most often well tolerated. Transient side effects on child's behaviour, increased genital pigmentation, appearance of pubic hair, penile skin irritation and redness, increased erections and peri-operative bleeding have been reported, but no persistent side effects related to hormonal stimulation have been reported in the literature. There is also no evidence about possible effects on bone maturation [200, 203, 204].

There are concerns regarding the negative impacts of testosterone on wound-healing and increased bleeding during surgery. Cessation of therapy is recommended 1-2 months prior to surgery to avoid adverse effects during or after surgery [205].

#### 3.5.5.3 *Age at surgery*

The age at surgery for primary hypospadias repair is usually 6-18 (24) months [198, 206, 207] (LE: 3). Age at surgery is not a risk factor for urethroplasty complication in pre-pubertal tubularised incised plate urethroplasty (TIP) repair [206] (LE: 2b). Complication rate after primary TIP repair was 2.5 times higher in adults than in the paediatric group according to a recent prospective controlled study [208] (LE: 2a).

#### 3.5.5.4 *Penile curvature*

If present, penile curvature is often released by degloving the penis (skin chordee) and by excision of the connective tissue of the genuine chordee on the ventral aspect of the penis in up to 70% [209]. The urethral plate has well vascularised connective tissue and does not cause curvature in most cases [210, 211]. The residual curvature is caused by corporeal disproportion and requires straightening of the penis, mostly using dorsal midline plication or orthoplasty (modification of the Nesbit plication with or without elevation of the neurovascular bundle). In more severe curvature (> 45°), which is often combined with a short urethral plate requiring transection, ventral penile lengthening is recommended to prevent shortening of the penis. This consists of a ventral transverse incision of tunica albuginea extending from the 3 to 9 o'clock position patched with tunica vaginalis flap or graft, or in several short ventral corporotomies without grafting (LE: 2b) [212]. After the ventral lengthening, a shorter dorsal midline plication is usually added.

According to a retrospective study, dorsal plication remained significantly associated with recurrent ventral curvature independently of the other factors. Ventral corporeal grafting for severe penile curvature gives good long-term results and safety profiles for erectile function [213] (LE: 2b).

#### 3.5.5.5 *Urethral reconstruction*

The mainstay of hypospadias repair is preservation of the well-vascularised urethral plate and its use for urethral reconstruction has become standard practice in hypospadias repair [211]. Mobilisation of the corpus spongiosum/urethral plate and the bulbar urethra decreases the need for urethral plate transection [212] (LE: 2b).

If the urethral plate is wide, it can be tubularised following the Thiersch-Duplay technique. If the plate is too narrow to be simply tubularised, it is recommended relaxing the plate by a midline incision and its subsequent tubularisation according to the Snodgrass-Orkiszewski TIP technique. This technique has become the treatment of choice in distal and mid-penile hypospadias [214-217]. If the incision of the plate is deep, it is recommended to cover the raw surface with inner preputial (or buccal) inlay graft in primary and secondary repairs [218]. This also enables extension of the incision beyond the end of the plate to prevent meatal stenosis [219, 220] (LE: 2a).

For distal forms of hypospadias, a range of other techniques is available (e.g. Mathieu, urethral advancement) [221] (LE: 2b). The TIP technique has become an option for proximal hypospadias as well [214-217, 222]. However, urethral plate elevation and urethral mobilisation should not be combined with TIP repair because it results in focal devascularisation of the neo-urethra with symptomatic stricture development [223] (LE: 2b). The onlay technique using a preputial island flap is a standard repair, preferred in proximal hypospadias, if a plate is unhealthy or too narrow [209]. An onlay preputial graft is an option for single-stage repair [224] (LE: 2b).


If the continuity of the urethral plate cannot be preserved, single or two-stage repairs are used. For the former, a modification of the tubularised flap (Duckett tube), such as a tube-onlay or an inlay-onlay flap, or onlay flap on albuginea are used to prevent urethral stricture [225-227] (LE: 3); alternatively the Koyanagi-Hayashi

technique is used [228-231]. The two-stage procedure has become preferable over the past few years because of lower recurrence of ventral curvature and more favourable results with variable long-term complication rate [220, 225, 232-236].

### 3.5.5.6 Re-do hypospadias repairs

For re-do hypospadias repairs, no definitive guidelines can be given. All the above-mentioned procedures are used in different ways and are often modified according to the individual findings and needs of the patient.

**Figure 3: Algorithm for the management of hypospadias**



DSD = disorders of sex development; GAP = glans approximation procedure; TIP = tubularised incised plate urethroplasty; MAGPI = meatal advancement and glanuloplasty incorporated.

### 3.5.5.7 Penile reconstruction following formation of the neo-urethra

Following formation of the neo-urethra, the procedure is completed by glansplasty and by reconstruction of the penile skin. If there is a shortage of skin covering, the preputial double-face technique or placement of the suture line into the scrotum according to Cecil-Michalowski is used. In countries where circumcision is not routinely performed, preputial reconstruction can be considered. Preputial reconstruction carries a risk of specific complications but does not seem to increase the risk of urethroplasty complications [237]. In TIP repair, the use of a preputial dartos flap reduces the fistula rate [214, 215] (LE: 2b).

### 3.5.5.8 Urine drainage and wound dressing

Urine is drained transurethrally (e.g. dripping stent) or with a suprapubic tube. No drainage after distal hypospadias repair is another option [238, 239]. Circular dressing with slight compression, as well as prophylactic antibiotics during surgery, are established procedures [239] (LE: 4). Post-operative prophylaxis after hypospadias repair is controversial [240, 241] (LE: 2b). There is no consensus on duration of stenting and dressing.



### 3.5.5.9 Outcome

Some studies have tried to determine risk factors for complications after hypospadias repair. An analysis of prospectively collected data found glans size (width < 14 mm), proximal meatal location and re-operation as independent risk factors for urethral complication [239, 242]. Low surgeon volume independently increases the risk of fistula, stricture or diverticulum repair [239, 243] (LE: 3).

A meta-analysis of complication rates of TIP repair found lower complication rate and incidence of re-operations in primary distal repairs (in 4.5%) than in primary proximal repairs (in 12.2%) and in secondary repair (in 23.3%) [214-217, 222, 239]. One should expect a predictable outcome with complication rates below 10% in distal hypospadias (fistula, meatal stenosis, dehiscence, recurrent ventral curvature, and haematoma) [243, 244]. A similar incidence of fistula (3.4-3.6%) can be expected after the Mathieu and TIP repairs of distal hypospadias [222, 245, 246].

The complication rate of TIP and onlay repairs of primary severe hypospadias is similar, 24% and 27%, respectively. It is higher in free graft and in preputial island tube urethroplasty [209]. The complication rate of single-stage Koyanagi and Hayashi modification repairs goes up 61%, according to a comparative study [228, 239]. Staged buccal mucosa graft requires a redo grafting in 13% of patients, after the second stage more than one third of patients have complications, mostly with some degree of graft fibrosis [246, 247]. A recent long-term study on two-stage flap repair showed a complication rate of 68% [239], another study showed a re-operation rate of 28% [220, 239].

### 3.5.6 Follow-up

Long-term follow-up is necessary up to adolescence to detect urethral stricture, voiding dysfunctions and recurrent penile curvature, diverticula, glanular dehiscence [248]. Up to half of complications requiring re-operation present after the first year post-operatively [249] (LE: 2b).

Obstructive flow curve is common after hypospadias repair and while most are not clinically significant, long-term follow-up is required [250-253] (LE: 2a). Urine flow is significantly lower in patients after hypospadias surgery, especially in those who had corrected chordee, but without significant association with lower urinary symptoms [254] (LE: 2a).

Objective scoring systems have been developed in order to evaluate the results of hypospadias surgery (HOSE) [255] (LE: 2b) and cosmetic appearance (HOPE-Hypospadias Objective Penile Evaluation) [256] (LE: 2a). The Pediatric Penile Perception Score (PPPS) is a reliable instrument to assess penile self-perception in children after hypospadias repair and for appraisal of the surgical result by caregivers and uninvolved urologists [257] (LE: 2a). The surgeon should admit that cosmetic results were judged more optimistically by surgeons as compared to caregivers using validated tools [258]. Current scoring systems have deficiencies in terms of patient reported outcomes, the long term outcomes and sexual function [259].

Adolescents and adults, who have undergone hypospadias repair in childhood, have a slightly higher rate of dissatisfaction with penile size, especially proximal hypospadias patients, but their sexual behaviour is not different from that of control groups [260, 261] (LE: 2a-b). Another long-term follow-up of men born with hypospadias revealed, in a controlled study, that these patients are less satisfied with penile cosmetic outcome according to all parameters of the PPPS, there was a difference in penile length (9.7 vs. 11.6 cm) and more patients had lower maximum urinary flow, and more prominent results were found in proximal hypospadias vs. controls [239, 262].

According to a systematic review of long-term patient satisfaction with cosmetic outcomes [263]:

- patient perception of penile size does not differ greatly from the norm;
- patients approaching puberty have a more negative perception and are more critical about the cosmetic outcomes of surgery;
- patients report high levels of perception of deformity and social embarrassment.

The majority of identified instruments focused on postoperative cosmetic satisfaction, with only one instrument considering urinary function, and no instruments evaluating sexual function and psychosocial sequelae [264].

### 3.5.7 Summary of evidence and recommendations for the management of hypospadias

Summary of evidence	LE
The suggested age at surgery for primary hypospadias repair is 6 - 18 (24) months.	3
The therapeutic objectives are to correct the penile curvature, to form a neo-urethra of an adequate size, to bring the new meatus to the tip of the glans, if possible, and to achieve an overall acceptable cosmetic appearance.	4
Androgen stimulation therapy results in increased penile length and glans circumference.	1b
The complication rate is about 10% in distal and 25% in proximal hypospadias one-stage repairs. Higher and variable rates (between 28 and 68%) can occur in two-stage repairs.	3
Sexual functions are usually well preserved but patients report high levels of perception of deformity and social embarrassment.	2b

Recommendations	Strength rating
At birth, differentiate isolated hypospadias from disorders of sex development which are mostly associated with cryptorchidism or micropenis.	Strong
Counsel caregivers on functional indications for surgery, aesthetically feasible operative procedures (psychological, cosmetic indications) and possible complications.	Strong
In children diagnosed with proximal hypospadias and a small appearing penis, reduced glans circumference or reduced urethral plate, pre-operative hormonal androgen stimulation treatment is an option and the body of evidence to accentuate its harms and benefits is inadequate.	Weak
For distal hypospadias, offer Duplay-Thiersch urethroplasty, original and modified tubularised incised plate urethroplasty; use the onlay urethroplasty or two-stage procedures in more severe hypospadias. A treatment algorithm is presented (Figure 3). Correct significant (> 30 degrees) curvature of the penis.	Weak
Ensure long-term follow-up to detect urethral stricture, voiding dysfunctions and recurrent penile curvature, ejaculation disorder, and to evaluate patient's satisfaction.	Strong
Use validated objective scoring systems to assist in evaluating the functional and cosmetic outcome.	Strong

## 3.6 Congenital penile curvature

### 3.6.1 Epidemiology, aetiology and pathophysiology

Congenital penile curvature presents penile bending of a normally formed penis due to corporal disproportion. The incidence at birth is 0.6% and congenital penile curvature is caused by asymmetry of the cavernous bodies and an orthotopic meatus [265] because of developmental arrest during embryogenesis [266]. On the other hand, the incidence of clinically significant congenital penile curvature is much lower, because the extent of the curvature and its associated sexual dysfunction varies widely [267]. Most of the cases are ventral deviations (48%), followed by lateral (24%), dorsal (5%), and a combination of ventral and lateral (23%) [268]. Most ventral curvatures are associated with hypospadias due to chordee or ventral dysplasia of cavernous bodies [269]. Similarly, dorsal curvature is mostly associated with exstrophy/epispadias complex.

Curvature > 30° is considered clinically significant; curvature > 60° may interfere with satisfactory sexual intercourse in adulthood (LE: 4). Minor penile curvature may be the result of ventral penile skin deficiency only and should be distinguished from corporal anomalies. For penile curvature associated with hypospadias or epispadias refer to the relevant chapters.

### 3.6.2 Diagnostic evaluation

Penile curvature is frequently not documented until later in childhood since the penis only appears abnormal when erect. Patients are usually concerned with the aesthetic and/or functional aspects of their penis [270]. Besides exact history taking to exclude any possibility of acquired penile curvature (e.g. post-traumatic) a thorough clinical examination is mandatory. In addition, photo documentation of the erect penis clearly showing the curvature from different angles serves as a pre-requisite in preoperative evaluation [271]. The exact degree of curvature is generally determined at the time of surgery using an artificial erection test.

### 3.6.3 Management

The treatment is surgical, starting with an artificial erection to determine the degree of curvature and to check symmetry after the repair [272]. The ultimate goal of any surgical method used to correct the curvature

is to achieve corpora of similar size. Various procedures are in use ranging from rather simple de-gloving and plication procedures, to corporal rotation, use of free dermal or tunica vaginalis grafts, to complete penile disassembly techniques [273, 274]. Reviews comparing the outcome of Nesbit/modified Nesbit procedures [275] to plication procedures [276] were able to demonstrate that while there is a decreased risk of complications and loss of sensation, it remains unclear whether plication techniques can lead to increased risk of recurrence [277]. Altogether these methods include the risk of post-operative shortening of the penis with an average loss of 2.5 cm in stretched penile length depending on the pre-operative degree of curvature and the type of repair used [278, 279].

Recently the non-corporotomy technique has been introduced with promising results enabling correction of any degree of ventral curvature with neither shortening of the penis nor the risk of post-operative erectile dysfunction [280].

### 3.6.4 **Summary of evidence and recommendations for the management of congenital penile curvature**

Summary of evidence	LE
Isolated congenital penile curvature is relatively uncommon.	2a
Congenital penile curvature is often associated with hypospadias.	2a
Diagnosis is usually made late in childhood.	2a
The penis only appears abnormal when erect.	1b
Congenital penile curvature can cause aesthetic as well as functional sexual problems.	1b
Congenital penile curvature is treated with surgery.	1b
The goal of surgery is to achieve corpora of similar size.	1b

Recommendations	LE	Strength rating
Ensure that a thorough medical history is taken and a full clinical examination done to rule out associated anomalies in boys presenting with congenital curvature.	1a	Strong
Provide photo documentation of the erect penis from different angles as a prerequisite in the pre-operative evaluation.	1b	Strong
Perform surgery after weighing aesthetic as well as functional implications of the curvature.	2b	Weak
At the beginning as well as at the end of surgery, perform artificial erection tests.	2a	Strong

## 3.7 **Varicocele in children and adolescents**

### 3.7.1 **Epidemiology, aetiology and pathophysiology**

Varicocele is defined as an abnormal dilatation of testicular veins in the pampiniformis plexus caused by venous reflux. It is unusual in boys under ten years of age and becomes more frequent at the beginning of puberty. It is found in 14-20% of adolescents, with a similar incidence during adulthood. It appears mostly on the left side (78-93% of cases). Right-sided varicoceles are less common; they are usually noted only when bilateral varicoceles are present and seldom occur as an isolated finding [281-283].

Varicocele develops during accelerated body growth and increased blood flow to the testes, by a mechanism that is not clearly understood. Genetic factors may be present. An anatomic abnormality leading to impaired venous drainage is expressed by the considerable prevalence of the left side condition where the internal spermatic vein drains into the renal vein. Varicocele can induce apoptotic pathways because of heat stress, androgen deprivation and accumulation of toxic materials. Severe damage is found in 20% of adolescents affected, with abnormal findings in 46% of affected adolescents. Histological findings are similar in children or adolescents and in infertile men. In 70% of patients with grade II and III varicocele, left testicular volume loss was found.

Several authors reported on reversal of testicular growth after varicolectomy in adolescents [284, 285]. An average proportion of catch-up growth of 76.4% (range: 52.6-93.8%) has been found according to a meta-analysis [286] (LE: 2a). However, this may partly be attributable to testicular oedema associated with the division of lymphatic vessels [287] (LE: 2).

In about 20% of adolescents with varicocele, fertility problems will arise [288]. The adverse influence of varicocele increases with time. Improvement in sperm parameters has been demonstrated after adolescent varicolectomy [289-292] (LE: 1).

### 3.7.2 **Classification systems**

Varicocele is classified into 3 grades [293]:

- Grade I - Valsalva positive (palpable at Valsalva manoeuvre only);
- Grade II - palpable (palpable without the Valsalva manoeuvre);
- Grade III - visible (visible at distance).

### 3.7.3 **Diagnostic evaluation**

Varicocele is mostly asymptomatic, rarely causing pain. It may be noticed by the patient or caregivers, or discovered by the paediatrician at a routine visit. The diagnosis depends upon the clinical finding of a collection of dilated and tortuous veins in the upright posture; the veins are more pronounced when the patient performs the Valsalva manoeuvre. The size of both testicles should be evaluated during palpation to detect a smaller testis.

Venous reflux into the plexus pampiniformis is diagnosed using Doppler US colour flow mapping in the supine and upright position [294]. Venous reflux detected on US only is classified as subclinical varicocele. To discriminate testicular hypoplasia, the testicular volume is measured by US examination or by orchidometer. In adolescents, a testis that is smaller by > 2 mL or 20% compared to the other testis is considered to be hypoplastic [295] (LE: 2).

Extension of Wilms tumour into the renal vein and inferior vena cava can cause a secondary varicocele. A renal US should be routinely added in pre-pubertal boys and in isolated right varicocele (LE: 4).

In order to assess testicular injury in adolescents with varicocele, supranormal FSH and LH responses to the luteinising hormone-releasing hormone (LHRH) stimulation test are considered reliable, because histopathological testicular changes have been found in these patients [291, 296].

### 3.7.4 **Management**

There is no evidence that treatment of varicocele at paediatric age will offer a better andrological outcome than an operation performed later. Beneficial effect of pubertal screening and treatment for varicocele regarding chance of paternity has been questioned according to a corresponding questionnaire in adult patients [297] (LE: 4). The recommended indication criteria for varicocelectomy in children and adolescents are [282]:

- varicocele associated with a small testis;
- additional testicular condition affecting fertility;
- bilateral palpable varicocele;
- pathological sperm quality (in older adolescents);
- symptomatic varicocele [297].

Testicular (left + right) volume loss in comparison with normal testes is a promising indication criterion, once the normal values are available [298]. Repair of a large varicocele, causing physical or psychological discomfort, may also be considered. Other varicoceles should be followed-up until a reliable sperm analysis can be performed (LE: 4).

Surgical intervention is based on ligation or occlusion of the internal spermatic veins. Ligation is performed at different levels:

- inguinal (or subinguinal) microsurgical ligation;
- suprainguinal ligation, using open or laparoscopic techniques [299-302].

The advantage of the former is the lower invasiveness of the procedure, while the advantage of the latter is a considerably lower number of veins to be ligated and safety of the incidental division of the internal spermatic at the suprainguinal level.

For surgical ligation, some form of optical magnification (microscopic or laparoscopic) should be used because the internal spermatic artery is 0.5 mm in diameter at the level of the internal ring [299, 301]. The recurrence rate is usually < 10%.

Lymphatic-sparing varicocelectomy is preferred to prevent hydrocele formation and testicular hypertrophy development and to achieve a better testicular function according to the LHRH stimulation test [287, 299, 300, 303] (LE: 2). The methods of choice are subinguinal or inguinal microsurgical (microscopic) repairs, or suprainguinal open or laparoscopic lymphatic-sparing repairs [299, 301, 304, 305]. Intrascrotal application of isosulphan blue was recommended to visualise the lymphatic vessels [306, 307]. In suprainguinal approach, an artery sparing varicocelectomy may not offer any advantage in regards to catch-up growth and is associated with a higher incidence of recurrent varicocele [308, 309].

Angiographic occlusion of the internal spermatic veins also meets the requirements of lymphatic sparing repair. It is based on retrograde or antegrade sclerotisation of the internal spermatic veins [310, 311]. However, although this method is less invasive and may not require general anaesthesia, it is associated with radiation burden, which is less controllable in the antegrade technique [282, 310, 311] (LE: 2).

There is low to moderate level of evidence that radiological or surgical treatment of adolescent varicocele is associated with improved testicular size/growth and sperm concentration - based on current available RCTs. The ultimate effects on fertility and paternity rates are not known [312].

Microsurgical varicocele repair in adolescents with varicocele significantly increases paternity rates and decreases time to conception post-operatively. Patients with varicocele who underwent microsurgical varicocele repair had increased sperm parameters and 3.63 times greater odds of paternity than controls who did not undergo varicocele surgery [313].

The Panel recently conducted a systematic review (SR) and meta-analysis regarding the treatment of varicocele in children and adolescents [314]. Of 1,550 articles identified, 98 articles including 16,130 patients were eligible for inclusion (12 RCTs, 47 NRSs and 39 case series). The key findings are summarised in the following paragraphs:

The meta-analysis of the 12 RCTs revealed that varicocele treatment improved testicular volume (mean difference 1.52 ml, 95% CI 0.73-2.31) and increased total sperm concentration (mean difference 25.54, 95% CI 12.84-38.25) when compared with observation. Lymphatic sparing surgery significantly decreased hydrocele rates ( $p=0.02$ ) and the OR was 0.08 (95% CI 0.01, 0.67). Due to the lack of RCTs, it was not possible to identify a surgical technique to being superior to the others. It remains unclear whether open surgery or laparoscopy is more successful for varicocele treatment (OR ranged from 0,13 to 2,84).

The success rates of the treatment (disappearance of varicocele) were between 85.1% and 100% whereas the complication rates were between 0% and 29% in the included studies. The most common complication reported was hydrocele. Resolution of pain after treatment was more than 90% in the reported series.

In conclusion, moderate evidence exists on the benefits of varicocele treatment in children and adolescents in terms of testicular volume and sperm concentration. Current evidence does not demonstrate superiority of any of the surgical/interventional techniques regarding treatment success. Lymphatic sparing surgery significantly decrease hydrocele formation. Long-term outcomes, including paternity and fertility, still remain unknown.

### 3.7.5 **Summary of evidence and recommendations for the management of varicocele**

<b>Summary of evidence</b>	<b>LE</b>
Varicocele becomes more frequent at the beginning of puberty and is found in 14-20% of adolescents. Fertility problems are expected in up to 20% of adolescents with a varicocele.	
Pubertal patients with a left grade II and III varicocele have the left testis smaller in up to 70% of cases; in late adolescence the contralateral right testis also becomes smaller.	1b
After adolescent varicocelectomy, left testis catch-up growth and improvement in sperm parameters has been demonstrated.	1a
There is no evidence that treatment of varicocele at paediatric age will offer a better andrological outcome than an operation performed later.	1b
Division of testicular lymphatics leads to hydrocele in up to 40% and to testicular hypertrophy.	1b
Lymphatic sparing surgery significantly decrease hydrocele rates	1a

Recommendations	LE	Strength rating
Examine varicocele in the standing position and classify into three grades.	4	Strong
Use scrotal ultrasound to detect venous reflux without Valsalva manoeuvre in the supine and upright position and to discriminate testicular hypoplasia.		Strong
In all pre-pubertal boys with a varicocele and in all isolated right varicoceles perform standard renal ultrasound to exclude a retroperitoneal mass.		Strong
Inform caregivers and patients and offer surgery for: <ul style="list-style-type: none"> <li>• varicocele associated with a persistent small testis (size difference of &gt; 2 mL or 20%);</li> <li>• varicocele associated with additional testicular condition affecting fertility (cryptorchidism, history of torsion, trauma);</li> <li>• varicocele associated with pathological sperm quality (in older adolescents);</li> <li>• symptomatic varicocele.</li> </ul>	2	Weak
Use some form of optical magnification (microscopic or laparoscopic magnification) for surgical ligation.	2	Strong
Use lymphatic-sparing varicolectomy to prevent hydrocele formation and testicular hypertrophy.	1	Strong

### 3.8 Urinary tract infections in children

#### 3.8.1 **Epidemiology, aetiology and pathophysiology**

Urinary tract infections (UTIs) represent the most common bacterial infection in children [315-317]. In neonates, the symptoms differ in many aspects from those in infants and children. The prevalence is higher; there is a male predominance; infections not caused by *Escherichia coli* are more frequent; and there is a higher risk of urosepsis [318, 319].

The incidence varies depending on age and sex. One meta-analysis showed that in the first three months of life UTIs were present in 7.5% of girls, 2.4% (CI: 1.4-3.5) of circumcised boys, and 20.1% (CI: 16.8-23.4) of uncircumcised boys, who presented with fever [318]. In the first year of life, UTIs are more common in boys (3.7%) than girls (2%). Later, the incidence of UTIs changes to ~3% in pre-pubertal girls and 1% in prepubertal boys [318-320].

*E. coli* is found in ~75% of UTIs and is more frequent in community-acquired than nosocomial infections. In the latter, *Klebsiella pneumoniae*, *Enterobacter spp.*, *Enterococcus spp.*, *Pseudomonas spp.* and *Candida spp.* are more frequent than in community-acquired UTIs. Neonatal UTI is frequently complicated by bacteraemia. In a retrospective study, 12.4% of blood cultures from neonates admitted for UTI were positive for bacteraemia [321], however, it is less frequent in community-acquired than in nosocomial UTI [321, 322].

#### 3.8.2 **Classification systems**

There are five widely used classification systems according to; the site, episode, severity, symptoms and complicating factors. For acute treatment, site and severity are most important.

##### 3.8.2.1 *Classification according to site*

Lower urinary tract (cystitis) is an inflammatory condition of the urinary bladder mucosa with general signs and symptoms including infection, dysuria, frequency, urgency, malodorous urine, enuresis, haematuria, and suprapubic pain.

Upper urinary tract (pyelonephritis) is a diffuse pyogenic infection of the renal pelvis and parenchyma. The onset of pyelonephritis is generally abrupt. Clinical signs and symptoms include fever (> 38°C), chills, costovertebral angle or flank pain, and tenderness. Older children may report cystitis symptoms along with fever/flank pain. Infants and children may have non-specific signs such as poor appetite, failure to thrive, lethargy, irritability, vomiting or diarrhoea.

##### 3.8.2.2 *Classification according to episode*

The first UTI may be a sign of anatomical anomalies that may predispose to complications of UTI and potential renal damage [323]. Anatomical evaluation is recommended (see below). Recurrent infection can be divided into unresolved and persistent infection.

In unresolved infection, initial therapy is inadequate for elimination of bacterial growth in the urinary tract (inadequate therapy, inadequate antimicrobial urinary concentration (poor renal concentration/gastrointestinal malabsorption), and infection involving multiple organisms with differing antimicrobial susceptibilities).

Persistent infection is caused by re-emergence of bacteria from a site within the urinary tract coming from a nidus for persistent infection that cannot be eradicated (e.g. infected stones, non-functioning or poorly functioning kidneys/renal segments, ureteral stumps after nephrectomy, necrotic papillae, urachal cyst, urethral diverticulum, peri-urethral gland, vesicointestinal, rectourethral or vesicovaginal fistulas). The

same pathogen is identified in recurrent infections, but episodes of sterile urine may occur during and shortly following antimicrobial treatment.

In re-infection, each episode can be caused by a variety of new infecting organisms, in contrast to bacterial persistence in which the same infecting organism is always isolated. However, the most common general pathogenic species is *E. coli*, which occurs in many different serotypes. Therefore, recurrent *E. coli* UTI does not equate to infection with the same organism.

#### 3.8.2.3 *Classification according to severity*

In simple UTI, children may have only mild pyrexia; are able to take fluids and oral medication; are only slightly or not dehydrated; and have a good expected level of compliance. When a low level of compliance is expected, such children should be managed as those with severe UTI. In severe UTI, infection is related to the presence of fever of > 39°C, the feeling of being ill, persistent vomiting, and moderate or severe dehydration.

#### 3.8.2.4 *Classification according to symptoms*

Asymptomatic bacteriuria indicates attenuation of uropathogenic bacteria by the host, or colonisation of the bladder by non-virulent bacteria that are incapable of activating a symptomatic response (no leukocyturia, no symptoms). Asymptomatic UTI includes leukocyturia but no other symptoms.

Symptomatic UTI, includes irritative voiding symptoms, suprapubic pain (cystitis), fever and malaise (pyelonephritis). Cystitis may represent early recognition of an infection destined to become pyelonephritis, or bacterial growth controlled by a balance of virulence and host response.

#### 3.8.2.5 *Classification according to complicating factors*

In uncomplicated UTI, infection occurs in a patient with a morphologically and functionally normal upper and lower urinary tract, normal renal function and competent immune system. This category includes mostly isolated or recurrent bacterial cystitis and is usually associated with a narrow spectrum of infecting pathogens that are easily eradicated by a short course of oral antimicrobial agents. Patients can be managed on an outpatient basis, with an emphasis on documenting resolution of bacteriuria, followed by elective evaluation for potential anatomical or functional abnormalities of the urinary tract [324].

All neonates, most patients with clinical evidence of pyelonephritis, and all children with known mechanical or functional obstructions of the urinary tract, are considered to have complicated UTI. Mechanical obstruction is commonly due to the presence of posterior urethral valves, strictures or stones, independent of their location. Functional obstruction often results from lower urinary tract dysfunction (LUTD) of either neurogenic or non-neurogenic origin and dilating vesicoureteral reflux (VUR). Patients with complicated UTI require hospitalisation and parenteral antibiotics. Prompt anatomical evaluation of the urinary tract is critical to exclude the presence of significant abnormalities [325]. If mechanical or functional abnormalities are present, adequate drainage of the infected urinary tract is necessary.

### 3.8.3 **Diagnostic evaluation**

#### 3.8.3.1 *Medical history*

Medical history includes the question of a primary (first) or secondary (recurring) infection; possible malformations of the urinary tract (e.g. pre- or post-natal US screening); prior operation; family history; and whether there is constipation or presence of lower urinary tract symptoms (LUTS).

#### 3.8.3.2 *Clinical signs and symptoms*

Neonates with pyelonephritis or urosepsis can present with non-specific symptoms (failure to thrive, jaundice, hyperexcitability and without fever). Urinary tract infection is the cause of fever in 4.1-7.5% of children who present to a paediatric clinic [326, 327]. Septic shock is unusual, even with very high fever. Signs of a UTI may be vague and unspecific in small children, but later on, when they are more than two years old, frequent voiding, dysuria and suprapubic, abdominal or lumbar pain can be detected.

#### 3.8.3.3 *Physical examination*

Physical examination includes a general examination of the throat, lymph nodes, abdomen (constipation, palpable and painful kidney, or palpable bladder), flank, the back (stigmata of spina bifida or sacral agenesis), genitalia (phimosis, labial adhesion, vulvitis, epididymo-orchitis), and temperature.

#### 3.8.3.4 *Urine sampling, analysis and culture*

Urine sampling has to be performed before any antimicrobial agent is administered. The technique for obtaining urine for urinalysis as well as culture affects the rate of contamination, which influences interpretation of the results. Especially in early infancy, it can be challenging and depends on the mode of urine sampling [328].

#### 3.8.3.4.1 Urine sampling

Urine must be collected under defined conditions and investigated as soon as possible to confirm or exclude UTI, especially in children with fever. In neonates, infants and non-toilet-trained children, there are four main methods with varying contamination rates and invasiveness to obtain urine:

(1) Plastic bag attached to the cleaned genitalia: This technique is most often used in daily practice. It is helpful when the culture results are negative. Also, if the dipstick is negative for both leukocyte esterase and nitrite, or microscopic analysis is negative for both pyuria and bacteriuria, UTI can be excluded without the need for confirmatory culture [329]. However, if the genitalia are not cleaned and culture is delayed, a high incidence of false-positive results (85-99%) can be found [330, 331].

(2) Clean-catch urine collection: The infant is placed in the lap of a caregiver or member of the nursing staff, who holds a sterile foil bowl underneath the infant's genitalia. The infant is offered oral fluids and urine collection is awaited [332]. This is time consuming and requires proper instruction of the caregivers. There seems to be a good correlation between the results of urine culture obtained by this method and suprapubic aspiration (SPA), with a false-positive rate of 5% and false-negative rate of 12% [332, 333]; however, the contamination rate is higher compared to SPA [334].

(3) Bladder catheterisation: In female infants and also in neonates, this technique may be an alternative to suprapubic bladder aspiration (SPA), at a higher contamination rate [335]. In a prospective study using bladder catheterisation in febrile children aged < 36 months, contamination was defined by multiple pathogens, non-pathogens, or colony counts < 10,000 cfu/mL. True UTI was found in 10% of children and 14% of the cultures were contaminated. Univariate analysis of potential predictors identified age less than six months, difficult catheterisation, and uncircumcised boys. In children less than six months and uncircumcised boys a new, sterile catheter with each repeated attempt at catheterisation may lead to less contamination [336], otherwise SPA should be the method of choice.

(4) Suprapubic bladder aspiration: This is the most sensitive method to obtain an uncontaminated urine sample in this age group [337, 338]. Using US to assess bladder filling, simplifies SPA and improves the diagnostic yield of obtaining a urine specimen from 60% to 97% [337, 338]. Complications are rare and have been reported in only 0.22% of cases, ranging from transient haematuria to bowel perforation [339]. However, bladder puncture causes more pain than catheterisation in infants less than two months old [340].

In older, toilet-trained children who can void on command, after carefully retracting the foreskin and cleaning the glans penis in boys and spreading the labia and cleaning the peri-urethral area in girls, the use of clean catch, especially midstream urine, could be an acceptable technique for obtaining urine. After cleaning the urethral meatus and perineum with gauze and liquid soap twice, the risk of contamination was reduced from 23.9% (41/171) to 7.8% (14/171) in a randomised trial [341].

If the clinical situation necessitates, and for differential diagnosis of sepsis, it is most appropriate to obtain an adequate urine sample by catheterisation or SPA [333]. In infants, a bag can only be used if the dipstick is negative, otherwise the urine should be obtained through catheterisation or SPA. This is also recommended in children, who are severely ill and a UTI needs to be excluded or confirmed. Blood sampling is dependent on the clinical situation.

#### 3.8.3.4.2 Urinalysis

There are three methods that are commonly used for urinalysis:

(1) Dipsticks: These are appealing because they provide rapid results, do not require microscopy, and are ready to use. Leukocyte esterase (as a surrogate marker for pyuria) and nitrite (which is converted from dietary nitrates by most Gram-negative enteric bacteria in the urine) are the most frequent markers, and are usually combined in a dipstick test. The conversion of dietary nitrates to nitrites by bacteria takes approximately four hours in the bladder [333, 342]. However, nitrite is not a very sensitive marker for infants, who empty their bladder frequently, and not all urinary pathogens reduce nitrate to nitrite. The test is helpful when the result is positive, because it is highly specific (i.e. there are few false-positive results) [333, 343].



**Table 1: Sensitivity and specificity of component of urinalysis, alone and in combination [333]\***

Test	Sensitivity (Range), %	Specificity (Range), %
Leukocyte esterase test	83 (67-94)	78 (64-92)
Nitrite test	53 (15-82)	98 (90-100)
Leukocyte esterase or nitrite test positive	93 (90-100)	72 (58-91)
Microscopy, white blood cells	73 (32-100)	81 (45-98)
Microscopy, bacteria	81 (16-99)	83 (11-100)
Leucocyte esterase test, nitrite test or microscopy positive	99.8 (99-100)	70 (60-92)

\*Reproduced with permission from Pediatrics 2011 Sep;128(3):595-610, Copyright© 2011 by the AAP [333].

(2) Microscopy: This is the standard method of assessing pyuria after centrifugation of the urine with a threshold of five white blood cells (WBCs) per high-power field (25 WBC/ $\mu$ L) [339]. In uncentrifuged urine,  $> 10$  WBC/ $\mu$ L has been demonstrated to be sensitive for UTI [344] and this could perform well in clinical situations [345]. However, this is rarely done in an outpatient setting.

(3) Flow imaging analysis technology: This is being used increasingly to classify particles in uncentrifuged urine specimens [346]. The numbers of WBCs, squamous epithelial cells and red cells correlate well with those found by manual methods [333].

#### 3.8.3.4.3 Urine culture

After negative results for dipstick, microscopic or automated urinalysis, urine culture is generally not necessary, especially if there is an alternative source of fever. If the dipstick result is positive, confirmation by urine culture is strongly recommended.

It is unclear what represents a significant UTI. In severe UTI,  $> 10^5$  cfu/mL can be expected. However, the count can vary and be related to the method of specimen collection, diuresis, and time and temperature of storage until cultivation occurs [319]. The classical definition of  $> 10^5$  cfu/mL of voided urine is still used to define a significant UTI [347, 348]. The American Academy of Pediatric Guidelines on Urinary Tract Infection suggest that the diagnosis should be based on the basis of the presence of both pyuria and at least  $10^5$  cfu/mL. However, some studies have shown that, in voided specimens,  $< 10^4$  organisms may indicate a significant UTI [349, 350]. If urine is obtained by catheterisation,  $10^3 - 10^5$  cfu/mL is considered to be positive, and any counts obtained after SPA should be considered as significant. Mixed cultures are indicative of contamination.

**Table 2: Criteria for UTI in children (adapted from the EAU Guidelines on Urological Infections [351])**

Urine specimen from suprapubic bladder puncture	Urine specimen from bladder catheterisation	Urine specimen from midstream void
Any number of cfu/mL (at least 10 identical colonies)	$> 10^3 - 10^5$ cfu/mL	$> 10^4$ cfu/mL with symptoms $> 10^5$ cfu/mL without symptoms

Pyuria without bacteriuria (sterile pyuria) may be due to incomplete antibiotic treatment, urolithiasis, or foreign bodies in the urinary tract, and infections caused by *Mycobacterium tuberculosis* or *Chlamydia trachomatis*.

#### 3.8.3.5 Imaging

##### 3.8.3.5.1 Ultrasound

Renal and bladder US within 24 hours is advised in infants with febrile UTI to exclude obstruction of the upper and lower urinary tract. Abnormal results are found in 15% of cases, and 1-2% have abnormalities that require prompt action (e.g. additional evaluation, referral, or surgery) [329]. In other studies, renal US revealed abnormalities in up to 37% of cases, whereas voiding cystourethrography (VCUG) showed VUR in 27% of cases [318]. Dilating VUR is missed by US in around one third of cases [352]. Post-void residual (PVR) urine should be measured in toilet-trained children to exclude voiding abnormalities as a cause of UTI. Elevated post-void residual urine volume predicts recurrence of UTIs in toilet-trained children [353].

##### 3.8.3.5.2 Radionuclide scanning

Changes in dimercaptosuccinic acid (DMSA) clearance during acute UTI indicate pyelonephritis or parenchymal damage, correlated well with the presence of dilating reflux and the risk of further pyelonephritis

episodes, breakthrough infections [354] and future renal scarring. In the acute phase of a febrile UTI (up to four to six weeks), DMSA-scan can demonstrate pyelonephritis by perfusion defects. Renal scars can be detected after three to six months [355]. These findings are different in neonates. After the first symptomatic, community-acquired UTI, the majority of renal units with VUR grade III or higher had normal early DMSA scanning [356]. The average effective radiation dose of a single DMSA scan was 2.84 (1-12) mSv in one study [357]. See also Chapter 3.13 on VUR.

#### 3.8.3.5.3 Voiding cystourethrography

The gold standard to exclude or confirm VUR is VCUG. Due to the risk of renal scarring, VCUG is recommended after the first episode of febrile UTI in boys and girls depending on sex, age and clinical presentation (see Figure 4 and Table 4) (see also Chapter 3.13). The timing of VCUG does not influence the presence or severity of VUR [358, 359]. Performance of early VCUG in patients with proven sterile urine does not cause any significant morbidity [360]. Another option is doing DMSA first, followed by VCUG if there is renal cortical uptake deficiency after UTI (see Chapter 3.13).

#### 3.8.3.6 Bladder and bowel dysfunction

Bladder and bowel dysfunction (BBD) are risk factors for which each child with UTI should be screened upon presentation. Normalisation of micturition disorders or bladder over-activity is important to lower the rate of UTI recurrence. If there are signs of BBD at infection-free intervals, further diagnosis and effective treatment are strongly recommended [361-364]. Treatment of constipation leads to a decrease in UTI recurrence [365-367]. Therefore, exclusion of BBD is strongly recommended in any child with febrile and/or recurrent UTI, and it should be treated if there is evidence of BBD.

### 3.8.4 Management

#### 3.8.4.1 Administration route

The choice between oral and parenteral therapy should be based on patient age; clinical suspicion of urosepsis; illness severity; refusal of fluids, food and/or oral medication; vomiting; diarrhoea; non-compliance; and complicated pyelonephritis (e.g. urinary obstruction). As a result of the increased incidence of urosepsis and severe pyelonephritis in newborns and infants aged less than two months, parenteral antibiotic therapy is recommended. Electrolyte disorders with life-threatening hyponatraemia and hyperkalaemia based on pseudohypoaldosteronism can occur in these cases [368, 369].

Parental combination treatment with ampicillin and an aminoglycoside (e.g. tobramycin or gentamicin) or, respectively, a third-generation cephalosporin achieves excellent therapeutic results (high efficacy of aminoglycosides, respectively cephalosporins against common uropathogens; enterococcus gap is closed with ampicillin). Compared to the division in two doses, a daily single dose of aminoglycosides is safe and effective [325, 370, 371].

The choice of agent is also based on local antimicrobial sensitivity patterns, and should later be adjusted according to sensitivity-testing of the isolated uropathogen [333]. Not all available antibiotics are approved by the national health authorities, especially in infancy. In uncomplicated nephritis, both oral and parenteral treatment can be considered, because both are equally effective in children without urinary tract abnormalities. Some studies have demonstrated that once daily parenteral administration of gentamicin or ceftriaxone in a day treatment centre is safe, effective and cost-effective in children with UTI [370, 372, 373]. Delaying treatment in children with a febrile UTI for more than 48-72 hours increase the risk of renal scars [374, 375].

#### 3.8.4.2 Duration of therapy

Prompt adequate treatment of UTI can prevent the spread of infection and renal scarring. Outcomes of short courses (one to three days) are inferior to those of seven to fourteen-day courses [333]. In newborns and young infants with a febrile UTI, up to 20% may have a positive blood culture [321, 325]. In late infancy, there are no differences between strategies regarding the incidence of parenchymal scars, as diagnosed with DMSA scan [376]. Some recent studies using exclusively oral therapy with a third-generation cephalosporin (e.g. cefixime or ceftibuten) have demonstrated that this is equivalent to the usual two to four days intravenous therapy followed by oral treatment [371, 377-379]. Similar data have been shown for amoxicillin-clavulanate [380]. If ambulatory therapy is chosen, adequate surveillance, medical supervision and, if necessary, adjustment of therapy must be guaranteed. In the initial phase of therapy, a close ambulant contact to the family is advised [381].


In complicated UTI, uropathogens other than *E. coli*, such as *Proteus mirabilis*, *Klebsiella spp.*, *Pseudomonas aeruginosa*, *enterococci* and *staphylococci* are more often the causative pathogens [325].

Parenteral treatment with broad-spectrum antibiotics is preferred. A temporary urinary diversion (suprapubiccystostomy or percutaneous nephrostomy) might be required in case of failure of conservative treatment in obstructive uropathy. Acute focal bacterial nephritis (lobar nephronia) is a localised bacterial

infection of the kidney that presents as an inflammatory mass without abscess formation. This may represent a relatively early stage of renal abscess. For the majority of children, the pathogenesis is related to ascending infection due to pre-existing uropathy, especially vesicoureteral reflux or urinary obstruction (mega-ureter).

Prolonged intravenous antibiotic treatment is sufficient in most cases [382], and intravenous and oral therapy tailored to the pathogen identified in culture is recommended [383].

**Figure 4: Algorithm for disease management of first febrile UTI**



*BBD = Bladder Bowel Dysfunction; DMSA = technetium<sup>99</sup>-labelled dimercaptosuccinic acid; MRI = magnetic resonance imaging; UTI = urinary tract infection; VCUG = voiding cystourethrography; VUR = vesicoureteral reflux.*

### 3.8.4.3 Antimicrobial agents

There is a great difference in the prevalence of antibiotic resistance of uropathogenic *E. coli* in different countries, with an alarmingly high resistance in Iran and Vietnam [384]. There are upcoming reports of UTIs caused by extended spectrum  $\beta$ -lactamase-producing *enterobacteriaceae* (ESBL) in children. In one study from Turkey, 49% of the children less than one year of age and 38% of those more than one year of age had ESBL-producing bacteria that were resistant to trimethoprim/sulfamethoxazole in 83%, to nitrofurantoin in 18%, to quinolones in 47%, and to aminoglycosides in 40% [385]. Fortunately, the outcome appears to be the same as for children with non-ESBL-producing bacteria, despite the fact that initial intravenous empirical antibiotic therapy was inappropriate in one study [386].

**Table 3: Frequently used antibacterial substances for the therapy of urinary tract infections in infants and children\***

Chemotherapeutics	Daily dosage	Application	Comments
<b>Parenteral cephalosporins</b>			
Group 3a, e.g. cefotaxime	100-200 mg/kg (Adolesc.: 3-6 g)	i.v. in 2-3 D	
Group 3b, e.g. ceftazidime	100-150 mg/kg (Adolesc.: 2-6 g)	i.v. in 2-3 D	
Ceftriaxone	75 mg/kg	i.v. in 1 D	
<b>Oral cephalosporins</b>			
Group 3, e.g. ceftibuten	9 mg/kg (Adolesc.: 0.4 g)	p.o. in 1-2 D	
Group 3, e.g. cefixime	8-12 mg/kg (Adolesc.: 0.4 g)	p.o. in 1-2 D	
Group 2, e.g. cefpodoxime proxetil	8-10 mg/kg (Adolesc.: 0.4 g)	p.o. in 2 D	
Group 2, e.g. cefuroximaxetil	20-30 mg/kg (Adolesc.: 0.5-1 g)	p.o. in 3 D	
Group 1, e.g. cefaclor	50 -100 mg/kg (Adolesc.: 1.5-4 g)	p.o. in 2-3 D	
Trimethoprim or Trimethoprim/sulfamethoxazole	5-6 mg/kg 5-6 mg/kg (TMP-Anteil) (Adolesc.: 320 mg)	p.o. in 2 D p.o. in 2 D	
Ampicillin	100-200 mg/kg (Adolesc.: 3-6 g)	i.v. in 3 D	Ampicillin and Amoxicillin are not eligible for calculated therapy
Amoxicillin	50-100 mg/kg (Adolesc.: 1.5-6 g)	i.v. in 3-4 D p.o. in 2-3 D <sup>1</sup>	
Amoxicillin/clavulanic acid (parenteral)	60-100 mg/kg (Adolesc.: 3.6-6.6 g)	p.o. in 2-3 D i.v. in 3 D	
Amoxicillin/clavulanic acid (oral)	45-60 mg/kg (Amoxicillinfraction) (Adolesc.: 1500 + 375 mg)	i.v. in 3 D p.o. in 3 D	
Piperacillin	300 mg/kg	p.o.in 3 D i.v. in 3-4 D	
Tobramycin	5 mg/kg (Adolesc.: 3-5 mg/ kg, max. 0.4 g)	i.v. in 1 D	
Gentamicin	5 mg/kg (Adolesc.: 3-5 mg/ kg, max. 0.4g)	i.v. in 1 D	
Ciprofloxacin	Children and adolesc. (1-17 years of age): 20-30 mg/kg (max. D: 400 mg) (parenterally)	i.v. in 3 D	Approved in most European countries as second- or third line medication for complicated UTIs, "reserve-antibiotic"!
	Children and adolesc. (1-17 years of age): 20-40 mg/kg (max. D 750 mg) (orally)	p.o. in 2 D	
Nitrofurantoin	3-5 mg	p.o. in 2 D	Contraindicated in the case of renal insufficiency

\* Reproduced with permission from the International Consultation on Urological Diseases (ICUD), International Consultation on Urogenital Infections, 2009. Copyright © by the European Association of Urology [387].

Dosage for adolescents in paracentesis, if differing. 1 Infants 2 D, children 1-12 ys. 3 D.

i.v. = intravenous; p.o. = by mouth.

**Table 4: Recommendations for calculated antibacterial therapy of pyelonephritis dependent on age and severity of the infection\***

Diagnosis	Proposal	Application	Duration of therapy	LE
Pyelonephritis during the first 0-6 months of life	Ceftazidime + Ampicillin <sup>1</sup> or Aminoglycoside + Ampicillin <sup>1</sup>	3-7 D parenterally, for at least 2 D after defervescence, then oral therapy <sup>2</sup> In newborns: parenteral therapy for 7-14 D, then oral therapy <sup>2</sup>	10 (-14) D Newborns 14-21 D	4
Uncomplicated pyelonephritis after 6 months of age	Cephalosporin group 3 <sup>2</sup>	Orally (initially parenterally, if necessary)	(7-)10 D	1
Complicated pyelonephritis/urosepsis (all ages)	Ceftazidime + Ampicillin <sup>1</sup> or Aminoglycoside + Ampicillin <sup>1</sup>	7 D parenterally, then oral therapy <sup>2</sup>	10-14 D	4

\* Reproduced with permission from the International Consultation on Urological Diseases (ICUD), International Consultation on Urogenital Infections, 2009. Copyright© by the European Association of Urology [387].

<sup>1</sup> after receipt of microbiological findings (pathogen, resistance) adaptation of therapy.

<sup>2</sup> i.v.: e.g. cefotaxime; orally: e.g. cefpodoxime proxetil, ceftibuten, cefixime.

**Table 5: Frequently used antibacterial agents used for the treatment of cystitis and cystourethritis (Dosages for children up to twelve years of age)\***

Chemotherapeutics	Daily dosage	Application
Oral cephalosporins		
Group 1, e.g. cefaclor	50 (-100) mg/kgbw	p.o. in 2-3 D
Group 1, e.g. cefalexin	50 mg/kgbw	p.o. in 3-4 D
Group 2, e.g. cefuroximaxetil	20-30 mg/kgbw	p.o. in 2 D
Group 2, e.g. cefpodoxime proxetil	8-10 mg/kgbw	p.o. in 2 D
Group 3, e.g. ceftibuten	9 mg/kgbw	p.o. in 1 D
Trimethoprim	5-6 mg/kgbw	p.o. in 2 D
Trimethoprim/sulfamethoxazole	5-6 mg/kgbw (TMP-fraction)	p.o. in 3 D
Amoxicillin/clavulanic acid	37.5-75 mg/kgbw (Amoxicillin-fraction)	p.o. in 3 D
Nitrofurantoin	3-5 mg/kgbw	p.o. in 2 D

\* Reproduced with permission from the International Consultation on Urological Diseases (ICUD), International Consultation on Urogenital Infections, 2009. Copyright© by the European Association of Urology [387].

#### 3.8.4.3 Chemoprophylaxis

Long-term antibacterial prophylaxis should be considered in cases of high susceptibility to UTI and risk of acquired renal damage. Some recently published prospective, randomised studies do not support the efficacy of antibacterial prophylaxis [388-391]. However, two prospective randomised trials as well as one recent meta-analysis demonstrated a significant risk reduction of developing another UTI by using continuous antibiotic prophylaxis [377, 392, 393] (see also Chapter 3.13 on VUR).

Cranberry juice as well as probiotics may also prevent recurrence of UTI as demonstrated by RCTs [394-396]. A Cochrane review could not rule out some benefit of using probiotics [397].

**Table 6: Drugs for antibacterial prophylaxis\***

Substance	Prophylactic dosage (mg/kg bw/d)	Limitations in neonates and infants
Trimethoprim**	1	Until six weeks of age
Trimethoprim Sulfamethoxazole	1-2 10-15	Not recommended under two months of age
Nitrofurantoin**	1	Until three months of age
Cefaclor	10	No age limitations
Cefixim	2	Preterms and newborns
Ceftibuten	2	***
Cefuroximaxetil	5	***

\* Reproduced with permission from the International Consultation on Urological Diseases (ICUD), International Consultation on Urogenital Infections, 2009. Copyright © by the European Association of Urology [387].

\*\* Substances of first choice are nitrofurantoin and trimethoprim. In exceptional cases, oral cephalosporin can be used.

\*\*\* In Germany, ceftibuten is not approved for infants < 3 months old.

#### 3.8.4.4 Monitoring of UTI

With successful treatment, urine usually becomes sterile after 24 hours, and leukocyturia normally disappears within three to four days. Normalisation of body temperature can be expected within 24-48 hours after the start of therapy in 90% of cases. In patients with prolonged fever and failing recovery, treatment-resistant uropathogens or the presence of congenital uropathy or acute urinary obstruction should be considered. Immediate US examination is recommended in these cases.

Procalcitonin (among other laboratory inflammatory parameters such as C-reactive protein and leukocyte count) can be used as reliable serum marker for early prediction of renal parenchymal inflammation with first febrile UTI [398]. In patients with febrile UTI, serum electrolytes and blood cell counts should be obtained.

#### 3.8.5 Summary of evidence and recommendations for the management of UTI in children

Summary of evidence	LE
Urinary tract infection represents the most common bacterial infection in children less than two years of age. The incidence varies depending on age and sex.	1b
Classifications are made according to the site, episode, severity, symptoms and complicating factors. For acute treatment, site and severity are most important.	2b
The number of colony forming units (cfu) in the urine culture can vary and is related to the method of specimen collection, diuresis, and time and temperature of storage until cultivation occurs.	2b
The classical definition of > 10 <sup>5</sup> cfu/mL in voided urine is still used to define a significant UTI.	3
Changes in DMSA clearance during acute UTI indicate pyelonephritis or parenchymal damage. If it is positive, reflux may be present.	2a

Recommendations	LE	Strength rating
Take a medical history, assess clinical signs and symptoms and perform a physical examination to diagnose children suspected of having a urinary tract infection (UTI).	3	Strong
Exclude bladder- and bowel dysfunction in any child with febrile and/or recurrent UTI and do not delay diagnosis and treatment of bladder-bowel-dysfunction.	3	Strong
The most effective way to collect an uncontaminated urine sample in an infant is through suprapubic bladder aspiration, bladder catheterisation is an alternative with a higher contamination rate.	2a	Strong
Do not use plastic bags for urine sampling in non-toilet-trained children since it has a high risk of false-positive results. Clean catch urine is an acceptable technique for toilet-trained children.	2a	Strong
Urinalysis by dipstick yields rapid results, but it should be used with caution. Microscopic investigation is the standard method of assessing pyuria after centrifugation. Using flow imaging analysis, the numbers of white blood cells (WBCs), squamous epithelial cells and red cells correlate well with manual methods.	2a	Weak
The choice between oral and parenteral therapy should be based on patient age; clinical suspicion of urosepsis; illness severity; refusal of fluids, food and/or oral medication; vomiting; diarrhoea; non-compliance; complicated pyelonephritis.	2a	Strong
Treat UTIs with four to seven day courses of oral or parenteral therapy.	1b	Strong
Offer long-term antibacterial prophylaxis in case of high susceptibility to UTI and risk of acquired renal damage and lower urinary tract symptoms.	1b	Weak
Treat complicated UTI, with broad-spectrum antibiotics (parenteral).	1b	Weak
In infants with febrile UTI, use renal and bladder ultrasound to exclude obstruction of the upper and lower urinary tract.	3	Strong
In all infants, exclude vesicoureteral reflux (VUR) after the first episode of febrile UTI, using voiding cystourethography (VCUG) or a dimercaptosuccinic acid (DMSA) scan first (in case of a positive DMSA-scan, follow-up with VCUG). In boys more than one year of age, exclude VUR after the second febrile UTI.	2a	Strong

### 3.9 Day-time lower urinary tract conditions

#### 3.9.1 Terminology, classification, epidemiology and pathophysiology

Urinary incontinence in children may be caused by congenital anatomical or neurologic abnormalities such as ectopic ureter, bladder exstrophy or myelomeningocele (MMC). In many children, however, there is no such obvious cause for the incontinence, and they are referred as having functional bladder problems. The most recent International Children's Continence Society (ICCS) document suggests using the term day-time lower urinary tract (LUT) conditions to group together all functional bladder problems in children.

Normal storage and emptying of the bladder at a socially accepted place and time is mostly achieved by age three to four. The children with LUT conditions would present with failure to achieve continence (being still wet after the age of four), urgency, weak stream, hesitancy, frequency and accompanied UTIs. Isolated nighttime wetting without any day-time symptoms is known as 'enuresis' and considered as a different entity (see chapter 3.10) [399].

As different studies have used varying definitions and criteria, it is difficult to give reliable percentages regarding the incidence of this problem. Reported prevalence ranges widely from 1% to 20% [400-408]. Due to increasing awareness and better access to specialised health care, the prevalence seems to be increasing [409, 410].

Lower urinary tract conditions in children may be due to disturbances of the filling phase, the voiding phase or a combination of both in varying severity. Mainly the conditions are divided into either overactive bladder (OAB) or dysfunctional voiding. They can, of course, coincide and one may even be causative of the other. Dysfunctional bowel emptying may also be part of the clinical problems and bladder bowel dysfunction (BBD) is the term used to cover concomitant bladder and bowel disturbances.

Lower urinary tract conditions are considered to be the result of incomplete or delayed maturation of the bladder sphincter complex. The pons is considered to be responsible for detrusor sphincter co-ordination while the cortical area is responsible for inhibition of the micturition reflex and voluntary initiation of micturition. Therefore overactivity would be the result of delayed maturation of cortical control, while dysfunctional voiding would be the result of non-maturation of the co-ordination. Detrusor overactivity should not be considered as

a sole bladder based problem but more a symptom of a centrally located dysfunction affecting bladder, bowel and even mood and behaviour [411].

A link between LUT and behavioural disorders such as ADHD (attention deficit/ hyperactivity disorder) has also been shown [412-414].

#### 3.9.1.1 *Filling-phase (storage) dysfunctions*

In filling-phase dysfunctions, the detrusor can be overactive, as in OAB, or underactive, as in underactive bladder (UAB). Overactivity of the bladder is the most common problem, seen mostly around five to seven years of age. This may lead to disturbances characterised by urgency, frequency and at times urgency incontinence. Some children habitually postpone micturition leading to voiding postponement. Therefore, holding manoeuvres such as leg crossing and squatting can often be seen in this group. Recurrent UTIs are common and high-pressure state of the bladder can be a cause of VUR. Constipation can be an additional aetiological factor, which needs to be assessed. In children with an underactive detrusor, voiding occurs with reduced or minimal detrusor contractions with post-void residuals. Urinary tract infections, straining to void, constipation and incontinence is common. Incontinence often occurs when the bladder is over distended in the form of overflow incontinence.

#### 3.9.1.2 *Voiding-phase (emptying) dysfunctions*

In voiding-phase (emptying), incomplete relaxation or tightening of the sphincteric mechanism and pelvic floor muscles results in staccato voiding pattern (continuous urine flow with periodic reductions in flow rate precipitated by bursts of pelvic floor activity) or an interrupted voiding pattern (unsustained detrusor contractions resulting in infrequent and incomplete voiding, with micturition in fractions). The general term for this condition is dysfunctional voiding and is associated with elevated bladder pressures and PVRs. Symptoms will vary depending on the severity of inco-ordination between bladder and the sphincter. Staccato voiding is in less severe forms and interrupted voiding and straining is in more severe forms. Children with dysfunctional voiding are also prone to constipation and recurrent UTIs [415].

In incomplete emptying, high voiding pressures generated by bladder working against a functional obstruction caused by non-relaxing sphincter may induce not only UTIs but also VUR. It is been shown that LUTD is more significant for the occurrence of UTI than VUR itself [416]. In the majority of children with dysfunctional voiding the recurrent infections disappear following successful treatment, which confirms the hypothesis that dysfunctional voiding is the main factor responsible for the infections. Spontaneous resolution of VUR may also be seen after successful treatment of dysfunctional voiding.

#### 3.9.2 **Diagnostic evaluation**

The evaluation of LUT conditions includes medical and voiding history (bladder diaries and structured questionnaires), a physical examination, a urinalysis, and uroflowmetry with post-void residual. The UUT needs to be evaluated in children with recurrent infections and dysfunctional voiding. Uroflowmetry can be combined with pelvic floor electromyography to demonstrate overactivity of the pelvic floor muscles during voiding. Urodynamic studies are usually reserved for patients with therapy resistant dysfunctional voiding and those not responding to treatment who are being considered for invasive treatment [414, 417-420].

In addition to a comprehensive medical history a detailed voiding diary provides documentation of voiding and defecation habits, frequency of micturition, voided volumes, night-time urine output, number and timing of incontinence episodes, and fluid intake. Voiding diary should at least be done for two days, although longer observation periods are preferred. A voiding diary provides information about storage function and incontinence frequency, while a pad test can help to quantify the urine loss. In the paediatric age group, where the history is taken from both the caregivers and child together, a structured approach is recommended using a questionnaire. Many signs and symptoms related to voiding and wetting will be unknown to the caregivers and should be specifically requested, using the questionnaire as a checklist. Some symptom scorings have been developed and validated [421, 422]. Although the reliability questionnaires are limited they are practical in a clinical setting to check the presence of the symptoms and have also been shown to be reliable to monitor the response to treatment. History taking should also include assessment of bowel function. For evaluation of bowel function in children, the Bristol Stool Scale is an easy-to-use tool [423, 424].

Urinalysis and urinary culture are essential to evaluate for UTI. Since transient voiding symptoms are common in the presence of UTI, exclusion of UTI is essential before further management of symptoms.



During clinical examination, genital inspection and observation of the lumbosacral spine and the lower extremities are necessary to exclude obvious uropathy and neuropathy.

Uroflowmetry with post-void residual evaluates the emptying ability, while an UUT US screens for (secondary) anatomical changes. A flow rate which reaches its maximum quickly and levels off ('tower shape') may be indicative of OAB whereas interrupted or staccato voiding patterns may be seen in dysfunctional voiding. Plateau uroflowmetry patterns are usually seen in anatomic obstruction of flow. A single uroflowmetry test may not always be representative of the clinical situation and more uroflowmetry tests, which all give a similar result, are more reliable. Uroflowmetry examination should be done when there is desire to empty the bladder and the voided volume should at least be 50% of the age expected capacity ((age in years) + 1) x 30 mL for the children. While testing the child in a clinical environment, the impact of stress and mood changes on bladder function should also be taken into account [425, 426].

In the case of treatment failure re-evaluation is warranted and (video)-urodynamic (VUD) studies and neurological evaluation may be considered. Sometimes, there are minor, underlying, urological or neurological problems, which can only be suspected using VUD. In these cases, structured psychological interviews to assess social stress should be added [427] (LE: 1b).

Video-urodynamics may also be used as initial investigational tool in patients with suspicion of reflux. In this case reflux may be observed along with bladder dynamics. In the case of anatomical problems, such as posterior urethral valve problems, syringocoeles, congenital obstructive posterior urethral membrane (COPUM) or Moormann's ring, it may be necessary to perform cystoscopy with treatment. If neuropathic disease is suspected, MRI of the lumbosacral spine and medulla can help to exclude tethered cord, lipoma or other rare conditions.

### 3.9.3 **Management**

The treatment of LUTD involves a multimodal approach, involving strategies such as behavioural modification, and anticholinergic medication along with underlying and potentially complicating conditions such as constipation and UTIs.

Behavioural modification, mostly referred to as urotherapy, is a term which covers all non-pharmacological and non-surgical treatment modalities. It includes standardisation of fluid intake, bowel management; timed voiding and basic relaxed voiding education. The child and family are educated about normal bladder function and responses to urgency. Voiding regimens are instituted and UTIs and any constipation are treated. Treatment is aimed at optimising bladder emptying and inducing full relaxation of the urinary sphincter or pelvic floor prior to and during voiding.

Strategies to achieve these goals include:

1. Information and demystification, which includes explanation about normal LUT function and how a particular child deviates from normal function.
2. Instructions about what to do about the problem:
  - Regular voiding habits, sound voiding posture, pelvic floor awareness and training to relax pelvic floor and avoiding holding manoeuvres.
  - Lifestyle advice, regarding fluid intake, prevention of constipation, etc.
  - Registration of symptoms and voiding habits using bladder diaries or frequency-volume charts.
  - Support and encouragement via regular follow-up by the caregiver.

Recurrent urinary infections and constipation should also be treated and prevented during the treatment period. In case of combined BBD it is advised to treat the bowel dysfunction first [409] as LUTS may disappear after successful management of bowel dysfunction.

Addition of other strategies, as below, may be needed:

- Pelvic floor muscle awareness practices with repeated sessions of biofeedback visualisation of uroflow curves and/or pelvic floor activity and relaxation.
- Clean intermittent self-catheterisation for large post-void residual volumes of urine.
- Antimuscarinic drug therapy if detrusor overactivity is present.
- If the bladder neck is associated with increased resistance to voiding, alpha-blocker drugs may be introduced.

Treatment efficacy can be evaluated by improvement in bladder emptying and resolution of associated symptom. Controlled studies of the various interventions are needed. As with detrusor overactivity, the natural history of untreated dysfunctional voiding is not well delineated and optimum duration of therapy is poorly described. A high success rate has been described for urotherapy programmes, independent of the components of the programme. However, the evidence level is low as most studies of urotherapy programmes are retrospective and non-controlled [428].

### 3.9.3.1 Specific interventions

As well as urotherapy, there are some specific interventions, including physiotherapy (e.g. pelvic floor exercises), biofeedback, alarm therapy and neuromodulation. Although good results with these treatment modalities have been reported, the level of evidence remains low, since only a few RCTs were published [361, 429-434].

A systematic review reports that biofeedback is an effective, non-invasive method of treating dysfunctional voiding, and approximately 80% of children benefited from this treatment. However, most reports were of low level of evidence and studies of more solid design such as RCT should be conducted [435].

A more recently published multicentre controlled trial of cognitive treatment, placebo, oxybutynin, bladder and pelvic floor training did not report better results with oxybutynin and pelvic floor training compared to standard urotherapy [427] (LE: 1b).

Two RCTs on underactive bladder without neurophatic disease have recently been published. Transcutaneous interferential electrical stimulation and animated biofeedback with pelvic floor exercise have been shown to be effective [436, 437]. In some cases, pharmacotherapy may be added. Some studies on orthosympathicomimetics have been published with a low level of evidence [438].

Overactive bladder is common in the paediatric population. Although a stepwise approach starting with behavioural therapy is advised, antimuscarinic agents remain the mainstay of medical treatment for OAB. Oxybutynin is the most commonly used antimuscarinic in the paediatric population. The response to antimuscarinics varies and many experience serious side effects. Although there have been reports about the use of tolterodine, fesoterodine, trospium, propiverine, and solifenacin in children, to date, most of them are off-label depending on age and national regulations. A few RCTs have been published, one on tolterodine showed safety but not efficacy [439], while another on propiverine showed both safety and efficacy [440] (LE:1). The recent study on solifenacin showed its efficacy with side effects like constipation and electrocardiogram changes [441].

The difference in results is probably due to study design. Despite the low level of evidence for the use of anticholinergics and antimuscarinics, their use is recommended because of the large number of studies reporting a positive effect on OAB symptoms. Although  $\alpha$ -blocking agents are used occasionally, an RCT showed no benefit [442]. Botulinum toxin injection seems promising, but can only be used off-label [443].

A meta-analysis reports that neuromodulation therapy may lead to better partial improvement of non-neurogenic OAB; however, it may not render a definitive complete response. Office-based neuromodulation seems more efficacious than self-administered neuromodulation [444].

These new treatment modalities can only be recommended for standard therapy resistant cases [445]. Despite early successful treatment, there is evidence that there is a high recurrence rate of symptoms in the long term which necessitates long-term follow-up [446]. In addition, many patients may present themselves later in adulthood with different forms of LUTD [447].

### 3.9.4 Summary of evidence and recommendations for the management of day-time lower urinary tract conditions

Summary of evidence	LE
The term 'bladder bowel dysfunction' should be used rather than 'dysfunctional elimination syndrome and voiding dysfunction'.	4
Day-time LUTS has a high prevalence (1% to 20%).	2

Recommendations	LE	Strength rating
Use two day voiding diaries and/or structured questionnaires for objective evaluation of symptoms, voiding drinking habits and response to treatment.	2	Strong
Use a stepwise approach, starting with the least invasive treatment in managing day-time lower urinary tract dysfunction in children.	4	Weak
Initially offer urotherapy involving bladder rehabilitation and bowel management.	2	Weak
If bladder bowel dysfunction is present, treat bowel dysfunction first, before treating the lower urinary tract condition.	2	Weak
Use pharmacotherapy (mainly antispasmodics and anticholinergics) as second line therapy in overactive bladder.	1	Strong
Use antibiotic prophylaxis if there are recurrent infections.	2	Weak
Re-evaluate in case of treatment failure; this may consist of (video) urodynamics MRI of lumbosacral spine and other diagnostic modalities, guiding to off-label treatment which should only be offered in highly experienced centres.	3	Weak

### 3.10 Monosymptomatic nocturnal enuresis - bedwetting

#### 3.10.1 *Epidemiology, aetiology and pathophysiology*

Monosymptomatic nocturnal enuresis, also known as bedwetting, is defined as an intermittent nocturnal incontinence. It is a relatively frequent symptom in children, 5-10% at seven years of age and 1–2% in adolescents. With a spontaneous yearly resolution rate of 15% (at any age), it is considered as a relatively benign condition [425, 448]. Seven out of 100 seven-year-old bedwetting children will continue to wet their bed into adulthood. Nocturnal enuresis is considered primary when a child has not yet had a prolonged period of being dry (six months). The term “secondary nocturnal enuresis” is used when a child or adult begins wetting again after having stayed dry.

Non-monosymptomatic nocturnal enuresis is defined as the condition of nocturnal enuresis in association with day-time lower urinary tracts symptoms (LUTS, recurrent UTIs and/or bowel dysfunction) [448, 449].

Nocturnal enuresis has significant secondary stressful, emotional and social consequences for the child and their caregivers. Therefore treatment is advised from the age of six to seven years onwards considering mental status, family expectations, social issues and cultural background.

There is a clear hereditary factor in nocturnal enuresis. If none of the parents or their immediate relatives has suffered from bedwetting, the child has a 15% chance of wetting its bed. If one of the parents, or their immediate relatives have suffered from bedwetting, the chance of bedwetting increases to 44%, and if both parents have a positive history the chance increases to 77%. However, from a genetic point of view, enuresis is a complex and heterogeneous disorder. Loci have been described on chromosomes 12, 13 and 22 [449]. There is also a gender difference: two boys to one girl at any age.

High arousal is the most important pathophysiological factor; the child does not wake up when the bladder is full. In addition to the high arousal, there needs to be an imbalance between night-time urine output and night-time bladder capacity and activity [425, 448, 449]. Recently, attention has been given to the chronobiology of micturition in which the existence of a circadian clock in kidney, brain and bladder is postulated [450] (LE: 1).

A high incidence of comorbidity and correlation between nocturnal urine production and sleep disordered breathing, such as obstructive sleep apnoea, has been found and investigated. Symptoms such as habitual snoring, apnoeas, excessive sweating at night and mouth breathing in the patient history or via sleep questionnaires can lead to the diagnosis of adenotonsillar hypertrophy.

#### 3.10.2 *Diagnostic evaluation*

The diagnosis is mainly obtained by history-taking. Focused questions to differentiate monosymptomatic vs. non-monosymptomatic, primary vs. secondary, comorbid factors such as behavioural or psychological problems and sleep disorder breathing, should be asked. In addition, a two day complete voiding and drinking diary, which records day-time bladder function and drinking habits will further exclude comorbid factors such as LUTS and polydipsia.

The night-time urine production should be registered by weighing the night-time diapers in the morning and adding the first morning voided volume [451]. The night-time urine production should be recorded over (at least) a two week period to diagnose an eventual differentiation between a high night-time production (more than 130% of the age expected bladder capacity) vs. a night-time OAB.

A physical examination should be performed with special attention to the external genitalia and surrounding skin as well as to the condition of the clothes (wet underwear or encopresis).

Urine analysis is indicated if there is a sudden onset of bedwetting, a suspicion or history of urinary tract infections, or inexplicable polydipsia.

A uroflowmetry and ultrasound is indicated only if there is a history of previous urethral or bladder surgery, straining while voiding, interrupted voiding, an abnormal weak or strong stream, a prolonged voiding time.

If the comorbid factor of possible sleep disordered breathing occurs, a referral to an ear-nose-throat (ENT) specialist should be advised.

If the comorbid factor of developmental, attention or learning difficulties, family problems, parental distress and possible punishment of the child, a referral to a psychologist should be advised and followed-up.

### 3.10.3 **Management**

Before introducing any form of possible treatment, it is of utmost importance to explain the bedwetting condition to the child and the caregivers in order to demystify the problem.

#### 3.10.3.1 *Supportive treatment measures*

Initially, supportive measures including normal and regular eating and drinking habits should be reviewed, stressing normal fluid intake during the day and reducing fluid intake in the hours before sleep. Keeping a chart depicting wet and dry nights, also called as basic bladder advice, has not been shown to be successful in the early treatment for nocturnal enuresis [452] (LE: 1a).

#### 3.10.3.2 *Conservative wait and see approach*

If the child and its family is unable to comply with a treatment, if the treatment options are not possible for the family situation, and if there is no social pressure, a “wait and see” approach can be chosen. However, in this approach, it is important to emphasise the fact that the child should wear diapers at night to ensure a normal quality of sleep.

#### 3.10.3.3 *Nocturnal enuresis wetting alarm treatment*

The nocturnal alarm treatment is the use of a device that is activated by getting wet. The goal is that the child wakes up by the alarm, which can be acoustic or tactile, either by itself or with the help of a care giver. The method of action is to repeat the awakening and therefore change the high arousal to a low arousal, specifically when a status of full bladder is reached. It is of utmost importance that the child is collaborating. Initial success rates of 80% are realistic, with low relapse rates, especially when night-time diuresis does not exceed age expected bladder capacity [453]. Regular follow-up will improve the success.


#### 3.10.3.4 *Medical therapy*

In the case of high night-time diuresis, success rates of 70% can be obtained with desmopressin (DDAVP), either as tablets (200-400 µg), or as sublingual DDAVP oral lyophilisate (120-240 µg). A nasal spray is no longer recommended due to the increased risk of overdose [454, 455] (LE: 1). Relapse rates can be high after DDAVP discontinuation [448], however recently, structured withdrawal has shown lower relapse rates [456] (LE: 1).

In the event of desmopressin resistant treatment for nocturnal enuresis or if a suspicion exists for night-time OAB, combination with antispasmodics or anticholinergics is safe and efficient [451]. Imipramine, which has been popular for treatment of the enuresis, achieves only a moderate response rate of 50% and has a high relapse rate. Furthermore, cardiotoxicity and death from overdose are described, its use should therefore be discouraged as the first line therapy [457] (LE: 1). Figure 5 presents stepwise assessment and management options for nocturnal enuresis.

Although the several forms of neuromodulation and acupuncture have been investigated for nocturnal enuresis treatment, the present literature data precludes its use because of its inefficiency, or at least no additional benefit.

**Figure 5: A stepwise assessment and management options for nocturnal enuresis**



ENT = ear, nose and throat.

**3.10.4 Summary of evidence and recommendations for the management of monosymptomatic enuresis**

Summary of evidence	LE
Chronobiology of micturition, in which the existence of a circadian clock has been proven in kidney, brain and bladder, and disturbances in this chronobiology play a major role in the pathophysiology of enuresis.	1

Recommendations	LE	Strength rating
Do not treat children less than five years of age in whom spontaneous cure is likely, but inform the family about the involuntary nature, the high incidence of spontaneous resolution and the fact that punishment will not help to improve the condition.	2	Strong
Use voiding diaries or questionnaires to exclude day-time symptoms.	2	Strong
Perform a urine test to exclude the presence of infection or potential causes such as diabetes insipidus.	2	Strong
Offer supportive measures in conjunction with other treatment modalities, of which pharmacological and alarm treatment are the two most important.	1	Strong
Offer desmopressin in proven night-time polyuria.	1	Strong
Offer alarm treatment in motivated and compliant families.	1	Strong

### 3.11 Management of neurogenic bladder

#### 3.11.1 *Epidemiology, aetiology and pathophysiology*

Neurogenic detrusor-sphincter dysfunction (NDS) can develop as a result of a lesion at any level in the nervous system. This condition contributes to various forms of LUTD, which may lead to incontinence, UTIs, VUR, and ultimately to renal scarring and renal failure requiring dialysis and/or transplantation. Conservative treatment starting in the first year of life is the first choice, however, surgery may be required at a later stage to establish adequate bladder storage, continence and drainage later on [458-460]. The main goals of treatment concerning the urinary tract are prevention of UTI's, urinary tract deterioration, achievement of continence at an appropriate age and promoting as good a QoL as possible. With regard to the associated bowel dysfunction, stool continence, with evacuation at a social acceptable moment, is another goal as well as education and treatment of disturbance in sexual function. Due to the increased risk of development of latex allergy, latex-free products (e.g., gloves, catheters etc.) should be used from the very beginning whenever possible [461].

Neurogenic bladder in children with myelodysplasia presents with various patterns of Detrusor-Sphincter-Dyssynergia with a wide range of severity [462]. About 12% of neonates with myelodysplasia have no signs of neuro-urological dysfunction at birth [463]. Newborns with myelodysplasia and initially normal urodynamic studies are at risk for neurological deterioration secondary to spinal cord tethering, especially during the first six years of life. Close follow-up of these children is important for the early diagnosis and timely surgical correction of tethered spinal cord, and for the prevention of progressive urinary tract deterioration [463]. At birth, the majority of patients have normal UUTs, but up to 60% develop upper tract deterioration due to bladder changes, UTI and /or VUR, if not treated properly [464-467]. Even today in a contemporary series around 50% of the patients are incontinent and 15% have an impaired renal function at the age of 29 years [468]. A recent SR concerning the outcome of adult meningocele patients demonstrated that around 37% (8-85%) are continent, 25% have some degree of renal damage and 1.3% end stage renal failure [469]. The term "continence" is used differently in the reports, and the definition of "always dry" was used in only a quarter of the reports [470].

The most common presentation at birth is myelodysplasia. The incidence of neural tube defects in Europe is 9.1 per 10,000 births and has not decreased in recent years, despite longstanding recommendations concerning folic acid supplementations [471]. The term myelodysplasia includes a group of developmental anomalies that result from defects in neural tube closure. Lesions include spina bifida aperta and occulta, meningocele, lipomyelomeningocele, or myelomeningocele. Myelomeningocele is by far the most common defect seen and the most detrimental.

With antenatal screening spina bifida can be diagnosed before birth with the possibility of intrauterine closure of the defect [472, 473]. Traumatic and neoplastic spinal lesions of the cord are less frequent in children, but can also cause severe urological problems. Other congenital malformations or acquired diseases can cause a neurogenic bladder, such as total or partial sacral agenesis which can be part of the caudal regression syndrome [474]. In any child presenting with anorectal malformation (ARM) and cloacal malformations, the development of a neurogenic bladder is possible [475]. Patients with cerebral palsy may also present with varying degrees of voiding dysfunction, usually in the form of uninhibited bladder contractions (often due to spasticity of the pelvic floor and sphincter complex) and wetting. Finally, a "non-neurogenic neurogenic" bladder, such as Hinman or Ochoa syndrome, has been described, in which no neurogenic anomaly can be found, but severe bladder dysfunction as seen in neurogenic bladders is present [476, 477].

#### 3.11.2 *Classification systems*

As bladder sphincter dysfunction is poorly correlated with the type and spinal level of the neurological lesion, urodynamic and functional classifications are much more practical for defining LUT pathology and planning treatment in children.

The bladder and sphincter are two units working in harmony to act as a single functional unit. In patients with a neurogenic disorder, the storage and emptying phase of the bladder function can be disturbed. The bladder and sphincter may function either overactive or underactive and present in 4 different combinations. This classification system is based on the urodynamic findings [478-480]:

- Overactive sphincter and overactive bladder
- Overactive sphincter and underactive bladder
- Underactive sphincter and overactive bladder
- Underactive sphincter and underactive bladder

### 3.11.3 **Diagnostic evaluation**

Today several guidelines and timetables are used [481-483]. The Panel advocate proactive management in children with spinal dysraphism. In those with a safe bladder during the first urodynamic investigation, the next urodynamic investigation can be delayed until one year of age.

#### 3.11.3.1 *History and clinical evaluation*

History should include questions on clean intermittent catheterisation (CIC) frequency, urine leakage, bladder capacity, UTI, medication, bowel function as well as changes of neurological status. A thorough clinical evaluation is mandatory including the external genitalia and the back. A two day diary, recording drinking volume and times as well as CIC intervals, bladder volume and leakage can provide additional information about the efficacy of the treatment.

#### 3.11.3.2 *Laboratory & Urinalysis*

After the first week of life, the plasma creatinine level should be obtained, later in life; the cystatin level is more accurate [484, 485]. If there is any sign of decreased renal function, physicians should be encouraged to optimise the treatment as much as possible.

The criteria for urine analysis are the same as for UTI (refer to Chapter 3.8). However, it is much easier for caregivers or patients to obtain a catheter urine in patients, who are on CIC. They can also perform a dip stick analysis to screen for UTI at home. For relevance see 3.11.4.5.

#### 3.11.3.3 *Ultrasound*

At birth, US of the kidneys and bladder should be performed and then repeated at least annually. If there are any clinical changes in between, another US should be performed. Dilatation of the UUT should be reported according to the classification system of Society of Foetal Urology [486], including the measurement of the caliceal dilatation and anterior posterior diameter of the renal pelvis. Residual urine and bladder wall thickness should also be mentioned. A dilated ureter behind the bladder should be recorded. Bladder wall thickness has been shown not to be predictive of high pressures in the bladder during voiding and storage and cannot be used as a non-invasive tool to judge the risk for the upper urinary tract [487].

#### 3.11.3.4 *Urodynamic studies/videourodynamic*

Urodynamic studies (UD) are one of the most important diagnostic tools in patients with neurogenic bladders. In newborns with spina bifida aperta (failure of mesodermal in-growth over the developing spinal canal results in an open lesion most commonly seen in the lumbosacral area including an incomplete closure of the vertebral column and not covered by skin), the first UD should be performed after the phase of the spinal shock after closure, usually between the second and third months of life [488]. Especially in newborns, performing and interpretation of UD may be difficult, as no normal values exist. After that it should be repeated annually, depending on the clinical situation. During and after puberty bladder capacity, maximum detrusor pressure and detrusor leak point pressure increase significantly [489]. Therefore, during this time, a careful follow-up is mandatory.

##### 3.11.3.4.1 *Preparation before urodynamic studies*

Before any UD a urine analysis should be done. The first assessment should be done under antibiotic prophylaxis. A Cochrane analysis of nine randomised controlled trials showed, that the administration of prophylactic antibiotics compared to placebo reduced the risk of significant bacteriuria from 12% to 4% after UD-studies. However, this was without significant difference for symptomatic UTI (20% versus 28%), fever or dysuria [490]. If there is a significant bacteriuria, antibacterial treatment should be discussed; especially in older patients a single shot may be sufficient [491].

Generally UD-parameters should include:

- the bladder cystometric capacity;
- the intravesical filling pressure;
- detrusor compliance;
- the intravesical pressure at the moment of voiding or leakage;
- the presence or absence of overactive detrusor;
- the competence of the internal and external sphincter;
- the degree of synergy of the detrusor and sphincter during voiding;
- the post-voiding residual urine volume.

In the infant period information on detrusor filling pressure and the pressure and bladder volume at which the child voids or leaks can be obtained [488]. Detrusor leak point pressure is more accurate than abdominal leak point pressure, but keeping the rectal probe in an infant in place can be challenging [488]. Addition of fluoroscopy (video-urodynamic study) will provide information about presence of VUR, at what pressures VUR starts and the configuration of the bladder neck during filling and leakage or voiding.

#### 3.11.3.4.2 Uroflowmetry

Unlike in children with non-neurogenic voiding dysfunction, uroflowmetry can rarely be used since most affected patients do not void spontaneously. In those with cerebral palsy, non-neurogenic-neurogenic bladder or other neurological conditions allowing active voiding it may be a practical tool. It provides an objective way of assessing the efficiency of voiding, while recording of pelvic floor activity with electromyography (EMG) can be used to evaluate synergy between detrusor and the sphincter. The post void residual urine is measured by US. The main limitation of uroflowmetry is a compliant child to follow instructions [492-495].

#### 3.11.3.5 Urodynamic studies

The standards of the ICCS should be applied to the UD in patients with neurogenic bladders and accordingly reported [417, 478]. Natural fill UD in children with neurogenic bladder detects more overactivity compared with diagnoses delivered by conventional UD [496, 497]. It may be an option in patients where the findings in the normal UD are inconsistent with clinical symptoms and other clinical findings [497].

#### 3.11.3.6 Voiding cystourethrogram

If video-urodynamic equipment is not available, a VCUG with UD is an alternative to confirm or exclude VUR and visualise the lower urinary tract including the urethra.

#### 3.11.3.7 Renal scan

DMSA (Technetium Dimercapto-Succinic Acid) Renal scan is the gold standard to evaluate renal parenchyma. In contemporary series, renal scars can be detected in up to 46% as patients get older [498-500]. A positive DMSA-Scan correlates well with hypertension in adulthood, whereas ultrasound has a poor correlation with renal scars [499]. Therefore, a DMSA scan as a baseline evaluation in the first year of life is recommended.

### 3.11.4 Management

The medical care of children with neurogenic bladder requires an on-going multidisciplinary approach. There is some controversy about optimal timing of the management; proactive vs. expectant management [458-460]. Even with a close expectant management e.g. in one series 11/60 need augmentation within a follow-up of 16 years and 7/58 had a decrease in total renal function, which was severe in 2 [501]. During the treatment it should be also taken into account with spina bifida patients, that QoL is related to urinary incontinence independent from the type and level of spinal dysraphism and the presence or absence of a liquor shunt [502].

Foetal open and endoscopic surgery for meningocele are performed to close the defect as early as possible to reduce the neurological, orthopaedic and urological problems [503]. In the MOMS-Trail, Brooks *et al.* found no difference between those closed *in utero* vs. those closed after birth concerning the need for CIC [473], but less trabeculation in the prenatal surgery group. Mean gestation age (28.3 vs. 35.2) seems to have no initial impact on bladder function in the first few years of life [504]. Despite some promising reports [504-507], caregivers need to be aware about the high risk of developing a neurogenic bladder as demonstrated by the Brazilian group [508]. Regular and close follow-up examinations including UD are indicated in all these patients.

#### 3.11.4.1 Early management with intermittent catheterisation

Starting intermittent catheterisation (IC) soon after birth and closure of the defect by the neurosurgeon in all infants has shown to decrease renal complications and the need for later augmentation [509-511]. In infants



without any clear sign of outlet obstruction, this may be delayed but only in very selected cases. These infants should be monitored very closely for UTIs and changes of the urinary tract with US and UD. The early initiation of IC in the newborn period makes it easier for caregivers to master the procedure and for children to accept it, as they grow older [512, 513].

A Cochrane review as well as some recent studies showed, that there is a lack of evidence to state that the incidence of UTI is affected by use of sterile or clean technique, coated or uncoated catheters, single (sterile) or multiple use (clean) catheters, self-catheterisation or catheterisation by others, or by any other strategy [514-517]. Looking at the microbiological milieu of the catheter, there was a trend for reduced recovery of potentially pathogenic bacteria with the use of hydrophilic catheters. Also, a trend for a higher patient satisfaction with the use of hydrophilic catheters was seen [518]. Based on the current data, it is not possible to state that one catheter type, technique or strategy is better than another.

#### 3.11.4.2 Medical therapy

Antimuscarinic/anticholinergic medication reduces/prevents detrusor overactivity and lowers intravesical pressure [519, 520]. Effects and side effects depend on the distribution of the M1-M5 receptors [521]. In the bladder, the subtype M2 and M3 are present [520, 522]. Oxybutynin is the most frequently used in children with neurogenic bladder with a success rate of up to 93% [523, 524]. Dose dependent side-effects (such as dry mouth, facial flushing, blurred vision heat intolerance etc.) limit the use. Intravesical administration has a significant higher bioavailability due to the circumvention of the intestinal first pass metabolism, as well as possible local influence on C-fiber-related and can be responsible for different clinical effect [525, 526]. Intravesical administration should be considered in patients with severe side-effects, as long-term results demonstrated that it was well-tolerated and effective [527, 528]. The transdermal administration leads also to a substantial lower ratio of N-desethyloxybutynin to oxybutynin plasma levels, however, there are treatment related skin reactions in 12/41 patients [529]. There are some concerns about central anticholinergic adverse effects associated with oxybutynin [530, 531]. A double blinded cross-over trial, as well as a case control study, showed no deleterious effect on children's attention and memory [532, 533]. Tolterodine, solifenacin, trospium chloride and propiverine and their combinations can be also used in children [534-540]. The oral dosage for oxybutynin is up to 0.2 mg/kg/every 8 hours [520] given three times daily. The intravesical dosage can be up to 0.7 mg/kg/daily and transdermal 1.3-3.9 mg/daily. The dosage of the other drugs is: Tolterodine 0.5 – 4 mg/day divided in two doses, Solifenacin 1.25 up to 10 mg per day (single dose), Propiverin 0.8 mg/kg/day divided in two dosages and trospium chloride up to 3 times 15 mg starting with 3 times 5 mg. Except for oxybutynin, all other anticholinergic drugs are off-label use, which should be explained to the caregivers.

Early prophylactic treatment with anticholinergics showed a lower rate of renal deterioration as well as a lower rate of progression to bladder augmentation [509, 511, 541].  $\beta_3$  agonists like mirabegron may be also an alternative agent and may be effective in patients with neurogenic bladders. Up to date, there is almost no experience with this drug [542], therefore no recommendation can be made.

$\alpha$ -adrenergic antagonists may facilitate emptying in children with neurogenic bladder [543]. Doxazosin with an initial dose of 0.5 to 1.0 mg or tamsulosin hydrochloride in a medium (0.0002-0.0004 mg/kg/day) or high dose (0.0004-0.0008 mg/kg/day) has been given to children with neurogenic bladders [543-545]. It was well tolerated but not effective at least in one study [544].

Botulinum toxin A injections: In neurogenic bladders that are refractory to anticholinergics, the off-label use of suburothelial or intramuscular injection of onabotulinum toxin A into the detrusor muscle is a treatment option [546, 547]. In children, continence could be achieved in 32-100% of patients, a decrease in maximum detrusor pressure of 32% to 54%, an increase of maximum cystometric capacity from 27% to 162%, and an improvement in bladder compliance of 28%-176% [546]. Onabotulinum toxin A seems to be more effective in bladders with obvious detrusor muscle over-activity, whereas non-compliant bladders without obvious contractions are unlikely to respond [548, 549]. Also, the injections into the trigone seems to be save in regard of reflux and upper tract damage, if it has some benefit is not further investigated [550].

The most commonly used dose of onabotulinum toxin A is 10 to 12 U/kg with a maximum dose between 200 U and 360 U [546]. However, in one study, 5 U/kg were used with comparable results [551]. Up to date, no randomised dose titration study has been published in children. The optimal dose in children as well as the time point when to inject which child is still unclear. Onabotulinum toxin A can be effective between three to twelve (0-25) months and repeated injections are effective up to ten years in one study [547, 552, 553].

Urethral sphincter onabotulinum toxin A injection has been shown to be effective in decreasing urethral resistance and improve voiding. The evidence is still too low to recommend its routine use in decreasing outlet resistance, but it could be considered as an alternative in refractory cases [554, 555].

#### Neuromodulation

Intravesical electrical stimulation of the bladder [556-558], sacral nerve stimulation [559, 560] and

transcutaneous neuromodulation [561] are still experimental and cannot be recommended outside of clinical trials. The same is true for the intradural somatic-to-autonomic nerve anastomosis [562, 563].

#### Urethral Dilatation

The aim is to lower the pop-off pressure by lowering the detrusor leak-point pressure by dilatation of the external sphincter under general anaesthesia up to 36 Charr. Some studies showed, that especially in females, the procedure is safe and in selected patients, effective [564-566].

#### Vesicostomy

Vesicostomy - preferably a Blocksom stoma [567] - is an option to reduce bladder pressure in children/newborns, if the caregivers are incompliant with IC and/or IC through the urethra is extremely difficult or impossible [568-570]. Especially in the young infant with severe upper tract dilatation or infections, a vesicostomy should be considered. Drawbacks are the problem to fit and maintain a collecting appliance in older patients. A cystostomy button may be an alternative, with a complication rate (mostly UTI) of up to 34% within a mean follow-up of 37 months [571].

#### 3.11.4.3 Management of faecal incontinence

Children with neurogenic bladder usually have also a neurogenic bowel function. Faecal incontinence may have an even greater impact on QoL, as the odor can be a reason for social isolation. The aim of each treatment is to obtain a smooth, regular bowel emptying and to achieve continence and impotence. The regime should be tailored to the patient's need, which may change over time. Beside a diet with small portioned fibre food and adequate fluid intake to keep a good fluid balance [520], follow-up options should be offered to the patients and caregivers.

At the beginning, faecal incontinence is managed most commonly with mild laxatives, such as mineral oil, combined with enemas to facilitate removal of bowel contents. To enable the child to defecate once a day at a given time rectal suppositories as well as digital stimulation by parents or caregivers can be used. Today, transanal irrigation is one of the most important treatments for patients with neurogenic bowel incontinence. Regular irrigations significantly reduce the risk for faecal incontinence and may have a positive effect on the sphincter tonus as well as the rectal volume [572]. The risk of irrigation induced perforation of the bowel is estimated as one per 50,000 [573]. During childhood, most children depend on the help of the caregivers. Later in some of them, transanal irrigation becomes difficult or impossible due to anatomic or social circumstances. In these patients antegrade irrigation using a MACE-stoma (Malone Antegrade Continence Enema) is an option, which can also be placed in the left abdomen [574, 575]. In a long-term study of 105 patients, 69% had successful bowel management. They were started on normal saline, but were switched to GoLYTELY (PEG-3350 and electrolyte solution). Additives (biscodyl, glycerin etc.) were needed in 34% of patients. Stomal complications occurred in 63% (infection, leakage, and stenosis) of patients, 33% required surgical revision and 6% eventually required diverting ostomies [576]. In addition, patients need to be informed, that the antegrade irrigation is also time consuming with at least 20 – 60 minutes.

#### 3.11.4.4 Urinary tract infection

Urinary tract infections are common in children with neurogenic bladders. However, there is no consensus in most European centres, for prevention, diagnosing and treating UTIs in children with neurogenic bladders performing CIC [577]. Although bacteriuria is seen in more than half of children on CIC, patients who are asymptomatic do not need treatment [578, 579]. Continuous antibiotic prophylaxis (CAP) creates more bacterial resistance as demonstrated by a randomised study. Those on stopping the prophylaxis had reduced bacterial resistance, however, 38/88 started antibiotic prophylaxis again due to recurrent UTIs or the caregivers request [580]. A cohort study with 20 patients confirmed these findings. Continuous antibiotic prophylaxis was not protective against the development of symptomatic UTIs and new renal scarring, however, increased the risk of bacterial resistance [581]. A randomised study in 20 children showed that cranberry capsules significantly reduced the UTI-rate as well as the rate of bacteriuria [582]. If VUR is present, prophylactic antibiotics should be started when patients experience recurrent UTIs [583, 584].

##### 3.11.4.4.1 Urinary tract infection and clean intermittent catheterisation

The incidence of asymptomatic bacteriuria ranges between 42% – 76% [512, 520, 585]. A cross-over study in 40 children with neurogenic bladder demonstrated, that the reuse of CIC-catheters for up to three weeks compared to one week increased the prevalence of bacteriuria from 34% to 74% (it was 60% at the start of the study). During the study-period of eighteen weeks, none of the patient developed a febrile UTI [586]. There is no medical benefit in performing CAP in children with neurogenic bladder, who perform CIC [520]. In those with recurrent UTI, intravesical instillation of gentamycin may be an option [587, 588].

## Reflux

Secondary reflux in patients with neurogenic bladder increases the risk for pyelonephritis. The treatment is primarily related to bladder function including anticholinergic therapy, CIC and may be later augmentation [589]. Those with early and post-therapy persistent reflux during videourodynamic studies at low pressure have a higher risk of pyelonephritis [590]. Patients with a high-grade reflux before augmentation have a higher risk for persistent symptomatic reflux after the enterocystoplasty [591]. Therefore simultaneous ureteral re-implantation in high grade symptomatic reflux especially in those with low-pressure high grade reflux should be discussed with the patient/caregivers. Endoscopic treatment has a failure rate of up to 75% after a median follow-up of 4.5 years [592] which is in contrast to the open techniques with a higher success rate [593], but may have an increased risk of inducing obstruction.

### 3.11.4.5 Sexuality

Sexuality, while not an issue in childhood, becomes progressively more important as the patient gets older. This issue has historically been overlooked in individuals with myelodysplasia. However, patients with myelodysplasia do have sexual encounters [594]. The prevalence of precocious puberty is higher in girls with meningomyelocele [595]. Studies indicate that at least 15-20% of males are capable of fathering children and 70% of females can conceive and carry a pregnancy to term. It is therefore important to counsel patients about sexual development in early adolescence.

Women seem to be more sexually active than men in some studies from the USA and the Netherlands [594, 596]; in an Italian study men were more active [596]. The level of the lesion was the main predictor to be sexually active [597, 598]. Erectile function can be improved by sildenafil in up to 80% of the male patients [599, 600]. Neurosurgical anastomosis between the inguinal nerve and the dorsal penile nerve in patients with a lesion below L3 and disturbed sensation is still to be considered as an experimental treatment [596, 601]. Only 17% to 1/3 of the patients talk to their doctors about sexuality, 25–68% were informed by their doctors about reproductive function [594]. Therefore, early discussion about sexuality in the adolescent is recommended and should be promoted by the paediatric urologist taking care of these patients.

### 3.11.4.6 Bladder augmentation

In patients where conservative treatment including onabotulinum toxin A (for indication see 3.11.4.3) fails to keep a low-pressure reservoir with a good capacity and compliance, bladder augmentation should be offered. For augmentation, ileal and colonic segments can be used [602]. Gastric segments are rarely used due to its associated complications like the haematuria-dysuria syndrome as well as secondary malignancies, which arise earlier than with other intestinal segments [603-606]. Enterocystoplasty increases bladder capacity, reduces storage pressure and can improve UUT drainage [607]. Good socially acceptable continence rate can be achieved with or without additional bladder outlet procedures [608]. In those, who are not able to perform CIC through the urethra, a continent cutaneous channel should be offered. Surgical complications and revision rate in this group of patients is high. The 30-day all over event rate in the American College of Surgeons' National Surgical Quality Database is approximately 30% (23-33%) with a re-operation rate in this short time period of 13% [609, 610]. In these patients with long-life expectancy the complication rate clearly increases with the follow-up period [609-612]. The ten-year cumulative complication incidence from the Paediatric Health Information System showed a rate of bladder rupture in up to 6.4%, small bowel obstruction in up to 10.3%, bladder stones in 36%, pyelonephritis in more than a third of the patients and a re-augmentation rate of up to 13% [613]. Bladder perforation, as one of the worst complications, occurs in 6-13% [614]. The rate of VP-shunt infections after gastrointestinal and urological procedures ranges between 0-22%. In a recent study, bowel preparation seems not to have a significant influence on the infection rate (10.5 vs 8.3%) [615]. Not only surgical complications must be considered; also metabolic complications and consequences after incorporating bowel segments have to be taken into account, such as imbalance of the acid base balance, decrease vitamin B12 levels and loss of bone density. Stool frequency can increase as well as diarrhoea after exclusion of bowel segments [616] and last, but not least, these patients have a lifelong increased risk to develop secondary malignancies [617-619]. Therefore, a lifelong follow-up of these patients is required including physical examination, US, blood gas analysis, (pH and base excess), renal function and vitamin B12 if ileum is used. Endoscopic evaluation starting ten years after augmentation is not cost-effective [620, 621], but may prevent some advanced cancer. Woodhouse *et al.* do not recommend cystoscopy within the first fifteen years after surgery [622]. The real value of annual cystoscopic evaluation has not been proven by any study. Urodynamic studies after bladder augmentation are only indicated, if upper tract dilatation and/or incontinence after the operation has not improved [623].

Adverse effects of intestinal cystoplasties can be avoided by the use of ureterocystoplasty. The combination of a small contracted bladder, associated with a severe dilation of the ureter of a non-functioning kidney is quite rare. The technique was first described in 1973 by Eckstein [624]; the success rate depends on patient selection and the re-augmentation rate can reach 73% [625, 626].

Auto-augmentation with partial detrusorectomy or detrusor myotomy creating a diverticulum avoids metabolic complications with the use of intestinal segments. The reports are conflicting, therefore, it may be used in very selected cases [627-630]. For a successful outcome, a pre-operative bladder capacity of 75-80% of the expected volume seems necessary [631, 632]. Seromuscular cystoplasty has also not proven to be as successful as standard augmentation with intestine [633]. Tissue engineering, even if successful *in vitro* and some animal models, does not reach the results by using intestinal segments with a higher complication rate [634, 635]. Therefore, these alternatives for bladder augmentation should be considered as experimental and should be used only in controlled trials.

#### 3.11.4.7 *Bladder outlet procedures*

So far, no available medical treatment has been validated to increase bladder outlet resistance.  $\alpha$ -adrenergic receptor stimulation of the bladder neck has not been very effective [636-641]. Using fascial slings with autologous fascial strip or artificial material a continence rate between 40 – 100% can be achieved. In most cases this is achieved in combination with bladder augmentation [642, 643]. Catheterising through a reconstructed bladder neck or a urethra compressed by a sling may not be easy; many surgeons prefer to combine this approach with a catheterisable channel [458]. In contrast to the autologous slings, artificial slings in girls with CIC through the urethra have a high complication rate [644]. In males, it may be an option [645], however as long as long-term results are missing this method has to be classified as experimental and should only be carried out in studies. Artificial urinary sphincters were introduced by Scott in 1973 [646]. The continence rates in the literature in selected patients can be up to 85% [647-650]. Postpubertal patients, who can void voluntarily are good candidates, if they are manually dexterous. In very selected patients, CIC through the sphincter in an augmented bladder is possible [651]. The erosion rate can be up to 29% and the revision-rate up to 100% depending on the follow-up time [652].

Patients, who underwent a bladder neck procedure only, have a chance of > 30% for an augmentation later on, half of them developed new upper tract damage in that time [653, 654]. In patients with a good bladder capacity and bladder compliance without an indication for bladder augmentation, there is a risk of post-operative changes of the bladder function. Therefore, a very close follow-up of these patients with UD is required to avoid upper tract damage and chronic renal failure.

Bladder neck reconstruction is used mostly in exstrophy patients with acceptable results. However, in children with a neurogenic bladder the results are less favorable [655]. In most patients, the creation of a continent catheterisable stoma is necessary due to difficulties to perform the CIC via urethra. In one series, 10% to a third still perform a CIC via urethra with a re-operation rate between 67% and 79% after a median follow-up between seven and ten years [656]. In patients who are still incontinent after a bladder outlet procedure, bladder neck closure with a continent catheterisable stoma is an option. The combination of a sling procedure together with a urethral lengthening procedure may improve the continence rates [657].

Bulking agents have a low success rate (10-40%), which is in most cases only temporary [658-660]. However, it does not adversely affect the outcome of further definite surgical procedures [661].

Bladder neck closure is often seen as the last resort to gain urinary continence in those patients with persistent urinary incontinence through the urethra. In girls, the transection is done between bladder neck and urethra and in boys above the prostate with preservation of the neurovascular bundle. It is an effective method to achieve continence together with a catheterisable cutaneous channel +/- augmentation as a primary or secondary procedure [662, 663]. A complication rate of up to 1/3 and a vesicourethral/vesicovaginal fistula in up to 15% should be considered [664], together with a higher risk for bladder stones, bladder perforation and deterioration of the upper tract function, if the patient is not compliant with CIC and bladder irrigations [664, 665].

#### 3.11.4.8 *Catheterisable cutaneous channel.*

In most patients with a neurogenic bladder IC is required. If this is not possible, or very time and/or resources consuming via the urethra, a continent cutaneous catheterisable channel should be offered as well as in those with bladder outlet procedures. It is especially beneficial to wheelchair-bound patients who often have difficulty with urethral catheterisation or are dependent on others to catheterise the bladder. In long-term studies the revision rate due to stenosis or incontinence can be as high as 50 to 60% depending on the type of channel [666, 667].

The stoma can be placed at the umbilicus or in the lower right abdominal wall using a VQZ plasty [668]. It should be carefully evaluated pre-operatively: it is extremely important that the patient can reach the stoma easily. Sometimes it has to be placed in the upper abdominal wall due to severe scoliosis mostly associated with obesity.

#### 3.11.4.9 *Continent and incontinent cutaneous urinary diversion*

Incontinent urinary diversion should be considered in patients, who are not willing or able to perform a CIC and who need urinary diversion because of upper tract deterioration or gain urinary continence due to social reasons. In children and adolescents, the colonic conduit has shown to be have less complications compared to the ileal conduit [669-672]. Total bladder replacement is extremely rare in children and adolescents, but may be necessary in some adults due to secondary malignancies or complications with urinary diversions. Any type of major bladder and bladder outlet construction should be performed in centres with sufficient experience in the surgical technique, and with experienced healthcare personnel to carry out post-operative follow-up [608, 673, 674].

An algorithm can be used for management of these patients (Figure 6).

#### 3.11.5 **Follow-up**


Neurogenic bladder patients require lifelong follow-up including not only urological aspects but also neurological and orthopaedic aspects. Regular investigation of upper and lower urinary tract is mandatory. In patients with changes of the function of the upper and/or lower urinary tract, a complete neurological re-investigation should be recommended including a total spine MRI to exclude a secondary tethered cord or worsening of the hydrocephalus. In addition, if some neurological changes are observed a complete investigation of the urinary tract should be undertaken.

In those patients with urinary tract reconstruction using bowel segments, regulatory investigations concerning renal function, acid base balance and vitamin B12 status are mandatory to avoid metabolic complications. There is an increased risk for secondary malignancies in patients with a neurogenic bladder either with or even without enteric bladder augmentations [618, 619, 675-681]. Therefore, patients need to be informed about this risk and possible signs like haematuria. Although there are poor data on follow-up schemes to discover secondary malignancies, after a reasonable follow-up time (e.g. ten to fifteen years), an annual cystoscopy can be considered.

#### 3.11.6 **Self-organisation of patients**

As patients' self-organisations can support the parents, caregivers and the patients in all aspects of their daily life, patients should be encouraged to join these organisations.

Figure 6: Algorithm for the management of children with myelodysplasia with a neurogenic bladder



CAP = continuous antibiotic prophylaxis; CIC = clean intermittent catheterisation; US = ultrasound; VCUG = voiding cystourethrography; VUD = videourodynamic; VUR = vesicoureteric reflux.

### 3.11.7 Summary of evidence and recommendations for the management of neurogenic bladder

Summary of evidence	LE
Neurogenic detrusor-sphincter dysfunction may result in different forms of LUTD and ultimately result in incontinence, UTIs, VUR, and renal scarring.	2a
In children, the most common cause of NDSD is myelodysplasia (a group of developmental anomalies that result from defects in neural tube closure).	2
Bladder sphincter dysfunction correlates poorly with the type and level of the spinal cord lesion. Therefore, urodynamic and functional classifications are more practical in defining the extent of the pathology and in guiding treatment planning.	2a
Children with neurogenic bladder can have disturbances of bowel function as well as urinary function which require monitoring and, if needed, management.	2a
The main goals of treatment are prevention of urinary tract deterioration and achievement of continence at an appropriate age.	2a
Injection of botulinum toxin into the detrusor muscle in children who are refractory to anticholinergics, has been shown to have beneficial effects on clinical and urodynamic variables.	2a

Recommendations	LE	Strength rating
Urodynamic studies should be performed in every patient with spina bifida as well as in every child with high suspicion of a neurogenic bladder to estimate the risk for the upper urinary tract and to evaluate the function of the detrusor and the sphincter.	2	Strong
In all newborns, intermittent catheterisation (IC) should be started soon after birth. In those with a clear underactive sphincter and no overactivity starting IC may be delayed. If IC is delayed, closely monitor babies for urinary tract infections, upper tract changes (US) and lower tract (UD).	3	Strong
Start early anticholinergic medication in the newborns with suspicion of an overactive detrusor.	2	Strong
The use of suburothelial or intradetrusor injection of onabotulinum toxin A is an alternative and a less invasive option in children who are refractory to anticholinergics in contrast to bladder augmentation.	2	Strong
Treatment of faecal incontinence is important to gain continence and independence. Treatment should be started with mild laxatives, rectal suppositories as well as digital. If not sufficient transanal irrigation is recommended, if not practicable or feasible, a Malone antegrade colonic enema (MACE)/Antegrade continence enema (ACE) stoma should be discussed.	3	Strong
Ileal or colonic bladder augmentation is recommended in patients with therapy-resistant overactivity of the detrusor, small capacity and poor compliance, which may cause upper tract damage and incontinence. The risk of surgical and nonsurgical complications and consequences outweigh the risk for permanent damage of the upper urinary tract +/- incontinence due to the detrusor.	2	Strong
In patients with a neurogenic bladder and a weak sphincter, a bladder outlet procedure should be offered. It should be done in most patients together with a bladder augmentation.	3	Weak
Creation of a continent cutaneous catheterisable channel should be offered to patients who have difficulties in performing an IC through the urethra.	3	Weak
A life long follow-up of renal and reservoir function should be available and offered to every patient. Addressing sexuality and fertility starting before/during puberty should be offered.	3	Weak
Urinary tract infections are common in children with neurogenic bladders, however, only symptomatic UTIs should be treated.	3	Weak

## 3.12 Dilatation of the upper urinary tract (UPJ and UVJ obstruction)

### 3.12.1 Epidemiology, aetiology and pathophysiology

Dilatation of the UUT remains a significant clinical challenge in deciding which patient will benefit from treatment. Ureteropelvic junction (UPJ) obstruction is defined as impaired urine flow from the pelvis into the proximal ureter with subsequent dilatation of the collecting system and the potential to damage the kidney. It is the most common pathological cause of neonatal hydronephrosis [682]. It has an overall incidence of 1:1,500 and a ratio of males to females of 2:1 in newborns.

Ureterovesical junction (UVJ) obstruction is an obstructive condition of the distal ureter as it enters the bladder, commonly called a primary obstructive megaureter. Megaureters are the second most likely cause of neonatal hydronephrosis. They occur more often in males and are more likely to occur on the left side [683].

It can be very difficult to define 'obstruction' as there is no clear division between 'obstructed' and 'non-obstructed' urinary tracts. Currently, the most popular definition is that an obstruction represents any restriction to urinary outflow that, if left untreated, will cause progressive renal deterioration [684].

### 3.12.2 **Diagnostic evaluation**

The widespread use of US during pregnancy has resulted in a higher detection rate for antenatal hydronephrosis [685]. The challenge in the management of dilated UUT is to decide which child should be observed, which should be managed medically, and which requires surgical intervention. Despite the wide range of diagnostic tests, there is no single test that can accurately distinguish obstructive from non-obstructive cases (see Figure 7).

#### 3.12.2.1 *Antenatal ultrasound*

Usually between the 16<sup>th</sup> and 18<sup>th</sup> weeks of pregnancy, the kidneys are visualised routinely, when almost all amniotic fluid consists of urine. The most sensitive time for foetal urinary tract evaluation is the 28<sup>th</sup> week. If dilatation is detected, US should focus on:

- laterality, severity of dilatation, and echogenicity of the kidneys;
- hydronephrosis or hydro-ureteronephrosis;
- bladder volume and bladder emptying;
- sex of the child;
- amniotic fluid volume [686].

#### 3.12.2.2 *Postnatal ultrasound*

Since transitory neonatal dehydration lasts about 48 hours after birth, imaging should be performed following this period of postnatal oliguria. However, in severe cases (bilateral dilatation, solitary kidney, oligohydramnios), immediate postnatal sonography is recommended [687]. Ultrasound should assess the anteroposterior diameter of the renal pelvis, calyceal dilatation, kidney size, thickness of the parenchyma, cortical echogenicity, ureters, bladder wall and residual urine.

#### 3.12.2.3 *Voiding cystourethrogram*

In newborns with identified UUT dilatation, the primary or important associated factors that must be detected include:

- vesicoureteral reflux (found in up to 25% of affected children) [688];
- urethral valves;
- ureteroceles;
- diverticula;
- neurogenic bladder.


Conventional VCUG is the method of choice for primary diagnostic procedures [689].

#### 3.12.2.4 *Diuretic renography*

Diuretic renography is the most commonly used diagnostic tool to detect the severity and functional significance of problems with urine transport. Technetium-99m (99mTc) mercaptoacetyltriglycine (MAG3) is the radionuclide of choice. It is important to perform the study under standardised circumstances (hydration, transurethral catheter) after the fourth and sixth weeks of life [690]. Oral fluid intake is encouraged prior to the examination. At fifteen minutes before the injection of the radionuclide, it is mandatory to administer normal saline intravenous infusion at a rate of 15 mL/kg over 30 minutes, with a subsequent maintenance rate of 4 mL/kg/h throughout the entire time of the investigation [691]. The recommended dose of furosemide is 1 mg/kg for infants during the first year of life, while 0.5 mg/kg should be given to children aged one to sixteen years, up to a maximum dose of 40 mg.



**Figure 7: Diagnostic algorithm for dilatation of the upper urinary tract**



\* A diagnostic work-up including VCUG must be discussed with the caregivers, as it is possible that, even if reflux is detected, it may have absolutely no clinical impact. However, it should be borne in mind that reflux has been detected in up to 25% of cases of prenatally detected and postnatally confirmed hydronephrosis [687]. US = ultrasound.

### 3.12.3 Management

#### 3.12.3.1 Prenatal management

Counselling the caregivers of an affected child is one of the most important aspects of care. The prognosis is hopeful for a hydronephrotic kidney, even if it is severely affected, as it may still be capable of meaningful renal function, unlike a severely hypoplastic and dysplastic kidney.

It is important to be able to tell the caregivers exactly when they will have a definitive diagnosis for their child and what this diagnosis will mean. In some cases, however, it will be immediately obvious that the child is severely affected; there will be evidence of massive bilateral dilatation, bilateral hypoplastic dysplasia, progressive bilateral dilatation with oligohydramnios, and pulmonary hypoplasia.

Intrauterine intervention is rarely indicated and should only be performed in well-experienced centres [692].

##### 3.12.3.1.1 Antibiotic prophylaxis for antenatal hydronephrosis

The benefits and harms of continuous antibiotic prophylaxis (CAP) vs. observation in patients with antenatal hydronephrosis are controversial. Currently, only two RCTs have been published, one of which is a pilot trial [693] and the other publication is only available as a congress abstract [694]. Both publications present incomplete data and outcomes.

The Panel conducted a SR assessing the literature from 1980 onwards [695]. The key findings are summarised below.

Due to the heterogeneity of the published literature it was not possible to draw strong conclusions as to whether CAP is superior to observation alone in children diagnosed with antibiotic prophylaxis for antenatal hydronephrosis (ANH). In the first RCT, a prospective longitudinal study [693], female gender, uncircumcised males, lack of CAP, high-grade hydronephrosis, hydroureteronephrosis and VUR were found to be the independent predictors for the development of UTI. The second RCT included in the SR, was published as an abstract only, presented limited data [694]. This trial seemed to focus mainly on patients with ANH and VUR and did not report any beneficial effect of CAP on UTI rates, but details on the study population were limited.

Key findings of the SR are that CAP may or may not be superior to observation in children with antenatal hydronephrosis in terms of decreasing UTI. Due to the low data quality it was also not possible to establish whether boys or girls are at a greater risk of developing a UTI, or ascertain the presence or absence of VUR impacts UTI rates. A correlation between VUR-grade and UTI could not be established either. However, non-circumcised infants, children diagnosed with high-grade hydronephrosis and hydroureteronephrosis were shown to be at higher risk of developing a UTI.

The SR also tried to identify the most effective antibiotic regimen and present data on adverse effects but, due to heterogeneity, the available data could not be statistically compared. The most commonly used antibiotic in infants with antenatal hydronephrosis is trimethoprim, but only one study reported side effects [693].

In conclusion, based on the currently available evidence, the benefits and harms of CAP in children with antenatal hydronephrosis remain unproven. Uncircumcised infants and infants with hydroureteronephrosis and high-grade hydronephrosis are more likely to develop a UTI. Continuous antibiotic prophylaxis should be reserved for this sub-group of children who are proven to be at high risk.

### 3.12.3.2 UPJ obstruction

It is most important that management decisions are made on the basis of serial investigations that have used the same technique and have been performed by the same institution under standardised circumstances.

Symptomatic obstruction (recurrent flank pain, UTI) requires surgical correction using a pyeloplasty, according to the standardised open technique of Hynes and Anderson [696]. In experienced hands, laparoscopic or retroperitoneoscopic techniques and robot-assisted techniques have the same success rates as standard open procedures. In asymptomatic cases, conservative follow-up is the treatment of choice.

Indications for surgical intervention comprise impaired split renal function (< 40%), a decrease of split renal function of > 10% in subsequent studies, poor drainage function after the administration of furosemide, increased anteroposterior diameter on US, and grade III and IV dilatation as defined by the Society for Fetal Urology [486].

Well-established benefits of conventional laparoscopy over open surgery are the decreased length of hospital stay, better cosmesis, less post-operative pain and early recovery [697, 698]. A recent meta-analysis in children has shown that laparoscopic pyeloplasty (LP) was associated with decreased length of hospital stay and complication rates but prolonged operative time when compared to open pyeloplasty (OP). Additionally, both LP and OP had equal success rates [699]. Robotic-assisted laparoscopic pyeloplasty (RALP) has all the same advantages as LP plus better manoeuvrability, improved vision, ease in suturing and increased ergonomics but higher costs [700, 701]. There does not seem to be any clear benefit of minimal invasive procedures in a very young child but current data is insufficient to defer a cut-off age.

### 3.12.3.3 Megaureter

The treatment options of secondary megaureters are reviewed in Chapter 3.13.3.

#### 3.12.3.3.1 Non-operative management

If a functional study reveals and confirms adequate ureteral drainage, conservative management is the best option. Initially, low-dose prophylactic antibiotics within the first year of life are recommended for the prevention of UTIs, although there are no existing prospective randomised trials evaluating the benefit of this regimen [702]. With spontaneous remission rates of up to 85% in primary megaureter cases, surgical management is no longer recommended, except for megaureters with recurrent UTIs, deterioration of split renal function and significant obstruction [703].

#### 3.12.3.3.2 Surgical management

In general, surgery is indicated for symptomatic children and if there is a drop in function in conservative follow-up and hydroureteronephrosis is increasing [704]. Data suggest that children with a ureteric diameter of > 10-15 mm are more likely to require intervention [705].

The initial approach to the ureter can be either intravesical, extravesical or combined. Straightening the ureter is necessary without devascularisation. Ureteral tapering should enhance urinary flow into the bladder. The ureter must be tapered to achieve a diameter for an anti-reflux repair. Several tailoring techniques exist, such as ureteral imbrication or excisional tapering [706]. Some institutions perform endoscopic stenting, but there is still no long-term data and no prospective randomised trials to confirm their outcome.

### 3.12.4 Conclusion

The use of routine perinatal sonography has resulted in increased detection of hydronephrosis caused by UPJ or UVJ obstruction. Meticulous and repeat postnatal evaluation is mandatory to try to identify obstructive cases at risk of renal deterioration and requiring surgical reconstruction. Surgical methods are quite standardised and have a good clinical outcome.

### 3.12.5 Summary of evidence and recommendations for the management of UPJ-, UVJ-obstruction

Summary of evidence	LE
Nowadays, most hydronephrotic kidneys have already been diagnosed prenatally during a maternal US investigation.	2
Ureteropelvic junction obstruction is the leading cause of hydronephrotic kidneys (40%).	1
In children diagnosed with antenatal hydronephrosis, a systematic review could not establish any benefits or harms related to continuous antibiotic prophylaxis.	1b
In children diagnosed with antenatal hydronephrosis, non-circumcised infants (LE: 1a), children diagnosed with high-grade hydronephrosis (LE: 2) and hydroureteronephrosis (LE: 1b) were shown to be at higher risk of developing UTI.	2

Recommendations	LE	Strength rating
Include serial ultrasound (US) and subsequent diuretic renogram and sometimes voiding cystourethrography in postnatal investigations.	2	Strong
Offer continuous antibiotic prophylaxis to the subgroup of children with antenatal hydronephrosis who are at high risk of developing urinary tract infection like uncircumcised infants, children diagnosed with hydroureteronephrosis and highgrade hydronephrosis, respectively.	2	Weak
Decide on surgical intervention based on the time course of the hydronephrosis and the impairment of renal function.	2	Weak
Offer surgical intervention in case of an impaired split renal function due to obstruction or a decrease of split renal function in subsequent studies and increased anteroposterior diameter on the US, and grade IV dilatation as defined by the Society for Fetal Urology.	2	Weak
Offer pyeloplasty when ureteropelvic junction obstruction has been confirmed clinically or with serial imaging studies proving a substantially impaired or decrease in function.	2	Weak
Do not offer surgery as a standard for primary megaureters since the spontaneous remission rates are as high as 85%.	2	Strong

### 3.13 Vesicoureteric reflux

Lack of robust prospective RCTs limits the strength of the established guidelines for the management of VUR. The scientific literature for reflux disease is still limited and the level of evidence is generally low. Most of the studies are retrospective, include different patient groups, and have poor stratification of quality. Also, there is a high risk of presenting misleading results by combining different types of studies when systematically extracting data. Therefore, for reflux disease, it is unfortunately not possible to produce recommendations based on high-quality studies. The Panel have assessed the current literature, but in the absence of conclusive findings, have provided recommendations based on panel consensus.

These Guidelines aim to provide a practical approach to the treatment of VUR based on risk analysis and selective indications for both diagnostics and intervention. Although the Panel tried to summarise most of the possible scenarios in one single table, the table itself is still quite busy. The panel strongly share the view that making simple and practical guidelines would underestimate the complexity of VUR as a sign of a wide range of pathologies [707].

#### 3.13.1 Epidemiology, aetiology and pathophysiology

Vesicoureteric reflux is an anatomical and/or functional disorder with potentially serious consequences, such as renal scarring, hypertension and renal failure. Patients with VUR present with a wide range of severity, and a good proportion of reflux patients do not develop renal scars and probably do not need any intervention [708]. Vesicoureteric reflux is a very common urological anomaly in children, with an incidence of nearly 1%.

The main management goal is the preservation of kidney function, by minimising the risk of pyelonephritis. By defining and analysing the risk factors for each patient (i.e. age, sex, reflux grade, LUTD, anatomical abnormalities, and kidney status), it is possible to identify those patients with a potential risk of UTIs and renal scarring. Controversy persists over the optimal management of VUR, particularly the choice of diagnostic procedures, treatment (medical, endoscopic or surgical), and the timing of treatment.

Many children present without symptoms of UTI and, because invasive diagnostic procedures are performed only when clinically indicated, the exact prevalence of VUR is unknown. However, the prevalence

of VUR in non-symptomatic children has been estimated at 0.4-1.8% [709]. Among infants prenatally identified with hydronephrosis on US, who were screened for VUR, the prevalence was 16.2% (7-35%) [710]. Siblings of children with VUR had a 27.4% (3-51%) risk of also having VUR, whereas the offspring of parents with VUR had a higher incidence of 35.7% (21.2-61.4%) [710].

However, reflux detected by sibling screening is associated with lower grades [710] and significantly earlier resolution [711]. When VUR is discovered in siblings after UTI, it is usually high-grade and associated with a high incidence of reflux nephropathy, particularly if the sibling is male and the grade of reflux was high in the index patient [712].

The incidence of VUR is much higher among children with UTIs (30-50%, depending on age). Urinary tract infections are more common in girls than boys due to anatomical differences. However, among all children with UTIs, boys are more likely to have VUR than girls (29% vs. 14%). Boys also tend to have higher grades of VUR diagnosed at younger ages, although their VUR is more likely to resolve itself [713-716].

There is a clear co-prevalence between LUTD and VUR [362]. Lower urinary tract dysfunction refers to the presence of LUTS, including urge, urge incontinence, weak stream, hesitancy, frequency and UTIs, which reflect the filling and/or emptying dysfunction and may be accompanied with bowel problems [362]. Some studies have described a prevalence of 40-60% for VUR in children with LUTD [717]. A published Swedish reflux trial has demonstrated LUTD in 34% of patients, and subdivision into groups characteristic of children revealed that 9% had isolated overactive bladder and 24% had voiding phase dysfunction [718].

The spontaneous resolution of VUR is dependent on age at presentation, sex, grade, laterality, mode of clinical presentation, and anatomy [711]. Faster resolution of VUR is more likely with age less than one year at presentation, lower grade of reflux (grade 1-3), and asymptomatic presentation with prenatal hydronephrosis or sibling reflux. The overall resolution rate is high in congenital high-grade VUR during the first years of life. In several Scandinavian studies, the complete resolution rate for high-grade VUR has been reported at > 25%, which is higher than the resolution rate for VUR detected after infancy [718-720].

The presence of renal cortical abnormality, bladder dysfunction, and breakthrough febrile UTIs are negative predictive factors for reflux resolution [721-723].

Dilating VUR increases the risk of developing acute pyelonephritis and renal scarring. Untreated recurrent UTIs may have a negative impact on somatic growth and medical status of the child. Evidence of renal scarring is present in 10-40% of children with symptomatic VUR, resulting from either congenital dysplasia and/or acquired post-infectious damage, which may have a negative impact on somatic growth and general well-being [724-726].

Scar rates vary in different patient groups. Patients with higher grades of VUR present with higher rates of renal scars. In those with prenatal hydronephrosis, renal scarring occurs in 10% of patients [727-732], whereas in patients with LUTD, this may increase up to 30% [500, 726, 733]. Renal scarring may adversely affect renal growth and function, with bilateral scarring increasing the risk of insufficiency. Reflux nephropathy (RN) may be the most common cause of childhood hypertension. Follow-up studies have shown that 10-20% of children with RN develop hypertension or end-stage renal disease [734].

### 3.13.2 **Diagnostic evaluation**

The diagnostic work-up should aim to evaluate the overall health and development of the child, the presence of UTIs, renal status, the presence of VUR, and LUT function. A basic diagnostic work-up comprises a detailed medical history (including family history, and screening for LUTD), physical examination including blood pressure measurement, urinalysis (assessing proteinuria), urine culture, and serum creatinine in patients with bilateral renal parenchymal abnormalities.

The standard imaging tests include renal and bladder US, VCUG and nuclear renal scans. The criterion standard in diagnosis of VUR is VCUG, especially at the initial work-up. This test provides precise anatomical detail and allows grading of VUR [735]. In 1985, the International Reflux Study Committee introduced a uniform system for the classification of VUR [736, 737] (Table 7). The grading system combines two earlier classifications and is based upon the extent of retrograde filling and dilatation of the ureter, renal pelvis and calyces on VCUG [737].

Radionuclide studies for detection of reflux have lower radiation exposure than VCUG, but the anatomical details depicted are inferior [738]. Recent studies on alternative imaging modalities for detection on VUR have yielded good results with voiding US and magnetic resonance VCUG [739-741]. Contrast enhanced voiding urosonography with intravesical instillation of different ultrasound contrast agents has been shown to be highly sensitive giving comparable results with conventional VCUG while avoiding exposure to ionising radiation [742, 743]. However, despite the concerns about ionising radiation and its invasive nature, conventional VCUG still remains the gold standard because it allows better determination of the grade of VUR (in a single or duplicated kidney) and assessment of the bladder and urethral configuration.

**Table 7: Grading system for VUR on VCUG, according to the International Reflux Study Committee [744]**

<b>Grade I</b>	Reflux does not reach the renal pelvis; varying degrees of ureteral dilatation
<b>Grade II</b>	Reflux reaches the renal pelvis; no dilatation of the collecting system; normal fornices
<b>Grade III</b>	Mild or moderate dilatation of the ureter, with or without kinking; moderate dilatation of the collecting system; normal or minimally deformed fornices
<b>Grade IV</b>	Moderate dilatation of the ureter with or without kinking; moderate dilatation of the collecting system; blunt fornices, but impressions of the papillae still visible
<b>Grade V</b>	Gross dilatation and kinking of the ureter, marked dilatation of the collecting system; papillary impressions no longer visible; intraparenchymal reflux

Dimercaptosuccinic acid is the best nuclear agent for visualising the cortical tissue and differential function between both kidneys. Dimercaptosuccinic acid is taken up by proximal renal tubular cells and is a good indicator of renal parenchyma function. In areas of acute inflammation or scarring, DMSA uptake is poor and appears as cold spots. Dimercaptosuccinic acid scans are therefore used to detect and monitor renal scarring. A baseline DMSA scan at the time of diagnosis can be used for comparison with successive scans later during follow-up [745]. Dimercaptosuccinic acid can also be used as a diagnostic tool during suspected episodes of acute pyelonephritis [746]. Children with a normal DMSA scan during acute UTI have a low-risk of renal damage [746, 747].

Video-urodynamic studies are only important in patients in whom secondary reflux is suspected, such as those with spina bifida or boys in whom VCUG is suggestive of posterior urethral valves. In the case of LUTS, diagnosis and follow-up can be limited to non-invasive tests (e.g. voiding charts, US, or uroflowmetry) [362]. Cystoscopy has a limited role in evaluating reflux, except for infravesical obstruction or ureteral anomalies that might influence therapy.

### 3.13.2.1 *Infants presenting because of prenatally diagnosed hydronephrosis*

Ultrasound of the kidney and bladder is the first standard evaluation tool for children with prenatally diagnosed hydronephrosis. It is non-invasive and provides reliable information regarding kidney structure, size, parenchymal thickness and collecting system dilatation [748, 749].

Ultrasound should be delayed until the first week after birth because of early oliguria in the neonate. It is essential to evaluate the bladder, as well as the kidneys. The degree of dilatation in the collecting system under US, when the bladder is both full and empty, may provide significant information about the presence of VUR. Bladder wall thickness and configuration may be an indirect sign of LUTD and reflux. The absence of hydronephrosis on postnatal US excludes the presence of significant obstruction; however, it does not exclude VUR.

Monitoring with careful US avoids unnecessary invasive and irradiating examinations. The first two US scans within the first one to two months of life are highly accurate for defining the presence or absence of renal pathology. In infants with two normal, successive scans, VUR is rare, and if present it is likely to be low-grade [727, 750]. The degree of hydronephrosis is not a reliable indicator for the presence of VUR, even though cortical abnormalities are more common in high-grade hydronephrosis [710]. The presence of cortical abnormalities on US (defined as cortical thinning and irregularity, as well as increased echogenicity) warrants the use of VCUG for detecting VUR [710]. Dimercaptosuccinic acid provides more reliable and quantitative measurement of the degree of cortical abnormalities, first detected with US.

The use of VCUG is recommended in patients with US findings of bilateral high-grade hydronephrosis, duplex kidneys with hydronephrosis, ureterocele, ureteric dilatation, and abnormal bladders, because the likelihood of VUR is much higher. In all other conditions, the use of VCUG to detect reflux is optional [710, 729, 751-753].

When infants who are diagnosed with prenatal hydronephrosis become symptomatic with UTIs, further evaluation with VCUG should be considered [752]. Patients with severe hydronephrosis and those whose hydronephrosis is sustained or progressive, need further evaluation to exclude obstruction.

### 3.13.2.2 *Siblings and offspring of reflux patients*

The screening of asymptomatic siblings and offspring is controversial. Some authors think that early identification of children with VUR may prevent episodes of UTI and therefore renal scarring, whereas others think that screening asymptomatic individuals is likely to result in significant over-treatment of clinically insignificant VUR. In screened populations the prevalence of VUR is 27.4% in siblings and 35.7% in offspring [744]. The overall estimate for renal cortical abnormalities is 19.3% (11-54%), with 27.8% having renal damage in cohorts of symptomatic and asymptomatic children combined. In asymptomatic siblings only,

the rate of renal damage is 14.4% (0-100%). Although early screening and therefore early diagnosis and treatment appears to be more effective than late screening in preventing further renal damage [710, 712, 754, 755], screening in all siblings and offspring cannot be recommended based on the available evidence. The lack of RCTs for screened patients to assess clinical health outcomes makes evidence-based guideline recommendations difficult.

### 3.13.2.3 Recommendations for paediatric screening of VUR

Recommendations	Strength rating
Inform parents of children with vesicoureteric reflux (VUR) that siblings and offspring have a high prevalence of VUR.	Strong
Use renal ultrasound (US) for screening of sibling(s).	Strong
Use voiding cystourethrography if there is evidence of renal scarring on US or a history of urinary tract infection.	Weak
Do not screen older toilet-trained children since there is no added value in screening for VUR.	Weak

### 3.13.2.4 Children with febrile urinary tract infections

A routine recommendation of VCUG at zero to two years of age after the first proven febrile UTI is the safest approach as the evidence for the criteria to selecting patients for reflux detection is weak. Children with febrile infections and abnormal renal US findings may have higher risk of developing renal scars and they should all be evaluated for reflux [756]. If reflux is diagnosed, further evaluation has traditionally consisted of a DMSA scan.

An alternative “top-down” approach is also an option, as suggested by several studies in the literature. This approach carries out an initial DMSA scan close to the time of a febrile UTI, to determine the presence of pyelonephritis, which is then followed by VCUG if the DMSA scan reveals kidney involvement. A normal DMSA scan with no subsequent VCUG will fail to spot VUR in 5-27% of cases, with the missed VUR presumably being less significant. In contrast, a normal DMSA scan with no VCUG avoids unnecessary VCUG in > 50% of those screened [355, 757-759].

### 3.13.2.5 Children with lower urinary tract symptoms and vesicoureteric reflux

Detection of LUTD is essential in treating children with VUR. It is suggested that reflux with LUTD resolves faster after LUTD correction, and that patients with LUTD are at higher risk for developing UTI and renal scarring [718, 760]. The co-existence of both conditions should be explored in any patient who has VUR. If there are symptoms suggestive of LUTD (e.g. urgency, wetting, constipation or holding manoeuvres), an extensive history and examination, including voiding charts, uroflowmetry and residual urine determination, will reliably diagnose underlying LUTD.

Among toilet-trained children, those with both LUTD and VUR are at higher risk of developing recurrent UTIs than children with isolated VUR [761].

In LUTD, VUR is often low-grade and US findings are normal, and there is no indication for performing VCUG in all children with LUTD, but the presence of febrile infections should be meticulously investigated. The co-existence of LUTD and VUR means it would be better to do a test covering both conditions, such as a videourodynamic study (VUDS). Any patient with LUTD and a history of febrile UTI should be investigated with a VUDS, if available. Furthermore, any child who fails standard therapy for LUTD should undergo urodynamic investigation. At this stage, combining a urodynamic study with VCUG is highly recommended.

## 3.13.3 Disease management

There are two main treatment approaches: conservative (non-surgical and surgical).

### 3.13.3.1 Non-surgical therapy

The objective of conservative therapy is prevention of febrile UTI. It is based on the understanding that:

- Vesicoureteric reflux resolves spontaneously, mostly in young patients with low-grade reflux. Resolution is nearly 80% in VUR grades I and II and 30-50% in VUR grades III-V within four to five years of follow-up. Spontaneous resolution is low for bilateral high-grade reflux [762].
- Vesicoureteric reflux does not damage the kidney when patients are free of infection and have normal LUT function.
- There is no evidence that small scars can cause hypertension, renal insufficiency or problems during pregnancy. Indeed, these are possible only in cases of severe bilateral renal damage.
- The conservative approach includes watchful waiting, intermittent or continuous antibiotic prophylaxis, and bladder rehabilitation in those with LUTD [500, 760, 763-765].

- Circumcision during early infancy may be considered as part of the conservative approach because it is effective in reducing the risk of infection in normal children [766].

#### 3.13.3.1.1 Follow-up

Regular follow-up with imaging studies (e.g. VCUG, nuclear cystography, or DMSA scan) is part of the conservative management to monitor spontaneous resolution and kidney status. Conservative management should be dismissed in all cases of febrile breakthrough infections, despite prophylaxis, and intervention should be considered.

#### 3.13.3.1.2 Continuous antibiotic prophylaxis

Vesicoureteral reflux increases the risk of UTI and renal scarring especially when in combination with LUTD. Many prospective studies have evaluated the role of continuous antibiotic prophylaxis in the prevention of recurrent UTI and renal scarring.

It is clear that antibiotic prophylaxis may not be needed in every reflux patient [767-769]. Trials show the benefit of CAP is none or minimal in low-grade reflux. Continuous antibiotic prophylaxis is useful in patients with grade III and IV reflux in preventing recurrent infections but its use in preventing further renal damage is not proven. Toilet-trained children and children with LUTD derive much better benefit from CAP [388-391, 769, 770]. The RIVUR trial was the largest, randomised, placebo-controlled, double blind, multi-centre study, involving 607 children aged 2-72 months with grade I-IV VUR. The RIVUR study showed that prophylaxis reduced the risk of recurrent UTI by 50% but not renal scarring and its consequences (hypertension and renal failure), at the cost of increased antimicrobial resistance. The benefit of prophylaxis was insignificant in patients with grade III or IV VUR and in the absence of LUTD [393, 771-773]. Additional review of the RIVUR data based on a risk classification system defines a high risk group (uncircumcised males; presence of BBD and high grade reflux) who would benefit from a antibiotic prophylaxis significantly. Therefore selective prophylaxis for this group is recommended [774].

It may be difficult and risky to select patients who do not need CAP. A safe approach would be to use CAP in most cases. Decision-making may be influenced by the presence of risk factors for UTI, such as young age, high-grade VUR, status of toilet-training/LUTS, female sex, and circumcision status. Although the literature does not provide any reliable information about the duration of CAP in reflux patients, a practical approach would be to use CAP until after children have been toilet-trained and ensuring that there is no LUTD. Continuous antibiotic prophylaxis is mandatory in patients with LUTD and reflux. Active surveillance of UTI is needed after CAP is discontinued. The follow-up scheme and the decision to perform an anti-reflux procedure or discontinuation of CAP may also depend on personal preferences and the attitude of patients and caregivers. It is strongly advised that the advantages and disadvantages should be discussed in detail with the family.

#### 3.13.3.2 *Surgical treatment*

Surgical treatment can be carried out by endoscopic injection of bulking agents or ureteral re-implantation.

##### 3.13.3.2.1 Subureteric injection of bulking materials

With the availability of biodegradable substances, endoscopic subureteric injection of bulking agents has become an alternative to long-term antibiotic prophylaxis and open surgical intervention in the treatment of VUR in children. Using cystoscopy, a bulking material is injected beneath the intramural part of the ureter in a submucosal location. The injected bulking agent elevates the ureteral orifice and the distal ureter, so that coaptation is increased. This results in narrowing of the lumen, which prevents reflux of urine into the ureter, while still allowing its antegrade flow.

Several bulking agents have been used over the past two decades, including polytetrafluoroethylene (PTFE or Teflon™), collagen, autologous fat, polydimethylsiloxane, silicone, chondrocytes, a solution of dextranomer/hyaluronic acid (Deflux, Dexell) and more recently polyacrylate-polyalcohol copolymer hydrogel (Vantris) [775, 776].

Although the best results have been obtained with PTFE [777], due to concerns about particle migration, PTFE has not been approved for use in children [778]. Although they are all biocompatible, other compounds such as collagen and chondrocytes have failed to provide a good outcome. Deflux was approved by the USA FDA in 2001 for the treatment of VUR in children. Initial clinical trials have demonstrated that this method is effective in treating reflux [779]. Studies with long-term follow-up have shown that there is a high recurrence rate which may reach as high as 20% in two years [769].

In a meta-analysis [780] of 5,527 patients and 8,101 renal units, the reflux resolution rate (by ureter) following one treatment for grades I and II reflux was 78.5%, 72% for grade III, 63% for grade IV, and 51% for grade V. If the first injection was unsuccessful, the second treatment had a success rate of 68% and the third treatment 34%. The aggregate success rate with one or more injections was 85%. The success rate was

significantly lower for duplicated (50%) vs. single (73%) systems, and neuropathic (62%) vs. normal (74%) bladders.

Obstruction at UVJ may happen in the long term follow-up after endoscopic correction of reflux. Patients with high grade reflux and dilated ureters are at risk of late obstruction. It is significantly more common when polyacrylate-polyalcohol copolymer is used as bulking substance [781-783].

Clinical validation of the effectiveness of anti-reflux endoscopy is currently hampered by the lack of methodologically appropriate studies. In the most recent prospective, randomised trials comparing three treatment arms: i) endoscopic injection; ii) antibiotic prophylaxis; iii) surveillance without antibiotic prophylaxis in 203 children aged one to two years with grade III/IV reflux, endoscopic treatment gave the highest resolution rate of 71% compared to 39% and 47% for treatment arms ii and iii, respectively, after two years' follow-up. The recurrence rate at two years after endoscopic treatment was 20%. The occurrence of febrile UTIs and scar formation was highest in the surveillance group at 57% and 11%, respectively. New scar formation rate was higher with endoscopic injection (7%) compared with antibiotic prophylaxis (0%) [784]. Longer follow-up studies are needed to validate these findings.

#### 3.13.3.2.2 Open surgical techniques

Various intra- and extravesical techniques have been described for the surgical correction of reflux. Although different methods have specific advantages and complications, they all share the basic principle of lengthening the intramural part of the ureter by submucosal embedding of the ureter. All techniques have been shown to be safe with a low rate of complications and excellent success rates (92-98%) [785].

The most popular and reliable open procedure is cross trigonal re-implantation described by Cohen [783]. The main concern with this procedure is the difficulty of accessing the ureters endoscopically if needed when the child is older. Alternatives are suprahiatal re-implantation (Politano-Leadbetter technique) and infrahiatal re-implantation (Glenn-Anderson technique). If an extravesical procedure (Lich-Gregoir) is planned, cystoscopy should be performed pre-operatively to assess the bladder mucosa and the position and configuration of the ureteric orifices. In bilateral reflux, an intravesical anti-reflux procedure may be considered, because simultaneous bilateral extravesical reflux repair carries an increased risk of temporary post-operative urine retention [786]. Overall, all surgical procedures offer very high and similar success rates for correcting VUR.

#### 3.13.3.2.3 Laparoscopy and robot-assisted

There have been a considerable number of case series of transperitoneal, extravesical and pneumovesicoscopic intravesical ureteral re-implantation, which have shown the feasibility of the techniques. Various anti-reflux surgeries have been performed with the robot and the extravesical approach is the most commonly used. Although initial reports give comparable outcomes to their open surgical counterparts in terms of successful resolution of reflux, recent meta-analysis of results of RALUR are within a wide range of variation and on average they are poor compared to open surgery. Operative times, costs and post-operative complications leading to secondary interventions are higher with RALUR but post-operative pain and hospital stay is less compared to open surgery [787-790].

Also, laparoscopic or robotic assisted approaches are more invasive than endoscopic correction and their advantages over open surgery are still debated. Therefore, at present, a laparoscopic approach cannot be recommended as a routine procedure. It can be offered as an alternative to the caregivers in centres where there is established experience [766, 791-799].



3.13.4 **Summary of evidence and recommendations for the management of vesicoureteric reflux in childhood**

<b>Summary of evidence</b>
There is no evidence that correction of persistent low-grade reflux (grades I-III) without symptoms and normal kidneys offers a significant benefit.
The traditional approach of initial medical treatment after diagnosis and shifting to interventional treatment in case of breakthrough infections and new scar formation needs to be challenged, because the treatment should be tailored to different risk groups.
Surgical correction should be considered in patients with persistent high-grade reflux (grades IV/V). There is no consensus about the timing and type of surgical correction. The outcome of open surgical correction is better than endoscopic correction for higher grades of reflux, whereas satisfactory results can be achieved by endoscopic injection for lower grades.
The choice of management depends on the presence of renal scars, clinical course, grade of reflux, ipsilateral renal function, bilaterality, bladder function, associated anomalies of the urinary tract, age, compliance, and parental preference. Febrile UTI, high-grade reflux, bilaterality, and cortical abnormalities are considered to be risk factors for possible renal damage. The presence of LUTD is an additional risk factor for new scars.

<b>Recommendations</b>	<b>Strength rating</b>
Initially treat all patients diagnosed within the first year of life with continuous antibiotic prophylaxis, regardless of the grade of reflux or presence of renal scars.	Weak
Offer immediate, parenteral antibiotic treatment for febrile breakthrough infections.	Strong
Offer definitive surgical or endoscopic correction to patients with frequent breakthrough infections.	Weak
Offer open surgical correction to patients with persistent high-grade reflux and endoscopic correction for lower grades of reflux.	Strong
Initially manage all children presenting at age one to five years conservatively.	Strong
Offer surgical repair to children above the age of one presenting with high-grade reflux and abnormal renal parenchyma.	Weak
Offer close surveillance without antibiotic prophylaxis to children presenting with lower grades of reflux and without symptoms.	Strong
Ensure that a detailed investigation for the presence of lower urinary tract dysfunction (LUTD) is done in all and especially in children after toilet-training. If LUTD is found, the initial treatment should always be for LUTD.	Strong
Offer surgical correction, if parents prefer definitive therapy to conservative management.	Strong
Select the most appropriate management option based on: <ul style="list-style-type: none"> <li>• the presence of renal scars;</li> <li>• clinical course;</li> <li>• the grade of reflux;</li> <li>• ipsilateral renal function;</li> <li>• bilaterality;</li> <li>• bladder function;</li> <li>• associated anomalies of the urinary tract;</li> <li>• age and gender;</li> <li>• compliance;</li> <li>• parental preference.</li> </ul> Refer to Table 8 for risk factors and follow-up.	Weak
In high-risk patients who already have renal impairment, a more aggressive, multidisciplinary approach is needed.	Strong

**Table 8: Management and follow-up according to different risk groups**

Risk Groups	Presentation	Initial treatment	Comment	Follow-up
High	Symptomatic male or female patients after toilet-training with high-grade reflux (grades IV-V), abnormal kidneys and LUTD	Initial treatment is always for LUTD with CAP; intervention may be considered in cases of BT infections or persistent reflux	Greater possibility of earlier intervention	More aggressive follow-up for UTI and LUTD; full re-evaluation after 6 months
High	Symptomatic male or female patients after toilet-training with high-grade reflux (grade IV-V), abnormal kidneys and no LUTD	Intervention should be considered	Open surgery has better results than endoscopic surgery	Post-operative VCUG on indication only; follow-up of kidney status until after puberty
Moderate	Symptomatic male or female patients before toilet-training, with high-grade reflux and abnormal kidneys	CAP is the initial treatment. Intervention may be considered in cases of BT infections or persistent reflux	Spontaneous resolution is higher in males	Follow-up for UTI/hydronephrosis; full re-evaluation after 12-24 months
Moderate	Asymptomatic patients (PNH or sibling) with high-grade reflux and abnormal kidneys	CAP is the initial treatment. Intervention may be considered in cases of BT, infections or persistent reflux		Follow-up for UTI/hydronephrosis; full re-evaluation after 12-24 months
Moderate	Symptomatic male or female patients after toilet-training, with high-grade reflux and normal kidneys with LUTD	Initial treatment is always for LUTD with CAP. Intervention may be considered in cases of BT infections or persistent reflux	In case of persistent LUTD, despite urotherapy, intervention should be considered. The choice of intervention is controversial	Follow-up for UTI and LUTD, kidney status; full re-evaluation after successful urotherapy
Moderate	Symptomatic male or female patients after toilet-training with low-grade reflux, abnormal kidneys with or without LUTD	Choice of treatment is controversial. Endoscopic treatment may be an option. LUTD treatment should be given if needed		Follow-up for UTI, LUTD, and kidney status until after puberty
Moderate	All symptomatic patients with normal kidneys, with low-grade reflux, with LUTD	Initial treatment is always for LUTD with or without CAP		Follow-up for UTI and LUTD
Low	All symptomatic patients with normal kidneys, with low-grade reflux, with no LUTD	No treatment or CAP	If no treatment is given, parents should be informed about risk of infection	Follow-up for UTI
Low	All asymptomatic patients with normal kidneys with low-grade reflux	No treatment or CAP in infants	If no treatment is given, parents should be informed about risk of infection	Follow-up for UTI

*BT = breakthrough; CAP = continuous antibiotic prophylaxis; LUTD = lower urinary tract dysfunction; PNH = prenatal diagnosed hydronephrosis; UTI = urinary tract infection; VCUG = voiding cystourethrography.*

### **3.14 Urinary stone disease**

#### **3.14.1 Epidemiology, aetiology and pathophysiology**

Paediatric stone disease is an important clinical problem in paediatric urology practice. Due to its recurrent nature, every effort should be made to discover the underlying metabolic abnormality so that it can be treated appropriately. Obtaining a stone-free state with close follow-up are of the utmost importance, although, it may not be possible in some circumstances (e.g. oxalosis or nephrocalcinosis).

Bladder stones are still common in underdeveloped areas of the world and are usually ammonium acid urate and uric acid stones, strongly implicating dietary factors [800]. Patients with augmented bladder constitute another important group with a risk of up to 15% [801].

The incidence and characteristics of stones show a wide geographical variation in children. Although urinary stone disease is generally considered to be a relatively rare disease, it is quite common in some parts of the world. Paediatric stone disease is endemic in Turkey, Pakistan and in some South Asian, African and South American states. However, recent epidemiological studies have shown that the incidence of paediatric stone disease is also increasing in the Western world [802-804], especially in girls, Caucasian ethnicity, African Americans and older children [805]. More than 70% of stones in children contain calcium oxalate, while infection stones are found more frequently in younger children [806].

#### **3.14.2 Classification systems**

Urinary stone formation is the result of a complex process involving metabolic, anatomical factors and presence of infection.

##### **3.14.2.1 Calcium stones**

Calcium stones are usually made from calcium oxalate or calcium phosphate. Super-saturation of calcium (hypercalciuria) and oxalate (hyperoxaluria) or decreased concentration of inhibitors, such as citrate (hypocitraturia) or magnesium (hypomagnesemia) play a major role in the formation of calcium oxalate stones.

*Hypercalciuria:* This is defined by a 24-hour urinary calcium excretion of more than 4 mg/kg/day (0.1 mmol/kg/day) in a child weighing < 60 kg. In infants younger than three months, 5 mg/kg/day (0.125 mmol/kg/day) is considered to be the upper limit for normal calcium excretion [807].

Hypercalciuria can be classified as either idiopathic or secondary. Idiopathic hypercalciuria is diagnosed when clinical, laboratory, and radiographic investigations fail to delineate an underlying cause leading to hypercalcaemia. Urinary calcium may increase in patients with high sodium chloride intake. Secondary hypercalciuria occurs when a known process produces excessive urinary calcium. In secondary (hypercalcemic) hypercalciuria, a high serum calcium level may be due to increased bone resorption (hyperparathyroidism, hyperthyroidism, immobilisation, acidosis, metastatic disease) or gastrointestinal hyperabsorption (hypervitaminosis D) [808].

A good screening test for hypercalciuria compares the ratio of urinary calcium to creatinine. The normal calcium-to-creatinine ratio in children is less than 0.2. If the calculated ratio is higher than 0.2, repeat testing is indicated. Neonates and infants have a higher calcium excretion and lower creatinine excretion than older children [807, 808]. If the follow-up ratios are normal, then no additional testing for hypercalciuria is needed.

However, if the ratio remains elevated, a timed 24-hour urine collection should be obtained and the calcium excretion calculated.

The 24-hour calcium excretion test is the standard criterion for the diagnosis of hypercalciuria. If calcium excretion is higher than 4 mg/kg/day (0.1 mmol/kg/day), the diagnosis of hypercalciuria is confirmed and further evaluation is warranted: levels of serum bicarbonate, creatinine, alkaline phosphatase, calcium, phosphorus, magnesium, pH, and parathyroid hormone. Freshly voided urine should be measured for pH [807-809]. In addition to calcium, the 24-hour urine analysis should also include phosphorus, sodium, magnesium, uric acid, citrate and oxalate.

Initial management is always to increase fluid intake and urinary flow. Dietary modification is a mandatory part of effective therapy. The child should be referred to a dietician to assess accurately the daily intake of calcium, animal protein, and sodium. Dietary sodium restriction is recommended as well as maintenance of calcium intake consistent with the daily needs of the child [810]. A brief trial of a low calcium diet can be carried out to determine if exogenous calcium intake and/or calcium hyperabsorption is contributing to high urinary calcium. Any recommendation to restrict calcium intake below the daily needs of the child should be avoided. Moreover, low calcium intake is a risk factor for stone formation [811] (LE: 3).

Hydrochlorothiazide and other thiazide-type diuretics may be used to treat idiopathic hypercalciuria,

especially with calcium renal leak, at a starting dosage of 0.5-1 mg/kg/day [812-815] (LE: 3). In long-term use of thiazide-type diuretics, a decrease in hypocalcaemic effect may be seen after the third month and may cause hypokalemia, hypocitraturia, hyperuricaemia and hypomagnesaemia. Therefore, control of blood and serum values should be performed with regular intervals. Citrate therapy is also useful if citrate levels are low or if hypercalciuria persists, despite other therapies [812, 816] (LE: 4).

*Hyperoxaluria:* Only 10-15% of oxalate comes from diet.

The average child excretes less than 50 mg (0.57 mmol)/1.73 m<sup>2</sup>/day [817-819], while infants excrete four times as much. Hyperoxaluria may result from increased dietary intake, enteric hyperabsorption (as in short bowel syndrome) or an inborn error of metabolism.

In rare primary hyperoxaluria, one of the two liver enzymes that play a role in the metabolism of oxalate may be deficient. With increased deposition of calcium oxalate in the kidneys, renal failure may ensue in resulting deposition of calcium oxalate in other tissues (oxalosis). The diagnosis is made upon laboratory findings of severe hyperoxaluria and clinical symptoms. The definitive diagnosis requires liver biopsy to assay the enzyme activity.

Other forms of hyperoxaluria, as mentioned earlier, may be due to hyperabsorption of oxalate in inflammatory bowel syndrome, pancreatitis and short bowel syndrome. Yet, the majority of children have 'mild' (idiopathic) hyperoxaluria, with urine oxalate levels elevated only mildly in these cases. The treatment of hyperoxaluria consists of the promotion of high urine flow, restriction of dietary oxalate and regular calcium intake. Pyridoxine may be useful in reducing urine levels, especially in primary hyperoxaluria. Citrate administration increases inhibitory urine activity [812, 820] (LE: 4).

*Hypocitraturia:* Citrate is a urinary stone inhibitor. Citrate acts by binding to calcium and by directly inhibiting the growth and aggregation of calcium oxalate as well as calcium phosphate crystals. Thus low urine citrate may be a significant cause of calcium stone disease. In adults, hypocitraturia is the excretion of citrate in urine of less than 320 mg/day (1.5 mmol/day) for adults; this value must be adjusted for children depending on body size [821-823].

Hypocitraturia usually occurs in the absence of any concurrent symptoms or any known metabolic derangements. It may also occur in association with any metabolic acidosis, distal tubular acidosis or diarrhoeal syndromes.

Environmental factors that lower urinary citrate include a high protein intake and excessive salt intake. Many reports emphasise the significance of hypocitraturia in paediatric calcium stone disease. The presence of hypocitraturia ranges from 30% to 60% in children with calcium stone disease [822, 824].

The restoration of normal citrate levels is advocated to reduce stone formation, although there are few relevant studies in children. Hypocitraturia is treated by potassium citrate at a starting dose of 1 mEq/kg, given in two divided doses [813] (LE: 3). The side effects of potassium citrate are very rare and most of the time they include non-specific gastrointestinal complaints. Potassium citrate should be used with caution in hyperkalemic and chronic renal failure conditions.

#### 3.14.2.2 *Uric acid stones*

Uric acid stones are responsible for urinary calculi in 4-8% of children. Uric acid is the end product of purine metabolism. Hyperuricosuria is the main cause of uric acid stone formation in children. A daily output of uric acid of more than 10 mg/kg/day (0.6 mmol/kg/day) is considered to be hyperuricosuria [812].

The formation of uric acid stones is mainly dependent on the presence of acidic urinary composition. Uric acid dissociation and solubility is strongly reduced at pH of < 5.8. As the pH becomes more alkaline, uric acid crystals become more soluble and the risk of uric acid stone formation is reduced.

In the familial or idiopathic form of hyperuricosuria, children usually have normal serum uric acid levels. In other children, it can be caused by uric acid overproduction secondary to inborn errors of metabolism, myeloproliferative disorders or other causes of cell breakdown. Hyperuricosuria is also caused by high purine and protein intake. Although hyperuricosuria is a risk factor for calcium oxalate stone formation in adults, this does not appear to be a significant risk factor in children.

Uric acid stones are non-opaque stones. Plain X-rays are insufficient to show uric acid stones, and renal sonography and spiral CT are used for diagnosis.

Alkalinisation of urine is the mainstay of therapy and prevention for uric acid stones. Citrate preparations are useful as alkalinising agents. Maintaining a urine pH of 6 to 6.5 is sufficient to prevent uric acid stones [812]. In cases who failed with conservative measures with sustaining hyperuricosuria and hyperuricemia, stone recurrences or myeloproliferative diseases, allopurinol (10 mg/kg) may be used. This medication may cause

several drug reactions (rash, diarrhoea, eosinophilia) and should be cautiously used in chronic renal failure patients.

#### 3.14.2.3 *Cystine stones*

Cystinuria is the cause of cystine stone formation and accounts for 2-6% of all urinary stones in children. Cystinuria is an incompletely recessive autosomal disorder characterised by failure of renal tubules to reabsorb four basic amino acids: cystine, ornithine, lysine and arginine.

Of these four amino acids, only cystine has poor solubility in urine, so that only cystine stones may form in the case of excessive excretion in urine. Cystine solubility is pH-dependent, with cysteine precipitation beginning at pH levels < 7.0. Other metabolic conditions, such as hypercalciuria, hypocitraturia and hyperuricosuria, may accompany cystinuria, so leading to the formation of mixed-composition stones. Cystine stones are faintly radiopaque and may be difficult to visualise on regular radiograph studies. They are also hard in texture and more difficult to disintegrate by extracorporeal shockwave lithotripsy (SWL).

The medical treatment for cystine stones aims to reduce cystine saturation in urine and increase its solubility. The initial treatment consists of maintaining a high urine flow and the use of alkalinising agents, such as potassium citrate to maintain urine pH at above 7.0 (better above 7.5). If this treatment fails, the use of alpha-mercaptopyronyl glycine or D-penicillamine may increase cystine solubility and reduce cystine levels in urine and prevent stone formation. Side effects of these drugs are mostly mild and include gastrointestinal complaints (alterations in taste and odour), fever and rash, however they can be associated with severe side-effects, such as bone marrow depression, nephrotic syndrome and epidermolysis [825] (LE: 4).

#### 3.14.2.4 *Infection stones (struvite stones)*

Infection-related stones constitute nearly 5% of urinary stones in children, though incidence increases over 10% in younger ages [826] and in non-endemic regions [806, 827]. Bacteria capable of producing urease enzyme (*Proteus*, *Klebsiella*, *Pseudomonas*) are responsible for the formation of such stones.

Urease converts urea into ammonia and bicarbonate, alkalinising the urine and further converting bicarbonate into carbonate. In the alkaline environment, triple phosphates form, eventually resulting in a supersaturated environment of magnesium ammonium phosphate and carbonate apatite, which in turn leads to stone formation.

In addition to bacterial elimination, stone elimination is essential for treatment, as stones will harbour infection and antibiotic treatment will not be effective. Consideration should be given to investigating any congenital problem that causes stasis and infection. Genitourinary tract anomalies predispose to formation of such stones.

#### 3.14.3 **Diagnostic evaluation**

Presentation tends to be age-dependent, with symptoms such as flank pain and haematuria being more common in older children. Non-specific symptoms (e.g. irritability, vomiting) are common in very young children. Haematuria, usually visible, occurring with or without pain, is less common in children. However, non-visible haematuria may be the sole indicator and is more common in children. In some cases, urinary infection may be the only finding leading to radiological imaging in which a stone is identified [828, 829].

##### 3.14.3.1 *Imaging*

Generally, US should be used as a first approach. Renal US is very effective for identifying stones in the kidney. Many radiopaque stones can be identified with a simple abdominal flat-plate examination. The most sensitive test for identifying stones in the urinary system (especially for ureteric stones) is non-contrast helical CT scanning. It is safe and rapid, with 97% sensitivity and 96% specificity [830-832] (LE: 2). Despite its high diagnostic accuracy, because of the potential radiation hazards, its use should be reserved for cases with non-informative US and/or plain abdominal roentgenogram. Low dose protocols have also been developed with the goal of reducing radiation dose with adequate image quality [833]. Intravenous pyelography is rarely used in children, but may be needed to delineate the caliceal anatomy prior to percutaneous or open surgery.

##### 3.14.3.2 *Metabolic evaluation*

Due to the high incidence of predisposing factors for urolithiasis in children and high stone recurrence rates, every child with a urinary stone should be given a complete metabolic evaluation [800, 825, 834, 835].


Metabolic evaluation includes:

- family and patient history of metabolic problems and dietary habits;
- analysis of stone composition (following stone analysis, metabolic evaluation can be modified according to the specific stone type);

- electrolytes, blood/urea/nitrogen (BUN), creatinine, calcium, phosphorus, alkaline phosphatase, uric acid, total protein, carbonate, albumin, and parathyroid hormone (if there is hypercalcaemia);
- spot urinalysis and culture, including ratio of calcium to creatinine;
- urine tests, including a 24-hour urine collection for calcium, phosphorus, magnesium, oxalate, uric acid citrate, protein, and creatinine clearance;
- 24-hour cystine analysis if cystinuria is suspected (positive sodium nitroprusside test, cystine stone, cystine hexagonal crystals in urine).

Figure 8 provides an algorithm of how to perform metabolic investigations in urinary stone disease in children and how to plan medical treatment accordingly.

**Figure 8: Algorithm for metabolic investigations in urinary stone disease in children**



Ca = calcium; HCTZ = hydrochlorothiazide; Mg = magnesium; Ox = oxalate; PTH = parathyroid hormone; SWL = extracorporeal shockwave lithotripsy; RTA = renal tubular acidosis; Uric-A = uric acid.

### 3.14.4 Management

Adequate fluid intake and restricting the use of salt within daily allowance range are the general recommendations besides the specific medical treatment against the detected metabolic abnormalities. With the advance of technology, stone management has changed from open surgical approaches to endoscopic techniques that are less invasive. Deciding on the type of treatment depends on the number, size, location, stone composition and the anatomy of the urinary tract [835-837]. Expectant management is the initial management in children with asymptomatic small size stones (< 4-5 mm) with a possibility of spontaneous clearance. There is no consensus on the size of stones for different ages eligible for clearance and the duration of conservative follow-up. Adult literature reveals the benefits of medical expulsive therapy (MET) using  $\alpha$ -blockers. Although, experience in children is limited showing different results [838], a meta-analysis of three randomised and two retrospective studies demonstrate that treatment with MET results in increased odds of spontaneous ureteral stone passage and a low rate of adverse events [839]. Currently, most paediatric stones can easily be managed by SWL. Endoscopic treatment can be applied for ureteric and bladder stones. Percutaneous removal of stones is also possible for kidney stones in children. Only a small portion of children will require open surgery but all attempts must be made to completely remove all stones since post-operative residual fragments pass spontaneously in only 20-25% of cases [840, 841]. A congenital obstructive uropathy should be managed together with stone removal therapy to prevent recurrence.

#### 3.14.4.1 Extracorporeal shockwave lithotripsy

Many reports confirm that SWL can be performed in children with no suspicion of long-term morbidity of the kidney [842-849].

The mean number of shockwaves for each treatment is approximately 1,800 and 2,000 (up to 4,000 if needed) and the mean power settings vary between 14 kV and 21 kV. The use of US and digital fluoroscopy has significantly decreased the radiation exposure and it has been shown that children are exposed to significantly lower doses of radiation compared to adults [836, 850, 851]. Concerns about anaesthesia no longer present a problem due to advances in technique and medication, even in the infant age group. The type of anaesthesia should be general or dissociative for children under ten years of age, whereas conventional intravenous sedation or patient-controlled analgesia is an option for older children who are able to co-operate [852] (LE: 2b).

Stone-free rates are significantly affected by various factors. Regardless of the location, as the stone size increases, the stone-free rates decrease and retreatment rate increases. The stone-free rates for < 1 cm, 1-2 cm, > 2 cm and overall, were reported as nearly 90%, 80%, 60% and 80%, respectively. As the stone size increases, the need for additional sessions increases [836, 850, 851, 853-857].

Localisation of the calculi has been described as a significant factor affecting the success rates in different studies. Stones in the renal pelvis and upper ureter seem to respond better to SWL. For these locations, the stone clearance rates are nearly 90%. However, SWL was found to be less effective for caliceal stones particularly the lower caliceal stones. Several studies reported stone-free rates for isolated lower caliceal stones varying between 50% and 62% [858-860].

Shockwave lithotripsy can also be used to treat ureteral calculi. However, this is a more specific issue and controversial. The success rates with SWL are less for distal ureteric stones. There may also be technical problems with localisation and focusing of ureteric stones in children [859-862].

The type of machine used has a strong effect on success rates and complications. First-generation machines can deliver more energy to a larger focal zone, resulting in higher fragmentation rates in a single therapy. However, general anaesthesia is usually required due to the intolerable discomfort associated with a first-generation machine. Later-generation machines have a smaller focal zone and deliver less energy, and have a lower risk of pulmonary trauma, however, additional treatments may be needed. The success rate is higher in younger children [855].

Although stenting does not affect stone clearance, overall complication rates are higher and hospital stay is longer in the unstented patient [855, 857]. Stenting is essential in solitary kidneys undergoing SWL treatment. Children with a large stone burden have a high risk of developing Steinstrasse and urinary obstruction and should be followed more closely for the risk of prolonged urinary tract obstruction after SWL. Post-SWL stent or nephrostomy tube placement may be needed in prolonged obstruction [825, 854].

The Hounsfield Unit (HU) of stone on noncontrast tomography has also been shown to be a predictive factor for success in children and SWL was found to be more successful in stones with HU less than 600 [841] and 1,000 [863]. Two nomogram studies revealed male gender, younger age, smaller stone size, single stone, non-lower pole localisation and negative history for previous intervention are favourable factors for stone clearance in paediatric SWL [864, 865].

Complications arising from SWL in children are usually self-limiting and transient. The most common are:

- renal colic;
- transient hydronephrosis;
- dermal ecchymosis;
- UTI;
- formation of Steinstrasse;
- sepsis;
- rarely, haemoptysis.

In children with sterile pre-operative urine cultures, antibiotic prophylaxis to decrease infectious complications is not recommended [866]. However, every effort should be made to sterilise the urine before performing SWL, ureteroscopy (URS), or percutaneous nephrolithotomy (PCNL).

Due to the smaller size of the probes, laser energy is easier to use in smaller instruments and is more useful for paediatric cases [867-876].

#### 3.14.4.2 Percutaneous nephrolithotomy

Shockwave lithotripsy is the first choice for treating most renal paediatric stones. However, percutaneous renal surgery should be used for larger and complex stones. Pre-operative evaluation, indication and surgical technique are similar in children and adults. In most cases, percutaneous nephrolithotomy (PCNL) is used as monotherapy, but is also used as an adjunctive procedure to other therapies.

The use of adult-sized instruments, in association with an increased number of tracts and sheath size, seems to increase blood loss. However, the development of small-calibre instruments means that PCNL can be used in children. In children (particularly smaller children), PCNL has some advantages, such as smaller skin incision, single-step dilation and sheath placement, good working access for paediatric instruments, variable length, and lower cost [866, 877, 878].

As monotherapy, PCNL is considerably effective and safe. The reported stone-free rates in the recent literature are between 86.9% and 98.5% after a single session. These rates increase with adjunctive measures, such as second-look PCNL, SWL and URS. Even in complete staghorn cases, a clearance rate of 89% has been achieved following a single session [870, 879-883].

The most frequently reported complications of PCNL in children are bleeding, post-operative fever or infection, and persistent urinary leakage. Bleeding requiring transfusion in the modern series is reported in less than 10% [884-889] and is closely associated with stone burden, operative time, sheath size and the number of tracts [888, 890, 891]. In recent studies, post-operative infectious complications, such as fever with or without documented UTI, are reported as less than 15% [884, 885, 887-889, 892] and the origin of fever is not always found to be the infection. With the availability of smaller size instruments, miniaturised PCNL ('miniperc') through a 13F or 14F sheath [878, 893, 894] as well as ultramini-PCNL (UMP) through 12F sheaths [895] have become possible, with decreased transfusion rates [893]. This miniaturisation has been further developed into the technique of 'micro-perc' using a 4.85F 'all-seeing needle'. This technique is still experimental and enables the stone to be fragmented by a laser *in situ* and left for spontaneous passage [896]. A recent study revealed that microperc provides a similar stone-free rate with similar complication rates and a lower additional treatment rate compared with SWL in the treatment of kidney stone disease in children [897] (LE: 3). For stones 10-20 mm, micro-PCNL was shown to have comparable results, with lesser bleeding, compared to mini-PCNL [898] (LE: 3). As experience has accumulated in adult cases, new approaches have also started to be applied in children, including tubeless PCNL. This technique has been used in uncomplicated surgery for stones < 2 cm, with patients left either with an indwelling catheter or double J stent in the ureter [886, 892] or totally tubeless [899]. Moreover, use of US for establishment of access [900] and supine approach [901] were also reported to be feasible in children.

The mean post-operative hospital stay is similar to adults. It is reported as three to four days in all published literature and is much shorter than open surgery. The less invasive nature of this technique has made it a promising alternative to open surgery for treating renal stones in children (LE: 2) [884, 886, 887, 889-892, 894-901].

#### 3.14.4.3 Ureterorenoscopy

The increasing availability of smaller size endourological equipment has made it possible to manage paediatric ureteral stones using endoscopic techniques.

The technique used in children is similar to the one used in adults. It is strongly recommended that guide wires are used and the procedure is performed using direct vision. Routine balloon dilation of ureterovesical junction and ureteral stenting are controversial. In general, ureteric dilatation is being performed much less and only in selected cases. There is a tendency to use hydrodilation more because it is similarly effective [866, 868, 874, 902-905] (LE: 3).



Different lithotripsy techniques, including ultrasonic, pneumatic and laser lithotripsy, have all been shown to be safe and effective. Due to the smaller size of the probes, laser energy is easier to use in smaller instruments and is more useful for paediatric cases [867-876].

All studies reporting the use of endoscopy for ureteric stones in children have clearly demonstrated that there is no significant risk of ureteric strictures or reflux with this mode of therapy (LE: 1). The risk of post-operative hydronephrosis depends on the presence of impacted stone and ureteral injury during operation [906]. A multi-institutional study on the use of semi-rigid ureteroscopy for ureteral calculi in children has revealed that the procedure is effective with a 90% stone-free rate and efficacy quotient. The study also focused on the factors affecting the complication rates. The authors found that although operating time, age, institutional experience, orifice dilation, stenting and stone burden were significant on univariate analysis, multivariate analysis revealed that operating time was the only significant parameter affecting the complication rate [907].

A recent literature review contains a growing number of case series on the use of flexible ureterorenoscopic interventions in children. Both intrarenal and ureteric stones can be treated using this approach [908-912]. In these series, the authors generally did not use active orifice dilation, but attempted to use a ureteral sheath where possible. However, an important problem was the inability to obtain retrograde access to the ureter in approximately half of the cases [909, 911]. This problem can be overcome by stenting and leaving the stent indwelling for passive dilation of the orifice, and performing the procedure in a second session. The success rates varied between 60 and 100%, with a negligible number of complications [908, 910-913]. The need for additional procedures was related to stone size [912]. A comparative study showed that retrograde intra-renal surgery (RIRS) had similar stone-free rate compared to ESWL after three months, with fewer sessions [914], however for stones larger than 2 cm, RIRS monotherapy has lower stone-free rates than mini-PCNL with the advantages of decreased radiation exposure, fewer complications and shorter hospital stay [915] (LE: 3). On the other hand, for stones between 10-20 mm, RIRS has similar success and complication rates and shorter hospital stay and low radiation exposure when compared to micro-PNL [916] (LE: 3). Two recent meta-analyses revealed RIRS have similar operative time and stone-free rate with a lower overall complication rate [917] where PCNL has higher stone-free rate in stones larger than 20 mm [918].

#### 3.14.4.4 *Open or laparoscopic stone surgery*

Most stones in children can be managed by SWL and endoscopic techniques. However, in some situations, open surgery is inevitable. Good candidates for open stone surgery include very young children with large stones and/or a congenitally obstructed system, which also require surgical correction. Open surgery is also necessary in children with severe orthopaedic deformities that limit positioning for endoscopic procedures.

In centres with a well-established experience, a laparoscopic approach may be a good alternative for some cases as a last resort before open surgery. Suitable candidates include patients who have a history of previous failed endoscopic procedures, complex renal anatomy (ectopic or retrorenal colon), concomitant ureteropelvic junction (UPJ) obstruction or caliceal diverticula, mega-ureter, or large impacted stones. Laparoscopic stone surgery via conventional or a robot-assisted transperitoneal or retroperitoneal approach can be attempted. However, there is very limited experience with these techniques and they are not routine therapeutic modalities [919-922].

Bladder stones in children can usually be managed by endoscopic techniques. Open surgery may also be used for very large bladder stones or for bladder stones caused by an anatomical problem.

In addition to the advantages and disadvantages of each treatment modality for the specific size and location of the stone, one will have to consider the availability of the instruments and the experience with each treatment modality before the choice of technique is made. Recommendations for interventional management are given in Table 9.

**Table 9: Recommendations for interventional management in paediatric stones**

Stone size and localisation*	Primary treatment option	Secondary treatment options	Comment
Staghorn stones	PCNL	Open/SWL	Multiple sessions and accesses with PCNL may be needed. Combination with SWL may be useful.
Pelvis < 10 mm	SWL	RIRS/PCNL/MicroPerc	
Pelvis 10-20 mm	SWL	PCNL/RIRS/MicroPerc/Open	Multiple sessions with SWL may be needed. PCNL has similar recommendation grade.
Pelvis > 20 mm	PCNL	SWL/Open	Multiple sessions with SWL may be needed.
Lower pole calyx	PCNL	SWL/Open	Multiple sessions with SWL may be needed.
< 10 mm	SWL	RIRS/PCNL/MicroPerc	Anatomical variations are important for complete clearance after SWL.
Lower pole calyx	SWL	RIRS/PCNL/MicroPerc	Anatomical variations are important for complete clearance after SWL.
> 10 mm	PCNL	SWL/MicroPerc	Anatomical variations are important for complete clearance after SWL.
Upper ureteric stones	SWL	PCNL/URS/Open	
Lower ureteric stones	URS	SWL/Open	Additional intervention need is high with SWL.
Bladder stones	Endoscopic		Open is easier and with less operative time with large stones.
Bladder stones	Endoscopic		Open is easier and with less operative time with large stones.

\* Cystine and uric acid stones excluded.

PCNL = percutaneous nephrolithostomy; SWL = shockwave lithotripsy; RIRS = retrograde intrarenal surgery; URS = ureteroscopy.

### 3.14.5 Summary of evidence and recommendations for the management of urinary stones

Summary of evidence	LE
The incidence of stone disease in children is increasing.	2
Contemporary surgical treatment is based on minimally invasive modalities. Open surgery is very rarely indicated.	2a
The term 'clinically insignificant residual fragments' is not appropriate for children since most of them become symptomatic and require intervention.	2b

Recommendations	LE	Strength rating
Use plain abdominal X-ray and ultrasound as the primary imaging techniques for the diagnosis and follow-up of stones.	2b	Strong
Use low-dose non-contrast computed tomography in cases with a doubtful diagnosis, especially of ureteral stones or complex cases requiring surgery.	2a	Strong
Perform a metabolic evaluation in any child with urinary stone disease. Any kind of interventional treatment should be supported with medical treatment for the underlying metabolic abnormality, if detected.	2a	Strong
Limit open surgery under circumstances in which the child is very young with large stones, in association with congenital problems requiring surgical correction and/or with severe orthopaedic deformities that limit positioning for endoscopic procedures.	2a	Strong

### **3.15 Obstructive pathology of renal duplication: ureterocele and ectopic ureter**

#### **3.15.1 Epidemiology, aetiology and pathophysiology**

Ureterocele and ectopic ureter are the two main anomalies associated with complete renal duplication, but they also occur in a single system. At present, antenatal US detects both conditions in the majority of cases if associated with obstruction, and diagnosis is confirmed after birth by further examination. Later in life, these anomalies are revealed by clinical symptoms: UTI, pain, calculus formation, disturbances of micturition, and urinary incontinence. There is a wide variation of symptoms in patients with ureterocele (from the asymptomatic patient to urosepsis, urinary retention and upper tract dilatation after birth).

##### **3.15.1.1 Ureterocele**

Ureterocele is four to seven times more frequent in female than in male patients; the overall incidence in autopsies is around one in 4,000 children. Around 80% is associated with the upper pole ureter in duplicated systems and 20% in single systems. About 10% of ureteroceles are bilateral [923].

##### **3.15.1.2 Ectopic ureter**

Ectopic ureter is less frequent than ureterocele (10 in 19,046 autopsies), but is also more common in female patients (male to female ratio is 1:5). Some remain asymptomatic, therefore, the true incidence is difficult to determine [924]. Eighty per cent of ectopic ureters are associated with complete renal duplication; however, in male patients about 50% of ectopic ureters are associated with a single system [925].

#### **3.15.2 Classification systems**

##### **3.15.2.1 Ureterocele**

Ureterocele is a cystic dilatation that develops in the intravesical part of the submucosal ureter. The aetiology remains unclear [926-928]. A single-system ureterocele is associated with a kidney with one ureter, and induplex systems, the ureterocele belongs to the upper pole.

Ureteroceles usually cause obstruction of the upper pole, but the degree of obstruction and functional impairment is variable according to the type of ureterocele and upper pole dysplasia. In the orthotopic form, there is often no or only mild obstruction, and frequently the function of the moiety is normal or slightly impaired, and the corresponding ureter may be dilated. Cystic renal dysplasia is also associated with a single system ureterocele [929]. Vesicoureteral reflux can be observed in 50% on the ipsilateral side and 20% on the contralateral side. Reflux into the ureterocele is uncommon [930]. In the ectopic form, the upper pole is altered, frequently dysplastic, and hypo-functional or non-functional [931, 932]. The corresponding ureter is a mega-ureter. In the caeco-ureterocele (see definition below), the upper pole of the renal duplication is dysplastic and non-functional. Histological evaluation demonstrated that the changes represent a process of maldevelopment and may not result from infections or obstruction [931, 932].

##### **3.15.2.1.1 Ectopic (extravesical) ureterocele**

If any portion of the ureterocele extends into the bladder neck or urethra, it is called an ectopic ureterocele. Ectopic ureterocele is the most common form of ureterocele (> 80%). It can be voluminous, dissociating the trigone and slipping into the urethra, and may prolapse through the urethral meatus (caeco-ureterocele). The ureterocele orifice is tight, and located in the bladder itself or below the neck. The ureter corresponding to the lower pole moiety is raised by the ureterocele and is frequently refluxing or compressed by the ureterocele, leading to an obstructive mega-ureter. A contralateral renal duplication is associated with 50% of cases. Occasionally, large ureteroceles are responsible for reflux or obstruction of the contralateral upper tract.

##### **3.15.2.1.2 Orthotopic (intravesical) ureterocele**

The intravesical or orthotopic ureterocele is completely located in the bladder. Intravesical ureteroceles are mostly combined with a single kidney system and account for about 15% of cases. It is diagnosed more in older children or adults.

##### **3.15.2.2 Ectopic ureter**

The term ectopic ureter describes a ureter with the orifice located at the bladder neck, in the urethra, or outside the urinary tract. The ureter can drain the upper pole of a duplex or single system. There is a fundamental difference between the sexes. In boys, the ectopic orifice is never below the external sphincter.

In girls, the ureteral orifice may be located [933]:

- in the urethra, from the bladder neck to the meatus (35%);
- in the vaginal vestibule (34%);
- in the vagina (25%);
- in the uterus and Fallopian tube (6%).

In boys, the ureteral orifice may be located [933]:

- in the posterior urethra (47%);
- in the prostatic utricle (10%);
- in the seminal vesicles (33%);
- in the vas deferens or ejaculatory ducts (10%).

### 3.15.3 **Diagnostic evaluation**

#### 3.15.3.1 *Ureterocele*

Prenatal US easily reveals voluminous obstructive ureteroceles [934]. In cases with a small upper pole or a slightly obstructive ureterocele, prenatal diagnosis is difficult.

If prenatal diagnosis is impossible, the following clinical symptoms, besides incidental findings, can reveal the congenital anomaly at birth or later:

- At birth, a prolapsed and sometimes strangulated ureterocele may be observed in front of the urethral orifice. In a newborn boy, it might cause acute urinary retention, simulating urethral valves.
- The early symptom of pyelonephritis in either sex may lead to the diagnosis.
- Later symptoms can include dysuria, recurrent cystitis and urgency.

In cases of prenatal diagnosis, at birth US confirms the ureteral dilatation that ends at the upper pole of a renal duplication. It also demonstrates the presence of a ureterocele in the bladder, with a dilated ureter behind the bladder.

At this point, it is important to assess the function of the upper pole using nuclear renography of the region of interest. This is best assessed with DMSA, however this requires a careful systematic review of the images [935]. Magnetic resonance urography may visualise the morphological status of the upper pole and lower moieties and of the contralateral kidney as well as it can detect renal scars [936, 937]. Using functional MR urography, differential renal function can be assessed with a quite low intra- and interobserver variability [938]. Based on the prevalence of high-grade reflux, VCUG is mandatory for identifying ipsilateral or contralateral reflux and assessing the degree of intra-urethral prolapse of the ureterocele [939]. Urethrocystoscopy may reveal the pathology in cases where it is difficult to make the differential diagnosis between ureterocele and ectopic mega-ureter.

#### 3.15.3.2 *Ectopic ureter*

Most of the ectopic mega-ureters are diagnosed primarily by US. In some cases, clinical symptoms can lead to diagnosis:

- In neonates: dribbling of urine, pyuria, and acute pyelonephritis.
- In young girls: permanent urinary incontinence besides normal voiding, or significant vaginal discharge as the equivalent of incontinence; an ectopic orifice may be found in the meatal region [940].
- In pre-adolescent boys: epididymitis is the usual clinical presentation and the seminal vesicle may be palpable.

Ultrasound, radionuclide studies (DMSA, VCUG, MR urography, high-resolution MRI, and cystoscopy) are the diagnostic tools to assess function, to detect reflux and rule out ipsilateral compression of the lower pole and urethral obstruction [941]. In some cases, the large ectopic ureter presses against the bladder and can look like a pseudo-ureterocele [942].

Girls who present with lifelong minimal urinary incontinence, never being dry, normal bladder function, complete emptying, and normal US are very suspicious for ectopic ureter. This needs to be excluded or confirmed by MRI as it is the most sensitive method [943].

### 3.15.4 **Management**

#### 3.15.4.1 *Ureterocele*

Management is controversial with a choice between a non-operative approach, endoscopic decompression, ureteral re-implantation, partial nephroureterectomy, or complete primary reconstruction [944-948]. The choice of a therapeutic modality depends on the following criteria: clinical status of the patient (e.g. urosepsis); patient age; function of the upper pole; presence of reflux or obstruction of the ipsilateral or contralateral ureter; presence of bladder neck obstruction caused by ureterocele; intravesical or ectopic ureterocele; and caregivers' and the surgeon's preferences [949]. When the diagnosis is made by US, prophylactic antibiotic treatment maybe indicated until a VCUG is performed.

##### 3.15.4.1.1 Early treatment

In the presence of febrile infection or obstruction at the bladder neck, immediate endoscopic incision or puncture of the ureterocele is recommended. In a clinically asymptomatic child with a ureterocele and a non-


or hypofunctional upper pole, without significant obstruction of the lower pole and without bladder outlet obstruction, prophylactic antibiotic treatment is given until follow-up procedures are instigated. Decompression of the dilated system facilitates later reconstructive surgery [950, 951].

#### 3.15.4.1.2 Re-evaluation

Conservative treatment may be adopted in asymptomatic patients without any bladder outlet obstruction, severe hydronephrosis of the ureterocele moiety or high-grade (over grade III) reflux [949, 952]. A meta-analysis showed that, after primary ureterocele-incision, the re-operation rate is higher in those with an ectopic ureterocele compared to those with an intravesical ureterocele [945]. Secondary surgery is necessary if decompression is not effective, significant reflux is present, or there is obstruction of the ipsi- or contralateral ureters, and/or bladder neck obstruction or retained ureterocele [953].

Surgery may vary from upper pole nephrectomy to complete unilateral LUT reconstruction [948, 954-956]. In an ectopic ureterocele with severe hydronephrosis and without reflux, the primary upper tract approach without endoscopic decompression (partial upper-pole nephroureterectomy, pyelo/ureteropyelo/ureterostomy and upper-pole ureterectomy) has an 80% chance of being the definitive treatment [949, 957]. Also a LUT approach in those with a poorly or non-functioning upper pole is an option [958]. Today, despite successful surgery, some authors think, that surgery may not be necessary at all in some patients [959], as less aggressive surgical treatment and non-operative management over time can achieve the same functional results [960].

**Figure 9: Algorithm for the management of duplex system ureteroceles after the first 3-6 months of life [949]**



DSU = duplex system ureterocele; HUN = hydronephrosis; UPPN = upper pole partial nephrectomy; VUR = vesicoureteric reflux to the lower pole.

Obstruction is considered to be the presence of non-refluxing dilatation of non-ureterocele-bearing moieties (especially of the lower pole) or of an obstructive drainage pattern on diuretic renography.

#### 3.15.4.2 Ectopic ureter

In the majority of cases, the upper pole is dysplastic and poorly functioning. There are a variety of therapeutic options, each with its advantages and disadvantages. In non-functioning moieties with recurrent infections, heminephro-ureterectomy is a definite solution. Ureteral reconstruction (ureteral re-implantation/ureteroureterostomy/ureteropyelostomy and upper-pole ureterectomy) are other therapeutic options especially in cases in which the upper pole has function worth preserving. These procedures can be performed through an open laparoscopic or robotic assisted approach [961-964]. So far there is no superior approach [965]. In patients with bilateral single ectopic ureters (a very rare condition), an individual approach depending on the sex and renal and bladder function of the patient is necessary. Usually the bladder neck is insufficient in these patients [966].

3.15.5 **Summary of evidence and recommendations for the management of obstructive pathology of renal duplication: ureterocele and ectopic ureter**

Summary of evidence	LE
Ureterocele and ectopic ureter are associated with complete renal duplication, but they also occur in a single system.	1
In most cases, in young children (first years of life) diagnosis is done by ultrasound.	1
In older children clinical symptoms will prompt assessment.	1
Management includes a conservative approach, endoscopic decompression, partial nephroureterectomy, or complete primary reconstruction. Choice of treatment will depend on: <ul style="list-style-type: none"> <li>clinical status of the patient (e.g., urosepsis);</li> <li>patient age;</li> <li>function of the upper pole;</li> <li>presence of reflux or obstruction of the ipsilateral or contralateral ureter;</li> <li>presence of bladder neck obstruction caused by ureterocele;</li> <li>intravesical or ectopic ureterocele;</li> <li>and caregivers' and surgeon's preferences.</li> </ul>	3

Recommendations			LE	Strength rating
Ureterocele	Diagnosis	Use ultrasound (US), radionuclide studies (mercaptoacetyltriglycine (MAG3)/dimercaptosuccinic acid (DMSA)), voiding cystourethrography (VCUG), magnetic resonance urography, high-resolution magnetic resonance imaging (MRI), and cystoscopy to assess function, to detect reflux and rule out ipsilateral compression of the lower pole and urethral obstruction.	3	Weak
	Treatment	Select treatment based on symptoms, function and reflux as well on surgical and parenteral choices: observation, endoscopic decompression, ureteral re-implantation, partial nephroureterectomy, complete primary reconstruction. Offer, early endoscopic decompression to patients with an obstructing ureterocele.	3	Weak
Ectopic ureter	Diagnosis	Use US, DMSA scan, VCUG or MRI for a definitive diagnosis.	3	Weak
	Treatment	In non-functioning moieties with recurrent infections, heminephro-ureterectomy is a definitive solution. Ureteral reconstruction (ureteral re-implantation/ ureteroureterostomy/ureteropyelostomy and upper-pole ureterectomy) are other therapeutic option especially in cases in which the upper pole has function worth preserving.	3	Weak

### 3.16 Disorders of sex development

#### 3.16.1 Introduction

The formerly called 'intersex disorders' were recently the subject of a consensus document in which it was decided that the term 'intersex' should be changed to 'disorders of sex development' (DSD) [967, 968].

The new classification has arisen due to advances in knowledge of the molecular genetic causes of abnormal sexual development, controversies inherent to clinical management and ethical issues. Controversial and negative terminology, e.g. 'pseudohermaphroditism' and 'hermaphroditism', have been renamed according to the new pathophysiological insights. Furthermore, some conditions presenting with severe male genital malformation, such as penile agenesis and cloacal exstrophy, which could not be categorised, have also been included. The term 'disorders of sex development' is proposed to indicate congenital conditions with atypical development of chromosomal, gonadal or anatomical sex.

In addition, in 2017, the Parliamentary Assembly of the Council of Europe decided on a resolution called: "Promoting the human rights of and eliminating discrimination against intersex people" [969]. The

Parliamentary Assembly concluded that the majority of intersex people are physically healthy and only a few suffer from medical conditions that put their health at risk. Furthermore, they state that the prevailing medical view has been that intersex children's bodies can and should be made to conform to either a male or a female paradigm, often through surgical and/or hormonal intervention and that this should be done as early as possible and that the children should then be raised in the gender corresponding to the sex assigned to their body. The Parliamentary Assembly considers that this approach involves serious breaches of physical integrity, in many cases concerning very young children or infants who are unable to give consent and whose gender identity is unknown.

Therefore the Parliamentary Assembly call on Council of Europe member states with regard to effectively protecting children's right to physical integrity and bodily autonomy and to empowering intersex people as regards the following rights: medically unnecessary sex-"normalising" surgery, sterilisation and other treatments practised on intersex children without their informed consent should be prohibited and in addition that it has to be ensured that, except in cases where the life of the child is at immediate risk, any treatment that seeks to alter the sex characteristics of the child, including their gonads, genitals or internal sex organs, is deferred until such time as the child is able to participate in the decision, based on the right to self-determination and on the principle of free and informed consent.

The Panel refers to the consensus documents mentioned above as well as on the Parliamentary Assembly resolution. This chapter will focus on what is relevant for the practising paediatric urologist as the urologist is likely to be involved in neonates with DSD conditions.

Overall, evidence-based literature on DSD is sparse. There are no RCTs and most studies are based on retrospective clinical descriptive studies or on expert opinion. An exception is the risk of gonadal cancer, for which the level of evidence is higher [970].

Disorders of sex development can present as prenatal diagnosis, neonatal diagnosis and late diagnosis. Prenatal diagnosis can be based on karyotype or US findings; neonatal diagnosis is based on genital ambiguity and late diagnosis is made on early or delayed puberty. In this guideline focus is on the neonatal presentation where the paediatric urologist plays a major role. For late diagnosis we refer to endocrinology and gynaecology guidelines on precocious and delayed puberty where paediatric urologists play a minor role [971, 972].

Dealing with neonates with DSD requires a multidisciplinary approach, which should include geneticists, neonatologists, paediatric and adult endocrinologists, gynaecologists, psychologists, ethicists and social workers. Each team member should be specialised in DSD and a team should have treated enough patients to ensure experience.

### 3.16.2 **Current classification of DSD conditions**

Since the International Consensus Conference on intersex and its subsequent publications on classification of the various conditions of DSD, several updates have been published with the latest published by the Global DSD Update Consortium in 2016 [973]. As the field of DSD is continuously developing and knowledge and viewpoints change over time, an effort was made to include representatives from a broad perspective including support and advocacy groups with the goal to focus patient care upon the best possible quality of life.

According to the international consensus back in 2005, DSDs were defined as congenital conditions within which the development of chromosomal, gonadal and anatomic sex is atypical. The changes that were made according to terminology are as follows:

**46XX DSD group** formerly called female pseudohermaphrodite, over-virilisation of an XX female, and masculinisation of an XX female.

In this group the vast majority is due to classic congenital adrenal hyperplasia (CAH) with various degrees of masculinisation. Among all DSD conditions together, 46XX CAH patients comprise approximately 80%. These conditions are extremely important since they can be potentially life threatening after birth because of salt loss phenomenon and immediate medical care is mandatory.

**46XY DSD group** in the past named male pseudohermaphrodite, undervirilisation of an XY male, and under-masculinisation of an XY male.

This group is often quite heterogenous and includes the partial androgen insensitivity syndrome (PAIS) as well as the complete androgen insensitivity syndrome (CAIS) formerly called testicular feminisation.

**Sex chromosome mosaicism DSD group** (45X, 45X/46XY, 47XXY) consists of multiple variants with the mixed gonadal dysgenesis being the most important one. Many have a normal male phenotype and others asymmetric genitalia. One scrotal half often contains a gonad which is likely to be a testis whereas the other side is more a labia majora with usually no palpable gonad, most likely to be a streak gonad.

**Ovotesticular DSD group** was in the past called true hermaphrodite because of the presence of ovarian and testicular tissue in the same individual meaning that both – female and male structures – live together. There is great variability in phenotype with uni- or bilateral undescended gonads which can present as one ovary and one testis or as one or two ovotestes.

**Non-hormonal/non-chromosomal DSD group** was introduced as well, including newborns with cloacal exstrophy where bladder and intestines are exposed, patients with aphallia, and severe micropenis. The latter one is a normally formed penis with a stretched length of < 2.5 standard deviation below the mean [967, 968, 974].

Micropenis should be distinguished from buried and webbed penis, which are usually of normal size. The length of the penis is measured on the dorsal aspect, while stretching the penis, from the pubic symphysis to the tip of the glans [968].

### 3.16.3 Diagnostic evaluation

#### 3.16.3.1 The neonatal emergency

The first step is to recognise the possibility of DSD (Table 10) and to refer the newborn baby immediately to a tertiary paediatric centre, fully equipped with neonatal, genetics, endocrinology and paediatric urology units. Diagnosis of a 46XX DSD due to congenital adrenal hyperplasia should not be delayed and represents a neonatal emergency situation since the possibility of salt loss phenomenon can be fatal.

**Table 10: Findings in a newborn suggesting the possibility of DSD (adapted from the American Academy of Pediatrics)**

<b>Apparent male</b>
Severe hypospadias associated with bifid scrotum
Undescended testis/testes with hypospadias
Bilateral non-palpable testes in a full-term apparently male infant
<b>Apparent female</b>
Clitoral hypertrophy of any degree, non-palpable gonads
Vulva with single opening
Indeterminate
Ambiguous genitalia

#### 3.16.3.2 Family history and clinical examination

A careful family history must be taken followed by a thorough clinical examination including various laboratory tests and imaging modalities (Table 11).

**Table 11: Diagnostic work-up of neonates with disorders of sex development**

<b>History (family, maternal, neonatal)</b>
Parental consanguinity
Previous DSD or genital anomalies
Previous neonatal deaths
Primary amenorrhoea or infertility in other family members
Maternal exposure to androgens
Failure to thrive, vomiting, diarrhoea of the neonate
<b>Physical examination</b>
Pigmentation of genital and areolar area
Hypospadias or urogenital sinus
Size of phallus
Palpable and/or symmetrical gonads
Blood pressure



Investigations
Blood analysis: 17-hydroxyprogesterone, electrolytes, LH, FSH, TST, cortisol, ACTH
Urine: adrenal steroids
Karyotype
Ultrasound
Genitogram
hCG stimulation test to confirm presence of testicular tissue
Androgen-binding studies
Endoscopy

*ACTH = adrenocorticotrophic hormone; FSH = follicle-stimulating hormone; hCG = human chorionic gonadotropin; LH = luteinising hormone; TST = testosterone.*

A thorough clinical examination in a neonate presenting with ambiguous genitalia is important. As well as an accurate description of the ambiguous genitalia, detailed information should be given on palpability and localisation of the gonads. Information gathered by the various examinations described below should help the team to come to a final diagnosis. Medical photography can be useful but requires sensitivity and consent [975].

*Palpable gonad:* If it is possible to feel a gonad, it is most likely to be a testis; this clinical finding therefore virtually excludes 46XX DSD.

*Phallus:* The phallus should be measured. A cotton bud placed at the suprapubic base of the implant of the stretched phallus allows for a good measurement of phallic length.

*Urogenital sinus opening:* The opening of the urogenital sinus must be well evaluated. A single opening has to be identified as well as a hymenal ring. Attention needs to be paid to the fusion of the labioscrotal folds as well as whether they show rugae or some discolouration.

*Ultrasound* can help to describe the palpated gonads or to detect non-palpable gonads. However, the sensitivity and specificity are not high. Müllerian structures like the vagina or utricular structures can be evaluated as well [976, 977].

*Genitography* can provide some more information on the urogenital sinus, especially on the exact position of the confluence. Moreover it gives evidence of possible duplication of the vagina.

*Invasive diagnostics* under general anaesthesia can be helpful in some cases.

On *cystoscopy*, the urogenital sinus can be evaluated as well as the level of confluence. It allows also for evaluation of the vagina or utriculus, the possible presence of a cervix at the top of the vagina.

*Laparoscopy* is necessary to obtain a final diagnosis on the presence of impalpable gonads and on the presence of Müllerian structures. If indicated, a gonadal biopsy can be performed [978, 979].

These investigations will help to distinguish the various conditions of DSD and provide quick evidence of congenital adrenal hyperplasia (CAH), which is the most frequently occurring DSD and the one that can become life-threatening within the first days of life because of salt loss phenomenon.

#### 3.16.4 **Gender assignment**

Nowadays it is obvious and clear that open and complete communications with caregivers and eventually the affected person are mandatory. Education and psychological support regarding the impact are needed for each individual to make sense of the condition, relate to their community and establish relationships. The lack of outcome data and different preferences make it extremely difficult to determine whether and when to pursue gonadal or genital surgery. Shared decision making is necessary, combining expert healthcare knowledge and the right of a patient or surrogate to make fully informed decisions. This entails a process of education, sharing of risks/benefits, articulating the uncertainties in DSD care and outcomes and providing time for the patient and family to articulate back the risks and benefits of each option. The goal of all involved should be to individualise and prioritise each patient.

However, adverse outcomes have led to recommendations to delay unnecessary surgery to an age when the patient can give informed consent. Surgery that alters appearance is not urgent. Recently the Parliamentary

Assembly of the Council of Europe, the European Society for Paediatric Urology (ESPU) as well as the Societies for Pediatric Urology have taken a position in the debate on surgery for DSD [969, 980, 981].

In an open letter to the Council of Europe, the European Society for Paediatric Urology expressed its attitude to the abovementioned resolution and concentrated on a worrying issue dealing with medico-surgical care for children with DSD. They state that surgical interventions in children with DSD only being applied in emergency conditions is discordant with the definition of health according to the World Health Organization (WHO), stating that health is not merely the absence of disease, but is a much broader concept, including physical, mental, and social domains. This especially applies to children, as favourable physical, social and emotional conditions are all critical factors for their optimal growth and development, which enables them to reach their full potential at adult age. As social and emotional interactions with the parents or caregivers, being the most important adults in a young child's life, form the basis for their future, treatment of children with DSD can best be organised in a patient- and family-centred multidisciplinary setting, in an atmosphere based on openness, commitment and trust. Physicians, who daily take care of children with a variety of congenital conditions, the same as their parents or caregivers, are committed to the current as well as the future health and well-being of all children entrusted to their care. In contrast to what is alleged in the recommendation, parents and caregivers implicitly act in the best interest of their children and should be respected as their outstanding representatives, and should not be put aside by claiming prohibition regulations regarding the well-informed decisions they make on their behalf. Finally in that open letter the ESPU advocate keeping the dialogue open with the professionals active in specialised centres for multidisciplinary, patient- and family-centred care as well as with patient societies, for which the present resolution is recognised as being a solid starting base [982].

### 3.16.5 **Risk of tumor development**

Individuals with DSD have an increased risk of developing cancers of the germ cell lineage, malignant germ cell tumors or germ cell cancer compared to the general population [983].

It is well recognised that the highest risk prevalence (30-50%) is seen in conditions characterised by disturbed gonadal development such as incomplete testis development combined with a full block of embryonic germ cell maturation in patients with 46XY gonadal dysgenesis and in some patients with 45X/46XY DSDs. Conversely, patients with testosterone biosynthesis disorders and androgen action disturbances show a much lower risk (1-15%) for carcinoma *in situ* (CIS) development during childhood and a limited tendency towards invasive progression of the lesions [984]. With regard to clinical management a gonadal biopsy at the time of a possible orchidopexy can be obtained for an initial assessment including regular self-exams and annual ultrasound [970].

### 3.16.6 **Recommendations for the management of disorders of sex development**

Recommendations	Strength rating
Newborns with disorders of sex development conditions warrant a multidisciplinary team approach.	Strong
Refer children to experienced centres where neonatology, paediatric endocrinology, paediatric urology, child psychology and transition to adult care are guaranteed.	Strong
Do not delay diagnosis and treatment of any neonate presenting with ambiguous genitalia since salt-loss in a 46XX CAH girl can be fatal.	Strong

## 3.17 **Posterior urethral valves**

### 3.17.1 **Epidemiology, aetiology and pathophysiology**

Posterior urethral valves (PUV) are one of the few life-threatening congenital anomalies of the urinary tract found during the neonatal period. A recent systematic review showed, that the risk for chronic kidney disease (CKD) could be up to 32% and for end-stage kidney disease (ESKD) up to 20% [985]. Up to 17% of paediatric end-stage kidney disease can be attributed to PUV [986]. An incidence of PUV of 1 in 7,000-8,000 live-births has been estimated [987, 988].

### 3.17.2 **Classification systems**

#### 3.17.2.1 **Urethral valve**

Despite some attempts to introduce new classification terms, such as 'congenital obstructive posterior urethral membrane' (COPUM) [989], the original classification by Young *et al.* remains the most commonly used [990].

Young *et al.* described three categories: type I, type II and type III. However, today, only type I and type III are found to be obstructive. As type II seems to be more like a fold and not obstructive, it is no longer referred to as a valve. Young's descriptions of type I and III are as follows:

Type I (90-95%). 'In the most common type there is a ridge lying on the floor of the urethra, continuous with the verumontanum, which takes an anterior course and divides into two fork-like processes in the region of the bulbomembranous junction. These processes are continued as thin membranous sheets, direct upward and forward which may be attached to the urethra throughout its entire circumference. It is generally supposed that the valves have complete fusion anteriorly, leaving only an open channel at the posterior urethral wall. Yet, the fusion of the valves anteriorly may not be complete in all cases, and at this point a slight separation of the folds exists' [990].

*Type III.* 'There is a third type which has been found at different levels of the posterior urethra and which apparently bears no such relation to the verumontanum. This obstruction was attached to the entire circumference of the urethra, with a small opening in the centre [988]. The transverse membrane described has been attributed to incomplete dissolution from the urogenital portion of the cloacal membrane [991]. The embryology of the urethral valves is poorly understood. The membrane may be an abnormal insertion of the mesonephric ducts into the foetal cloaca [992].

### 3.17.3 **Diagnostic evaluation**

An obstruction above the level of the urethra affects the whole urinary tract to varying degrees.

- The prostatic urethra is distended and the ejaculatory ducts may be dilated due to urinary reflux.
- The bladder neck is hypertrophied and rigid.
- The hypertrophied bladder occasionally has multiple diverticula.
- Nearly all valve patients have dilatation of both upper urinary tract. This may be due to the valve itself and the high pressure in the bladder, or due to obstruction of the ureterovesical junction by the hypertrophied bladder.
- If there is secondary reflux, the affected kidney functions poorly in most cases.

During prenatal US screening, bilateral hydronephrosis and a distended bladder are suspicious signs of a urethral valve. A thick-walled bladder seems to be of a better predictor of a PUV than a dilated posterior urethra ('keyhole' sign) [993]. In the presence of increased echogenicity of the kidney, dilatation of the urinary tract and oligohydramnion, the diagnosis of a PUV should strongly be considered.

Voiding cystourethrogram confirms the diagnosis of a PUV. This study is essential whenever there is a question of an infravesical obstruction, as the urethral anatomy is well outlined during voiding. A secondary reflux is observed in at least 50% of patients with PUV [994]. Reflux is consistently associated with renal dysplasia in patients with PUV. It is generally accepted that reflux in the renal units acts as a 'pressure pop-off valve', which would protect the other kidney, leading to a better prognosis [995]. Other types of pop-off mechanism include bladder diverticula and urinary extravasation, with or without urinary ascites [996]. However, in the long-term, a supposed protective effect did not show a significant difference compared to other patients with PUV [997, 998].

Nuclear renography with split renal function is important to assess kidney function (DMSA or MAG3). Creatinine, blood urea nitrogen and electrolytes should be monitored closely during the first few days. Initial management includes a multidisciplinary team involving a paediatric nephrologist. The clinician must be aware of a noteworthy association between PUV and undescended testicles (UDT) and/or inguinal hernia [999]. UDT occurred in 12–17% of PUV consistent with a 10-fold increase [1000].

### 3.17.4 **Management**

#### 3.17.4.1 *Antenatal treatment*

About 40-60% of PUV are discovered before birth [1001]. The intrauterine obstruction leads to a decreased urine output, which could result in an oligohydramnios. Amniotic fluid is necessary for normal development of the lung and its absence may lead to pulmonary hypoplasia, causing a life-threatening problem. Intrauterine attempts have been made to treat a foetus with PUV.

As renal dysplasia is not reversible, it is important to identify those foetuses with good renal function. A sodium level below 100 mmol/L, a chloride value of < 90mmol/L and an osmolarity below 200 mOsm/L found in three foetal urine samples gained on three different days are associated with a better prognosis [1002]. Urine samples before 23 weeks of gestation ( $\beta_2$ -microglobulin, sodium, chloride and calcium) may be helpful to distinguish between those who could benefit from intrauterine therapy and those in whom the outcome is most likely to be compromised [1003]. The status of amniotic fluid, the appearance of the kidneys as well as the fetal urine biochemistry is helpful in counselling the caregivers.

The placing of a vesicoamniotic shunt (VAS) has a complication rate of 21-59%, dislocation of the shunt occurs in up to 44%, mortality lies between 33% and 43%, and renal insufficiency is above 50% [1002, 1004, 1005].

Although shunting is effective in reversing oligohydramnios, it makes no difference to the outcome and long-term results of patients with PUV [1004, 1005]. The PLUTO-trial (randomised study) as well as a recent meta-analysis failed to show any long-term benefit on renal function by placing a VAS [1006, 1007]. Foetal cystoscopy with laser ablation has a high complication rate without evidence for the effectiveness of these interventions [1008, 1009]. The number of patients and designs of these studies are insufficient to give any recommendations.

#### 3.17.4.2 Postnatal treatment

**Bladder drainage.** If a boy is born with suspected PUV, drainage of the bladder and, if possible, an immediate VCUG is necessary. A neonate can be catheterised with a small catheter without a balloon, preferably a feeding tube. A VCUG is performed to see if the diagnosis is correct and whether the catheter is within the bladder and not in the posterior urethra. An alternative option is to place a suprapubic catheter, perform a VCUG and leave the tube until the neonate is stable enough to perform an endoscopic incision or resection of the valve.

**Valve ablation.** When the medical situation of the neonate has stabilised and the creatinine level decreased, the next step is to remove the intravesical obstruction. In cases where the urethra is too small to safely pass a small foetal cystoscope, a suprapubic diversion is performed until valve ablation can be performed. Small paediatric cystoscopes and resectoscopes are now available either to incise, ablate or to resect the valve at the 4-5, 7-8 or 12 o'clock position, or at all three positions, depending on the surgeon's preference. It is important to avoid extensive electrocoagulation, as the most common complication of this procedure is stricture formation. Two studies demonstrated a lower urethral stricture rate using the cold knife compared to diathermy [1010, 1011]. Within the three months following initial treatment, effectiveness of the treatment should be demonstrated either by clinical improvement (ultrasound and renal function) control VCUG or a re-look cystoscopy, depending on the clinical course [1012-1014].

**Vesicostomy.** If the child is too small and/or too ill to undergo endoscopic surgery, a suprapubic diversion is performed to drain the bladder temporarily. If initially a suprapubic tube has been inserted, this can be left in place for six to twelve weeks. Otherwise, a cutaneous vesicostomy provides an improvement or stabilisation of the upper urinary tract (UUT) in up to 90% of cases [1015]. Although there has been concern that a vesicostomy could decrease bladder compliance or capacity, so far there are no valid data to support these expectations [1016, 1017]. Moreover, it was shown in PUV patients with stage 3 CKD that adding vesicostomy to valve ablation no long-term benefit was noted from diversion in the ultimate incidence of end stage renal disease [1018].

**High diversion.** If bladder drainage is insufficient to drain the UUT, high urinary diversion should be considered. Diversion may be suitable if there are recurrent infections of the upper tract, no improvement in renal function and/or an increase in upper tract dilatation, despite adequate bladder drainage. The choice of urinary diversion depends on the surgeon's preference for high loop ureterostomy, ring ureterostomy, end ureterostomy or pyelostomy, with each technique having advantages and disadvantages [1019-1021]. Diversion can delay progression to end stage renal failure [1018]. Reconstructive surgery should be delayed until the UUT has improved as much as can be expected.

Reflux is very common in PUV patients (up to 72%) and it is described bilaterally in up to 32% [1022]. During the first months of life, antibiotic prophylaxis may be given especially in those with high-grade reflux [769] and in those with a phimosis, circumcision can be discussed in order to reduce the risk of UTIs [1023]. However, there are no randomised studies to support this for patients with PUV. Early administration of oxybutynin may improve bladder function as shown in one study with 18 patients [1024]. High-grade reflux is associated with a poor functioning kidney and is considered a poor prognostic factor [1025, 1026]. However, early removal of the renal unit seems to be unnecessary, as long as it causes no problems. Moreover, in the long term it may be necessary to augment the bladder and in this case the ureter may be used [1027]. Deterioration of renal function without a fixed obstruction and higher urine output (polyuria) may lead to an overdistension of the bladder during the night. Drainage of the bladder during the night by a catheter may be beneficial for the hydronephrosis as well as for renal function [1028, 1029]. Patients with high daytime post void residual urine may benefit from CIC [1030, 1031]. In those who do not want or are not able to perform a CIC via urethra, the placement of a Mitrofanoff is a good alternative [1032].


#### 3.17.5 Follow-up

Several prognostic factors have been described. Different serum nadir creatinine levels are given in the literature (0.85 mg/dl – 1.2mg/d (µmol/L) [1033-1036]. Renal parenchyma quantity (total renal parenchymal area) and quality (corticomedullary differentiation and renal echogenicity) on initial postnatal ultrasound also have prognostic value [1037].

Life-long monitoring of these patients is mandatory, as bladder dysfunction ('valve bladder') is not uncommon and the delay in day- and night-time continence is a major problem [994, 1038, 1039]. The literature demonstrates that urodynamic studies play an important role in the management of patients with valve bladder especially in those with suspicion of bladder dysfunction [1040, 1041]. Poor bladder sensation and compliance, detrusor instability and polyuria (especially at night) and their combination are responsible for bladder dysfunction. In those with bladder instability, anticholinergic therapy can improve bladder function. However, with a low risk of reversible myogenic failure (3/37 patients in one study) [1042, 1043]. In patients with poor bladder emptying,  $\alpha$ -blocker can be used to reduce the PVR urine, as demonstrated in one study with 42 patients using terazosin (mean PVR) was reduced from 16 to 2 mL) [1044]; in another study tamsulosin was effective [1045]. Concerning bladder neck incision, there is no panel consensus concerning indication and efficacy. High creatinine nadir (>1 mg/dl) and severe bladder dysfunction are risk factors for renal replacement therapy [1046, 1047]. Renal transplantation in these patients can be performed safely and effectively [1048, 1049]. Deterioration of the graft function is mainly related to LUTD [1048]. An assessment and treatment algorithm is provided in Figure 10.

There are only few reports on sexual function and fertility in patients with PUV demonstrating some impairment especially in those who are on dialysis [1050, 1051]. In a recent review the majority have good erectile function (74-94%) and a fertility comparable to the normal population [1052]. However, a negative influence of the individual patient's fertility has to be taken into account as these patients have a higher risk for bilateral cryptorchidism, recurrent epididymitis and ESRD [1052].

Figure 10: An algorithm on the assessment, management and follow-up of newborns with possible PUV



CIC = clean intermittent catheterisation; OAB = overactive bladder; PUV = posterior urethral valve; RF = renal function; UT = urinary tract; UUT = upper urinary tract; VCUG = voiding cystourethrogram.

### 3.17.6 Summary

Posterior urethral valves are one of the few life-threatening congenital anomalies of the urinary tract found during the neonatal period and despite optimal treatment result in renal insufficiency in nearly one-third of cases. Bilateral hydronephrosis and a distended bladder are suspicious signs of a PUV in neonates. A VCUG confirms a PUV diagnosis. Nuclear renography with split renal function is important to assess kidney function and serum creatinine nadir above 80  $\mu\text{mol/L}$  is correlated with a poor prognosis.

Postnatal treatment includes bladder drainage either transurethral or suprapubic and if the child is stable enough, endoscopic incision of the valve is performed. If a child is too small and/or too ill to undergo endoscopic surgery, a vesicostomy is an option for bladder drainage. If bladder drainage is insufficient to drain the UUT, high urinary diversion should be considered.

In all patients life-long monitoring is mandatory, as bladder dysfunction is quite common and may cause progressive upper tract deterioration, if not managed properly. In the long-term between 10% and 47% of patients may develop end-stage renal failure. Renal transplantation in these patients can be performed safely and effectively.

### 3.17.7 Summary of evidence and recommendations for the management of posterior urethral valves

Summary of evidence	LE
Posterior urethral valves are one of the few life-threatening congenital anomalies of the urinary tract found during the neonatal period.	1b
Despite optimal treatment nearly one-third of patients end up in renal insufficiency.	2b
Bilateral hydronephrosis and a distended bladder are suspicious signs on US; a VCUG confirms the diagnosis.	2b
Serum creatinine nadir above 85 µmol/L is correlated with a poor prognosis.	2a
In the long-term up to 20% of patients develop end-stage renal failure due to primary dysplasia and/or further deterioration because of bladder dysfunction. Renal transplantation in these patients is safe and effective, if the bladder function is normalised.	2a

Recommendations	LE	Strength rating
Diagnose posterior urethral valves (PUV) initially by ultrasound but a voiding cystourethrogram (VCUG) is required to confirm the diagnosis.	3	Strong
Assess split renal function by dimercaptosuccinic acid scan or mercaptoacetyltriglycine (MAG3) clearance. Use serum creatinine as a prognostic marker.		Strong
Vesico-amniotic shunt antenatally is not recommended to improve renal outcome.	1b	Weak
Offer endoscopic valve ablation after bladder drainage and stabilisation of the child.	3	Strong
Offer suprapubic diversion for bladder drainage if the child is too small for valve ablation.		Strong
Offer a high urinary diversion if bladder drainage is insufficient to drain the upper urinary tract and the child remains unstable.		Strong
Monitor bladder and renal function lifelong, in all patients.	3	Strong

## 3.18 Paediatric urological trauma

Trauma is the leading cause of morbidity and mortality in children and is responsible for more childhood deaths than the total of all other causes [1053]. In about 3% of children seen at paediatric hospital trauma centres, there is significant involvement of the genitourinary tract [1054]. This is caused by either blunt injuries from falls, car accidents, sports injuries, physical assault, and sexual abuse, or penetrating injuries, usually due to falls onto sharp objects or from gunshot or knife wounds.

### 3.18.1 Paediatric renal trauma

#### 3.18.1.1 Epidemiology, aetiology and pathophysiology

In blunt abdominal trauma, the kidney is the most commonly affected organ, accounting for about 10% of all blunt abdominal injuries [1053].

Children are more likely than adults to sustain renal injuries after blunt trauma because of their anatomy. Compared to an adult kidney, a child's kidney is larger in relation to the rest of the body and often retains foetal lobulations, so that blunt trauma is more likely to lead to a local parenchymal disruption. The paediatric kidney is also less well protected than the adult kidney. Children have less peri-renal fat, much weaker abdominal muscles, and a less ossified and therefore much more elastic and compressible thoracic cage [1055].

Blunt renal trauma is usually a result of sudden deceleration of the child's body, particularly due to sport accidents, falls, and contact with blunt objects. Deceleration or crush injuries result in contusion, laceration or avulsion of the less well-protected paediatric renal parenchyma.

#### 3.18.1.2 Classification systems

Renal injuries are classified according to the kidney injury scale of the American Association for the Surgery of Trauma (Table 13) [1056].

**Table 13: Renal injury classified according to the kidney injury scale of the American Association for the Surgery of Trauma [1056]**

Grade	Type of injury	Description
I	Contusion	Non-visible or visible haematuria
	Haematoma	Normal urological studies
II	Haematoma	Non-expanding subcapsular haematoma
	Laceration	Laceration of the cortex of < 1.0 cm
III	Laceration	Laceration > 1.0 cm without rupture of collecting system
IV	Laceration	Through the cortex, medulla and collecting system
	Vascular	Vascular injury
V	Laceration	Completely shattered kidney
	Vascular	Avulsion of the renal hilum

### 3.18.1.3 Diagnostic evaluation

In a child who has sustained blunt abdominal trauma, renal involvement can often be predicted from the history, physical examination and laboratory evaluation. Renal involvement may be associated with abdominal or flank tenderness, lower rib fractures, fractures or vertebral pedicles, trunk contusions and abrasions, and haematuria.

#### 3.18.1.3.1 Haematuria

Haematuria may be a reliable finding. In severe renal injuries, 65% suffer visible haematuria and 33% nonvisible, while only 2% have no haematuria at all [1057].

The radiographic evaluation of children with suspected renal trauma remains controversial. Some centres rely on the presence of haematuria to diagnose renal trauma, with a threshold for renal involvement of 50 RBCs/HPF. Although this may be a reliable threshold for significant non-visible in trauma, there have been many reports of significant renal injuries that manifest with little or even no blood in the urine [1058]. It is therefore compulsory to consider all the clinical aspects involved, including the history, physical examination, consciousness of the child, overall clinical status and laboratory findings to decide on the diagnostic algorithm and whether or not a child needs further imaging studies.

#### 3.18.1.3.2 Blood pressure

It is important to consider that children, unlike adults, are able to maintain their blood pressure, even in the presence of hypovolaemia, due to compliance of the vascular tree and mechanisms for cardiac compensation [1059]. Because blood pressure is an unreliable predictor of renal involvement in children, some centres recommend imaging of the urinary tract in children with any degree of haematuria following significant abdominal trauma.

#### 3.18.1.3.3 Choice of imaging method

Nowadays, CT is the best imaging method for renal involvement in children. Computed tomography scanning is the cornerstone of modern staging of blunt renal injuries especially when it comes to grading the severity of renal trauma.

Computed tomography scanning is quite rapid and usually performed with the injection of contrast media. To detect extravasation, a second series of images is necessary since the initial series usually finishes 60 seconds after injection of the contrast material and may therefore fail to detect urinary extravasation [1060]. In acute trauma, US may be used as a screening tool and for reliably following the course of renal injury. However, US is of limited value in the initial and acute evaluation of trauma. The standard intravenous pyelogram (IVP) is a good alternative imaging method if a CT scan is not available. It is superior to US but not as good as CT scanning for diagnostic purposes.

### 3.18.1.4 Disease management

The modern management of trauma is multidisciplinary, requiring paediatricians, emergency physicians, surgeons, urologists, and other specialties as required.

Non-surgical conservative management with bed rest, fluids and monitoring has become the standard approach for treating blunt renal trauma. Even in high-grade renal injuries, a conservative approach is effective and recommended for stable children. However, this approach requires close clinical observation, serial CT scans, and frequent re-assessment of the patient's overall condition.

Absolute indications for surgery include persistent bleeding into an expanding or unconfined haematoma. Relative indications for surgery are massive urinary extravasation and extensive non-viable renal tissue [1061].



### 3.18.1.5 Recommendations for the diagnosis and management of paediatric renal trauma

Recommendations	Strength rating
Use imaging in all children who have sustained a blunt or penetrating trauma with any level of haematuria, especially when the history reveals a deceleration trauma, direct flank trauma or a fall from a height.	Strong
Use rapid spiral computed tomography scanning for diagnostic and staging purposes.	Strong
Manage most injured kidneys conservatively.	Strong
Offer surgical intervention in case of haemodynamic instability and a Grade V renal injury.	Strong

### 3.18.2 Paediatric ureteral trauma

Injuries to the ureter are rare. The ureter is well protected; the upper part is protected by its close approximation to the vertebral column and paraspinal muscles and the lower part by its route through the bony pelvis. In addition, the ureter is a small target, and both flexible and mobile. This also means that ureteral injuries are caused more often by penetrating trauma than blunt trauma [1062]. Since the ureter is the sole conduit for urinary transport between the kidney and the bladder, any ureteral injury can threaten the function of the ipsilateral kidney.

#### 3.18.2.1 Diagnostic evaluation

Since there are no classical clinical symptoms suggestive of ureteral trauma, it is important to carry out a careful diagnostic work-up using different imaging modalities. Unfortunately, initial imaging studies, such as IVP and routine CT scans, are unreliable; a study of eleven disruptions of the ureteropelvic junction found that 72% had a normal or non-diagnostic IVP on initial studies [1062]. Diagnostic accuracy of CT scanning can be improved by performing a delayed CT scan up to ten minutes after injection of the contrast material [1063]. The most sensitive diagnostic test is a retrograde pyelogram.

Quite a few patients present several days after the injury, when the urinoma produces flank and abdominal pain, nausea and fever.

Because the symptoms may often be quite vague, it is important to remain suspicious of a potential undiagnosed urinary injury following significant blunt abdominal trauma in a child.

#### 3.18.2.2 Management

Immediate repair during abdominal exploration is rare. Minimally invasive procedures are the method of choice, especially since many ureteral injuries are diagnosed late after the traumatic event. Percutaneous or nephrostomy tube drainage of urinomas can be successful, as well as internal stenting of ureteral injuries [1064].

If endoscopic management is not possible, primary repair of partial lacerations should be followed by internal stenting. The management of complete lacerations, avulsions or crush injuries depends on the amount of ureter lost and its location. If there is an adequate healthy length of ureter, a primary ureteroureterostomy can be performed. If primary re-anastomosis is not achievable, distal ureteral injuries can be managed using a psoas bladder hitch, Boari flap or even nephropexy. Proximal injuries can be managed using transureteroureterostomy, autotransplantation or ureteral replacement with bowel or appendix [1065].

### 3.18.2.3 Recommendations for the diagnosis and management of paediatric ureteral trauma

Recommendations	Strength rating
Diagnose suspected ureteral injuries by retrograde pyelogram.	Strong
Manage ureteral injuries endoscopically, using internal stenting or drainage of an urinoma, either percutaneously or via a nephrostomy tube.	Weak

### 3.18.3 Paediatric bladder injuries

The paediatric bladder is less protected than the adult bladder, and is therefore more susceptible to injuries than the adult bladder, especially when it is full, due to:

- Its higher position in the abdomen and its exposure above the bony pelvis.
- The fact that the abdominal wall provides less muscular protection.
- The fact that there is less pelvic and abdominal fat surrounding the bladder to cushion it in trauma.

Blunt trauma is the most common cause of significant bladder injury. In adults, bladder injury is often associated with pelvic fractures. This is less common in children because the paediatric bladder sits above

the pelvic ring. In a large prospective study, only 57% of children with pelvic fractures also had a bladder injury compared to 89% of adults [1066].

### 3.18.3.1 Diagnostic evaluation

The characteristic signs of bladder injury are suprapubic pain and tenderness, an inability to urinate, and visible haematuria (95% of injuries). Patients with a pelvic fracture and visible haematuria present with a bladder rupture in up to 45% of cases [1067].

The diagnosis of bladder rupture can be difficult in some cases. The bladder should be imaged both when fully distended and after drainage using standard radiography or a CT scan. The best results can be achieved by retrograde filling of the bladder using a catheter. Despite advances in CT imaging, the bladder must still be filled to capacity to accurately diagnose a possible bladder injury [1068].

Blunt injuries to the bladder are categorised as:

- contusions with damage to the bladder mucosa or muscle, without loss of bladder wall continuity or extravasation;
- ruptures, which are either intraperitoneal or extraperitoneal.

Intraperitoneal bladder ruptures are more common in children because of the bladder's exposed position and the acute increase in pressure during trauma. These cause the bladder to burst at its weakest point, i.e. the dome. Extraperitoneal lesions occur in the lower half of the bladder and are almost always associated with pelvic fractures. A cystogram will show extravasation into the perivesical soft tissue in a typical flame pattern and the contrast material is confined to the pelvis.

### 3.18.3.2 Management

Contusions usually present with varying degrees of haematuria and are treated with catheter drainage alone.

#### 3.18.3.2.1 Intraperitoneal injuries

The accepted management of intraperitoneal bladder ruptures is open surgical exploration and primary repair. Post-operative drainage with a suprapubic tube is mandatory. Recent data suggest that transurethral drainage may be as effective, with fewer complications, resulting in shorter periods of diversion [1069]. Usually, after about seven to ten days, a repeat cystogram is performed to ensure healing is taking place properly.

#### 3.18.3.2.2 Extraperitoneal injuries

Non-operative management with catheter drainage for seven to ten days alone is the method of choice for extraperitoneal bladder rupture. However, if there are bone fragments within the bladder, these must be removed and the bladder must then be repaired and drained, according to the principles for treating intraperitoneal ruptures [1070].

### 3.18.3.3 Recommendations for the diagnosis and management of paediatric bladder injuries

Recommendations	Strength rating
Use retrograde cystography to diagnose suspected bladder injuries.	Strong
Ensure that the bladder has been filled to its full capacity and an additional film is taken after drainage.	Strong
Manage extra-peritoneal bladder ruptures conservatively with a transurethral catheter left in place for seven to ten days.	Strong
Do not delay treatment of intra-peritoneal bladder ruptures by surgical exploration and repair as well as post-operative drainage for seven to ten days.	Strong

### 3.18.4 Paediatric urethral injuries

Except for the penile part of the urethra, the paediatric urethra is quite well protected. In addition, its shape and elasticity mean the urethra is seldom injured by trauma. However, a urethral injury should be suspected in any patient with a pelvic fracture or significant trauma to the perineum until confirmed otherwise by a diagnostic work-up.

#### 3.18.4.1 Diagnostic evaluation

Patients with suspected urethral trauma and pelvic fractures usually present with a history of severe trauma, often involving other organ systems.

Signs of urethral injury are blood at the meatus, visible haematuria, and pain during voiding or an inability to void. There may also be perineal swelling and haematoma involving the scrotum. A rectal examination to determine the position and fixation of the prostate is important in any male with a suspected urethral injury. The prostate, as well as the bladder, may be displaced up out of the pelvis, especially in membranous urethral trauma.

Radiographic evaluation of the urethra requires a retrograde urethrogram. It is important to expose the entire urethral length, including the bladder neck. If a catheter has already been placed by someone else and there is suspected urethral trauma, the catheter should be left in place and should not be removed. Instead, a small infant feeding tube can be placed into the distal urethra along the catheter to allow the injection of contrast material for a diagnostic scan [1071].

#### 3.18.4.2 Disease management

Since many of these patients are unstable, the urologist's initial responsibility is to provide a method of draining and monitoring urine output.

A transurethral catheter should only be inserted if there is a history of voiding after the traumatic event, and if a rectal and pelvic examination, as described above, has not suggested a urethral rupture. If the catheter does not pass easily, an immediate retrograde urethrogram should be performed.

A suprapubic tube may be placed in the emergency department percutaneously, or even in the operating room, if the patient has to undergo immediate exploration because of other life-threatening injuries.

There are often no associated injuries with a bulbous urethral or straddle injury and management is therefore usually straightforward. In these cases, a transurethral catheter is the best option for preventing urethral bleeding and/or painful voiding [1072].

The initial management of posterior urethral injuries remains controversial, mainly regarding the long-term results with primary realignment compared to simple suprapubic drainage with later reconstruction.

The main goals in the surgical repair of posterior urethral injuries are:

- Providing a stricture-free urethra.
- Avoiding the complications of urinary incontinence and impotence.

Suprapubic drainage and late urethral reconstruction was first attempted because immediate surgical repair had a poor outcome, with significant bleeding and high rates of incontinence (21%) and impotence in up to 56% of cases [1073]. In adults, a study of the success rates of delayed repair reported re-structure rates of 11-30%, continence rates of 90-95% and impotence rates of 62-68% [1074]. However, in children, there is much less experience with delayed repair. The largest paediatric series of delayed repair in 68 boys reported a success rate of 90% [1075]. Another study reported strictures and impotence in 67% of boys, although all the boys were continent [1074].

An alternative to providing initial suprapubic drainage and delayed repair is primary realignment of the urethra via a catheter. The catheter is usually put in place during open cystostomy by passing it from either the bladder neck or meatus and through the injured segment. In a series of fourteen children undergoing this procedure, this resulted in a stricture rate of 29% and incontinence in 7% of patients [1076].

#### 3.18.4.3 Recommendations for the diagnosis and management of paediatric trauma

Recommendations	Strength rating
Assess the urethra by retrograde urethrogram in case of suspected urethral trauma.	Strong
Perform a rectal examination to determine the position of the prostate.	Strong
Manage bulbous urethral injuries conservatively with a transurethral catheter.	Strong
Manage posterior urethral disruption by either: <ul style="list-style-type: none"> <li>• primary reconstruction;</li> <li>• primary drainage with a suprapubic catheter alone and delayed repair;</li> <li>• primary re-alignment with a transurethral catheter.</li> </ul>	Weak

### 3.19 Post-operative fluid management

#### 3.19.1 Epidemiology, aetiology and pathophysiology

Compared to adults, children have a different total body fluid distribution, renal physiology and electrolyte requirements, as well as weaker cardiovascular compensation mechanisms [1077]. As children are developing, they have a high metabolic rate and lower fat and nutrient stores, which means they are more susceptible to metabolic disturbances caused by surgical stress [1078]. The metabolic response to anaesthesia and surgery in infants and children is related to the severity of the operation [1079].

### 3.19.2 Disease management

#### 3.19.2.1 Pre-operative fasting

Pre-operative fasting has been advocated for elective surgery to avoid the complications associated with pulmonary aspiration during induction of anaesthesia. Table 14 gives the current guidelines for pre-operative fasting for elective surgery [1080, 1081].

**Table 14: Pre-operative fasting times for elective surgery**

Ingested material	Minimum fasting period (hours)
Clear liquids	2
Breast milk	4
Infant formula	4 (< 3 months old) to 6 (> 3 months old)
Non-human milk	6
Light meal	6

Although hypoglycaemia is an important issue in children, research has shown that hypoglycaemia is uncommon if children are still fed up to four hours before the induction of anaesthesia [1082]. Newborns often have low glycogen stores and impaired gluconeogenesis, both of which can be helped by limiting the period of pre-operative starvation and feeding with glucose-containing solutions. It is important to monitor blood glucose and to adjust the glucose supply continuously in neonates and children who are small for their age, as this helps to prevent excessive fluctuation in blood glucose levels [1083].

#### 3.19.2.2 Maintenance therapy and intra-operative fluid therapy

Generally, the anaesthetist is responsible for intra-operative management and the surgeon is responsible for post-operative instructions. The goal of intra-operative fluid management is to sustain homeostasis by providing the appropriate amount of parenteral fluid; this maintains adequate intravascular volume, cardiac output and oxygen delivery to tissues at a time when normal physiological functions have been altered by surgical stress and anaesthetic agents .

The fluids for maintenance therapy replace losses from two sources: insensible (evaporation) and urinary loss. They do not replace blood loss or third-space fluid loss into the interstitial space or gut. The main formulae for calculating the daily maintenance requirement for water have not changed in the past 50 years (Table 15) [1084]. Calculations have shown that anaesthetised and non-anaesthetised children have similar fluid requirements [1085].

The combination of maintenance fluid and electrolyte requirements results in a hypotonic electrolyte solution. The usual intravenous maintenance fluid given to children by paediatricians is one-quarter to one-third strength saline [1086].

**Table 15: Hourly and daily fluid requirements according to body weight**

Body weight	Hourly	Daily
< 10 kg	4 mL/kg	100 mL/kg
10-20 kg	40 mL + 2 mL/kg; > 10 kg	1,000 mL + 50 mL/kg; > 10 kg
> 20 kg	60 mL + 1 mL/kg; > 20 kg	1,500 mL + 20 mL/kg; > 20 kg

The fasting deficit is calculated by multiplying the hourly maintenance fluid requirement by the number of hours of fluid restriction. It is recommended that 50% of the fasting deficit is replaced in the first hour and 25% in the second and third hours [1087]. Berry proposed simplified guidelines for fluid administration according to the child's age and severity of surgical trauma [1088] (Table 16).

**Table 16: Intra-operative fluid management adapted for children fasted for six to eight hours, following the classical recommendation 'nil per oral after midnight'**

Furman <i>et al.</i> [1087]			
Hour of fluid replacement	Maintenance fluid	Fasting deficit replacement	Persistent losses
First hour	As Table 15	50%	Third space + blood loss replacement
Second hour		25%	
Third hour		25%	
Berry [1088]			
First hour	< 3 years: 25 mL/kg > 4 years: 15 mL/kg		Blood replacement 1:1 with blood or colloid <b>or</b> 3:1 with crystalloids
All other hours	Maintenance volume = 4 mL/kg/h Maintenance + mild trauma = 6 mL/kg/h Maintenance + moderate trauma = 8 mL/kg/h Maintenance + severe trauma = 10 mL/kg/h		Blood replacement 1:1 with blood or colloid <b>or</b> 3:1 with crystalloids

\* Reduce the amount of fluid given during the first hour if children are fasting for a shorter period of time, or if the child was already being given intravenous fluid prior to surgery.

Five percent dextrose with one-quarter to half-normal saline is often used as a maintenance fluid, while balanced salt solution or normal saline is used as replacement fluid. Blood losses are replaced with a 1:1 ratio of blood or colloid or a 3:1 ratio of crystalloid. However, the administration of a large volume of normal saline can cause dilutional acidosis or hyperchloremic acidosis, while a large volume of balanced salt solution, such as lactated Ringer's solution, can decrease serum osmolality, which is not beneficial in patients with decreased intracranial compliance. If appropriate, albumin, plasma, synthetic colloids, and blood should be administered [1083].

Third-space losses may vary from 1 mL/kg/h for a minor surgical procedure to 15-20 mL/kg/h for major abdominal procedures, or even up to 50 mL/kg/h for surgery of necrotising enterocolitis in premature infants. Third-space losses should be replaced with crystalloids (normal saline or Ringer's lactate) [1081].

Most of the fluids required during surgery are needed to replace fasting deficit or third-space losses, which are mainly extracellular fluids. Hydrating solutions should contain high concentrations of sodium and chloride and low concentrations of bicarbonate, calcium and potassium.

Intra-operative hypoglycaemia is rare in children. In contrast, hyperglycaemia is commonly encountered during anaesthesia and surgery. The replacement fluid should be free of dextrose or should not have > 1% dextrose. Current recommendations include the use of low-dextrose-containing solutions for maintenance fluid therapy, except in patients who are at high risk of hypoglycaemia [1077, 1086]. Intra-operative administration of glucose-free isotonic hydrating solutions should be the routine practice for most procedures in children over four to five years of age. In infants and young children, 5% dextrose solutions should be avoided, but it is appropriate to use 1% or 2% dextrose in lactated Ringer's solution [1081].

### 3.19.2.3 Post-operative fluid management

During the post-operative period, the fundamental principle is to monitor gastrointestinal function and to continue oral or enteral nutrition as much as possible [1078], while remembering that withholding oral fluids post-operatively from children undergoing day surgery helps prevent vomiting [1089]. In minor surgical procedures, intra-operative administration of large volumes of crystalloids is associated with a reduced incidence of post-operative nausea and vomiting after anaesthesia in both paediatric and adult patients [1090]. Berry's fluid replacement guidelines can be followed, provided the child is given lactated Ringer's solution or polyionique B66, which has an osmolality similar to plasma [1091].

It is not obligatory to check serum chemistry after uncomplicated surgery in children with normal pre-operative renal and hepatic function. However, if oral intake has been postponed for > 24 hours (e.g. as in intestinal surgery), there is an increased risk of electrolyte abnormalities, requiring further assessment and subsequent management, particularly with potassium. Post-operative findings, such as decreased bowel movements and ileus, may be signs of hypokalemia, which may be corrected with a solution of 20 mmol/L potassium and an infusion rate of not more than 3 mmol/kg/day. The potassium should be given via peripheral venous access if the duration of infusion is not expected to exceed five days, or via central venous access when long-term parenteral nutrition is necessary.

The goals of fluid therapy are to provide basic metabolic requirements and to compensate for gastrointestinal and additional losses. If hypovolemia is present, it should be treated rapidly. Hyponatremia is

the most frequent electrolyte disorder in the post-operative period [1091, 1092]. This means that hypotonic fluid should not be routinely administered to hospitalised children because they have several stimuli for producing arginine vasopressin and are therefore at high risk for developing hyponatremia [1081, 1091, 1093-1096]. The preferred fluids for maintenance therapy are 0.45% saline with dextrose or isotonic fluids, in the absence of a specific indication for 0.25% saline. It is also advisable to administer isotonic fluids intra-operatively and also immediately post-operatively, albeit at two-thirds of the calculated maintenance rate in the recovery room. Fluid composition should balance high sodium requirements, energy requirements and solution osmolality. The extra losses from gastric or chest tubes should be replaced with lactated Ringer's solution. Fluid that has been given to dilute medications must also be taken into account [1081].

Children who undergo interventions to relieve any kind of obstructive diseases deserve particular attention, especially due to the risk of polyuria as a result of post-obstructive diuresis. In children who develop polyuria, it is important to monitor fluid intake and urine output, as well as renal function and serum electrolytes. If necessary, clinicians should not hesitate in consulting with a paediatric nephrologist.

#### 3.19.2.4 Post-operative fasting

It has been reported that fasting reduces the risk of vomiting by up to 50% [1089, 1097, 1098]. However, a study found that if children were freely allowed to drink and eat when they felt ready or requested it, the incidence of vomiting did not increase and the children felt happier and were significantly less bothered by pain than children who were fasting [1099]. The mean times until first drink and first eating in the children who were free to eat or drink were 108 and 270 minutes, respectively, which were four hours and three hours earlier than in the fasting group. Previous studies have suggested that gastric motility returns to normal one hour after emergence from anaesthesia in children who have undergone non-abdominal surgery [1100]. The first oral intake in children at one hour after emergence from anaesthesia for minor surgery did not cause an increase in the incidence of vomiting, provided that the fluid ingested was at body temperature [1101]. The Panel therefore recommend encouraging an early intake of fluid in children who have undergone minor or non-abdominal urological surgery.

### 3.19.3 Summary of evidence and recommendations for the management of post-operative fluid management

Summary of evidence	LE
Children are not simply smaller physiological versions of adults. They have their own unique metabolic features, which must be considered during surgery.	2

Recommendations	Strength rating
Ensure that shorter pre-operative fasting periods apply for elective surgeries (up to four hours).	Strong
Use fluids with lower dextrose concentrations since hyperglycaemia is common in children, compared to intra-operative hypoglycaemia (which is very rare).	Strong
Do not routinely use hypotonic fluid in hospitalised children because they are at high risk of developing hyponatraemia.	Strong
Assess the baseline and daily levels of serum electrolytes, glucose, urea and/or creatinine in every child who receives intravenous fluids, especially in intestinal surgery (e.g. ileal augmentation), regardless of the type of solution chosen since there is an increased risk of electrolyte abnormalities in children undergoing such surgery.	Strong
Start early oral fluid intake in patients scheduled for minor surgical procedures.	Strong

## 3.20 Post-operative pain management: general information

### 3.20.1 Epidemiology, aetiology and pathophysiology

The provision of adequate pain control requires proper pain evaluation, accurate choice of drug and route of administration, and consideration of age, physical condition and type of surgery and anaesthesia [1102]. However, there is still no standardised algorithm for management of post-operative pain in children [1103]. There is an urgent need for a post-operative pain management protocol in children, particularly for guidance on the frequency of pain assessment, use of parenteral opioids, introduction of regional anaesthesia, and the application of rescue analgesics [1104].

Traditional medical beliefs that neonates are incapable of experiencing pain have now been abandoned following recent and better understanding of how the pain system matures in humans, better pain assessment methods and a knowledge of the clinical consequences of pain in neonates [1105-1109]. Many studies have indicated that deficient or insufficient analgesia may be the cause of future behavioural and

somatic sequelae [1110-1113]. Our current understanding of pain management in children depends fully on the belief that all children, irrespective of age, deserve adequate treatment.

### 3.20.2 **Diagnostic evaluation**

Assessment of pain is the first step in pain management. Validated pain assessment tools are needed for this purpose and it is important to select the appropriate pain assessment technique. Several pain assessment tools have been developed according to the child's age, cultural background, mental status, communication skills and physiological reactions [1114, 1115].

One of the most important topics in paediatric pain management is informing and involving the child and caregivers during this process. Caregivers and patients can manage post-operative pain at home or in hospital if provided with the correct information. Caregivers and patients, if they are old enough, can actively take part in pain management in patient-family-controlled analgesia applications [1116-1121].

### 3.20.3 **Disease management**

#### 3.20.3.1 *Drugs and route of administration*

Pre-emptive analgesia is an important concept that aims to induce the suppression of pain before neural hypersensitisation occurs [1122]. Local anaesthetics or non-steroidal analgesics are given intra-operatively to delay post-operative pain and to decrease post-operative analgesic consumption. Analgesics must be titrated until an appropriate response is achieved. Opioids can be administered to children by the oral, mucosal, transdermal, subcutaneous, intramuscular or intravenous routes [1121]. The combination of opioids with nonsteroidal anti-inflammatory drugs (NSAIDs) or local anaesthetics (balanced or multimodal analgesia) can be used to increase the quality of analgesia and decrease undesired effects related to opioids [1123]. The same combination of local anaesthetics, opioids, and non-opioid drugs used in adults can also be used in children taking into account their age, body weight and individual medical status.

The World Health Organization's 'pain ladder' is a useful tool for the pain management strategy [1124]. A three-level strategy seems practical for clinical use. Post-operative management should be based on sufficient intra-operative pre-emptive analgesia with regional or caudal blockade followed by balanced analgesia.

Paracetamol and NSAIDs are the drugs of choice at the first level. As they become insufficient to prevent pain, weak and strong opioids are added to oral drugs to achieve balanced analgesia. Every institute must build their own strategy for post-operative analgesia. A proposed strategy for post-operative analgesia may be as follows:

1. Intra-operative regional or caudal block.
2. Paracetamol + NSAID.
3. Paracetamol + NSAID + weak opioid (e.g. tramadol or codeine).
4. Paracetamol + NSAID + strong opioid (e.g. morphine, fentanyl, oxycodone or pethidine).

#### 3.20.3.2 *Circumcision*

Circumcision without anaesthesia, irrespective of age, is not recommended. Circumcision requires proper pain management [1125]. Despite this, adequate pain management is still below expectation [1126]. Potential analgesic interventions during circumcision include the use of a dorsal penile nerve block (DPNB) or ring block, topical anaesthetics (e.g. lidocaine-prilocaine cream, or 4% liposomal lidocaine cream), a less painful clamp (e.g. Mogen clamp), a pacifier, sucrose, and swaddling, preferably in combination [1127-1131].

Although DPNB and topical anaesthetics seem to have a similar post-operative analgesic effect, DPNB is still the most preferred method [1132] (LE: 1a). Ultrasound guidance may improve the results, with an increase in procedural time [1133, 1134]. Caudal blockade methods have similar efficacy compared to DPNB. However, caregivers should be informed about the more frequent incidence of post-operative motor weakness and micturition problems [1135-1140].

#### 3.20.3.2.1 *Penile, inguinal and scrotal surgery*

Caudal block is the most studied method for analgesia following surgery for hypospadias. Several agents with different doses, concentrations and administration techniques have been used with similar outcomes [1141-1155]. Both single and combined use of these agents is effective [1142-1144, 1147, 1152, 1153].

Penile blocks can be used for post-operative analgesia and have similar post-operative analgesic properties as caudal blocks [1156]. Two penile blocks at the beginning and end of surgery seems to provide better pain relief [1157]. Severe bladder spasms caused by the presence of the bladder catheter may sometimes cause more problems than pain and is managed with antimuscarinic medications.

For inguinoscrotal surgery, all anaesthetic methods, such as caudal blocks [421, 1158-1160] nerve block [1161, 1162], wound infiltration or instillation, and irrigation with local anaesthetics [1163-1165] have been shown to have adequate post-operative analgesic properties. Combinations may improve the results [1166].

Table 17: List of several drugs used in post-operative pain management in children [1107, 1110, 1118, 1167-1169]]

Name	Route of administration	Dose	Side effects	General remarks	Caution
<b>Non-narcotics</b>					
Acetaminophen	Rectal	40 mg/kg loading, 20 mg/kg/dose 4 times/day	Nephrotoxicity, hepatotoxicity (neonates)	Most common used analgesic Antipyretic effect Opioid-sparing effect Wide safety range	Slow onset time and variable absorption via the rectal route; dividing the vehicle is not recommended. Total dose should not exceed: 100 mg/kg for children; 75 mg/kg for infants; 60 mg/kg for term and preterm neonates > 32 weeks post-conceptual age; and 40 mg/kg for preterm neonates < 32 weeks post-conceptual age
	Oral	15-40 mg/kg, followed by 30 mg/ kg/8 h			
	Intravenous	Propacetamol (prodrug)			
Ibuprofen	Oral, rectal	4-10 mg/kg/dose 3-4 times/day		Better analgesic than paracetamol	Safety not established for infants < 6 months old
Diclofenac	Tablet, syrup, suppository	1-1.5 mg/kg 2-3 times/day	Nephrotoxicity, gastrointestinal disturbances	Better than ibuprofen	> 6 years old
Ketorolac	Oral, IV, IM	0.2-0.5 mg/kg every 6 h (48 h) Total dose < 2 mg/kg/day, maximum 5 days		Opioid-sparing effect	
Ketamine	Oral, rectal, IM, SC, IV, intraspinal	< 2 mg/kg (IM) < 1 mg/kg (IV, epidural)			
Metamizole, dipyrrone	Oral, IM Oral drop	10-15 mg/kg/dose (max 40 mg/ kg total) 10-15 mg/kg 1 drop/kg/dose, up to 4 times/day	Risk of agranulocytosis, not clarified definitely	Very effective antipyretic	Not approved in some countries including USA, Sweden, Japan and Australia
<b>Narcotics</b>					
<b>Opioids</b>					
Tramadol (weak opioid)	Oral, rectal, IV, IM (dose can be repeated 4-6 times/day)	2-3 mg/kg/dose (oral, drop) 1-2 mg/kg/dose (oral, tablet) 1.5-3 mg/kg/dose (rectal) 0.75-2 mg/kg/dose (IM) 2-2.5 mg/kg/dose (IV) 0.1-0.25 mg/kg/h (continuous)	Nausea, vomiting, dyspepsia, constipation, urinary retention, respiratory depression, drowsiness, euphoria Nausea, vomiting, pruritus and rash	Does not inhibit prostaglandin synthesis	An IM injection is not recommended. Slow IV infusion. Be careful in patients taking psychoactive medications and with seizures



Codeine	Oral	1 mg/kg, single dose	Respiratory depression not seen after single dose	Both antitussive and analgesic effect	
Morphine	IM, IV	6-12 months: 0.1 mg/kg, IM 0.05 mg/kg, IV		Most commonly used opioid, but not the most suitable opioid for pain relief in children	IM injection not recommended < 2 months old: be careful
Nalbuphine	IV	< 3 months old: 0.05 mg/kg/dose > 3 months old: 0.05-0.10 mg/kg/dose (4-6 times/day)			
Piritramide	IV	0.05-0.10 mg/kg/dose (4-6 times/day)			
Dextromethorphan	Oral, syrup	1 mg/kg			
Pethidine/meperidine	IM, IV	1.5-2 mg/kg IM as premedicant 1 mg/kg IV as analgesic	No advantage over morphine		
Fentanyl	IV	1-2 µg/kg			
Buprenorphine	IV	3-5 mg/kg			
Pentazocine	IV, IM	1 mg/kg IM 0.5-0.75 mg/kg IV	In small infants, observe respiration after IV administration		
<b>Regional (local) anaesthetics</b>					
Bupivacaine		Maximum single bolus dose: 2.5-3.0 mg/kg Maximum infusion: 0.4-0.5 mg/kg/h (10-20 mg/kg/day) in older infants and children; 0.2-0.25 mg/kg/h (5-6 mg/kg/day) in neonates	Cardiotoxicity, convulsion		
Levobupivacaine	IV, IM	0.2-0.25% 1-2.5 mg/kg for single-shot epidural 0.2-0.4 mg/kg/h for IV continuous administration	Less toxic than bupivacaine		
Ropivacaine	IV, IM	0.2-0.25% 1-2.5 mg/kg for single-shot epidural 0.2-0.4 mg/kg/h for IV continuous administration	Less toxic than levobupivacaine		

### 3.20.3.3 Bladder and kidney surgery

Continuous epidural infusion of local anaesthetics [1170-1172], as well as systemic (intravenous) application of analgesics [1173], has been shown to be effective. Ketorolac is an effective agent that is underused. It decreases the frequency and severity of bladder spasms and the length of post-operative hospital stay and costs [1159, 1174-1177].

Open kidney surgery is particularly painful because all three muscle layers are cut during conventional loin incision. A dorsal lumbotomy incision may be a good alternative because of the shorter post-operative hospital stay and earlier return to oral intake and unrestricted daily activity [1178].

Caudal blocks plus systemic analgesics [1179], and continuous epidural analgesia, are effective in terms of decreased post-operative morphine requirement after renal surgery [1180, 1181]. However, when there is a relative contraindication to line insertion, a less experienced anaesthetist is available, or caregivers prefer it [1182], non-invasive regimens composed of intra-operative and post-operative analgesics may be the choice. Particularly in this group of patients, stepwise analgesia protocols can be developed [1183]. For laparoscopic approaches, intra-peritoneal spraying of local anaesthetic before incision of the perirenal fascia may be beneficial [1184].

**Table 18: A simple pain management strategy for paediatric urological surgery**

Intensity of surgery	First step	Second step	Third step
Mild (inguinal, scrotal, penile)	Paracetamol and wound infiltration with local anaesthetics	non-steroidal anti-inflammatory drugs (NSAIDs)	Regional block/weak opioid or IV strong opioid with small increments as rescue analgesia (e.g. nalbuphine, fentanyl, meperidine, morphine)
Moderate (lower abdominal)			Peripheral nerve block (single shot or continuous infusion)/opioid injection (intravenous patient-controlled analgesia (IV PCA))
Severe (upper abdominal or lombotomy)			Epidural local/major peripheral nerve/plexus block/opioid injection (IV PCA)

### 3.20.4 Summary of evidence and recommendations for the management of post-operative pain

Summary of evidence	LE
Neonates experience pain.	3
Pain may cause behavioural and somatic sequelae.	3
Every institute must develop their own well-structured strategy for post-operative analgesia.	4

Recommendations	Strength rating
Prevent/treat pain in children of all ages.	Strong
Evaluate pain using age-compatible assessment tools.	Strong
Inform patients and caregivers accurately.	Strong
Use pre-emptive and balanced analgesia in order to decrease the side effects of opioids.	Strong

## 4. REFERENCES

1. Radmayr, C., *et al.* Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. *J Pediatr Urol*, 2016. <https://www.ncbi.nlm.nih.gov/pubmed/28734950>
2. Stein, R., *et al.* Urinary tract infections in children: EAU/ESPU guidelines. *Eur Urol*, 2015. 67: 546. <https://www.ncbi.nlm.nih.gov/pubmed/25477258>
3. Tekgul, S., *et al.* EAU guidelines on vesicoureteral reflux in children. *Eur Urol*, 2012. 62: 534. <https://www.ncbi.nlm.nih.gov/pubmed/22698573>
4. Riedmiller, H., *et al.* EAU Guidelines on Paediatric Urology. *Eur Urol*, 2001. Nov; 40 (5): 589. <https://www.ncbi.nlm.nih.gov/pubmed/11752871>

5. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
6. Guyatt, G.H., *et al.* What is “quality of evidence” and why is it important to clinicians? *BMJ*, 2008. 336: 995.  
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
7. Phillips B, *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.  
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
8. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
9. Gairdner, D. The fate of the foreskin, a study of circumcision. *Br Med J*, 1949. 2: 1433.  
<https://www.ncbi.nlm.nih.gov/pubmed/15408299>
10. Kuehhas, F.E., *et al.* Incidence of balanitis xerotica obliterans in boys younger than 10 years presenting with phimosis. *Urol Int*, 2013. 90: 439.  
<https://www.ncbi.nlm.nih.gov/pubmed/23296396>
11. Celis, S., *et al.* Balanitis xerotica obliterans in children and adolescents: a literature review and clinical series. *J Pediatr Urol*, 2014. 10: 34.  
<https://www.ncbi.nlm.nih.gov/pubmed/24295833>
12. Oster, J. Further fate of the foreskin. Incidence of preputial adhesions, phimosis, and smegma among Danish schoolboys. *Arch Dis Child*, 1968. 43: 200.  
<https://www.ncbi.nlm.nih.gov/pubmed/5689532>
13. Palmer, L.S., *et al.*, Management of abnormalities of the external genitalia in boys. In: Campbell-Walsh Urology. 11th ed. Vol. 4. 2016, Philadelphia.
14. Liu, J., *et al.* Is steroids therapy effective in treating phimosis? A meta-analysis. *Int Urol Nephrol*, 2016. 48: 335.  
<https://www.ncbi.nlm.nih.gov/pubmed/26725071>
15. Chu, C.C., *et al.* Topical steroid treatment of phimosis in boys. *J Urol*, 1999. 162: 861.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458396>
16. ter Meulen, P.H., *et al.* A conservative treatment of phimosis in boys. *Eur Urol*, 2001. 40: 196.  
<https://www.ncbi.nlm.nih.gov/pubmed/11528198>
17. Elmore, J.M., *et al.* Topical steroid therapy as an alternative to circumcision for phimosis in boys younger than 3 years. *J Urol*, 2002. 168: 1746.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352350>
18. Zavras, N., *et al.* Conservative treatment of phimosis with fluticasone propionate 0.05%: a clinical study in 1185 boys. *J Pediatr Urol*, 2009. 5: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/19097823>
19. Reddy, S., *et al.* Local steroid therapy as the first-line treatment for boys with symptomatic phimosis - a long-term prospective study. *Acta Paediatr*, 2012. 101: e130.  
<https://www.ncbi.nlm.nih.gov/pubmed/22103624>
20. Golubovic, Z., *et al.* The conservative treatment of phimosis in boys. *Br J Urol*, 1996. 78: 786.  
<https://www.ncbi.nlm.nih.gov/pubmed/8976781>
21. Pileggi, F.O., *et al.* Is suppression of hypothalamic-pituitary-adrenal axis significant during clinical treatment of phimosis? *J Urol*, 2010. 183: 2327.  
<https://www.ncbi.nlm.nih.gov/pubmed/20400146>
22. Wu, X., *et al.* A report of 918 cases of circumcision with the Shang Ring: comparison between children and adults. *Urology*, 2013. 81: 1058.  
<https://www.ncbi.nlm.nih.gov/pubmed/23465168>
23. Pedersini, P., *et al.* “Trident” preputial plasty for phimosis in childhood. *J Pediatr Urol*, 2017. 13: 278. e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/28359779>
24. Miernik, A., *et al.* Complete removal of the foreskin--why? *Urol Int*, 2011. 86: 383.  
<https://www.ncbi.nlm.nih.gov/pubmed/21474914>
25. Wiswell, T.E. The prepuce, urinary tract infections, and the consequences. *Pediatrics*, 2000. 105: 860.  
<https://www.ncbi.nlm.nih.gov/pubmed/10742334>
26. Hiraoka, M., *et al.* Meatus tightly covered by the prepuce is associated with urinary infection. *Pediatr Int*, 2002. 44: 658.  
<https://www.ncbi.nlm.nih.gov/pubmed/12421265>

27. To, T., *et al.* Cohort study on circumcision of newborn boys and subsequent risk of urinary-tract infection. *Lancet*, 1998. 352: 1813.  
<https://www.ncbi.nlm.nih.gov/pubmed/9851381>
28. Herndon, C.D., *et al.* A multicenter outcomes analysis of patients with neonatal reflux presenting with prenatal hydronephrosis. *J Urol*, 1999. 162: 1203.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458467>
29. Ladenhauf, H.N., *et al.* Reduced bacterial colonisation of the glans penis after male circumcision in children--a prospective study. *J Pediatr Urol*, 2013. 9: 1137.  
<https://www.ncbi.nlm.nih.gov/pubmed/23685114>
30. Larke, N.L., *et al.* Male circumcision and penile cancer: a systematic review and meta-analysis. *Cancer Causes Control*, 2011. 22: 1097.  
<https://www.ncbi.nlm.nih.gov/pubmed/21695385>
31. Thompson, H.C., *et al.* Report of the ad hoc task force on circumcision. *Pediatrics*, 1975. 56: 610.  
<https://www.ncbi.nlm.nih.gov/pubmed/1174384>
32. American Academy of Pediatrics: Report of the Task Force on Circumcision. *Pediatrics*, 1989. 84: 388.  
<https://www.ncbi.nlm.nih.gov/pubmed/2664697>
33. Elalfy, M.S., *et al.* Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. *Pediatr Hematol Oncol*, 2012. 29: 485.  
<https://www.ncbi.nlm.nih.gov/pubmed/22866674>
34. Karaman, M.I., *et al.* Circumcision in bleeding disorders: improvement of our cost effective method with diathermic knife. *Urol J*, 2014. 11: 1406.  
<https://www.ncbi.nlm.nih.gov/pubmed/24807751>
35. Christakis, D.A., *et al.* A trade-off analysis of routine newborn circumcision. *Pediatrics*, 2000. 105: 246.  
<https://www.ncbi.nlm.nih.gov/pubmed/10617731>
36. Griffiths, D.M., *et al.* A prospective survey of the indications and morbidity of circumcision in children. *Eur Urol*, 1985. 11: 184.  
<https://www.ncbi.nlm.nih.gov/pubmed/4029234>
37. Morris, B.J., *et al.* A 'snip' in time: what is the best age to circumcise? *BMC Pediatr*, 2012. 12: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/22373281>
38. Ross, J.H., Circumcision: Pro and con., in *Pediatric urology for the general urologist*, J.S. Elder, Editor. 1996, Igaku-Shoin: New York.
39. Weiss, H.A., *et al.* Complications of circumcision in male neonates, infants and children: a systematic review. *BMC Urol*, 2010. 10: 2.  
<https://www.ncbi.nlm.nih.gov/pubmed/20158883>
40. Homer, L., *et al.* Meatal stenosis in boys following circumcision for lichen sclerosus (balanitis xerotica obliterans). *J Urol*, 2014. 192: 1784.  
<https://www.ncbi.nlm.nih.gov/pubmed/24992332>
41. Anand, A., *et al.* Mannitol for paraphimosis reduction. *Urol Int*, 2013. 90: 106.  
<https://www.ncbi.nlm.nih.gov/pubmed/23257575>
42. DeVries, C.R., *et al.* Reduction of paraphimosis with hyaluronidase. *Urology*, 1996. 48: 464.  
<https://www.ncbi.nlm.nih.gov/pubmed/8804504>
43. Sijstermans, K., *et al.* The frequency of undescended testis from birth to adulthood: a review. *Int J Androl*, 2008. 31: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/17488243>
44. Berkowitz, G.S., *et al.* Prevalence and natural history of cryptorchidism. *Pediatrics*, 1993. 92: 44.  
<https://www.ncbi.nlm.nih.gov/pubmed/8100060>
45. Kaefer, M., *et al.* The incidence of intersexuality in children with cryptorchidism and hypospadias: stratification based on gonadal palpability and meatal position. *J Urol*, 1999. 162: 1003.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458421>
46. Kollin, C., *et al.* Cryptorchidism: a clinical perspective. *Pediatr Endocrinol Rev*, 2014. 11 Suppl 2: 240.  
<https://www.ncbi.nlm.nih.gov/pubmed/24683948>
47. Caesar, R.E., *et al.* The incidence of the cremasteric reflex in normal boys. *J Urol*, 1994. 152: 779.  
<https://www.ncbi.nlm.nih.gov/pubmed/7912745>
48. Barthold, J.S., *et al.* The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. *J Urol*, 2003. 170: 2396.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634436>

49. Turek, P.J., *et al.* The absent cryptorchid testis: surgical findings and their implications for diagnosis and etiology. *J Urol*, 1994. 151: 718.  
<https://www.ncbi.nlm.nih.gov/pubmed/7905931>
50. Rabinowitz, R., *et al.* Late presentation of cryptorchidism: the etiology of testicular re-ascent. *J Urol*, 1997. 157: 1892.  
<https://www.ncbi.nlm.nih.gov/pubmed/9112557>
51. Cendron, M., *et al.* Anatomical, morphological and volumetric analysis: a review of 759 cases of testicular maldescent. *J Urol*, 1993. 149: 570.  
<https://www.ncbi.nlm.nih.gov/pubmed/8094761>
52. Braga, L.H., *et al.* Is there an optimal contralateral testicular cut-off size that predicts monorchism in boys with nonpalpable testicles? *J Pediatr Urol*, 2014. 10: 693.  
<https://www.ncbi.nlm.nih.gov/pubmed/25008806>
53. Hurwitz, R.S., *et al.* How well does contralateral testis hypertrophy predict the absence of the nonpalpable testis? *J Urol*, 2001. 165: 588.  
<https://www.ncbi.nlm.nih.gov/pubmed/11176443>
54. Elert, A., *et al.* Population-based investigation of familial undescended testis and its association with other urogenital anomalies. *J Pediatr Urol*, 2005. 1: 403.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947580>
55. Hrebinko, R.L., *et al.* The limited role of imaging techniques in managing children with undescended testes. *J Urol*, 1993. 150: 458.  
<https://www.ncbi.nlm.nih.gov/pubmed/8100860>
56. Tasian, G.E., *et al.* Diagnostic performance of ultrasound in nonpalpable cryptorchidism: a systematic review and meta-analysis. *Pediatrics*, 2011. 127: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/21149435>
57. Elder, J.S. Ultrasonography is unnecessary in evaluating boys with a nonpalpable testis. *Pediatrics*, 2002. 110: 748.  
<https://www.ncbi.nlm.nih.gov/pubmed/12359789>
58. Wenzler, D.L., *et al.* What is the rate of spontaneous testicular descent in infants with cryptorchidism? *J Urol*, 2004. 171: 849.  
<https://www.ncbi.nlm.nih.gov/pubmed/14713841>
59. Park, K.H., *et al.* Histological evidences suggest recommending orchiopexy within the first year of life for children with unilateral inguinal cryptorchid testis. *Int J Urol*, 2007. 14: 616.  
<https://www.ncbi.nlm.nih.gov/pubmed/17645605>
60. Engeler, D.S., *et al.* Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. *Urology*, 2000. 56: 144.  
<https://www.ncbi.nlm.nih.gov/pubmed/10869645>
61. Forest, M.G., *et al.* Undescended testis: comparison of two protocols of treatment with human chorionic gonadotropin. Effect on testicular descent and hormonal response. *Horm Res*, 1988. 30: 198.  
<https://www.ncbi.nlm.nih.gov/pubmed/2907898>
62. Rajfer, J., *et al.* Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone. *N Engl J Med*, 1986. 314: 466.  
<https://www.ncbi.nlm.nih.gov/pubmed/2868413>
63. Pyorala, S., *et al.* A review and meta-analysis of hormonal treatment of cryptorchidism. *J Clin Endocrinol Metab*, 1995. 80: 2795.  
<https://www.ncbi.nlm.nih.gov/pubmed/7673426>
64. Rajfer, J., *et al.* The incidence of intersexuality in patients with hypospadias and cryptorchidism. *J Urol*, 1976. 116: 769.  
<https://www.ncbi.nlm.nih.gov/pubmed/12377>
65. Lala, R., *et al.* Combined therapy with LHRH and HCG in cryptorchid infants. *Eur J Pediatr*, 1993. 152 Suppl 2: S31.  
<https://www.ncbi.nlm.nih.gov/pubmed/8101810>
66. Forest, M.G., *et al.* Effects of human chorionic gonadotropin, androgens, adrenocorticotropin hormone, dexamethasone and hyperprolactinemia on plasma sex steroid-binding protein. *Ann N Y Acad Sci*, 1988. 538: 214.  
<https://www.ncbi.nlm.nih.gov/pubmed/2847619>
67. Aycan, Z., *et al.* Evaluation of low-dose hCG treatment for cryptorchidism. *Turk J Pediatr*, 2006. 48: 228.  
<https://www.ncbi.nlm.nih.gov/pubmed/17172066>

68. Hesse, V., *et al.* Three injections of human chorionic gonadotropin are as effective as ten injections in the treatment of cryptorchidism. *Horm Res*, 1988. 30: 193.  
<https://www.ncbi.nlm.nih.gov/pubmed/2907897>
69. Hagberg, S., *et al.* Treatment of undescended testes with intranasal application of synthetic LH-RH. *Eur J Pediatr*, 1982. 139: 285.  
<https://www.ncbi.nlm.nih.gov/pubmed/6133757>
70. Hadziselimovic, F., *et al.* Treatment with a luteinizing hormone-releasing hormone analogue after successful orchiopexy markedly improves the chance of fertility later in life. *J Urol*, 1997. 158: 1193.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258170>
71. Schwentner, C., *et al.* Neoadjuvant gonadotropin-releasing hormone therapy before surgery may improve the fertility index in undescended testes: a prospective randomized trial. *J Urol*, 2005. 173: 974.  
<https://www.ncbi.nlm.nih.gov/pubmed/15711353>
72. Cortes, D., *et al.* Hormonal treatment may harm the germ cells in 1 to 3-year-old boys with cryptorchidism. *J Urol*, 2000. 163: 1290.  
<https://www.ncbi.nlm.nih.gov/pubmed/10737531>
73. Ritzen, E.M. Undescended testes: a consensus on management. *Eur J Endocrinol*, 2008. 159 Suppl 1: S87.  
<https://www.ncbi.nlm.nih.gov/pubmed/18728121>
74. Kollin, C., *et al.* Surgical treatment of unilaterally undescended testes: testicular growth after randomization to orchiopexy at age 9 months or 3 years. *J Urol*, 2007. 178: 1589.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707045>
75. Novaes, H.F., *et al.* Single scrotal incision orchiopexy - a systematic review. *Int Braz J Urol*, 2013. 39: 305.  
<https://www.ncbi.nlm.nih.gov/pubmed/23849581>
76. Docimo, S.G. The results of surgical therapy for cryptorchidism: a literature review and analysis. *J Urol*, 1995. 154: 1148.  
<https://www.ncbi.nlm.nih.gov/pubmed/7637073>
77. Ziylan, O., *et al.* Failed orchiopexy. *Urol Int*, 2004. 73: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/15604574>
78. Prentiss, R.J., *et al.* Undescended testis: surgical anatomy of spermatic vessels, spermatic surgical triangles and lateral spermatic ligament. *J Urol*, 1960. 83: 686.  
<https://www.ncbi.nlm.nih.gov/pubmed/14434738>
79. Kozminski, D.J., *et al.* Orchiopexy without Transparenchymal Fixation Suturing: A 29-Year Experience. *J Urol*, 2015. 194: 1743.  
<https://www.ncbi.nlm.nih.gov/pubmed/26141850>
80. Martin, J.M., *et al.* Is radiotherapy a good adjuvant strategy for men with a history of cryptorchism and stage I seminoma? *Int J Radiat Oncol Biol Phys*, 2010. 76: 65.  
<https://www.ncbi.nlm.nih.gov/pubmed/19362785>
81. Na, S.W., *et al.* Single scrotal incision orchiopexy for children with palpable low-lying undescended testis: early outcome of a prospective randomized controlled study. *Korean J Urol*, 2011. 52: 637.  
<https://www.ncbi.nlm.nih.gov/pubmed/22025961>
82. Parsons, J.K., *et al.* The low scrotal approach to the ectopic or ascended testicle: prevalence of a patent processus vaginalis. *J Urol*, 2003. 169: 1832.  
<https://www.ncbi.nlm.nih.gov/pubmed/12686856>
83. Wayne, C., *et al.* What is the ideal surgical approach for intra-abdominal testes? A systematic review. *Pediatr Surg Int*, 2015. 31: 327.  
<https://www.ncbi.nlm.nih.gov/pubmed/25663531>
84. Cortesi, N., *et al.* Diagnosis of bilateral abdominal cryptorchidism by laparoscopy. *Endoscopy*, 1976. 8: 33.  
<https://www.ncbi.nlm.nih.gov/pubmed/16743>
85. Jordan, G.H., *et al.* Laparoscopic single stage and staged orchiopexy. *J Urol*, 1994. 152: 1249.  
<https://www.ncbi.nlm.nih.gov/pubmed/7915336>
86. Chandrasekharam, V.V. Laparoscopy vs inguinal exploration for nonpalpable undescended testis. *Indian J Pediatr*, 2005. 72: 1021.  
<https://www.ncbi.nlm.nih.gov/pubmed/16388149>
87. Snodgrass, W.T., *et al.* Scrotal exploration for unilateral nonpalpable testis. *J Urol*, 2007. 178: 1718.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707015>
88. Cisek, L.J., *et al.* Current findings in diagnostic laparoscopic evaluation of the nonpalpable testis. *J Urol*, 1998. 160: 1145.  
<https://www.ncbi.nlm.nih.gov/pubmed/9719296>

89. Patil, K.K., *et al.* Laparoscopy for impalpable testes. *BJU Int*, 2005. 95: 704.  
<https://www.ncbi.nlm.nih.gov/pubmed/15784081>
90. Elderwy, A.A., *et al.* Laparoscopic versus open orchiopexy in the management of peeping testis: a multi-institutional prospective randomized study. *J Pediatr Urol*, 2014. 10: 605.  
<https://www.ncbi.nlm.nih.gov/pubmed/25042877>
91. Kirsch, A.J., *et al.* Surgical management of the nonpalpable testis: the Children's Hospital of Philadelphia experience. *J Urol*, 1998. 159: 1340.  
<https://www.ncbi.nlm.nih.gov/pubmed/9507881>
92. Fowler, R., *et al.* The role of testicular vascular anatomy in the salvage of high undescended testes. *Aust N Z J Surg*, 1959. 29: 92.  
<https://www.ncbi.nlm.nih.gov/pubmed/13849840>
93. Koff, S.A., *et al.* Treatment of high undescended testes by low spermatic vessel ligation: an alternative to the Fowler-Stephens technique. *J Urol*, 1996. 156: 799.  
<https://www.ncbi.nlm.nih.gov/pubmed/8683787>
94. Esposito, C., *et al.* Exploration of inguinal canal is mandatory in cases of non palpable testis if laparoscopy shows elements entering a closed inguinal ring. *Eur J Pediatr Surg*, 2010. 20: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/19746341>
95. Radmayr, C., *et al.* Long-term outcome of laparoscopically managed nonpalpable testes. *J Urol*, 2003. 170: 2409.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634439>
96. Baker, L.A., *et al.* A multi-institutional analysis of laparoscopic orchidopexy. *BJU Int*, 2001. 87: 484.  
<https://www.ncbi.nlm.nih.gov/pubmed/11298039>
97. Dave, S., *et al.* Open versus laparoscopic staged Fowler-Stephens orchiopexy: impact of long loop vas. *J Urol*, 2009. 182: 2435.  
<https://www.ncbi.nlm.nih.gov/pubmed/19765743>
98. Wacksman, J., *et al.* Laparoscopically assisted testicular autotransplantation for management of the intraabdominal undescended testis. *J Urol*, 1996. 156: 772.  
<https://www.ncbi.nlm.nih.gov/pubmed/8683780>
99. Penson, D., *et al.* Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. *Pediatrics*, 2013. 131: e1897.  
<https://www.ncbi.nlm.nih.gov/pubmed/23690511>
100. Koni, A., *et al.* Histopathological evaluation of orchiectomy specimens in 51 late postpubertal men with unilateral cryptorchidism. *J Urol*, 2014. 192: 1183.  
<https://www.ncbi.nlm.nih.gov/pubmed/24840535>
101. Trussell, J.C., *et al.* The relationship of cryptorchidism to fertility. *Curr Urol Rep*, 2004. 5: 142.  
<https://www.ncbi.nlm.nih.gov/pubmed/15028208>
102. Hadziselimovic, F., *et al.* The importance of both an early orchidopexy and germ cell maturation for fertility. *Lancet*, 2001. 358: 1156.  
<https://www.ncbi.nlm.nih.gov/pubmed/11597673>
103. Lee, P.A. Fertility after cryptorchidism: epidemiology and other outcome studies. *Urology*, 2005. 66: 427.  
<https://www.ncbi.nlm.nih.gov/pubmed/16098371>
104. Chua, M.E., *et al.* Hormonal therapy using gonadotropin releasing hormone for improvement of fertility index among children with cryptorchidism: a meta-analysis and systematic review. *J Pediatr Surg*, 2014. 49: 1659.  
<https://www.ncbi.nlm.nih.gov/pubmed/25475814>
105. Coughlin, M.T., *et al.* Age at unilateral orchiopexy: effect on hormone levels and sperm count in adulthood. *J Urol*, 1999. 162: 986.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458417>
106. Tasian, G.E., *et al.* Age at orchiopexy and testis palpability predict germ and Leydig cell loss: clinical predictors of adverse histological features of cryptorchidism. *J Urol*, 2009. 182: 704.  
<https://www.ncbi.nlm.nih.gov/pubmed/19539332>
107. Dieckmann, K.P., *et al.* Clinical epidemiology of testicular germ cell tumors. *World J Urol*, 2004. 22: 2.  
<https://www.ncbi.nlm.nih.gov/pubmed/15034740>
108. Pettersson, A., *et al.* Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med*, 2007. 356: 1835.  
<https://www.ncbi.nlm.nih.gov/pubmed/17476009>
109. Walsh, T.J., *et al.* Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. *J Urol*, 2007. 178: 1440.  
<https://www.ncbi.nlm.nih.gov/pubmed/17706709>

110. Kapur, P., *et al.* Pediatric hernias and hydroceles. *Pediatr Clin North Am*, 1998. 45: 773.  
<https://www.ncbi.nlm.nih.gov/pubmed/9728185>
111. Barthold, J.S., Abnormalities of the testis and scrotum and their surgical management, In: Campbell-Walsh Urology, A.J. Wein & e. al., Eds. 2012, Elsevier Saunders: Philadelphia.
112. Schneck, F.X., *et al.*, Abnormalities of the testes and scrotum and their surgical management In: Campbell's Urology, Walsh P.C., Retik A.B., Vaughan, E.D. & Wein, A.J. Editors. 2002, WB Saunders: Philadelphia.
113. Rubenstein, R.A., *et al.* Benign intrascrotal lesions. *J Urol*, 2004. 171: 1765.  
<https://www.ncbi.nlm.nih.gov/pubmed/15076274>
114. Lin, H.C., *et al.* Testicular teratoma presenting as a transilluminating scrotal mass. *Urology*, 2006. 67: 1290.e3.  
<https://www.ncbi.nlm.nih.gov/pubmed/16750249>
115. Skoog, S.J. Benign and malignant pediatric scrotal masses. *Pediatr Clin North Am*, 1997. 44: 1229.  
<https://www.ncbi.nlm.nih.gov/pubmed/9326960>
116. Koski, M.E., *et al.* Infant communicating hydroceles--do they need immediate repair or might some clinically resolve? *J Pediatr Surg*, 2010. 45: 590.  
<https://www.ncbi.nlm.nih.gov/pubmed/20223325>
117. Stringer, M.D., *et al.*, Patent processus vaginalis. , in *Pediatric urology*, J.P. Gearhart, R.C. Rink & P.D. Mouriquand, Editors. 2001, WB Saunders: Philadelphia.
118. Stylianos, S., *et al.* Incarceration of inguinal hernia in infants prior to elective repair. *J Pediatr Surg*, 1993. 28: 582.  
<https://www.ncbi.nlm.nih.gov/pubmed/8483072>
119. Hall, N.J., *et al.* Surgery for hydrocele in children-an avoidable excess? *J Pediatr Surg*, 2011. 46: 2401.  
<https://www.ncbi.nlm.nih.gov/pubmed/22152892>
120. Saad, S., *et al.* Ten-year review of groin laparoscopy in 1001 pediatric patients with clinical unilateral inguinal hernia: an improved technique with transhernia multiple-channel scope. *J Pediatr Surg*, 2011. 46: 1011.  
<https://www.ncbi.nlm.nih.gov/pubmed/21616272>
121. Christensen, T., *et al.* New onset of hydroceles in boys over 1 year of age. *Int J Urol*, 2006. 13: 1425.  
<https://www.ncbi.nlm.nih.gov/pubmed/17083397>
122. Cavusoglu, Y.H., *et al.* Acute scrotum -- etiology and management. *Indian J Pediatr*, 2005. 72: 201.  
<https://www.ncbi.nlm.nih.gov/pubmed/15812112>
123. Klin, B., *et al.* Epididymitis in childhood: a clinical retrospective study over 5 years. *Isr Med Assoc J*, 2001. 3: 833.  
<https://www.ncbi.nlm.nih.gov/pubmed/11729579>
124. Makela, E., *et al.* A 19-year review of paediatric patients with acute scrotum. *Scand J Surg*, 2007. 96: 62.  
<https://www.ncbi.nlm.nih.gov/pubmed/17461315>
125. McAndrew, H.F., *et al.* The incidence and investigation of acute scrotal problems in children. *Pediatr Surg Int*, 2002. 18: 435.  
<https://www.ncbi.nlm.nih.gov/pubmed/12415374>
126. Sakellaris, G.S., *et al.* Acute epididymitis in Greek children: a 3-year retrospective study. *Eur J Pediatr*, 2008. 167: 765.  
<https://www.ncbi.nlm.nih.gov/pubmed/17786475>
127. Varga, J., *et al.* Acute scrotal pain in children--ten years' experience. *Urol Int*, 2007. 78: 73.  
<https://www.ncbi.nlm.nih.gov/pubmed/17192737>
128. Bingol-Kologlu, M., *et al.* An exceptional complication following appendectomy: acute inguinal and scrotal suppuration. *Int Urol Nephrol*, 2006. 38: 663.  
<https://www.ncbi.nlm.nih.gov/pubmed/17160451>
129. Dayanir, Y.O., *et al.* Epididymoorchitis mimicking testicular torsion in Henoch-Schonlein purpura. *Eur Radiol*, 2001. 11: 2267.  
<https://www.ncbi.nlm.nih.gov/pubmed/11702171>
130. Diamond, D.A., *et al.* Neonatal scrotal haematoma: mimicker of neonatal testicular torsion. *BJU Int*, 2003. 91: 675.  
<https://www.ncbi.nlm.nih.gov/pubmed/12699483>
131. Ha, T.S., *et al.* Scrotal involvement in childhood Henoch-Schonlein purpura. *Acta Paediatr*, 2007. 96: 552.  
<https://www.ncbi.nlm.nih.gov/pubmed/17306010>
132. Hara, Y., *et al.* Acute scrotum caused by Henoch-Schonlein purpura. *Int J Urol*, 2004. 11: 578.  
<https://www.ncbi.nlm.nih.gov/pubmed/15242376>



133. Klin, B., *et al.* Acute idiopathic scrotal edema in children--revisited. *J Pediatr Surg*, 2002. 37: 1200.  
<https://www.ncbi.nlm.nih.gov/pubmed/12149702>
134. Krause, W. Is acute idiopathic scrotal edema in children a special feature of neutrophilic eccrine hidradenitis? *Dermatology*, 2004. 208: 86; author reply 86.  
<https://www.ncbi.nlm.nih.gov/pubmed/14730248>
135. Matsumoto, A., *et al.* Torsion of the hernia sac within a hydrocele of the scrotum in a child. *Int J Urol*, 2004. 11: 789.  
<https://www.ncbi.nlm.nih.gov/pubmed/15379947>
136. Myers, J.B., *et al.* Torsion of an indirect hernia sac causing acute scrotum. *J Pediatr Surg*, 2004. 39: 122.  
<https://www.ncbi.nlm.nih.gov/pubmed/14694389>
137. Ng, K.H., *et al.* An unusual presentation of acute scrotum after appendicitis. *Singapore Med J*, 2002. 43: 365.  
<https://www.ncbi.nlm.nih.gov/pubmed/12437045>
138. Singh, S., *et al.* Acute scrotum in children: a rare presentation of acute, non-perforated appendicitis. *Pediatr Surg Int*, 2003. 19: 298.  
<https://www.ncbi.nlm.nih.gov/pubmed/12682749>
139. van Langen, A.M., *et al.* Acute idiopathic scrotal oedema: four cases and a short review. *Eur J Pediatr*, 2001. 160: 455.  
<https://www.ncbi.nlm.nih.gov/pubmed/11475590>
140. Vlazakis, S., *et al.* Right acute hemiscrotum caused by insertion of an inflamed appendix. *BJU Int*, 2002. 89: 967.  
<https://www.ncbi.nlm.nih.gov/pubmed/12010250>
141. D'Andrea, A., *et al.* US in the assessment of acute scrotum. *Crit Ultrasound J*, 2013. 5: S8.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711727/>
142. Davis, J.E., *et al.* Scrotal emergencies. *Emerg Med Clin North Am*, 2011. 29: 469.  
<https://www.ncbi.nlm.nih.gov/pubmed/21782069>
143. Jimoh, B.M., *et al.* Idiopathic scrotal hematoma in neonate: a case report and review of the literature. *Case Rep Urol*, 2014. 2014: 212914.  
<https://www.ncbi.nlm.nih.gov/pubmed/24982811>
144. Matzek, B.A., *et al.* Traumatic testicular dislocation after minor trauma in a pediatric patient. *J Emerg Med*, 2013. 45: 537.  
<https://www.ncbi.nlm.nih.gov/pubmed/23899815>
145. Wright, S., *et al.* Emergency ultrasound of acute scrotal pain. *Eur J Emerg Med*, 2015. 22: 2.  
<https://www.ncbi.nlm.nih.gov/pubmed/24910960>
146. Yusuf, G.T., *et al.* A review of ultrasound imaging in scrotal emergencies. *J Ultrasound*, 2013. 16: 171.  
<https://www.ncbi.nlm.nih.gov/pubmed/24432171>
147. Remer, E.M., *et al.* ACR Appropriateness Criteria (R) acute onset of scrotal pain--without trauma, without antecedent mass. *Ultrasound Q*, 2012. 28: 47.  
<https://www.ncbi.nlm.nih.gov/pubmed/22357246>
148. Kadish, H.A., *et al.* A retrospective review of pediatric patients with epididymitis, testicular torsion, and torsion of testicular appendages. *Pediatrics*, 1998. 102: 73.  
<https://www.ncbi.nlm.nih.gov/pubmed/9651416>
149. Sauvat, F., *et al.* [Age for testicular torsion?]. *Arch Pediatr*, 2002. 9: 1226.  
<https://www.ncbi.nlm.nih.gov/pubmed/12536102>
150. Somekh, E., *et al.* Acute epididymitis in boys: evidence of a post-infectious etiology. *J Urol*, 2004. 171: 391.  
<https://www.ncbi.nlm.nih.gov/pubmed/14665940>
151. Yerkes, E.B., *et al.* Management of perinatal torsion: today, tomorrow or never? *J Urol*, 2005. 174: 1579.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148656>
152. Boettcher, M., *et al.* Clinical and sonographic features predict testicular torsion in children: a prospective study. *BJU Int*, 2013. 112: 1201.  
<https://www.ncbi.nlm.nih.gov/pubmed/23826981>
153. Nelson, C.P., *et al.* The cremasteric reflex: a useful but imperfect sign in testicular torsion. *J Pediatr Surg*, 2003. 38: 1248.  
<https://www.ncbi.nlm.nih.gov/pubmed/12891505>
154. Mushtaq, I., *et al.* Retrospective review of paediatric patients with acute scrotum. *ANZ J Surg*, 2003. 73: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/12534742>

155. Murphy, F.L., *et al.* Early scrotal exploration in all cases is the investigation and intervention of choice in the acute paediatric scrotum. *Pediatr Surg Int*, 2006. 22: 413.  
<https://www.ncbi.nlm.nih.gov/pubmed/16602024>
156. Baker, L.A., *et al.* An analysis of clinical outcomes using color doppler testicular ultrasound for testicular torsion. *Pediatrics*, 2000. 105: 604.  
<https://www.ncbi.nlm.nih.gov/pubmed/10699116>
157. Gunther, P., *et al.* Acute testicular torsion in children: the role of sonography in the diagnostic workup. *Eur Radiol*, 2006. 16: 2527.  
<https://www.ncbi.nlm.nih.gov/pubmed/16724203>
158. Kalfa, N., *et al.* Multicenter assessment of ultrasound of the spermatic cord in children with acute scrotum. *J Urol*, 2007. 177: 297.  
<https://www.ncbi.nlm.nih.gov/pubmed/17162068>
159. Karmazyn, B., *et al.* Clinical and sonographic criteria of acute scrotum in children: a retrospective study of 172 boys. *Pediatr Radiol*, 2005. 35: 302.  
<https://www.ncbi.nlm.nih.gov/pubmed/15503003>
160. Lam, W.W., *et al.* Colour Doppler ultrasonography replacing surgical exploration for acute scrotum: myth or reality? *Pediatr Radiol*, 2005. 35: 597.  
<https://www.ncbi.nlm.nih.gov/pubmed/15761770>
161. Schalamon, J., *et al.* Management of acute scrotum in children--the impact of Doppler ultrasound. *J Pediatr Surg*, 2006. 41: 1377.  
<https://www.ncbi.nlm.nih.gov/pubmed/16863840>
162. Pepe, P., *et al.* Does color Doppler sonography improve the clinical assessment of patients with acute scrotum? *Eur J Radiol*, 2006. 60: 120.  
<https://www.ncbi.nlm.nih.gov/pubmed/16730939>
163. Kalfa, N., *et al.* Ultrasonography of the spermatic cord in children with testicular torsion: impact on the surgical strategy. *J Urol*, 2004. 172: 1692.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371792>
164. Nussbaum Blask, A.R., *et al.* Color Doppler sonography and scintigraphy of the testis: a prospective, comparative analysis in children with acute scrotal pain. *Pediatr Emerg Care*, 2002. 18: 67.  
<https://www.ncbi.nlm.nih.gov/pubmed/11973493>
165. Paltiel, H.J., *et al.* Acute scrotal symptoms in boys with an indeterminate clinical presentation: comparison of color Doppler sonography and scintigraphy. *Radiology*, 1998. 207: 223.  
<https://www.ncbi.nlm.nih.gov/pubmed/9530319>
166. Terai, A., *et al.* Dynamic contrast-enhanced subtraction magnetic resonance imaging in diagnostics of testicular torsion. *Urology*, 2006. 67: 1278.  
<https://www.ncbi.nlm.nih.gov/pubmed/16765192>
167. Yuan, Z., *et al.* Clinical study of scrotum scintigraphy in 49 patients with acute scrotal pain: a comparison with ultrasonography. *Ann Nucl Med*, 2001. 15: 225.  
<https://www.ncbi.nlm.nih.gov/pubmed/11545192>
168. Karmazyn, B., *et al.* Duplex sonographic findings in children with torsion of the testicular appendages: overlap with epididymitis and epididymoorchitis. *J Pediatr Surg*, 2006. 41: 500.  
<https://www.ncbi.nlm.nih.gov/pubmed/16516624>
169. Lau, P., *et al.* Acute epididymitis in boys: are antibiotics indicated? *Br J Urol*, 1997. 79: 797.  
<https://www.ncbi.nlm.nih.gov/pubmed/9158522>
170. Abul, F., *et al.* The acute scrotum: a review of 40 cases. *Med Princ Pract*, 2005. 14: 177.  
<https://www.ncbi.nlm.nih.gov/pubmed/15863992>
171. Cornel, E.B., *et al.* Manual derotation of the twisted spermatic cord. *BJU Int*, 1999. 83: 672.  
<https://www.ncbi.nlm.nih.gov/pubmed/10233577>
172. Garel, L., *et al.* Preoperative manual detorsion of the spermatic cord with Doppler ultrasound monitoring in patients with intravaginal acute testicular torsion. *Pediatr Radiol*, 2000. 30: 41.  
<https://www.ncbi.nlm.nih.gov/pubmed/10663509>
173. Sessions, A.E., *et al.* Testicular torsion: direction, degree, duration and disinformation. *J Urol*, 2003. 169: 663.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544339>
174. Visser, A.J., *et al.* Testicular function after torsion of the spermatic cord. *BJU Int*, 2003. 92: 200.  
<https://www.ncbi.nlm.nih.gov/pubmed/12887467>
175. Tryfonas, G., *et al.* Late postoperative results in males treated for testicular torsion during childhood. *J Pediatr Surg*, 1994. 29: 553.  
<https://www.ncbi.nlm.nih.gov/pubmed/8014814>

176. Anderson, M.J., *et al.* Semen quality and endocrine parameters after acute testicular torsion. *J Urol*, 1992. 147: 1545.  
<https://www.ncbi.nlm.nih.gov/pubmed/1593686>
177. Arap, M.A., *et al.* Late hormonal levels, semen parameters, and presence of antisperm antibodies in patients treated for testicular torsion. *J Androl*, 2007. 28: 528.  
<https://www.ncbi.nlm.nih.gov/pubmed/17287456>
178. Mor, Y., *et al.* Testicular fixation following torsion of the spermatic cord--does it guarantee prevention of recurrent torsion events? *J Urol*, 2006. 175: 171.  
<https://www.ncbi.nlm.nih.gov/pubmed/16406900>
179. Figueroa, V., *et al.* Comparative analysis of detorsion alone versus detorsion and tunica albuginea decompression (fasciotomy) with tunica vaginalis flap coverage in the surgical management of prolonged testicular ischemia. *J Urol*, 2012. 188: 1417.  
<https://www.ncbi.nlm.nih.gov/pubmed/22906680>
180. Akcora, B., *et al.* The protective effect of darbepoetin alfa on experimental testicular torsion and detorsion injury. *Int J Urol*, 2007. 14: 846.  
<https://www.ncbi.nlm.nih.gov/pubmed/17760753>
181. Aksoy, H., *et al.* Dehydroepiandrosterone treatment attenuates reperfusion injury after testicular torsion and detorsion in rats. *J Pediatr Surg*, 2007. 42: 1740.  
<https://www.ncbi.nlm.nih.gov/pubmed/17923206>
182. Haj, M., *et al.* Effect of external scrotal cooling on the viability of the testis with torsion in rats. *Eur Surg Res*, 2007. 39: 160.  
<https://www.ncbi.nlm.nih.gov/pubmed/17341878>
183. Unal, D., *et al.* Protective effects of trimetazidine on testicular ischemia-reperfusion injury in rats. *Urol Int*, 2007. 78: 356.  
<https://www.ncbi.nlm.nih.gov/pubmed/17495496>
184. Yazihan, N., *et al.* Protective role of erythropoietin during testicular torsion of the rats. *World J Urol*, 2007. 25: 531.  
<https://www.ncbi.nlm.nih.gov/pubmed/17690891>
185. Lian, B.S., *et al.* Factors Predicting Testicular Atrophy after Testicular Salvage following Torsion. *Eur J Pediatr Surg*, 2016. 26: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/26509312>
186. Philip, J., *et al.* Mumps orchitis in the non-immune postpubertal male: a resurgent threat to male fertility? *BJU Int*, 2006. 97: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/16336344>
187. Gielchinsky, I., *et al.* Pregnancy Rates after Testicular Torsion. *J Urol*, 2016. 196: 852.  
<https://www.ncbi.nlm.nih.gov/pubmed/27117442>
188. Bergman, J.E., *et al.* Epidemiology of hypospadias in Europe: a registry-based study. *World J Urol*, 2015. 33: 2159.  
<https://www.ncbi.nlm.nih.gov/pubmed/25712311>
189. Morera, A.M., *et al.* A study of risk factors for hypospadias in the Rhone-Alpes region (France). *J Pediatr Urol*, 2006. 2: 169.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947603>
190. Springer, A., *et al.* Worldwide prevalence of hypospadias. *J Pediatr Urol*, 2016. 12: 152 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26810252>
191. van der Zanden, L.F., *et al.* Exploration of gene-environment interactions, maternal effects and parent of origin effects in the etiology of hypospadias. *J Urol*, 2012. 188: 2354.  
<https://www.ncbi.nlm.nih.gov/pubmed/23088992>
192. Fredell, L., *et al.* Heredity of hypospadias and the significance of low birth weight. *J Urol*, 2002. 167: 1423.  
<https://www.ncbi.nlm.nih.gov/pubmed/11832761>
193. Lund, L., *et al.* Prevalence of hypospadias in Danish boys: a longitudinal study, 1977-2005. *Eur Urol*, 2009. 55: 1022.  
<https://www.ncbi.nlm.nih.gov/pubmed/19155122>
194. Mouriquand, O.D., *et al.*, Hypospadias., In: *Pediatric Urology*, J. Gearhart, R. Rink & P.D.E. Mouriquand, Editors. 2001, WB Saunders: Philadelphia.
195. van Rooij, I.A., *et al.* Risk factors for different phenotypes of hypospadias: results from a Dutch case-control study. *BJU Int*, 2013. 112: 121.  
<https://www.ncbi.nlm.nih.gov/pubmed/23305310>
196. Netto, J.M., *et al.* Hormone therapy in hypospadias surgery: a systematic review. *J Pediatr Urol*, 2013. 9: 971.  
<https://www.ncbi.nlm.nih.gov/pubmed/23602841>

197. Chariatte, V., *et al.* Uroradiological screening for upper and lower urinary tract anomalies in patients with hypospadias: a systematic literature review. *Evid Based Med*, 2013. 18: 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/22815315>
198. Belman, A.B., Hypospadias and chordee, In: *Clinical Pediatric Urology* A.B. Belman, L.R. King & S.A. Kramer, Editors. 2002, Martin Dunitz: London.
199. Malik, R.D., *et al.* Survey of pediatric urologists on the preoperative use of testosterone in the surgical correction of hypospadias. *J Pediatr Urol*, 2014.  
<https://www.ncbi.nlm.nih.gov/pubmed/24726783>
200. Wright, I., *et al.* Effect of preoperative hormonal stimulation on postoperative complication rates after proximal hypospadias repair: a systematic review. *J Urol*, 2013. 190: 652.  
<https://www.ncbi.nlm.nih.gov/pubmed/23597451>
201. Rynja, S.P., *et al.* Testosterone prior to hypospadias repair: Postoperative complication rates and long-term cosmetic results, penile length and body height. *J Pediatr Urol*, 2018. 14: 31.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/29174377>
202. Paiva, K.C., *et al.* Biometry of the hypospadiac penis after hormone therapy (testosterone and estrogen): A randomized, double-blind controlled trial. *J Pediatr Urol*, 2016. 12: 200.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/27321554>
203. Chua, M.E., *et al.* Preoperative hormonal stimulation effect on hypospadias repair complications: Meta-analysis of observational versus randomized controlled studies. *J Pediatr Urol*, 2017. 13: 470.  
<https://www.ncbi.nlm.nih.gov/pubmed/28939350>
204. Kaya, C., *et al.* The role of pre-operative androgen stimulation in hypospadias surgery. *Transl Androl Urol*, 2014. 3: 340.  
<https://www.ncbi.nlm.nih.gov/pubmed/26816790>
205. Menon, P., *et al.* Outcome of urethroplasty after parenteral testosterone in children with distal hypospadias. *J Pediatr Urol*, 2017. 13: 292.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/28111208>
206. Bush, N.C., *et al.* Age does not impact risk for urethroplasty complications after tubularized incised plate repair of hypospadias in prepubertal boys. *J Pediatr Urol*, 2013. 9: 252.  
<https://www.ncbi.nlm.nih.gov/pubmed/22542204>
207. Perlmutter, A.E., *et al.* Impact of patient age on distal hypospadias repair: a surgical perspective. *Urology*, 2006. 68: 648.  
<https://www.ncbi.nlm.nih.gov/pubmed/16979730>
208. Bhat, A., *et al.* Comparison of variables affecting the surgical outcomes of tubularized incised plate urethroplasty in adult and pediatric hypospadias. *J Pediatr Urol*, 2016. 12: 108 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26778183>
209. Castagnetti, M., *et al.* Surgical management of primary severe hypospadias in children: systematic 20-year review. *J Urol*, 2010. 184: 1469.  
<https://www.ncbi.nlm.nih.gov/pubmed/20727541>
210. Baskin, L.S., *et al.* Changing concepts of hypospadias curvature lead to more onlay island flap procedures. *J Urol*, 1994. 151: 191.  
<https://www.ncbi.nlm.nih.gov/pubmed/8254812>
211. Hollowell, J.G., *et al.* Preservation of the urethral plate in hypospadias repair: extended applications and further experience with the onlay island flap urethroplasty. *J Urol*, 1990. 143: 98.  
<https://www.ncbi.nlm.nih.gov/pubmed/2294275>
212. Snodgrass, W., *et al.* Straightening ventral curvature while preserving the urethral plate in proximal hypospadias repair. *J Urol*, 2009. 182: 1720.  
<https://www.ncbi.nlm.nih.gov/pubmed/19692004>
213. Braga, L.H., *et al.* Ventral penile lengthening versus dorsal plication for severe ventral curvature in children with proximal hypospadias. *J Urol*, 2008. 180: 1743.  
<https://www.ncbi.nlm.nih.gov/pubmed/18721961>
214. el-Kassaby, A.W., *et al.* Modified tubularized incised plate urethroplasty for hypospadias repair: a long-term results of 764 patients. *Urology*, 2008. 71: 611.  
<https://www.ncbi.nlm.nih.gov/pubmed/18295308>
215. El-Sherbiny, M.T., *et al.* Comprehensive analysis of tubularized incised-plate urethroplasty in primary and re-operative hypospadias. *BJU Int*, 2004. 93: 1057.  
<https://www.ncbi.nlm.nih.gov/pubmed/15142164>
216. Orkiszewski, M., *et al.* Morphology and urodynamics after longitudinal urethral plate incision in proximal hypospadias repairs: long-term results. *Eur J Pediatr Surg*, 2004. 14: 35.  
<https://www.ncbi.nlm.nih.gov/pubmed/15024677>

217. Snodgrass, W.T., *et al.* Tubularized incised plate hypospadias repair for distal hypospadias. *J Pediatr Urol*, 2010. 6: 408.  
<https://www.ncbi.nlm.nih.gov/pubmed/17222659>
218. Schwentner, C., *et al.* Interim outcome of the single stage dorsal inlay skin graft for complex hypospadias reoperations. *J Urol*, 2006. 175: 1872.  
<https://www.ncbi.nlm.nih.gov/pubmed/16600785>
219. Ahmed, M., *et al.* Is combined inner preputial inlay graft with tubularized incised plate in hypospadias repair worth doing? *J Pediatr Urol*, 2015. 11: 229 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26119452>
220. Pippi Salle, J.L., *et al.* Proximal hypospadias: A persistent challenge. Single institution outcome analysis of three surgical techniques over a 10-year period. *J Pediatr Urol*, 2016. 12: 28 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26279102>
221. Meyer-Junghanel, L., *et al.* Experience with repair of 120 hypospadias using Mathieu's procedure. *Eur J Pediatr Surg*, 1995. 5: 355.  
<https://www.ncbi.nlm.nih.gov/pubmed/8773227>
222. Pfistermuller, K.L., *et al.* Meta-analysis of complication rates of the tubularized incised plate (TIP) repair. *J Pediatr Urol*, 2015. 11: 54.  
<https://www.ncbi.nlm.nih.gov/pubmed/25819601>
223. Snodgrass, W.T., *et al.* Urethral strictures following urethral plate and proximal urethral elevation during proximal TIP hypospadias repair. *J Pediatr Urol*, 2013. 9: 990.  
<https://www.ncbi.nlm.nih.gov/pubmed/23707201>
224. Cambareri, G.M., *et al.* Hypospadias repair with onlay preputial graft: a 25-year experience with long-term follow-up. *BJU Int*, 2016. 118: 451.  
<https://www.ncbi.nlm.nih.gov/pubmed/26780179>
225. Castagnetti, M., *et al.* Primary severe hypospadias: comparison of reoperation rates and parental perception of urinary symptoms and cosmetic outcomes among 4 repairs. *J Urol*, 2013. 189: 1508.  
<https://www.ncbi.nlm.nih.gov/pubmed/23154207>
226. Kocvara, R., *et al.* Inlay-onlay flap urethroplasty for hypospadias and urethral stricture repair. *J Urol*, 1997. 158: 2142.  
<https://www.ncbi.nlm.nih.gov/pubmed/9366331>
227. Perovic, S., *et al.* Onlay island flap urethroplasty for severe hypospadias: a variant of the technique. *J Urol*, 1994. 151: 711.  
<https://www.ncbi.nlm.nih.gov/pubmed/8308994>
228. Catti, M., *et al.* Original Koyanagi urethroplasty versus modified Hayashi technique: outcome in 57 patients. *J Pediatr Urol*, 2009. 5: 300.  
<https://www.ncbi.nlm.nih.gov/pubmed/19457720>
229. DeFoor, W., *et al.* Results of single staged hypospadias surgery to repair penoscrotal hypospadias with bifid scrotum or penoscrotal transposition. *J Urol*, 2003. 170: 1585.  
<https://www.ncbi.nlm.nih.gov/pubmed/14501667>
230. Hayashi, Y., *et al.* Neo-modified Koyanagi technique for the single-stage repair of proximal hypospadias. *J Pediatr Urol*, 2007. 3: 239.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947743>
231. Koyanagi, T., *et al.* One-stage repair of hypospadias: is there no simple method universally applicable to all types of hypospadias? *J Urol*, 1994. 152: 1232.  
<https://www.ncbi.nlm.nih.gov/pubmed/8072111>
232. Ahmed, S., *et al.* Buccal mucosal graft for secondary hypospadias repair and urethral replacement. *Br J Urol*, 1997. 80: 328.  
<https://www.ncbi.nlm.nih.gov/pubmed/9284210>
233. Bracka, A. Hypospadias repair: the two-stage alternative. *Br J Urol*, 1995. 76 Suppl 3: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/8535768>
234. Lam, P.N., *et al.* 2-stage repair in infancy for severe hypospadias with chordee: long-term results after puberty. *J Urol*, 2005. 174: 1567.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148653>
235. Mokhless, I.A., *et al.* The multistage use of buccal mucosa grafts for complex hypospadias: histological changes. *J Urol*, 2007. 177: 1496.  
<https://www.ncbi.nlm.nih.gov/pubmed/17382762>
236. Stanasel, I., *et al.* Complications following Staged Hypospadias Repair Using Transposed Preputial Skin Flaps. *J Urol*, 2015. 194: 512.  
<https://www.ncbi.nlm.nih.gov/pubmed/25701546>

237. Castagnetti, M., *et al.* Does Preputial Reconstruction Increase Complication Rate of Hypospadias Repair? 20-Year Systematic Review and Meta-Analysis. *Front Pediatr*, 2016. 4: 41.  
<https://www.ncbi.nlm.nih.gov/pubmed/27200322>
238. Chalmers, D.J., *et al.* Distal hypospadias repair in infants without a postoperative stent. *Pediatr Surg Int*, 2015. 31: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/25475503>
239. Hsieh, M.H., *et al.* Surgical antibiotic practices among pediatric urologists in the United States. *J Pediatr Urol*, 2011. 7: 192.  
<https://www.ncbi.nlm.nih.gov/pubmed/20537590>
240. Kanaroglou, N., *et al.* Is there a role for prophylactic antibiotics after stented hypospadias repair? *J Urol*, 2013. 190: 1535.  
<https://www.ncbi.nlm.nih.gov/pubmed/23416639>
241. Meir, D.B., *et al.* Is prophylactic antimicrobial treatment necessary after hypospadias repair? *J Urol*, 2004. 171: 2621.  
<https://www.ncbi.nlm.nih.gov/pubmed/15118434>
242. Bush, N.C., *et al.* Glans size is an independent risk factor for urethroplasty complications after hypospadias repair. *J Pediatr Urol*, 2015. 11: 355 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26320396>
243. Lee, O.T., *et al.* Predictors of secondary surgery after hypospadias repair: a population based analysis of 5,000 patients. *J Urol*, 2013. 190: 251.  
<https://www.ncbi.nlm.nih.gov/pubmed/23376710>
244. Braga, L.H., *et al.* Tubularized incised plate urethroplasty for distal hypospadias: A literature review. *Indian J Urol*, 2008. 24: 219.  
<https://www.ncbi.nlm.nih.gov/pubmed/19468401>
245. Wang, F., *et al.* Systematic review and meta-analysis of studies comparing the perimeatal-based flap and tubularized incised-plate techniques for primary hypospadias repair. *Pediatr Surg Int*, 2013. 29: 811.  
<https://www.ncbi.nlm.nih.gov/pubmed/23793987>
246. Wilkinson, D.J., *et al.* Outcomes in distal hypospadias: a systematic review of the Mathieu and tubularized incised plate repairs. *J Pediatr Urol*, 2012. 8: 307.  
<https://www.ncbi.nlm.nih.gov/pubmed/21159560>
247. Leslie, B., *et al.* Critical outcome analysis of staged buccal mucosa graft urethroplasty for prior failed hypospadias repair in children. *J Urol*, 2011. 185: 1077.  
<https://www.ncbi.nlm.nih.gov/pubmed/21256520>
248. Howe, A.S., *et al.* Management of 220 adolescents and adults with complications of hypospadias repair during childhood. *Asian J Urol*, 2017. 4: 14.  
<https://www.ncbi.nlm.nih.gov/pubmed/29264201>
249. Spinoit, A.F., *et al.* Hypospadias repair at a tertiary care center: long-term followup is mandatory to determine the real complication rate. *J Urol*, 2013. 189: 2276.  
<https://www.ncbi.nlm.nih.gov/pubmed/23306089>
250. Andersson, M., *et al.* Hypospadias repair with tubularized incised plate: Does the obstructive flow pattern resolve spontaneously? *J Pediatr Urol*, 2011. 7: 441.  
<https://www.ncbi.nlm.nih.gov/pubmed/20630805>
251. Andersson, M., *et al.* Normalized Urinary Flow at Puberty after Tubularized Incised Plate Urethroplasty for Hypospadias in Childhood. *J Urol*, 2015. 194: 1407.  
<https://www.ncbi.nlm.nih.gov/pubmed/26087380>
252. Gonzalez, R., *et al.* Importance of urinary flow studies after hypospadias repair: a systematic review. *Int J Urol*, 2011. 18: 757.  
<https://www.ncbi.nlm.nih.gov/pubmed/21883491>
253. Hueber, P.A., *et al.* Long-term functional outcomes of distal hypospadias repair: a single center retrospective comparative study of TIPs, Mathieu and MAGPI. *J Pediatr Urol*, 2015. 11: 68 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25824882>
254. Perera, M., *et al.* Long-term urethral function measured by uroflowmetry after hypospadias surgery: comparison with an age matched control. *J Urol*, 2012. 188: 1457.  
<https://www.ncbi.nlm.nih.gov/pubmed/22906660>
255. Holland, A.J., *et al.* HOSE: an objective scoring system for evaluating the results of hypospadias surgery. *BJU Int*, 2001. 88: 255.  
<https://www.ncbi.nlm.nih.gov/pubmed/11488741>

256. van der Toorn, F., *et al.* Introducing the HOPE (Hypospadias Objective Penile Evaluation)-score: a validation study of an objective scoring system for evaluating cosmetic appearance in hypospadias patients. *J Pediatr Urol*, 2013. 9: 1006.  
<https://www.ncbi.nlm.nih.gov/pubmed/23491983>
257. Weber, D.M., *et al.* The Penile Perception Score: an instrument enabling evaluation by surgeons and patient self-assessment after hypospadias repair. *J Urol*, 2013. 189: 189.  
<https://www.ncbi.nlm.nih.gov/pubmed/23174225>
258. Haid, B., *et al.* Penile appearance after hypospadias correction from a parent's point of view: Comparison of the hypospadias objective penile evaluation score and parents penile perception score. *J Pediatr Urol*, 2016. 12: 33.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26725130>
259. Krull, S., *et al.* Outcome after Hypospadias Repair: Evaluation Using the Hypospadias Objective Penile Evaluation Score. *Eur J Pediatr Surg*, 2018. 28: 268.  
<https://www.ncbi.nlm.nih.gov/pubmed/28505692>
260. Moriya, K., *et al.* Long-term cosmetic and sexual outcome of hypospadias surgery: norm related study in adolescence. *J Urol*, 2006. 176: 1889.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945681>
261. Rynja, S.P., *et al.* Functional, cosmetic and psychosexual results in adult men who underwent hypospadias correction in childhood. *J Pediatr Urol*, 2011. 7: 504.  
<https://www.ncbi.nlm.nih.gov/pubmed/21429804>
262. Ortqvist, L., *et al.* Long-term followup of men born with hypospadias: urological and cosmetic results. *J Urol*, 2015. 193: 975.  
<https://www.ncbi.nlm.nih.gov/pubmed/25268894>
263. Adams, J., *et al.* Reconstructive surgery for hypospadias: A systematic review of long-term patient satisfaction with cosmetic outcomes. *Indian J Urol*, 2016. 32: 93.  
<https://www.ncbi.nlm.nih.gov/pubmed/27127350>
264. Sullivan, K.J., *et al.* Assessing quality of life of patients with hypospadias: A systematic review of validated patient-reported outcome instruments. *J Pediatr Urol*, 2017. 13: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/28089292>
265. Nyirady, P., *et al.* Management of congenital penile curvature. *J Urol*, 2008. 179: 1495.  
<https://www.ncbi.nlm.nih.gov/pubmed/18295273>
266. Baskin, L.S., *et al.* Neuroanatomical ontogeny of the human fetal penis. *Br J Urol*, 1997. 79: 628.  
<https://www.ncbi.nlm.nih.gov/pubmed/9126098>
267. Ebbehøj, J., *et al.* Congenital penile angulation. *Br J Urol*, 1987. 60: 264.  
<https://www.ncbi.nlm.nih.gov/pubmed/3676675>
268. Kelami, A. Congenital penile deviation and its treatment with the Nesbit-Kelami technique. *Br J Urol*, 1987. 60: 261.  
<https://www.ncbi.nlm.nih.gov/pubmed/3676674>
269. Yachia, D., *et al.* The incidence of congenital penile curvature. *J Urol*, 1993. 150: 1478.  
<https://www.ncbi.nlm.nih.gov/pubmed/8411431>
270. Hsieh, J.T., *et al.* Correction of congenital penile curvature using modified tunical plication with absorbable sutures: the long-term outcome and patient satisfaction. *Eur Urol*, 2007. 52: 261.  
<https://www.ncbi.nlm.nih.gov/pubmed/17234333>
271. Sasso, F., *et al.* Penile curvature: an update for management from 20 years experience in a high volume centre. *Urologia*, 2016. 83: 130.  
<https://www.ncbi.nlm.nih.gov/pubmed/27103093>
272. Gittes, R.F., *et al.* Injection technique to induce penile erection. *Urology*, 1974. 4: 473.  
<https://www.ncbi.nlm.nih.gov/pubmed/4418594>
273. Schultheiss, D., *et al.* Congenital and acquired penile deviation treated with the essed plication method. *Eur Urol*, 2000. 38: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/10895008>
274. Yachia, D. Modified corporoplasty for the treatment of penile curvature. *J Urol*, 1990. 143: 80.  
<https://www.ncbi.nlm.nih.gov/pubmed/2294269>
275. Rehman, J., *et al.* Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunica shaving and plication). *J Urol*, 1997. 157: 1288.  
<https://www.ncbi.nlm.nih.gov/pubmed/9120923>
276. Poulsen, J., *et al.* Treatment of penile curvature--a retrospective study of 175 patients operated with plication of the tunica albuginea or with the Nesbit procedure. *Br J Urol*, 1995. 75: 370.  
<https://www.ncbi.nlm.nih.gov/pubmed/7735803>

277. Leonardo, C., *et al.* Plication corporoplasty versus Nesbit operation for the correction of congenital penile curvature. A long-term follow-up. *Int Urol Nephrol*, 2012. 44: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/21559790>
278. Cavallini, G., *et al.* Pilot study to determine improvements in subjective penile morphology and personal relationships following a Nesbit plication procedure for men with congenital penile curvature. *Asian J Androl*, 2008. 10: 512.  
<https://www.ncbi.nlm.nih.gov/pubmed/18097530>
279. Vatne, V., *et al.* Functional results after operations of penile deviations: an institutional experience. *Scand J Urol Nephrol Suppl*, 1996. 179: 151.  
<https://www.ncbi.nlm.nih.gov/pubmed/8908683>
280. Shaeer, O., *et al.* Shaeer's Corporal Rotation III: Shortening-Free Correction of Congenital Penile Curvature-The Noncorporotomy Technique. *Eur Urol*, 2016. 69: 129.  
<https://www.ncbi.nlm.nih.gov/pubmed/26298209>
281. Akbay, E., *et al.* The prevalence of varicocele and varicocele-related testicular atrophy in Turkish children and adolescents. *BJU Int*, 2000. 86: 490.  
<https://www.ncbi.nlm.nih.gov/pubmed/10971279>
282. Kogan, S.J., The pediatric varicocele. , In: *Pediatric urology*, J.P. Gearhart, R.C. Rink & P.D.E. Mouriquand, Editors. 2001, WB Saunders: Philadelphia.
283. Oster, J. Varicocele in children and adolescents. An investigation of the incidence among Danish school children. *Scand J Urol Nephrol*, 1971. 5: 27.  
<https://www.ncbi.nlm.nih.gov/pubmed/5093090>
284. Kass, E.J., *et al.* Reversal of testicular growth failure by varicocele ligation. *J Urol*, 1987. 137: 475.  
<https://www.ncbi.nlm.nih.gov/pubmed/3820376>
285. Paduch, D.A., *et al.* Repair versus observation in adolescent varicocele: a prospective study. *J Urol*, 1997. 158: 1128.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258155>
286. Li, F., *et al.* Effect of varicoelectomy on testicular volume in children and adolescents: a meta-analysis. *Urology*, 2012. 79: 1340.  
<https://www.ncbi.nlm.nih.gov/pubmed/22516359>
287. Kocvara, R., *et al.* Division of lymphatic vessels at varicoelectomy leads to testicular oedema and decline in testicular function according to the LH-RH analogue stimulation test. *Eur Urol*, 2003. 43: 430.  
<https://www.ncbi.nlm.nih.gov/pubmed/12667726>
288. The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. *World Health Organization. Fertil Steril*, 1992. 57: 1289.  
<https://www.ncbi.nlm.nih.gov/pubmed/1601152>
289. Laven, J.S., *et al.* Effects of varicocele treatment in adolescents: a randomized study. *Fertil Steril*, 1992. 58: 756.  
<https://www.ncbi.nlm.nih.gov/pubmed/1426322>
290. Nork, J.J., *et al.* Youth varicocele and varicocele treatment: a meta-analysis of semen outcomes. *Fertil Steril*, 2014. 102: 381.  
<https://www.ncbi.nlm.nih.gov/pubmed/24907913>
291. Okuyama, A., *et al.* Surgical repair of varicocele at puberty: preventive treatment for fertility improvement. *J Urol*, 1988. 139: 562.  
<https://www.ncbi.nlm.nih.gov/pubmed/3343743>
292. Pinto, K.J., *et al.* Varicocele related testicular atrophy and its predictive effect upon fertility. *J Urol*, 1994. 152: 788.  
<https://www.ncbi.nlm.nih.gov/pubmed/8022015>
293. Dubin, L., *et al.* Varicocele size and results of varicoelectomy in selected subfertile men with varicocele. *Fertil Steril*, 1970. 21: 606.  
<https://www.ncbi.nlm.nih.gov/pubmed/5433164>
294. Tasci, A.I., *et al.* Color doppler ultrasonography and spectral analysis of venous flow in diagnosis of varicocele. *Eur Urol*, 2001. 39: 316.  
<https://www.ncbi.nlm.nih.gov/pubmed/11275726>
295. Diamond, D.A., *et al.* Relationship of varicocele grade and testicular hypotrophy to semen parameters in adolescents. *J Urol*, 2007. 178: 1584.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707046>
296. Aragona, F., *et al.* Correlation of testicular volume, histology and LHRH test in adolescents with idiopathic varicocele. *Eur Urol*, 1994. 26: 61.  
<https://www.ncbi.nlm.nih.gov/pubmed/7925532>



297. Bogaert, G., *et al.* Pubertal screening and treatment for varicocele do not improve chance of paternity as adult. *J Urol*, 2013. 189: 2298.  
<https://www.ncbi.nlm.nih.gov/pubmed/23261480>
298. Chen, J.J., *et al.* Is the comparison of a left varicocele testis to its contralateral normal testis sufficient in determining its well-being? *Urology*, 2011. 78: 1167.  
<https://www.ncbi.nlm.nih.gov/pubmed/21782220>
299. Goldstein, M., *et al.* Microsurgical inguinal varicocelectomy with delivery of the testis: an artery and lymphatic sparing technique. *J Urol*, 1992. 148: 1808.  
<https://www.ncbi.nlm.nih.gov/pubmed/1433614>
300. Hopps, C.V., *et al.* Intraoperative varicocele anatomy: a microscopic study of the inguinal versus subinguinal approach. *J Urol*, 2003. 170: 2366.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634418>
301. Kocvara, R., *et al.* Lymphatic sparing laparoscopic varicocelectomy: a microsurgical repair. *J Urol*, 2005. 173: 1751.  
<https://www.ncbi.nlm.nih.gov/pubmed/15821575>
302. Riccabona, M., *et al.* Optimizing the operative treatment of boys with varicocele: sequential comparison of 4 techniques. *J Urol*, 2003. 169: 666.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544340>
303. Marmar, J., *et al.* New scientific information related to varicoceles. *J Urol*, 2003. 170: 2371.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634419>
304. Minevich, E., *et al.* Inguinal microsurgical varicocelectomy in the adolescent: technique and preliminary results. *J Urol*, 1998. 159: 1022.  
<https://www.ncbi.nlm.nih.gov/pubmed/9474223>
305. Mirilas, P., *et al.* Microsurgical subinguinal varicocelectomy in children, adolescents, and adults: surgical anatomy and anatomically justified technique. *J Androl*, 2012. 33: 338.  
<https://www.ncbi.nlm.nih.gov/pubmed/21835913>
306. Esposito, C., *et al.* Technical standardization of laparoscopic lymphatic sparing varicocelectomy in children using isosulfan blue. *J Pediatr Surg*, 2014. 49: 660.  
<https://www.ncbi.nlm.nih.gov/pubmed/24726132>
307. Oswald, J., *et al.* The use of isosulphan blue to identify lymphatic vessels in high retroperitoneal ligation of adolescent varicocele--avoiding postoperative hydrocele. *BJU Int*, 2001. 87: 502.  
<https://www.ncbi.nlm.nih.gov/pubmed/11298043>
308. Fast, A.M., *et al.* Adolescent varicocelectomy: does artery sparing influence recurrence rate and/or catch-up growth? *Andrology*, 2014. 2: 159.  
<https://www.ncbi.nlm.nih.gov/pubmed/24339439>
309. Kim, K.S., *et al.* Impact of internal spermatic artery preservation during laparoscopic varicocelectomy on recurrence and the catch-up growth rate in adolescents. *J Pediatr Urol*, 2014. 10: 435.  
<https://www.ncbi.nlm.nih.gov/pubmed/24314813>
310. Fayad, F., *et al.* Percutaneous retrograde endovascular occlusion for pediatric varicocele. *J Pediatr Surg*, 2011. 46: 525.  
<https://www.ncbi.nlm.nih.gov/pubmed/21376204>
311. Thon, W.F., *et al.* Percutaneous sclerotherapy of idiopathic varicocele in childhood: a preliminary report. *J Urol*, 1989. 141: 913.  
<https://www.ncbi.nlm.nih.gov/pubmed/2926889>
312. Locke, J.A., *et al.* Treatment of varicocele in children and adolescents: A systematic review and meta-analysis of randomized controlled trials. *J Pediatr Urol*, 2017. 13: 437.  
<https://www.ncbi.nlm.nih.gov/pubmed/28851509>
313. Cayan, S., *et al.* Paternity Rates and Time to Conception in Adolescents with Varicocele Undergoing Microsurgical Varicocele Repair vs Observation Only: A Single Institution Experience with 408 Patients. *J Urol*, 2017. 198: 195.  
<https://www.ncbi.nlm.nih.gov/pubmed/28153511>
314. Silay, M.S., *et al.* Treatment of Varicocele in Children and Adolescents: A Systematic Review and Meta-analysis from the European Association of Urology/European Society for Paediatric Urology Guidelines Panel. *Eur Urol*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/30316583>
315. Hoberman, A., *et al.* Prevalence of urinary tract infection in febrile infants. *J Pediatr*, 1993. 123: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/8320616>
316. Marild, S., *et al.* Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age. *Acta Paediatr*, 1998. 87: 549.  
<https://www.ncbi.nlm.nih.gov/pubmed/9641738>

317. O'Brien, K., *et al.* Prevalence of urinary tract infection (UTI) in sequential acutely unwell children presenting in primary care: exploratory study. *Scand J Prim Health Care*, 2011. 29: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/21323495>
318. Shaikh, N., *et al.* Prevalence of urinary tract infection in childhood: a meta-analysis. *Pediatr Infect Dis J*, 2008. 27: 302.  
<https://www.ncbi.nlm.nih.gov/pubmed/18316994>
319. Zorc, J.J., *et al.* Clinical and demographic factors associated with urinary tract infection in young febrile infants. *Pediatrics*, 2005. 116: 644.  
<https://www.ncbi.nlm.nih.gov/pubmed/16140703>
320. Rushton, H.G., *et al.* Pyelonephritis in male infants: how important is the foreskin? *J Urol*, 1992. 148: 733.  
<https://www.ncbi.nlm.nih.gov/pubmed/1640557>
321. Magin, E.C., *et al.* Efficacy of short-term intravenous antibiotic in neonates with urinary tract infection. *Pediatr Emerg Care*, 2007. 23: 83.  
<https://www.ncbi.nlm.nih.gov/pubmed/17351406>
322. Sastre, J.B., *et al.* Urinary tract infection in the newborn: clinical and radio imaging studies. *Pediatr Nephrol*, 2007. 22: 1735.  
<https://www.ncbi.nlm.nih.gov/pubmed/17665222>
323. Shortliffe, L.M.D., *et al.*, Pediatric urinary tract infections., In: *Pediatric Urology*, J.P. Gearhart, R.C. Rink & P.D.E. Mouriquand, Editors. 2001, Saunders: Philadelphia.
324. Burns, M.W., *et al.* Pediatric urinary tract infection. Diagnosis, classification, and significance. *Pediatr Clin North Am*, 1987. 34: 1111.  
<https://www.ncbi.nlm.nih.gov/pubmed/3658502>
325. Beetz, R., *et al.* [Urinary tract infections in infants and children -- a consensus on diagnostic, therapy and prophylaxis]. *Urologe A*, 2007. 46: 112.  
<https://www.ncbi.nlm.nih.gov/pubmed/17225140>
326. Craig, J.C., *et al.* The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. *BMJ*, 2010. 340: c1594.  
<https://www.ncbi.nlm.nih.gov/pubmed/20406860>
327. Lin, D.S., *et al.* Urinary tract infection in febrile infants younger than eight weeks of Age. *Pediatrics*, 2000. 105: E20.  
<https://www.ncbi.nlm.nih.gov/pubmed/10654980>
328. Tullus, K. Difficulties in diagnosing urinary tract infections in small children. *Pediatr Nephrol*, 2011. 26: 1923.  
<https://www.ncbi.nlm.nih.gov/pubmed/21773821>
329. Whiting, P., *et al.* Rapid tests and urine sampling techniques for the diagnosis of urinary tract infection (UTI) in children under five years: a systematic review. *BMC Pediatr*, 2005. 5: 4.  
<https://www.ncbi.nlm.nih.gov/pubmed/15811182>
330. Koch, V.H., *et al.* [Urinary tract infection: a search for evidence]. *J Pediatr (Rio J)*, 2003. 79 Suppl 1: S97.  
<https://www.ncbi.nlm.nih.gov/pubmed/14506522>
331. Ma, J.F., *et al.* Urinary tract infection in children: etiology and epidemiology. *Urol Clin North Am*, 2004. 31: 517.  
<https://www.ncbi.nlm.nih.gov/pubmed/15313061>
332. Ramage, I.J., *et al.* Accuracy of clean-catch urine collection in infancy. *J Pediatr*, 1999. 135: 765.  
<https://www.ncbi.nlm.nih.gov/pubmed/10586183>
333. Roberts, K.B., *et al.* Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*, 2011. 128: 595.  
<https://www.ncbi.nlm.nih.gov/pubmed/21873693>
334. Tosif, S., *et al.* Contamination rates of different urine collection methods for the diagnosis of urinary tract infections in young children: an observational cohort study. *J Paediatr Child Health*, 2012. 48: 659.  
<https://www.ncbi.nlm.nih.gov/pubmed/22537082>
335. Austin, B.J., *et al.* Is urethral catheterization a successful alternative to suprapubic aspiration in neonates? *J Paediatr Child Health*, 1999. 35: 34.  
<https://www.ncbi.nlm.nih.gov/pubmed/10234632>
336. Wingerter, S., *et al.* Risk factors for contamination of catheterized urine specimens in febrile children. *Pediatr Emerg Care*, 2011. 27: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/21178815>

337. Buys, H., et al. Suprapubic aspiration under ultrasound guidance in children with fever of undiagnosed cause. *BMJ*, 1994. 308: 690.  
<https://www.ncbi.nlm.nih.gov/pubmed/8142792>
338. Kiernan, S.C., et al. Ultrasound guidance of suprapubic bladder aspiration in neonates. *J Pediatr*, 1993. 123: 789.  
<https://www.ncbi.nlm.nih.gov/pubmed/8229492>
339. Hildebrand, W.L., et al. Suprapubic bladder aspiration in infants. *Am Fam Physician*, 1981. 23: 115.  
<https://www.ncbi.nlm.nih.gov/pubmed/7234629>
340. Kozler, E., et al. Pain in infants who are younger than 2 months during suprapubic aspiration and transurethral bladder catheterization: a randomized, controlled study. *Pediatrics*, 2006. 118: e51.  
<https://www.ncbi.nlm.nih.gov/pubmed/16818537>
341. Vaillancourt, S., et al. To clean or not to clean: effect on contamination rates in midstream urine collections in toilet-trained children. *Pediatrics*, 2007. 119: e1288.  
<https://www.ncbi.nlm.nih.gov/pubmed/17502345>
342. Powell, H.R., et al. Urinary nitrite in symptomatic and asymptomatic urinary infection. *Arch Dis Child*, 1987. 62: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/3548604>
343. Stull, T.L., et al. Epidemiology and natural history of urinary tract infections in children. *Med Clin North Am*, 1991. 75: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/1996034>
344. Hoberman, A., et al. Is urine culture necessary to rule out urinary tract infection in young febrile children? *Pediatr Infect Dis J*, 1996. 15: 304.  
<https://www.ncbi.nlm.nih.gov/pubmed/8866798>
345. Herr, S.M., et al. Enhanced urinalysis improves identification of febrile infants ages 60 days and younger at low risk for serious bacterial illness. *Pediatrics*, 2001. 108: 866.  
<https://www.ncbi.nlm.nih.gov/pubmed/11581437>
346. Mayo, S., et al. Clinical laboratory automated urinalysis: comparison among automated microscopy, flow cytometry, two test strips analyzers, and manual microscopic examination of the urine sediments. *J Clin Lab Anal*, 2008. 22: 262.  
<https://www.ncbi.nlm.nih.gov/pubmed/18623125>
347. Kass, E.H. Asymptomatic infections of the urinary tract. *Trans Assoc Am Physicians*, 1956. 69: 56.  
<https://www.ncbi.nlm.nih.gov/pubmed/13380946>
348. Lohr, J.A. Use of routine urinalysis in making a presumptive diagnosis of urinary tract infection in children. *Pediatr Infect Dis J*, 1991. 10: 646.  
<https://www.ncbi.nlm.nih.gov/pubmed/1923675>
349. Bollgren, I., et al. Low urinary counts of P-fimbriated *Escherichia coli* in presumed acute pyelonephritis. *Arch Dis Child*, 1984. 59: 102.  
<https://www.ncbi.nlm.nih.gov/pubmed/6142697>
350. Stamm, W.E. Measurement of pyuria and its relation to bacteriuria. *Am J Med*, 1983. 75: 53.  
<https://www.ncbi.nlm.nih.gov/pubmed/6349345>
351. Grabe, M., et al., EAU Guidelines on Urological Infections. Presented at the EAU Annual Congress, ed. European Association of Urology. 2011, Arnhem, The Netherlands  
<https://uroweb.org/guideline/urological-infections/?type=archive>
352. Preda, I., et al. Value of ultrasound in evaluation of infants with first urinary tract infection. *J Urol*, 2010. 183: 1984.  
<https://www.ncbi.nlm.nih.gov/pubmed/20303537>
353. Chang, S.J., et al. Elevated postvoid residual urine volume predicting recurrence of urinary tract infections in toilet-trained children. *Pediatr Nephrol*, 2015. 30: 1131.  
<https://www.ncbi.nlm.nih.gov/pubmed/25673516>
354. Shiraishi, K., et al. Risk factors for breakthrough infection in children with primary vesicoureteral reflux. *J Urol*, 2010. 183: 1527.  
<https://www.ncbi.nlm.nih.gov/pubmed/20172558>
355. Quirino, I.G., et al. Combined use of late phase dimercapto-succinic acid renal scintigraphy and ultrasound as first line screening after urinary tract infection in children. *J Urol*, 2011. 185: 258.  
<https://www.ncbi.nlm.nih.gov/pubmed/21074813>
356. Siomou, E., et al. Implications of 99mTc-DMSA scintigraphy performed during urinary tract infection in neonates. *Pediatrics*, 2009. 124: 881.  
<https://www.ncbi.nlm.nih.gov/pubmed/19661052>
357. Michaud, J.E., et al. Cost and radiation exposure in the workup of febrile pediatric urinary tract infections. *J Surg Res*, 2016. 203: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/27363638>

358. Doganis, D., *et al.* Timing of voiding cystourethrography in infants with first time urinary infection. *Pediatr Nephrol*, 2009. 24: 319.  
<https://www.ncbi.nlm.nih.gov/pubmed/18853200>
359. Sathapornwajana, P., *et al.* Timing of voiding cystourethrogram after urinary tract infection. *Arch Dis Child*, 2008. 93: 229.  
<https://www.ncbi.nlm.nih.gov/pubmed/17626141>
360. Spencer, J.D., *et al.* The accuracy and health risks of a voiding cystourethrogram after a febrile urinary tract infection. *J Pediatr Urol*, 2012. 8: 72.  
<https://www.ncbi.nlm.nih.gov/pubmed/21126919>
361. Hoebcke, P., *et al.* Assessment of lower urinary tract dysfunction in children with non-neuropathic bladder sphincter dysfunction. *Eur Urol*, 1999. 35: 57.  
<https://www.ncbi.nlm.nih.gov/pubmed/9933796>
362. Koff, S.A., *et al.* The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. *J Urol*, 1998. 160: 1019.  
<https://www.ncbi.nlm.nih.gov/pubmed/9719268>
363. van Gool, J.D. Dysfunctional voiding: a complex of bladder/sphincter dysfunction, urinary tract infections and vesicoureteral reflux. *Acta Urol Belg*, 1995. 63: 27.  
<https://www.ncbi.nlm.nih.gov/pubmed/7484519>
364. van Gool, J.D., *et al.* Bladder-sphincter dysfunction, urinary infection and vesico-ureteral reflux with special reference to cognitive bladder training. *Contrib Nephrol*, 1984. 39: 190.  
<https://www.ncbi.nlm.nih.gov/pubmed/6744871>
365. De Paepe, H., *et al.* Pelvic-floor therapy and toilet training in young children with dysfunctional voiding and obstipation. *BJU Int*, 2000. 85: 889.  
<https://www.ncbi.nlm.nih.gov/pubmed/10792172>
366. Loening-Baucke, V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. *Pediatrics*, 1997. 100: 228.  
<https://www.ncbi.nlm.nih.gov/pubmed/9240804>
367. O'Regan, S., *et al.* Constipation, bladder instability, urinary tract infection syndrome. *Clin Nephrol*, 1985. 23: 152.  
<https://www.ncbi.nlm.nih.gov/pubmed/3987104>
368. Nandagopal, R., *et al.* Transient Pseudohypoaldosteronism due to Urinary Tract Infection in Infancy: A Report of 4 Cases. *Int J Pediatr Endocrinol*, 2009. 2009: 195728.  
<https://www.ncbi.nlm.nih.gov/pubmed/19946403>
369. Tutunculer, F., *et al.* Transient Pseudohypoaldosteronism in an infant with urinary tract anomaly. *Pediatr Int*, 2004. 46: 618.  
<https://www.ncbi.nlm.nih.gov/pubmed/15491397>
370. Contopoulos-Ioannidis, D.G., *et al.* Extended-interval aminoglycoside administration for children: a meta-analysis. *Pediatrics*, 2004. 114: e111.  
<https://www.ncbi.nlm.nih.gov/pubmed/15231982>
371. Hodson, E.M., *et al.* Antibiotics for acute pyelonephritis in children. *Cochrane Database Syst Rev*, 2007: CD003772.  
<https://www.ncbi.nlm.nih.gov/pubmed/17943796>
372. Dore-Bergeron, M.J., *et al.* Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. *Pediatrics*, 2009. 124: 16.  
<https://www.ncbi.nlm.nih.gov/pubmed/19564278>
373. Gauthier, M., *et al.* Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. *Pediatrics*, 2004. 114: e469.  
<https://www.ncbi.nlm.nih.gov/pubmed/15466073>
374. Karavanaki, K.A., *et al.* Delayed treatment of the first febrile urinary tract infection in early childhood increased the risk of renal scarring. *Acta Paediatr*, 2017. 106: 149.  
<https://www.ncbi.nlm.nih.gov/pubmed/27748543>
375. Shaikh, N., *et al.* Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring. *JAMA Pediatr*, 2016. 170: 848.  
<https://www.ncbi.nlm.nih.gov/pubmed/27455161>
376. Bouissou, F., *et al.* Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. *Pediatrics*, 2008. 121: e553.  
<https://www.ncbi.nlm.nih.gov/pubmed/18267977>
377. Craig, J.C., *et al.* Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med*, 2009. 361: 1748.  
<https://www.ncbi.nlm.nih.gov/pubmed/19864673>

378. Hoberman, A., *et al.* Oral versus initial intravenous therapy for urinary tract infections in young febrile children. *Pediatrics*, 1999. 104: 79.  
<https://www.ncbi.nlm.nih.gov/pubmed/10390264>
379. Neuhaus, T.J., *et al.* Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. *Eur J Pediatr*, 2008. 167: 1037.  
<https://www.ncbi.nlm.nih.gov/pubmed/18074149>
380. Salomonsson, P., *et al.* Best oral empirical treatment for pyelonephritis in children: Do we need to differentiate between age and gender? *Infect Dis (Lond)*, 2016. 48: 721.  
<https://www.ncbi.nlm.nih.gov/pubmed/27300266>
381. Mak, R.H., *et al.* Are oral antibiotics alone efficacious for the treatment of a first episode of acute pyelonephritis in children? *Nat Clin Pract Nephrol*, 2008. 4: 10.  
<https://www.ncbi.nlm.nih.gov/pubmed/17971799>
382. Klar, A., *et al.* Focal bacterial nephritis (lobar nephronia) in children. *J Pediatr*, 1996. 128: 850.  
<https://www.ncbi.nlm.nih.gov/pubmed/8648547>
383. Cheng, C.H., *et al.* Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. *Pediatrics*, 2006. 117: e84.  
<https://www.ncbi.nlm.nih.gov/pubmed/16326693>
384. Ramos, N.L., *et al.* Characterisation of uropathogenic *Escherichia coli* from children with urinary tract infection in different countries. *Eur J Clin Microbiol Infect Dis*, 2011. 30: 1587.  
<https://www.ncbi.nlm.nih.gov/pubmed/21509475>
385. Kizilca, O., *et al.* Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. *Pediatr Int*, 2012. 54: 858.  
<https://www.ncbi.nlm.nih.gov/pubmed/22882781>
386. Tratselas, A., *et al.* Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. *Pediatr Infect Dis J*, 2011. 30: 707.  
<https://www.ncbi.nlm.nih.gov/pubmed/21248655>
387. Naber, K.G., *et al.*, EAU/International Consultation on Urological Infections 2010, European Association of Urology: The Netherlands.
388. Garin, E.H., *et al.* Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. *Pediatrics*, 2006. 117: 626.  
<https://www.ncbi.nlm.nih.gov/pubmed/16510640>
389. Montini, G., *et al.* Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. *Pediatrics*, 2008. 122: 1064.  
<https://www.ncbi.nlm.nih.gov/pubmed/18977988>
390. Pennesi, M., *et al.* Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. *Pediatrics*, 2008. 121: e1489.  
<https://www.ncbi.nlm.nih.gov/pubmed/18490378>
391. Roussey-Kesler, G., *et al.* Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. *J Urol*, 2008. 179: 674.  
<https://www.ncbi.nlm.nih.gov/pubmed/18082208>
392. Hari, P., *et al.* Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med*, 2014. 371: 1071.  
<https://www.ncbi.nlm.nih.gov/pubmed/25207775>
393. Wang, H.H., *et al.* Efficacy of antibiotic prophylaxis in children with vesicoureteral reflux: systematic review and meta-analysis. *J Urol*, 2015. 193: 963.  
<https://www.ncbi.nlm.nih.gov/pubmed/25196653>
394. Afshar, K., *et al.* Cranberry juice for the prevention of pediatric urinary tract infection: a randomized controlled trial. *J Urol*, 2012. 188: 1584.  
<https://www.ncbi.nlm.nih.gov/pubmed/22910239>
395. Lee, S.J., *et al.* Probiotics prophylaxis in infants with primary vesicoureteral reflux. *Pediatr Nephrol*, 2015. 30: 609.  
<https://www.ncbi.nlm.nih.gov/pubmed/25354903>
396. Salo, J., *et al.* Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized placebo-controlled trial. *Clin Infect Dis*, 2012. 54: 340.  
<https://www.ncbi.nlm.nih.gov/pubmed/22100577>
397. Schwenger, E.M., *et al.* Probiotics for preventing urinary tract infections in adults and children. *Cochrane Database Syst Rev*, 2015: CD008772.  
<https://www.ncbi.nlm.nih.gov/pubmed/26695595>

398. Kotoula, A., *et al.* Comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection. *Urology*, 2009. 73: 782.  
<https://www.ncbi.nlm.nih.gov/pubmed/19152962>
399. Austin, P.F., *et al.* The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. *Neurourol Urodyn*, 2016. 35: 471.  
<https://www.ncbi.nlm.nih.gov/pubmed/25772695>
400. Bakker, E., *et al.* Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. *Scand J Urol Nephrol*, 2002. 36: 354.  
<https://www.ncbi.nlm.nih.gov/pubmed/12487740>
401. Hellstrom, A.L., *et al.* Micturition habits and incontinence in 7-year-old Swedish school entrants. *Eur J Pediatr*, 1990. 149: 434.  
<https://www.ncbi.nlm.nih.gov/pubmed/2332015>
402. Soderstrom, U., *et al.* Urinary and faecal incontinence: a population-based study. *Acta Paediatr*, 2004. 93: 386.  
<https://www.ncbi.nlm.nih.gov/pubmed/15124844>
403. Sureshkumar, P., *et al.* A population based study of 2,856 school-age children with urinary incontinence. *J Urol*, 2009. 181: 808.  
<https://www.ncbi.nlm.nih.gov/pubmed/19110268>
404. Bloom, D.A., *et al.* Toilet habits and continence in children: an opportunity sampling in search of normal parameters. *J Urol*, 1993. 149: 1087.  
<https://www.ncbi.nlm.nih.gov/pubmed/8483218>
405. Bower, W.F., *et al.* The epidemiology of childhood enuresis in Australia. *Br J Urol*, 1996. 78: 602.  
<https://www.ncbi.nlm.nih.gov/pubmed/8944518>
406. Mattsson, S. Urinary incontinence and nocturia in healthy schoolchildren. *Acta Paediatr*, 1994. 83: 950.  
<https://www.ncbi.nlm.nih.gov/pubmed/7819693>
407. Sureshkumar, P., *et al.* Daytime urinary incontinence in primary school children: a population-based survey. *J Pediatr*, 2000. 137: 814.  
<https://www.ncbi.nlm.nih.gov/pubmed/11113838>
408. Vaz, G.T., *et al.* Prevalence of lower urinary tract symptoms in school-age children. *Pediatr Nephrol*, 2012. 27: 597.  
<https://www.ncbi.nlm.nih.gov/pubmed/21969094>
409. Borch, L., *et al.* Bladder and bowel dysfunction and the resolution of urinary incontinence with successful management of bowel symptoms in children. *Acta Paediatr*, 2013. 102: e215.  
<https://www.ncbi.nlm.nih.gov/pubmed/23368903>
410. Veiga, M.L., *et al.* Constipation in children with isolated overactive bladders. *J Pediatr Urol*, 2013. 9: 945.  
<https://www.ncbi.nlm.nih.gov/pubmed/23462384>
411. Franco, I. Overactive bladder in children. Part 1: Pathophysiology. *J Urol*, 2007. 178: 761.  
<https://www.ncbi.nlm.nih.gov/pubmed/17631323>
412. Niemczyk, J., *et al.* Incontinence in children with treated attention-deficit/hyperactivity disorder. *J Pediatr Urol*, 2015. 11: 141.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25863677>
413. Chang, S.J., *et al.* Treatment of daytime urinary incontinence: A standardization document from the International Children's Continence Society. *Neurourol Urodyn*, 2015.  
<https://www.ncbi.nlm.nih.gov/pubmed/24980793>
414. Hoebeke, P., *et al.* Diagnostic evaluation of children with daytime incontinence. *J Urol*, 2010. 183: 699.  
<https://www.ncbi.nlm.nih.gov/pubmed/26473630>
415. Hjalmas, K., *et al.* Lower urinary tract dysfunction and urodynamics in children. *Eur Urol*, 2000. 38: 655.  
<https://www.ncbi.nlm.nih.gov/pubmed/11096254>
416. Chen, J.J., *et al.* Infant vesicoureteral reflux: a comparison between patients presenting with a prenatal diagnosis and those presenting with a urinary tract infection. *Urology*, 2003. 61: 442.  
<https://www.ncbi.nlm.nih.gov/pubmed/12597964>
417. Bauer, S.B., *et al.* International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children. *Neurourol Urodyn*, 2015. 34: 640.  
<https://www.ncbi.nlm.nih.gov/pubmed/25998310>

418. Parekh, D.J., *et al.* The use of radiography, urodynamic studies and cystoscopy in the evaluation of voiding dysfunction. *J Urol*, 2001. 165: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/11125409>
419. Pfister, C., *et al.* The usefulness of a minimal urodynamic evaluation and pelvic floor biofeedback in children with chronic voiding dysfunction. *BJU Int*, 1999. 84: 1054.  
<https://www.ncbi.nlm.nih.gov/pubmed/10571635>
420. Schewe, J., *et al.* Voiding dysfunction in children: role of urodynamic studies. *Urol Int*, 2002. 69: 297.  
<https://www.ncbi.nlm.nih.gov/pubmed/12444287>
421. Akbal, C., *et al.* Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. *J Urol*, 2005. 173: 969.  
<https://www.ncbi.nlm.nih.gov/pubmed/15711352>
422. Farhat, W., *et al.* The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. *J Urol*, 2000. 164: 1011.  
<https://www.ncbi.nlm.nih.gov/pubmed/10958730>
423. Burgers, R.E., *et al.* Management of functional constipation in children with lower urinary tract symptoms: report from the Standardization Committee of the International Children's Continence Society. *J Urol*, 2013. 190: 29.  
<https://www.ncbi.nlm.nih.gov/pubmed/23313210>
424. Chang, S.J., *et al.* Constipation is associated with incomplete bladder emptying in healthy children. *Neurourol Urodyn*, 2012. 31: 105.  
<https://www.ncbi.nlm.nih.gov/pubmed/22038844>
425. Neveus, T., *et al.* The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. *J Urol*, 2006. 176: 314.  
<https://www.ncbi.nlm.nih.gov/pubmed/16753432>
426. Yang, S.S., *et al.* Home uroflowmetry for the evaluation of boys with urinary incontinence. *J Urol*, 2003. 169: 1505.  
<https://www.ncbi.nlm.nih.gov/pubmed/12629404>
427. van Gool, J.D., *et al.* Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. *Neurourol Urodyn*, 2014. 33: 482.  
<https://www.ncbi.nlm.nih.gov/pubmed/23775924>
428. Campos, R.M., *et al.* Comparative, prospective, and randomized study between urotherapy and the pharmacological treatment of children with urinary incontinence. *Einstein (Sao Paulo)*, 2013. 11: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/23843062>
429. Barroso, U., Jr., *et al.* Electrical stimulation for lower urinary tract dysfunction in children: a systematic review of the literature. *Neurourol Urodyn*, 2011. 30: 1429.  
<https://www.ncbi.nlm.nih.gov/pubmed/21717502>
430. Bower, W.F., *et al.* A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children. *Neurourol Urodyn*, 2004. 23: 63.  
<https://www.ncbi.nlm.nih.gov/pubmed/14694460>
431. De Paepe, H., *et al.* Pelvic-floor therapy in girls with recurrent urinary tract infections and dysfunctional voiding. *Br J Urol*, 1998. 81 Suppl 3: 109.  
<https://www.ncbi.nlm.nih.gov/pubmed/9634033>
432. Hellstrom, A.L. Urotherapy in children with dysfunctional bladder. *Scand J Urol Nephrol Suppl*, 1992. 141: 106.  
<https://www.ncbi.nlm.nih.gov/pubmed/1609245>
433. Lordelo, P., *et al.* Prospective study of transcutaneous parasacral electrical stimulation for overactive bladder in children: long-term results. *J Urol*, 2009. 182: 2900.  
<https://www.ncbi.nlm.nih.gov/pubmed/19846164>
434. Vijverberg, M.A., *et al.* Bladder rehabilitation, the effect of a cognitive training programme on urge incontinence. *Eur Urol*, 1997. 31: 68.  
<https://www.ncbi.nlm.nih.gov/pubmed/9032538>
435. Desantis, D.J., *et al.* Effectiveness of biofeedback for dysfunctional elimination syndrome in pediatrics: a systematic review. *J Pediatr Urol*, 2011. 7: 342.  
<https://www.ncbi.nlm.nih.gov/pubmed/21527216>
436. Kajbafzadeh, A.M., *et al.* Transcutaneous interferential electrical stimulation for the management of non-neuropathic underactive bladder in children: a randomised clinical trial. *BJU Int*, 2016. 117: 793.  
<https://www.ncbi.nlm.nih.gov/pubmed/26086897>

437. Ladi-Seyedian, S., *et al.* Management of non-neuropathic underactive bladder in children with voiding dysfunction by animated biofeedback: a randomized clinical trial. *Urology*, 2015. 85: 205.  
<https://www.ncbi.nlm.nih.gov/pubmed/25444633>
438. Featherstone, N., *et al.* Ephedrine hydrochloride: novel use in the management of resistant non-neurogenic daytime urinary incontinence in children. *J Pediatr Urol*, 2013. 9: 915.  
<https://www.ncbi.nlm.nih.gov/pubmed/23332206>
439. Nijman, R.J., *et al.* Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. *J Urol*, 2005. 173: 1334.  
<https://www.ncbi.nlm.nih.gov/pubmed/15758796>
440. Marschall-Kehrel, D., *et al.* Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. *Eur Urol*, 2009. 55: 729.  
<https://www.ncbi.nlm.nih.gov/pubmed/18502028>
441. Newgreen, D., *et al.* Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. *J Urol*, 2017. 198: 928.  
<https://www.ncbi.nlm.nih.gov/pubmed/28506854>
442. Kramer, S.A., *et al.* Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. *J Urol*, 2005. 173: 2121.  
<https://www.ncbi.nlm.nih.gov/pubmed/15879863>
443. Hoebeke, P., *et al.* The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. *J Urol*, 2006. 176: 328.  
<https://www.ncbi.nlm.nih.gov/pubmed/16753434>
444. Fernandez, N., *et al.* Neurostimulation Therapy for Non-neurogenic Overactive Bladder in Children: A Meta-analysis. *Urology*, 2017. 110: 201.  
<https://www.ncbi.nlm.nih.gov/pubmed/28823638>
445. Groen, L.A., *et al.* Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience. *J Urol*, 2012. 188: 1313.  
<https://www.ncbi.nlm.nih.gov/pubmed/22902022>
446. Beksac, A.T., *et al.* Postvoidal residual urine is the most significant non-invasive diagnostic test to predict the treatment outcome in children with non-neurogenic lower urinary tract dysfunction. *J Pediatr Urol*, 2016. 12: 215.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/27233211>
447. Bower, W.F., *et al.* The transition of young adults with lifelong urological needs from pediatric to adult services: An international children's continence society position statement. *Neurourol Urodyn*, 2017. 36: 811.  
<https://www.ncbi.nlm.nih.gov/pubmed/27177245>
448. Lackgren, G., *et al.* Nocturnal enuresis: a suggestion for a European treatment strategy. *Acta Paediatr*, 1999. 88: 679.  
<https://www.ncbi.nlm.nih.gov/pubmed/10419258>
449. Neveus, T., *et al.* Enuresis--background and treatment. *Scand J Urol Nephrol Suppl*, 2000: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/11196246>
450. Negoro, H., *et al.* Chronobiology of micturition: putative role of the circadian clock. *J Urol*, 2013. 190: 843.  
<https://www.ncbi.nlm.nih.gov/pubmed/23429068>
451. Hjalmas, K., *et al.* Nocturnal enuresis: an international evidence based management strategy. *J Urol*, 2004. 171: 2545.  
<https://www.ncbi.nlm.nih.gov/pubmed/15118418>
452. Caldwell, P.H., *et al.* Simple behavioural interventions for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2013. 7: CD003637.  
<https://www.ncbi.nlm.nih.gov/pubmed/23881652>
453. Glazener, C.M., *et al.* Alarm interventions for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2005: CD002911.  
<https://www.ncbi.nlm.nih.gov/pubmed/15846643>
454. Dehoorne, J.L., *et al.* Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. *J Urol*, 2006. 176: 754.  
<https://www.ncbi.nlm.nih.gov/pubmed/16813936>
455. Glazener, C.M., *et al.* Desmopressin for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2002, 3: CD002112.  
<https://www.ncbi.nlm.nih.gov/pubmed/12137645>



456. Gokce, M.I., *et al.* Does structured withdrawal of desmopressin improve relapse rates in patients with monosymptomatic enuresis? *J Urol*, 2014. 192: 530.  
<https://www.ncbi.nlm.nih.gov/pubmed/24518770>
457. Glazener, C.M., *et al.* Tricyclic and related drugs for nocturnal enuresis in children. *Cochrane Database Syst Rev*, 2003: CD002117.  
<https://www.ncbi.nlm.nih.gov/pubmed/12917922>
458. Snow-Lisy, D.C., *et al.* Update on Urological Management of Spina Bifida from Prenatal Diagnosis to Adulthood. *J Urol*, 2015. 194: 288.  
<https://www.ncbi.nlm.nih.gov/pubmed/25839383>
459. Lee, B., *et al.* British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. *J Pediatr Urol*, 2016. 12: 76.  
<https://www.ncbi.nlm.nih.gov/pubmed/26946946>
460. Kessler, T.M., *et al.* Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. *Neurourol Urodyn*, 2006. 25: 758.  
<https://www.ncbi.nlm.nih.gov/pubmed/16986135>
461. Rendeli, C., *et al.* Latex sensitisation and allergy in children with myelomeningocele. *Childs Nerv Syst*, 2005.  
<https://www.ncbi.nlm.nih.gov/pubmed/15703967>
462. Bauer, S.B. Neurogenic bladder: Etiology and assessment. *Pediatr Nephrol*, 2008. 23: 541.  
<https://www.ncbi.nlm.nih.gov/pubmed/18270749>
463. Tarcan, T., *et al.* Long-term followup of newborns with myelodysplasia and normal urodynamic findings: Is followup necessary? *J Urol*, 2001. 165: 564.  
<https://www.ncbi.nlm.nih.gov/pubmed/11176436>
464. McGuire, E.J., *et al.* Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia: a followup study. *J Urol*, 1983. 129: 823.  
<https://www.ncbi.nlm.nih.gov/pubmed/6842712>
465. Hopps, C.V., *et al.* Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. *J Urol*, 2003. 169: 305.  
<https://www.ncbi.nlm.nih.gov/pubmed/12478177>
466. Bauer, S. Clean intermittent catheterization of infants with myelodysplasia - the argument for early assessment and treatment of infants with spina bifida. *Dialog Ped Urol*, 2000. 23: 2. [No abstract available].
467. Sillen, U., *et al.* Development of the urodynamic pattern in infants with myelomeningocele. *Br J Urol*, 1996. 78: 596.  
<https://www.ncbi.nlm.nih.gov/pubmed/8944517>
468. Thorup, J., *et al.* Urological outcome after myelomeningocele: 20 years of follow-up. *BJU Int*, 2011. 107: 994.  
<https://www.ncbi.nlm.nih.gov/pubmed/20860652>
469. Veenboer, P.W., *et al.* Upper and Lower Urinary Tract Outcomes in Adult Myelomeningocele Patients: A Systematic Review. *PLoS ONE*, 2012. 7: e48399.  
<https://www.ncbi.nlm.nih.gov/pubmed/23119003>
470. Lloyd, J.C., *et al.* Reviewing definitions of urinary continence in the contemporary spina bifida literature: A call for clarity. *J Pediatr Urol*, 2013. 9: 567.  
<https://www.ncbi.nlm.nih.gov/pubmed/23507290>
471. Khoshnood, B., *et al.* Long term trends in prevalence of neural tube defects in Europe: population based study. *BMJ*, 2015. 351: h5949.  
<https://www.ncbi.nlm.nih.gov/pubmed/26601850>
472. Adzick, N.S., *et al.* A randomized trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med*, 2011. 364: 993.  
<https://www.ncbi.nlm.nih.gov/pubmed/21306277>
473. Brock, J.W., 3rd, *et al.* Bladder Function After Fetal Surgery for Myelomeningocele. *Pediatrics*, 2015. 136: e906.  
<https://www.ncbi.nlm.nih.gov/pubmed/26416930>
474. Torre, M., *et al.* Long-term urologic outcome in patients with caudal regression syndrome, compared with meningomyelocele and spinal cord lipoma. *J Pediatr Surg*, 2008. 43: 530.  
<https://www.ncbi.nlm.nih.gov/pubmed/18358295>
475. Maerzheuser, S., *et al.* German network for congenital uro-rectal malformations: first evaluation and interpretation of postoperative urological complications in anorectal malformations. *Pediatr Surg Int*, 2011. 27: 1085.  
<https://www.ncbi.nlm.nih.gov/pubmed/21792651>

476. Hinman, F., *et al.* Vesical and Ureteral Damage from Voiding Dysfunction in Boys Without Neurologic or Obstructive Disease. *J Urol*, 2017. 197: S127.  
<https://www.ncbi.nlm.nih.gov/pubmed/28012756>
477. Ochoa, B. Can a congenital dysfunctional bladder be diagnosed from a smile? The Ochoa syndrome updated. *Pediatr Nephrol*, 2004. 19: 6.  
<https://www.ncbi.nlm.nih.gov/pubmed/14648341>
478. Drzewiecki, B.A., *et al.* Urodynamic testing in children: Indications, technique, interpretation and significance. *J Urol*, 2011. 186: 1190.  
<https://www.ncbi.nlm.nih.gov/pubmed/21849190>
479. Bauer, S.B., *et al.* Predictive value of urodynamic evaluation in newborns with myelodysplasia. *Jama*, 1984. 252: 650.  
<https://www.ncbi.nlm.nih.gov/pubmed/6737668>
480. Madersbacher, H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. *Paraplegia*, 1990. 28: 217.  
<https://www.ncbi.nlm.nih.gov/pubmed/2235029>
481. Wide, P., *et al.* Renal preservation in children with neurogenic bladder-sphincter dysfunction followed in a national program. *J Pediatr Urol*, 2012. 8: 187.  
<https://www.ncbi.nlm.nih.gov/pubmed/21411372>
482. Stein, R., *et al.* Diagnostik und Therapie der neurogenen Blasenfunktionsstörungen bei Patienten mit Meningomyelocele. S2k Leitlinie AWMF Register 043/047. 2013.  
[http://spina-hydro.ch/wp-content/uploads/2015/09/ASBH\\_KG\\_2014\\_Stein\\_Leitlinien\\_Urologie.pdf](http://spina-hydro.ch/wp-content/uploads/2015/09/ASBH_KG_2014_Stein_Leitlinien_Urologie.pdf)
483. Routh, J.C., *et al.* Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida. *J Urol*, 2016. 196: 1728.  
<https://www.ncbi.nlm.nih.gov/pubmed/27475969>
484. Fox, J.A., *et al.* Cystatin C as a marker of early renal insufficiency in children with congenital neuropathic bladder. *J Urol*, 2014. 191: 1602.  
<https://www.ncbi.nlm.nih.gov/pubmed/24679869>
485. Dangle, P.P., *et al.* Cystatin C-calculated Glomerular Filtration Rate-A Marker of Early Renal Dysfunction in Patients With Neuropathic Bladder. *Urology*, 2017. 100: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/27542858>
486. Fernbach, S.K., *et al.* Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. *Pediatr Radiol*, 1993. 23: 478.  
<https://www.ncbi.nlm.nih.gov/pubmed/8255658>
487. Kim, W.J., *et al.* Can Bladder Wall Thickness Predict Videourodynamic Findings in Children with Spina Bifida? *J Urol*, 2015.  
<https://www.ncbi.nlm.nih.gov/pubmed/25776909>
488. Bauer, S.B., *et al.* International Children's Continence Society's recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. *Neurourol Urodyn*, 2012. 31: 610.  
<https://www.ncbi.nlm.nih.gov/pubmed/22532312>
489. Almodhen, F., *et al.* Postpubertal Urodynamic and Upper Urinary Tract Changes in Children With Conservatively Treated Myelomeningocele. *J Urol*, 2007. 178: 1479.  
<https://www.ncbi.nlm.nih.gov/pubmed/17706702>
490. Foon, R., *et al.* Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. *Cochrane Database Syst Rev*, 2012. 10: CD008224.  
<https://www.ncbi.nlm.nih.gov/pubmed/23076941>
491. Shekarriz, B., *et al.* Lack of morbidity from urodynamic studies in children with asymptomatic bacteriuria. *Urology*, 1999. 54: 359.  
<https://www.ncbi.nlm.nih.gov/pubmed/10443739>
492. Aoki, H., *et al.* [Evaluation of neurogenic bladder in patients with spinal cord injury using a CMG. EMG study and CMG.UFM.EMG study]. *Hinyokika Kiyo*, 1985. 31: 937.  
<https://www.ncbi.nlm.nih.gov/pubmed/4061211>
493. Bradley, C.S., *et al.* Urodynamic evaluation of the bladder and pelvic floor. *Gastroenterol Clin North Am*, 2008. 37: 539.  
<https://www.ncbi.nlm.nih.gov/pubmed/18793995>
494. Casado, J.S., *et al.* [Urodynamic assessment of the voiding phase in childhood]. *Arch Esp Urol*, 2002. 55: 177.  
<https://www.ncbi.nlm.nih.gov/pubmed/12014050>

495. Wen, J.G., *et al.* Cystometry techniques in female infants and children. *Int Urogynecol J Pelvic Floor Dysfunct*, 2000. 11: 103.  
<https://www.ncbi.nlm.nih.gov/pubmed/10805268>
496. Zermann, D.H., *et al.* Diagnostic value of natural fill cystometry in neurogenic bladder in children. *Eur Urol*, 1997. 32: 223.  
<https://www.ncbi.nlm.nih.gov/pubmed/9286658>
497. Jorgensen, B., *et al.* Natural Fill Urodynamics and Conventional Cystometrogram in Infants With Neurogenic Bladder. *J Urol*, 2009. 181: 1862.  
<https://www.ncbi.nlm.nih.gov/pubmed/19233391>
498. Shiroyanagi, Y., *et al.* The Significance of  $<sup>99m</sup>$ Tc-Dimercapto-Succinic Acid Renal Scan in Children With Spina Bifida During Long-Term Followup. *J Urol*, 2009. 181: 2262.  
<https://www.ncbi.nlm.nih.gov/pubmed/19296988>
499. Veenboer, P.W., *et al.* Diagnostic accuracy of Tc-99m DMSA scintigraphy and renal ultrasonography for detecting renal scarring and relative function in patients with spinal dysraphism. *Neurourol Urodyn*, 2015. 34: 513.  
<https://www.ncbi.nlm.nih.gov/pubmed/24706504>
500. Leonardo, C.R., *et al.* Risk factors for renal scarring in children and adolescents with lower urinary tract dysfunction. *Pediatr Nephrol*, 2007. 22: 1891.  
<https://www.ncbi.nlm.nih.gov/pubmed/17874252>
501. Jorgensen, B., *et al.* Long-term follow-up in spinal dysraphism: Outcome of renal function and urinary and faecal continence. *Scan J Urol Nephrol*, 2010. 44: 95.  
<https://www.ncbi.nlm.nih.gov/pubmed/20187759>
502. Olesen, J.D., *et al.* The association between urinary continence and quality of life in paediatric patients with spina bifida and tethered cord. *Paediatrics and Child Health (Canada)*, 2013. 18: e32.  
<https://www.ncbi.nlm.nih.gov/pubmed/24421717>
503. Araujo, E.J., *et al.* Outcomes of infants followed-up at least 12 months after fetal open and endoscopic surgery for meningomyelocele: a systematic review and meta-analysis. *J Evid Based Med*, 2016.  
<https://www.ncbi.nlm.nih.gov/pubmed/27305320>
504. Leal da Cruz, M., *et al.* A 4-year prospective urological assessment of in utero Myelomeningocele repair: Does gestational age at birth play a role at later neurogenic bladder pattern? *J Urol*, 2016. 14: 14.  
<https://www.ncbi.nlm.nih.gov/pubmed/27988193>
505. Carr, M.C. Urological results after fetal myelomeningocele repair in pre-MOMS trial patients at the children's hospital of Philadelphia. *Fetal Diagn Ther*, 2015. 37: 211.  
<https://www.ncbi.nlm.nih.gov/pubmed/25012042>
506. Danzer, E., *et al.* Long-term neurofunctional outcome, executive functioning, and behavioral adaptive skills following fetal myelomeningocele surgery. *Am J Obstet Gynecol*, 2016. 214: 269.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26440692>
507. Horst, M., *et al.* Prenatal myelomeningocele repair: Do bladders better? *Neurourol Urodyn*, 2016.  
<https://www.ncbi.nlm.nih.gov/pubmed/27862250>
508. Macedo, A., *et al.* Urological evaluation of patients that had undergone in utero myelomeningocele closure: A prospective assessment at first presentation and early follow-up. Do their bladder benefit from it? *Neurourol Urodyn*, 2015. 34: 461.  
<https://www.ncbi.nlm.nih.gov/pubmed/24729268>
509. Kaefer, M., *et al.* Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. *J Urol*, 1999. 162: 1068.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458433>
510. Park, J.M. Early reduction of mechanical load of the bladder improves compliance: experimental and clinical observations. *Dialog Pediatr Urol*, 2000. 23: 6.  
<https://www.ncbi.nlm.nih.gov/pubmed/2740179>
511. Dik, P., *et al.* Early start to therapy preserves kidney function in spina bifida patients. *Eur Urol*, 2006. 49: 908.  
<https://www.ncbi.nlm.nih.gov/pubmed/16458416>
512. Joseph, D.B., *et al.* Clean, intermittent catheterization of infants with neurogenic bladder. *Pediatrics*, 1989. 84: 78.  
<http://pediatrics.aappublications.org/content/84/1/78.short>
513. Lindehall, B., *et al.* Long-term intermittent catheterization: the experience of teenagers and young adults with myelomeningocele. *J Urol*, 1994. 152: 187.  
<https://www.ncbi.nlm.nih.gov/pubmed/8201663>

514. Kiddoo, D., *et al.* Randomized Crossover Trial of Single Use Hydrophilic Coated vs Multiple Use Polyvinylchloride Catheters for Intermittent Catheterization to Determine Incidence of Urinary Infection. *J Urol*, 2015.  
<https://www.ncbi.nlm.nih.gov/pubmed/25584995>
515. Prieto, J., *et al.* Intermittent catheterisation for long-term bladder management [Systematic Review]. *Cochrane Database Syst Rev*, 2014. 9: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/25208303>
516. Moore, K.N., *et al.* Long-term bladder management by intermittent catheterisation in adults and children. *Cochrane Database Syst Rev*, 2007: CD006008.  
<https://www.ncbi.nlm.nih.gov/pubmed/17943874>
517. Lindehall, B., *et al.* Complications of clean intermittent catheterization in young females with myelomeningocele: 10 to 19 years of followup. *J Urol*, 2007. 178: 1053.  
<https://www.ncbi.nlm.nih.gov/pubmed/17632181>
518. Lucas, E.J., *et al.* Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization. *J Pediatr Urol*, 2016. 12: 172.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26951923>
519. Andersson, K.E., *et al.* Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. *Curr Opin Urol*, 2009. 19: 380.  
<https://www.ncbi.nlm.nih.gov/pubmed/19448545>
520. Rawashdeh, Y.F., *et al.* International children's continence society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. *NeuroUrol Urodyn*, 2012. 31: 615.  
<https://www.ncbi.nlm.nih.gov/pubmed/22532368>
521. Abrams, P., *et al.* Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol*, 2006. 148: 565.  
<https://www.ncbi.nlm.nih.gov/pubmed/16751797>
522. Hegde, S.S., *et al.* Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. *Life Sci*, 1999. 64: 419.  
<https://www.ncbi.nlm.nih.gov/pubmed/10069505>
523. Goessl, C., *et al.* Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. *Urology*, 1998. 51: 94.  
<https://www.ncbi.nlm.nih.gov/pubmed/9457296>
524. Lee, J.H., *et al.* Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: A retrospective, multicenter, observational study. *Korean J Urol*, 2014. 55: 828.  
<https://www.ncbi.nlm.nih.gov/pubmed/25512818>
525. Krause, P., *et al.* Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. *J Urol*, 2013. 190: 1791.  
<https://www.ncbi.nlm.nih.gov/pubmed/23669567>
526. Van Meel, T.D., *et al.* The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. *NeuroUrol Urodyn*, 2010. 29: 391.  
<https://www.ncbi.nlm.nih.gov/pubmed/19787712>
527. Humblet, M., *et al.* Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: With special reference to age-dependent parameters. *NeuroUrol Urodyn*, 2015. 34: 336.  
<https://www.ncbi.nlm.nih.gov/pubmed/24436114>
528. Guerra, L.A., *et al.* Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review. *J Urol*, 2008. 180: 1091.  
<https://www.ncbi.nlm.nih.gov/pubmed/18639290>
529. Cartwright, P.C., *et al.* Efficacy and Safety of Transdermal and Oral Oxybutynin in Children With Neurogenic Detrusor Overactivity. *J Urol*, 2009. 182: 1548.  
<https://www.ncbi.nlm.nih.gov/pubmed/19683731>
530. Gish, P., *et al.* Spectrum of Central Anticholinergic Adverse Effects Associated with Oxybutynin: Comparison of Pediatric and Adult Cases. *J Pediatr*, 2009. 155: 432.  
<https://www.ncbi.nlm.nih.gov/pubmed/19732583>
531. Todorova, A., *et al.* Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. *J Clin Pharmacol*, 2001. 41: 636.  
<https://www.ncbi.nlm.nih.gov/pubmed/11402632>

532. Giramonti, K.M., *et al.* The effects of anticholinergic drugs on attention span and short-term memory skills in children. *Neurourol Urodyn*, 2008. 27: 315.  
<https://www.ncbi.nlm.nih.gov/pubmed/17828786>
533. Veenboer, P.W., *et al.* Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: A case control study. *J Urol*, 2013. 190: 2228.  
<https://www.ncbi.nlm.nih.gov/pubmed/23792150>
534. Reddy, P.P., *et al.* Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. *J Pediatr Urol*, 2008. 4: 428.  
<https://www.ncbi.nlm.nih.gov/pubmed/19013412>
535. Mahanta, K., *et al.* Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. *J Pediatr Urol*, 2008. 4: 118.  
<https://www.ncbi.nlm.nih.gov/pubmed/18631906>
536. Bolduc, S., *et al.* Double anticholinergic therapy for refractory overactive bladder. *J Urol*, 2009. 182: 2033.  
<https://www.ncbi.nlm.nih.gov/pubmed/19695628>
537. Bolduc, S., *et al.* Prospective open label study of solifenacin for overactive bladder in children. *J Urol*, 2010. 184: 1668.  
<https://www.ncbi.nlm.nih.gov/pubmed/20728124>
538. Christoph, F., *et al.* Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. *Urol Int*, 2007. 79: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/17627170>
539. Nadeau, G., *et al.* Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. *Can Urol Ass J*, 2014. 8: 175.  
<https://www.ncbi.nlm.nih.gov/pubmed/25024786>
540. Schulte-Baukloh, H., *et al.* Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: Results of a prospective long-term study. *J Pediatr Urol*, 2012. 8: 386.  
<https://www.ncbi.nlm.nih.gov/pubmed/21907623>
541. Wu, H.Y., *et al.* Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment. *J Urol*, 1997. 157: 2295.  
<https://www.ncbi.nlm.nih.gov/pubmed/9146656>
542. Wollner, J., *et al.* Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. *Spinal Cord*, 2016. 54: 78.  
<https://www.ncbi.nlm.nih.gov/pubmed/26503222>
543. Austin, P.F., *et al.* Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. *J Urol*, 1999. 162: 1064.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458432>
544. Homsy, Y., *et al.* Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. *J Urol*, 2011. 186: 2033.  
<https://www.ncbi.nlm.nih.gov/pubmed/21944133>
545. Tsuda, Y., *et al.* Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. *Brit Clin Pharmacol*, 2010. 70: 88.  
<https://www.ncbi.nlm.nih.gov/pubmed/20642551>
546. Hascoet, J., *et al.* Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: A systematic review. [Review]. *Neurourol Urodyn*, 2016. 17: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/27187872>
547. Sager, C., *et al.* Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a. *Isrn Urology Print*, 2012. 2012: 763159.  
<https://www.ncbi.nlm.nih.gov/pubmed/22720170>
548. Tiryaki, S., *et al.* Botulinum injection is useless on fibrotic neuropathic bladders. *J Pediatr Urol*, 2015. 11: 27.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25448589>
549. Horst, M., *et al.* Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. *Neurourol Urodyn*, 2011. 30: 1546.  
<https://www.ncbi.nlm.nih.gov/pubmed/21674597>
550. Mascarenhas, F., *et al.* Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. *Neurourol Urodyn*, 2008. 27: 311.  
<https://www.ncbi.nlm.nih.gov/pubmed/17914742>

551. Altaweel, W., *et al.* Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. *J Urol*, 2006. 175: 1102.  
<https://www.ncbi.nlm.nih.gov/pubmed/16469632>
552. Leitner, L., *et al.* More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned. *Eur Urol*, 2016. 70: 522.  
<https://www.ncbi.nlm.nih.gov/pubmed/27106070>
553. Greer, T., *et al.* Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. *J Pediatr Urol*, 2016. 12: 94.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26472538>
554. Franco, I., *et al.* The Use of Botulinum Toxin A Injection for the Management of External Sphincter Dyssynergia in Neurologically Normal Children. *J Urol*, 2007. 178: 1775.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707430>
555. Mokhless, I., *et al.* Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. *J Urol*, 2006. 176: 1767.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945643>
556. Hagerty, J.A., *et al.* Intravesical Electrotherapy for Neurogenic Bladder Dysfunction: A 22-Year Experience. *J Urol*, 2007. 178: 1680.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707024>
557. Boone, T.B., *et al.* Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial. *J Urol*, 1992. 148: 550.  
<https://www.ncbi.nlm.nih.gov/pubmed/1640520>
558. Cheng, E.Y., *et al.* Bladder stimulation therapy improves bladder compliance: results from a multi-institutional trial. *J Urol*, 1996. 156: 761.  
<https://www.ncbi.nlm.nih.gov/pubmed/8683778>
559. Guys, J.M., *et al.* Sacral neuromodulation for neurogenic bladder dysfunction in children. *J Urol*, 2004. 172: 1673.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371787>
560. Lansen-Koch, S.M.P., *et al.* Sacral nerve modulation for defaecation and micturition disorders in patients with spina bifida. *Colorectal Disease*, 2012. 14: 508.  
<https://www.ncbi.nlm.nih.gov/pubmed/21689346>
561. Capitanucci, M.L., *et al.* Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. *J Urol*, 2009. 182: 2056.  
<https://www.ncbi.nlm.nih.gov/pubmed/19695611>
562. Xiao, C.G., *et al.* An artificial somatic-central nervous system-autonomic reflex pathway for controllable micturition after spinal cord injury: preliminary results in 15 patients. *J Urol*, 2003. 170: 1237.  
<https://www.ncbi.nlm.nih.gov/pubmed/14501733>
563. Tuite, G.F., *et al.* Urological Outcome of the Xiao Procedure in Children with Myelomeningocele and Lipomyelomeningocele Undergoing Spinal Cord Detethering. *J Urol*, 2016. 196: 1735.  
<https://www.ncbi.nlm.nih.gov/pubmed/27288694>
564. Bloom, D.A., *et al.* Urethral dilation improves bladder compliance in children with myelomeningocele and high leak point pressures. *J Urol*, 1990. 144: 430.  
<https://www.ncbi.nlm.nih.gov/pubmed/2374216>
565. Park, J.M., *et al.* External urethral sphincter dilation for the management of high risk myelomeningocele: 15-year experience. *J Urol*, 2001. 165: 2383.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371982>
566. Wan, J. The role of urethral dilation in managing pediatric neurogenic bladder dysfunction. *Curr Urol Rep*, 2009. 10: 153.  
<https://www.ncbi.nlm.nih.gov/pubmed/19239821>
567. Blocksom, B.H., Jr. Bladder pouch for prolonged tubeless cystostomy. *J Urol*, 1957. 78: 398.  
<https://www.ncbi.nlm.nih.gov/pubmed/13476506>
568. Lee, M.W., *et al.* Intractable high-pressure bladder in female infants with spina bifida: clinical characteristics and use of vesicostomy. *Urology*, 2005. 65: 568.  
<https://www.ncbi.nlm.nih.gov/pubmed/15780378>
569. Morrisroe, S.N., *et al.* Vesicostomy revisited: the best treatment for the hostile bladder in myelodysplastic children? *BJU Int*, 2005. 96: 397.  
<https://www.ncbi.nlm.nih.gov/pubmed/16042737>
570. Hutcheson, J.C., *et al.* The use of vesicostomy as permanent urinary diversion in the child with myelomeningocele. *J Urol*, 2001. 166: 2351.  
<https://www.ncbi.nlm.nih.gov/pubmed/11696783>

571. Mosiello, G., *et al.* Button Cystostomy: Is it really a Safe and Effective Therapeutic Option in Paediatric Patients with Neurogenic Bladder? *Urology*, 2016. 29: 29.  
<https://www.ncbi.nlm.nih.gov/pubmed/27693876>
572. Ausili, E., *et al.* Transanal irrigation in myelomeningocele children: an alternative, safe and valid approach for neurogenic constipation. *Spinal Cord*, 2010. 48: 560.  
<https://www.ncbi.nlm.nih.gov/pubmed/20084075>
573. Christensen, P., *et al.* Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. *Dis Colon Rectum*, 2009. 52: 286.  
<https://www.ncbi.nlm.nih.gov/pubmed/19279425>
574. Malone, P.S., *et al.* Preliminary report: the antegrade continence enema. *Lancet*, 1990. 336: 1217.  
<https://www.ncbi.nlm.nih.gov/pubmed/1978072>
575. Anselmo, C.B., *et al.* Left-colon antegrade enema (LACE): Long-term experience with the Macedo-Malone approach. *Neurourol Urodyn*, 2017. 36: 111.  
<https://www.ncbi.nlm.nih.gov/pubmed/26417710>
576. Siddiqui, A.A., *et al.* Long-term follow-up of patients after antegrade continence enema procedure. *J Pediatr Gastroenterol Nutr*, 2011. 52: 574.  
<https://www.ncbi.nlm.nih.gov/pubmed/21502828>
577. Zegers, B.S.H.J., *et al.* Urinary tract infections in children with spina bifida: An inventory of 41 European centers. *Pediatr Nephrol*, 2009. 24: 783.  
<https://www.ncbi.nlm.nih.gov/pubmed/19066975>
578. Hansson, S., *et al.* Untreated bacteriuria in asymptomatic girls with renal scarring. *Pediatrics*, 1989. 84: 964.  
<https://www.ncbi.nlm.nih.gov/pubmed/2587151>
579. Hansson, S., *et al.* Untreated asymptomatic bacteriuria in girls: I--Stability of urinary isolates. *BMJ*, 1989. 298: 853.  
<https://www.ncbi.nlm.nih.gov/pubmed/2497822>
580. Zegers, S.H., *et al.* The influence of antibiotic prophylaxis on bacterial resistance in urinary tract infections in children with spina bifida. *BMC Infect Dis*, 2017. 17: 63.  
<https://www.ncbi.nlm.nih.gov/pubmed/28081719>
581. Akil, I., *et al.* Do patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? *Turk J Med Sci*, 2016. 46: 1151.  
<https://www.ncbi.nlm.nih.gov/pubmed/27513418>
582. Mutlu, H., *et al.* Urinary tract infection prophylaxis in children with neurogenic bladder with cranberry capsules: randomized controlled trial. *Isrn Pediatrics Print*, 2012. 2012: 317280.  
<https://www.ncbi.nlm.nih.gov/pubmed/22811926>
583. Johnson, H.W., *et al.* A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization. *Pediatrics*, 1994. 93: 752.  
<https://www.ncbi.nlm.nih.gov/pubmed/8165073>
584. Schlager, T.A., *et al.* Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. *J Pediatr*, 1998. 132: 704.  
<https://www.ncbi.nlm.nih.gov/pubmed/9580774>
585. Schlager, T.A., *et al.* Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. *Pediatrics*, 2001. 108: E71.  
<https://www.ncbi.nlm.nih.gov/pubmed/11581479>
586. Kanaheswari, Y., *et al.* Urinary tract infection and bacteriuria in children performing clean intermittent catheterization with reused catheters. *Spinal Cord*, 2014. 25: 25.  
<https://www.ncbi.nlm.nih.gov/pubmed/25420498>
587. Defoor, W., *et al.* Safety of gentamicin bladder irrigations in complex urological cases. *J Urol*, 2006. 175: 1861.  
<https://www.ncbi.nlm.nih.gov/pubmed/16600780>
588. Wan, J., *et al.* Intravesical instillation of gentamicin sulfate: in vitro, rat, canine, and human studies. *Urology*, 1994. 43: 531.  
<https://www.ncbi.nlm.nih.gov/pubmed/8154077>
589. Misseri, R., *et al.* Reflux in cystoplasties. *Arch Esp Urol*, 2008. 61: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/18491737>
590. Soygur, T., *et al.* The need for ureteric re-implantation during augmentation cystoplasty: video-urodynamic evaluation. *BJU Int*, 2010. 105: 530.  
<https://www.ncbi.nlm.nih.gov/pubmed/19583716>

591. Helmy, T.E., *et al.* Vesicouretral reflux with neuropathic bladder: Studying the resolution rate after ileocystoplasty. *Urology*, 2013. 82: 425.  
<https://www.ncbi.nlm.nih.gov/pubmed/23639239>
592. Polackwich, A.S., *et al.* Long-term followup after endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid copolymer in patients with neurogenic bladder. *J Urol*, 2012. 188: 1511.  
<https://www.ncbi.nlm.nih.gov/pubmed/22910250>
593. Engel, J.D., *et al.* Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction. *J Urol*, 1997. 157: 2291.  
<https://www.ncbi.nlm.nih.gov/pubmed/9146655>
594. Verhoef, M., *et al.* Sex education, relationships, and sexuality in young adults with spina bifida. *Arch Phys Med Rehabil*, 2005. 86: 979.  
<https://www.ncbi.nlm.nih.gov/pubmed/15895345>
595. Elias, E.R., *et al.* Precocious puberty in girls with myelodysplasia. *Pediatrics*, 1994. 93: 521.  
<https://www.ncbi.nlm.nih.gov/pubmed/8115222>
596. Cardenas, D.D., *et al.* Sexual Functioning in Adolescents and Young Adults With Spina Bifida. *Archives of Physical Medicine and Rehabilitation*, 2008. 89: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/18164327>
597. Gatti, C., *et al.* Predictors of successful sexual partnering of adults with spina bifida. *J Urol*, 2009. 182: 1911.  
<https://www.ncbi.nlm.nih.gov/pubmed/19695634>
598. Lassmann, J., *et al.* Sexual function in adult patients with spina bifida and its impact on quality of life. *J Urol*, 2007. 178: 1611.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707040>
599. Palmer, J.S., *et al.* Erectile dysfunction in patients with spina bifida is a treatable condition. *J Urol*, 2000. 164: 958.  
<https://www.ncbi.nlm.nih.gov/pubmed/10958716>
600. Bong, G.W., *et al.* Sexual health in adult men with spina bifida. *ScientificWorldJournal*, 2007. 7: 1466.  
<https://www.ncbi.nlm.nih.gov/pubmed/17767363>
601. Overgoor, M.L.E., *et al.* Increased sexual health after restored genital sensation in male patients with spina bifida or a spinal cord injury: The TOMAX procedure. *J Urol*, 2013. 189: 626.  
<https://www.ncbi.nlm.nih.gov/pubmed/23079372>
602. Stein, R., *et al.* Bladder augmentation and urinary diversion in patients with neurogenic bladder: Surgical considerations. *J Pediatr Urol*, 2012. 8: 153.  
<https://www.ncbi.nlm.nih.gov/pubmed/22264521>
603. Castellan, M., *et al.* Complications after use of gastric segments for lower urinary tract reconstruction. *J Urol*, 2012. 187: 1823.  
<https://www.ncbi.nlm.nih.gov/pubmed/22425048>
604. Nguyen, D.H., *et al.* The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. *J. Urol.*, 1993. 150: 707  
<https://www.ncbi.nlm.nih.gov/pubmed/8326629>
605. Boissier, R., *et al.* What is the outcome of paediatric gastrocystoplasty when the patients reach adulthood? *BJU Int*, 2016. 118: 980.  
<https://www.ncbi.nlm.nih.gov/pubmed/27322857>
606. Bogaert, G.A., *et al.* The physiology of gastrocystoplasty: once a stomach, always a stomach. *J Urol*, 1995. 153: 1977.  
<https://www.ncbi.nlm.nih.gov/pubmed/7752376>
607. Herschorn, S., *et al.* Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. *Urology*, 1998. 52: 672.  
<https://www.ncbi.nlm.nih.gov/pubmed/9763092>
608. Medel, R., *et al.* Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia. *J Urol*, 2002. 168: 1849.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352374>
609. McNamara, E.R., *et al.* 30-Day morbidity after augmentation enterocystoplasty and appendicovesicostomy: A NSQIP pediatric analysis. *J Pediatr Urol*, 2015. 11: 209.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26049255>
610. Du, K., *et al.* Enterocystoplasty 30-day outcomes from National Surgical Quality Improvement Program Pediatric 2012. *J Pediatr Surg*, 2015. 50: 1535.  
<https://www.ncbi.nlm.nih.gov/pubmed/25957024>



611. Scales, C.D., Jr., *et al.* Evaluating outcomes of enterocystoplasty in patients with spina bifida: a review of the literature. *J Urol*, 2008. 180: 2323.  
<https://www.ncbi.nlm.nih.gov/pubmed/18930285>
612. Metcalfe, P.D., *et al.* Bladder augmentation: complications in the pediatric population. *Curr Urol Rep*, 2007. 8: 152.  
<https://www.ncbi.nlm.nih.gov/pubmed/17303021>
613. Schlomer, B.J., *et al.* Cumulative incidence of outcomes and urologic procedures after augmentation cystoplasty. *J Pediatr Urol*, 2014. 10: 1043.  
<https://www.ncbi.nlm.nih.gov/pubmed/24766857>
614. Roth, J., *et al.* Long-Term Sequela of Pediatric Bladder Reconstruction. *Curr Bladder Dysf Rep*, 2015. 10: 419.  
<https://link.springer.com/article/10.1007/s11884-015-0336-1>
615. Casperon, K.J., *et al.* Ventriculoperitoneal shunt infections after bladder surgery: is mechanical bowel preparation necessary? *J Urol*, 2011. 186: 1571.  
<https://www.ncbi.nlm.nih.gov/pubmed/21855924>
616. Stein, R., *et al.* Bladder augmentation and urinary diversion in patients with neurogenic bladder: non-surgical considerations. *J Pediatr Urol*, 2012. 8: 145.  
<https://www.ncbi.nlm.nih.gov/pubmed/21493159>
617. Biardeau, X., *et al.* Risk of malignancy after augmentation cystoplasty: A systematic review. *Neurourol Urodyn*, 2016. 35: 675.  
<https://www.ncbi.nlm.nih.gov/pubmed/25867054>
618. Higuchi, T.T., *et al.* Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. *J Urol*, 2010. 184: 2492.  
<https://www.ncbi.nlm.nih.gov/pubmed/20961577>
619. Husmann, D.A., *et al.* Long-term follow up of enteric bladder augmentations: The risk for malignancy. *J Pediatr Urol*, 2008. 4: 381.  
<https://www.ncbi.nlm.nih.gov/pubmed/18653384>
620. Higuchi, T.T., *et al.* Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. *J Urol*, 2011. 186: 1791.  
<https://www.ncbi.nlm.nih.gov/pubmed/21944100>
621. Kokorowski, P.J., *et al.* Screening for malignancy after augmentation cystoplasty in children with spina bifida: A decision analysis. *J Urol*, 2011. 186: 1437.  
<https://www.ncbi.nlm.nih.gov/pubmed/21855939>
622. Hamid, R., *et al.* Routine surveillance cystoscopy for patients with augmentation and substitution cystoplasty for benign urological conditions: is it necessary? *BJU Int*, 2009. 104: 392.  
<https://www.ncbi.nlm.nih.gov/pubmed/19239457>
623. Lopez Pereira, P., *et al.* Are urodynamic studies really needed during bladder augmentation follow-up? *J Pediatr Urol*, 2009. 5: 30.  
<https://www.ncbi.nlm.nih.gov/pubmed/18774747>
624. Eckstein, H.B., *et al.* Uretero-Cystoplastik. *Akt. Urol*, 1973. 4: 255. [No abstract available].
625. Youssif, M., *et al.* Augmentation ureterocystoplasty in boys with valve bladder syndrome. *J Pediatr Urol*, 2007. 3: 433.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947790>
626. Husmann, D.A., *et al.* Ureterocystoplasty: indications for a successful augmentation. *J Urol*, 2004. 171: 376.  
<https://www.ncbi.nlm.nih.gov/pubmed/14665935>
627. Marte, A., *et al.* A long-term follow-up of autoaugmentation in myelodysplastic children. *BJU Int*, 2002. 89: 928.  
<https://www.ncbi.nlm.nih.gov/pubmed/12010242>
628. Cartwright, P.C., *et al.* Bladder autoaugmentation: early clinical experience. *J Urol*, 1989. 142: 505.  
<https://www.ncbi.nlm.nih.gov/pubmed/2746767>
629. Chrzan, R., *et al.* Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders. *J Pediatr Urol*, 2013. 9: 193.  
<https://www.ncbi.nlm.nih.gov/pubmed/22364713>
630. Hansen, E.L., *et al.* Promising long-term outcome of bladder autoaugmentation in children with neurogenic bladder dysfunction. *J Urol*, 2013. 190: 1869.  
<https://www.ncbi.nlm.nih.gov/pubmed/23707450>
631. Cartwright, P.C. Bladder autoaugmentation (partial detrusor myectomy)--where does it stand after 2 decades? *J Urol*, 2013. 190: 1643.  
<https://www.ncbi.nlm.nih.gov/pubmed/23954194>

632. Dik, P., *et al.* Detrusorectomy for neuropathic bladder in patients with spinal dysraphism. *J Urol*, 2003. 170: 1351.  
<https://www.ncbi.nlm.nih.gov/pubmed/14501768>
633. Bandi, G., *et al.* Comparison of traditional enterocystoplasty and seromuscular colocolocystoplasty lined with urothelium. *J Pediatr Urol*, 2007. 3: 484.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947800>
634. Joseph, D.B., *et al.* Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: Phase II study in children and adolescents with spina bifida. *J Urol*, 2014. 191: 1389.  
<https://www.ncbi.nlm.nih.gov/pubmed/24184366>
635. Atala, A., *et al.* Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet*, 2006. 367: 1241.  
<https://www.ncbi.nlm.nih.gov/pubmed/16631879>
636. Austin, P.F., *et al.* Advantages of rectus fascial slings for urinary incontinence in children with neuropathic bladders. *J Urol*, 2001. 165: 2369.  
<https://www.ncbi.nlm.nih.gov/pubmed/11398778>
637. Guys, J.M., *et al.* Endoscopic treatment of urinary incontinence: long-term evaluation of the results. *J Urol*, 2001. 165: 2389.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371983>
638. Holmes, N.M., *et al.* Placement of artificial urinary sphincter in children and simultaneous gastrocystoplasty. *J Urol*, 2001. 165: 2366.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371944>
639. Kassouf, W., *et al.* Collagen injection for treatment of urinary incontinence in children. *J Urol*, 2001. 165: 1666.  
<https://www.ncbi.nlm.nih.gov/pubmed/11342951>
640. Kryger, J.V., *et al.* Long-term results of artificial urinary sphincters in children are independent of age at implantation. *J Urol*, 2001. 165: 2377.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371981>
641. Naglo, A.S. Continence training of children with neurogenic bladder and detrusor hyperactivity: effect of atropine. *Scand J Urol Nephrol*, 1982. 16: 211.  
<https://www.ncbi.nlm.nih.gov/pubmed/7163785>
642. Castellan, M., *et al.* Bladder neck sling for treatment of neurogenic incontinence in children with augmentation cystoplasty: long-term followup. *J Urol*, 2005. 173: 2128.  
<https://www.ncbi.nlm.nih.gov/pubmed/15879865>
643. Chrzan, R., *et al.* Sling suspension of the bladder neck for pediatric urinary incontinence. *J Pediatr Urol*, 2009. 5: 82.  
<https://www.ncbi.nlm.nih.gov/pubmed/18976960>
644. Pannek, J., *et al.* Clinical usefulness of the transobturator sub-urethral tape in the treatment of stress urinary incontinence in female patients with spinal cord lesion. *J Spinal Cord Med*, 2012. 35: 102.  
<https://www.ncbi.nlm.nih.gov/pubmed/22525323>
645. Groen, L.A., *et al.* The advance male sling as a minimally invasive treatment for intrinsic sphincter deficiency in patients with neurogenic bladder sphincter dysfunction: A pilot study. *Neurourol Urodyn*, 2012. 31: 1284.  
<https://www.ncbi.nlm.nih.gov/pubmed/22847896>
646. Scott, F.B., *et al.* Treatment of incontinence secondary to myelodysplasia by an implantable prosthetic urinary sphincter. *South Med J*, 1973. 66: 987.  
<https://www.ncbi.nlm.nih.gov/pubmed/4582131>
647. Catti, M., *et al.* Artificial Urinary Sphincter in Children-Voiding or Emptying? An Evaluation of Functional Results in 44 Patients. *J Urol*, 2008. 180: 690.  
<https://www.ncbi.nlm.nih.gov/pubmed/18554645>
648. Gonzalez, R., *et al.* Seromuscular colocolocystoplasty lined with urothelium: experience with 16 patients. *Urology*, 1995. 45: 124.  
<https://www.ncbi.nlm.nih.gov/pubmed/7817464>
649. Kryger, J.V., *et al.* The outcome of artificial urinary sphincter placement after a mean 15-year follow-up in a paediatric population. *BJU Int*, 1999. 83: 1026.  
<https://www.ncbi.nlm.nih.gov/pubmed/10368250>
650. Herndon, C.D., *et al.* The Indiana experience with artificial urinary sphincters in children and young adults. *J Urol*, 2003. 169: 650.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544336>

651. Simeoni, J., *et al.* Artificial urinary sphincter implantation for neurogenic bladder: a multi-institutional study in 107 children. *Br J Urol*, 1996. 78: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/8813930>
652. Kryger, J.V., *et al.* Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. *J Urol*, 2000. 163: 256.  
<https://www.ncbi.nlm.nih.gov/pubmed/10604371>
653. Grimsby, G.M., *et al.* Long-Term Outcomes of Bladder Neck Reconstruction without Augmentation Cystoplasty in Children. *J Urol*, 2016. 195: 155.  
<https://www.ncbi.nlm.nih.gov/pubmed/26173106>
654. Whittam, B., *et al.* Long-term fate of the bladder after isolated bladder neck procedure. *J Pediatr Urol*, 2014. 10: 886.  
<https://www.ncbi.nlm.nih.gov/pubmed/24517903>
655. Hayes, M.C., *et al.* The Pippi Salle urethral lengthening procedure; experience and outcome from three United Kingdom centres. *BJU Int*, 1999. 84: 701.  
<https://www.ncbi.nlm.nih.gov/pubmed/10510119>
656. Szymanski, K.M., *et al.* Long-term outcomes of the Kropp and Salle urethral lengthening bladder neck reconstruction procedures. *J Pediatr Urol*, 2016. 12: 403.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/27687531>
657. Churchill, B.M., *et al.* Improved continence in patients with neurogenic sphincteric incompetence with combination tubularized posterior urethroplasty and fascial wrap: The lengthening, narrowing and tightening procedure. *J Urol*, 2010. 184: 1763.  
<https://www.ncbi.nlm.nih.gov/pubmed/20728163>
658. Alova, I., *et al.* Long-term effects of endoscopic injection of dextranomer/hyaluronic acid based implants for treatment of urinary incontinence in children with neurogenic bladder. *J Urol*, 2012. 188: 1905.  
<https://www.ncbi.nlm.nih.gov/pubmed/22998918>
659. Guys, J.M., *et al.* Endoscopic injection with polydimethylsiloxane for the treatment of pediatric urinary incontinence in the neurogenic bladder: long-term results. *J Urol*, 2006. 175: 1106.  
<https://www.ncbi.nlm.nih.gov/pubmed/16469633>
660. De Vocht, T.F., *et al.* Long-Term Results of Bulking Agent Injection for Persistent Incontinence in Cases of Neurogenic Bladder Dysfunction. *J Urol*, 2010. 183: 719.  
<https://www.ncbi.nlm.nih.gov/pubmed/20022056>
661. Alova, I., *et al.* Outcome of continence procedures after failed endoscopic treatment with dextranomer-based implants (DEFLEX<sup><sup></sup>). *J Pediatr Urol*, 2012. 8: 40.  
<https://www.ncbi.nlm.nih.gov/pubmed/21277831></sup>
662. De Troyer, B., *et al.* A comparative study between continent diversion and bladder neck closure versus continent diversion and bladder neck reconstruction in children. *J Pediatr Urol*, 2011. 7: 209.  
<https://www.ncbi.nlm.nih.gov/pubmed/20488754>
663. Kavanagh, A., *et al.* Bladder neck closure in conjunction with enterocystoplasty and mitrofanoff diversion for complex incontinence: Closing the door for good. *J Urol*, 2012. 188: 1561.  
<https://www.ncbi.nlm.nih.gov/pubmed/22910244>
664. Shpall, A.I., *et al.* Bladder neck closure with lower urinary tract reconstruction: technique and long-term followup. *J Urol*, 2004. 172: 2296.  
<https://www.ncbi.nlm.nih.gov/pubmed/15538252>
665. Landau, E.H., *et al.* Bladder neck closure in children: a decade of followup. *J Urol*, 2009. 182: 1797.  
<https://www.ncbi.nlm.nih.gov/pubmed/19692069>
666. Deuker, M., *et al.* Long-term outcome after urinary diversion using the ileocecal segment in children and adolescents: Complications of the efferent segment. *J Pediatr Urol*, 2016. 12: 247.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/27282550>
667. Faure, A., *et al.* Bladder continent catheterizable conduit (the Mitrofanoff procedure): Long-term issues that should not be underestimated. *J Pediatr Surg*, 2016. 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/27707652>
668. Landau, E.H., *et al.* Superiority of the VQZ over the tubularized skin flap and the umbilicus for continent abdominal stoma in children. *J Urol*, 2008. 180: 1761.  
<https://www.ncbi.nlm.nih.gov/pubmed/18721990>
669. Stein, R., *et al.* Urinary diversion in children and adolescents with neurogenic bladder: the Mainz experience Part III: Colonic conduit. *Pediatr Nephrol*, 2005.  
<https://www.ncbi.nlm.nih.gov/pubmed/15864655>
670. Cass, A.S., *et al.* A 22-year followup of ileal conduits in children with a neurogenic bladder. *J Urol*, 1984. 132: 529.  
<https://www.ncbi.nlm.nih.gov/pubmed/6471190>

671. Dunn, M., *et al.* The long-term results of ileal conduit urinary diversion in children. *Br J Urol*, 1979. 51: 458.  
<https://www.ncbi.nlm.nih.gov/pubmed/534825>
672. Middleton, A.W., Jr., *et al.* Ileal conduits in children at the Massachusetts General Hospital from 1955 to 1970. *J Urol*, 1976. 115: 591.  
<https://www.ncbi.nlm.nih.gov/pubmed/1271557>
673. Mitchell, M.E., *et al.* Intestinocystoplasty and total bladder replacement in children and young adults: followup in 129 cases. *J Urol*, 1987. 138: 579.  
<https://www.ncbi.nlm.nih.gov/pubmed/3625861>
674. Shekarriz, B., *et al.* Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. *Urology*, 2000. 55: 123.  
<https://www.ncbi.nlm.nih.gov/pubmed/10654908>
675. Balachandra, B., *et al.* Adenocarcinoma arising in a gastrocystoplasty. *J Clin Pathol*, 2007. 60: 85.  
<https://www.ncbi.nlm.nih.gov/pubmed/17213351>
676. Castellan, M., *et al.* Tumor in bladder reservoir after gastrocystoplasty. *J Urol*, 2007. 178: 1771.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707009>
677. Soergel, T.M., *et al.* Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. *J Urol*, 2004. 172: 1649.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371782>
678. Sung, M.T., *et al.* Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. *Histopathology*, 2009. 55: 161.  
<https://www.ncbi.nlm.nih.gov/pubmed/19694823>
679. Vemulakonda, V.M., *et al.* Metastatic adenocarcinoma after augmentation gastrocystoplasty. *J Urol*, 2008. 179: 1094.  
<https://www.ncbi.nlm.nih.gov/pubmed/18206936>
680. Austin, J.C., *et al.* Patients With Spina Bifida and Bladder Cancer: Atypical Presentation, Advanced Stage and Poor Survival. *J Urol*, 2007. 178: 798.  
<https://www.ncbi.nlm.nih.gov/pubmed/17631349>
681. Sammer, U., *et al.* Do we need surveillance urethro-cystoscopy in patients with neurogenic lower urinary tract dysfunction? *PLoS ONE*, 2015. 10: e0140970.  
<https://www.ncbi.nlm.nih.gov/pubmed/26513149>
682. Lebowitz, R.L., *et al.* Neonatal hydronephrosis: 146 cases. *Radiol Clin North Am*, 1977. 15: 49.  
<https://www.ncbi.nlm.nih.gov/pubmed/139634>
683. Brown, T., *et al.* Neonatal hydronephrosis in the era of sonography. *AJR Am J Roentgenol*, 1987. 148: 959.  
<https://www.ncbi.nlm.nih.gov/pubmed/3034009>
684. Koff, S.A. Problematic ureteropelvic junction obstruction. *J Urol*, 1987. 138: 390.  
<https://www.ncbi.nlm.nih.gov/pubmed/3599261>
685. Gunn, T.R., *et al.* Antenatal diagnosis of urinary tract abnormalities by ultrasonography after 28 weeks' gestation: incidence and outcome. *Am J Obstet Gynecol*, 1995. 172: 479.  
<https://www.ncbi.nlm.nih.gov/pubmed/7856673>
686. Grignon, A., *et al.* Ureteropelvic junction stenosis: antenatal ultrasonographic diagnosis, postnatal investigation, and follow-up. *Radiology*, 1986. 160: 649.  
<https://www.ncbi.nlm.nih.gov/pubmed/3526403>
687. Flashner, S.C., *et al.*, Ureteropelvic junction, In: *Clinical Pediatric Urology*. 1976, WB Saunders: Philadelphia.
688. Thomas, D.F. Prenatally detected uropathy: epidemiological considerations. *Br J Urol*, 1998. 81 Suppl 2: 8.  
<https://www.ncbi.nlm.nih.gov/pubmed/9602790>
689. Ebel, K.D. Uroradiology in the fetus and newborn: diagnosis and follow-up of congenital obstruction of the urinary tract. *Pediatr Radiol*, 1998. 28: 630.  
<https://www.ncbi.nlm.nih.gov/pubmed/9716640>
690. O'Reilly, P., *et al.* Consensus on diuresis renography for investigating the dilated upper urinary tract. Radionuclides in Nephrourology Group. Consensus Committee on Diuresis Renography. *J Nucl Med*, 1996. 37: 1872.  
<https://www.ncbi.nlm.nih.gov/pubmed/8917195>
691. Choong, K.K., *et al.* Volume expanded diuretic renography in the postnatal assessment of suspected uretero-pelvic junction obstruction. *J Nucl Med*, 1992. 33: 2094.  
<https://www.ncbi.nlm.nih.gov/pubmed/1460498>

692. Reddy, P.P., *et al.* Prenatal diagnosis. Therapeutic implications. *Urol Clin North Am*, 1998. 25: 171.  
<https://www.ncbi.nlm.nih.gov/pubmed/9633572>
693. Braga, L.H., *et al.* Pilot randomized, placebo controlled trial to investigate the effect of antibiotic prophylaxis on the rate of urinary tract infection in infants with prenatal hydronephrosis. *J Urol*, 2014. 191: 1501.  
<https://www.ncbi.nlm.nih.gov/pubmed/24679865>
694. Craig, J., *et al.*, Long-term antibiotics to prevent urinary tract infection in children with isolated vesicoureteric reflux: a placebo-controlled randomized trial., In: Australian and New Zealand Society of Nephrology 38th Annual Scientific Meeting 2002: Sydney.
695. Silay, M.S., *et al.* The role of antibiotic prophylaxis in antenatal hydronephrosis: A systematic review. *J Ped Urol*, 2017. 13: 306.  
<https://www.ncbi.nlm.nih.gov/pubmed/28462806>
696. Novick, A.C., *et al.*, Surgery of the kidney, In: Campbell's Urology. 1998, WB Saunders: Philadelphia.
697. Reddy, M.N., *et al.* The laparoscopic pyeloplasty: is there a role in the age of robotics? *Urol Clin North Am*, 2015. 42: 43.  
<https://www.ncbi.nlm.nih.gov/pubmed/25455171>
698. Tasian, G.E., *et al.* The robotic-assisted laparoscopic pyeloplasty: gateway to advanced reconstruction. *Urol Clin North Am*, 2015. 42: 89.  
<https://www.ncbi.nlm.nih.gov/pubmed/25455175>
699. Huang, Y., *et al.* An updated meta-analysis of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children. *Int J Clin Exp Med*, 2015. 8: 4922.  
<https://www.ncbi.nlm.nih.gov/pubmed/26131065>
700. Cundy, T.P., *et al.* Meta-analysis of robot-assisted vs conventional laparoscopic and open pyeloplasty in children. *BJU Int*, 2014. 114: 582.  
<https://www.ncbi.nlm.nih.gov/pubmed/25383399>
701. Trevisani, L.F., *et al.* Current controversies in pediatric urologic robotic surgery. *Curr Opin Urol*, 2013. 23: 72.  
<https://www.ncbi.nlm.nih.gov/pubmed/23169150>
702. Arena, F., *et al.* Conservative treatment in primary neonatal megaureter. *Eur J Pediatr Surg*, 1998. 8: 347.  
<https://www.ncbi.nlm.nih.gov/pubmed/9926303>
703. Peters, C.A., *et al.* Congenital obstructed megaureters in early infancy: diagnosis and treatment. *J Urol*, 1989. 142: 641.  
<https://www.ncbi.nlm.nih.gov/pubmed/2746792>
704. Onen, A., *et al.* Long-term followup of prenatally detected severe bilateral newborn hydronephrosis initially managed nonoperatively. *J Urol*, 2002. 168: 1118.  
<https://www.ncbi.nlm.nih.gov/pubmed/12187248>
705. Shukla, A.R., *et al.* Prenatally detected primary megaureter: a role for extended followup. *J Urol*, 2005. 173: 1353.  
<https://www.ncbi.nlm.nih.gov/pubmed/15758800>
706. Sripathi, V., *et al.* Primary obstructive megaureter. *J Pediatr Surg*, 1991. 26: 826.  
<https://www.ncbi.nlm.nih.gov/pubmed/1895193>
707. Lee, T., *et al.* Impact of Clinical Guidelines on Voiding Cystourethrogram Use and Vesicoureteral Reflux Incidence. *J Urol*, 2018. 199: 831.  
<https://www.ncbi.nlm.nih.gov/pubmed/28866466>
708. Fanos, V., *et al.* Antibiotics or surgery for vesicoureteric reflux in children. *Lancet*, 2004. 364: 1720.  
<https://www.ncbi.nlm.nih.gov/pubmed/15530633>
709. Sargent, M.A. What is the normal prevalence of vesicoureteral reflux? *Pediatr Radiol*, 2000. 30: 587.  
<https://www.ncbi.nlm.nih.gov/pubmed/11009294>
710. Skoog, S.J., *et al.* Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis. *J Urol*, 2010. 184: 1145.  
<https://www.ncbi.nlm.nih.gov/pubmed/20650494>
711. Estrada, C.R., Jr., *et al.* Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children. *J Urol*, 2009. 182: 1535.  
<https://www.ncbi.nlm.nih.gov/pubmed/19683762>
712. Pirker, M.E., *et al.* Renal scarring in familial vesicoureteral reflux: is prevention possible? *J Urol*, 2006. 176: 1842.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945668>

713. Alsaywid, B.S., *et al.* High grade primary vesicoureteral reflux in boys: long-term results of a prospective cohort study. *J Urol*, 2010. 184: 1598.  
<https://www.ncbi.nlm.nih.gov/pubmed/20728178>
714. Hannula, A., *et al.* Vesicoureteral reflux in children with suspected and proven urinary tract infection. *Pediatr Nephrol*, 2010. 25: 1463.  
<https://www.ncbi.nlm.nih.gov/pubmed/20467791>
715. Menezes, M., *et al.* Familial vesicoureteral reflux--is screening beneficial? *J Urol*, 2009. 182: 1673.  
<https://www.ncbi.nlm.nih.gov/pubmed/19692047>
716. Noe, H.N. The long-term results of prospective sibling reflux screening. *J Urol*, 1992. 148: 1739.  
<https://www.ncbi.nlm.nih.gov/pubmed/1433599>
717. Ural, Z., *et al.* Bladder dynamics and vesicoureteral reflux: factors associated with idiopathic lower urinary tract dysfunction in children. *J Urol*, 2008. 179: 1564.  
<https://www.ncbi.nlm.nih.gov/pubmed/18295262>
718. Sillen, U., *et al.* The Swedish reflux trial in children: v. Bladder dysfunction. *J Urol*, 2010. 184: 298.  
<https://www.ncbi.nlm.nih.gov/pubmed/20488486>
719. Esbjorner, E., *et al.* Management of children with dilating vesico-ureteric reflux in Sweden. *Acta Paediatr*, 2004. 93: 37.  
<https://www.ncbi.nlm.nih.gov/pubmed/14989437>
720. Sjostrom, S., *et al.* Spontaneous resolution of high grade infantile vesicoureteral reflux. *J Urol*, 2004. 172: 694.  
<https://www.ncbi.nlm.nih.gov/pubmed/15247764>
721. Knudson, M.J., *et al.* Predictive factors of early spontaneous resolution in children with primary vesicoureteral reflux. *J Urol*, 2007. 178: 1684.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707023>
722. Sjostrom, S., *et al.* Predictive factors for resolution of congenital high grade vesicoureteral reflux in infants: results of univariate and multivariate analyses. *J Urol*, 2010. 183: 1177.  
<https://www.ncbi.nlm.nih.gov/pubmed/20096864>
723. Yeung, C.K., *et al.* Renal and bladder functional status at diagnosis as predictive factors for the outcome of primary vesicoureteral reflux in children. *J Urol*, 2006. 176: 1152.  
<https://www.ncbi.nlm.nih.gov/pubmed/16890714>
724. Mohanan, N., *et al.* Renal parenchymal damage in intermediate and high grade infantile vesicoureteral reflux. *J Urol*, 2008. 180: 1635.  
<https://www.ncbi.nlm.nih.gov/pubmed/18708232>
725. Olbing, H., *et al.* New renal scars in children with severe VUR: a 10-year study of randomized treatment. *Pediatr Nephrol*, 2003. 18: 1128.  
<https://www.ncbi.nlm.nih.gov/pubmed/14523634>
726. Peters, C., *et al.* Vesicoureteral reflux associated renal damage: congenital reflux nephropathy and acquired renal scarring. *J Urol*, 2010. 184: 265.  
<https://www.ncbi.nlm.nih.gov/pubmed/20483150>
727. Coplen, D.E., *et al.* Correlation of prenatal and postnatal ultrasound findings with the incidence of vesicoureteral reflux in children with fetal renal pelvic dilatation. *J Urol*, 2008. 180: 1631.  
<https://www.ncbi.nlm.nih.gov/pubmed/18718617>
728. Estrada, C.R., *et al.* Vesicoureteral reflux and urinary tract infection in children with a history of prenatal hydronephrosis--should voiding cystourethrography be performed in cases of postnatally persistent grade II hydronephrosis? *J Urol*, 2009. 181: 801.  
<https://www.ncbi.nlm.nih.gov/pubmed/19095265>
729. Lee, R.S., *et al.* Antenatal hydronephrosis as a predictor of postnatal outcome: a meta-analysis. *Pediatrics*, 2006. 118: 586.  
<https://www.ncbi.nlm.nih.gov/pubmed/16882811>
730. Mallik, M., *et al.* Antenatally detected urinary tract abnormalities: more detection but less action. *Pediatr Nephrol*, 2008. 23: 897.  
<https://www.ncbi.nlm.nih.gov/pubmed/18278521>
731. Phan, V., *et al.* Vesicoureteral reflux in infants with isolated antenatal hydronephrosis. *Pediatr Nephrol*, 2003. 18: 1224.  
<https://www.ncbi.nlm.nih.gov/pubmed/14586679>
732. Ylilin, E., *et al.* Risk of renal scarring in vesicoureteral reflux detected either antenatally or during the neonatal period. *Urology*, 2003. 61: 1238.  
<https://www.ncbi.nlm.nih.gov/pubmed/12809909>
733. Naseer, S.R., *et al.* New renal scars in children with urinary tract infections, vesicoureteral reflux and voiding dysfunction: a prospective evaluation. *J Urol*, 1997. 158: 566.  
<https://www.ncbi.nlm.nih.gov/pubmed/9224361>

734. Blumenthal, I. Vesicoureteric reflux and urinary tract infection in children. *Postgrad Med J*, 2006. 82: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/16397077>
735. Darge, K., *et al.* Current status of vesicoureteral reflux diagnosis. *World J Urol*, 2004. 22: 88.  
<https://www.ncbi.nlm.nih.gov/pubmed/15173954>
736. Lebowitz, R.L., *et al.* International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. *Pediatr Radiol*, 1985. 15: 105.  
<https://www.ncbi.nlm.nih.gov/pubmed/3975102>
737. Westwood, M.E., *et al.* Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review. *BMC Pediatr*, 2005. 5: 2.  
<https://www.ncbi.nlm.nih.gov/pubmed/15769296>
738. Snow, B.W., *et al.* Non-invasive vesicoureteral reflux imaging. *J Pediatr Urol*, 2010. 6: 543.  
<https://www.ncbi.nlm.nih.gov/pubmed/20488755>
739. Darge, K. Voiding urosonography with US contrast agents for the diagnosis of vesicoureteric reflux in children. II. Comparison with radiological examinations. *Pediatr Radiol*, 2008. 38: 54.  
<https://www.ncbi.nlm.nih.gov/pubmed/17639371>
740. Papadopoulou, F., *et al.* Harmonic voiding urosonography with a second-generation contrast agent for the diagnosis of vesicoureteral reflux. *Pediatr Radiol*, 2009. 39: 239.  
<https://www.ncbi.nlm.nih.gov/pubmed/19096835>
741. Takazakura, R., *et al.* Magnetic resonance voiding cystourethrography for vesicoureteral reflux. *J Magn Reson Imaging*, 2007. 25: 170.  
<https://www.ncbi.nlm.nih.gov/pubmed/17154372>
742. Duran, C., *et al.* Contrast-enhanced Voiding Urosonography for Vesicoureteral Reflux Diagnosis in Children. *Radiographics*, 2017. 37: 1854.  
<https://www.ncbi.nlm.nih.gov/pubmed/29019761>
743. Ntoulia, A., *et al.* Contrast-enhanced voiding urosonography (ceVUS) with the intravesical administration of the ultrasound contrast agent Optison for vesicoureteral reflux detection in children: a prospective clinical trial. *Pediatr Radiol*, 2018. 48: 216.  
<https://www.ncbi.nlm.nih.gov/pubmed/29181582>
744. Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee Pediatrics, 1981. 67: 392.  
<https://www.ncbi.nlm.nih.gov/pubmed/7017578>
745. Scherz, H.C., *et al.* The selective use of dimercaptosuccinic acid renal scans in children with vesicoureteral reflux. *J Urol*, 1994. 152: 628.  
<https://www.ncbi.nlm.nih.gov/pubmed/8021985>
746. Hoberman, A., *et al.* Imaging studies after a first febrile urinary tract infection in young children. *N Engl J Med*, 2003. 348: 195.  
<https://www.ncbi.nlm.nih.gov/pubmed/12529459>
747. Hong, I.K., *et al.* Prediction of vesicoureteral reflux in children with febrile urinary tract infection using relative uptake and cortical defect in DMSA scan. *Pediatr Neonatol*, 2018. 59: 618.  
<https://www.ncbi.nlm.nih.gov/pubmed/29576374>
748. Grazioli, S., *et al.* Antenatal and postnatal ultrasound in the evaluation of the risk of vesicoureteral reflux. *Pediatr Nephrol*, 2010. 25: 1687.  
<https://www.ncbi.nlm.nih.gov/pubmed/20524012>
749. Lidefelt, K.J., *et al.* Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis. *Pediatr Nephrol*, 2008. 23: 2021.  
<https://www.ncbi.nlm.nih.gov/pubmed/18560902>
750. Hafez, A.T., *et al.* Analysis of trends on serial ultrasound for high grade neonatal hydronephrosis. *J Urol*, 2002. 168: 1518.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352447>
751. Lee, J.H., *et al.* Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection. *J Urol*, 2008. 179: 1524.  
<https://www.ncbi.nlm.nih.gov/pubmed/18295269>
752. Sidhu, G., *et al.* Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. *Pediatr Nephrol*, 2006. 21: 218.  
<https://www.ncbi.nlm.nih.gov/pubmed/16362721>
753. Visuri, S., *et al.* Postnatal imaging of prenatally detected hydronephrosis-when is voiding cystourethrogram necessary? *Pediatr Nephrol*, 2018. 33: 1751.  
<https://www.ncbi.nlm.nih.gov/pubmed/29626243>

754. Houle, A.M., *et al.* Impact of early screening for reflux in siblings on the detection of renal damage. *BJU Int*, 2004. 94: 123.  
<https://www.ncbi.nlm.nih.gov/pubmed/15217445>
755. Puri, P., *et al.* Urinary tract infection and renal damage in sibling vesicoureteral reflux. *J Urol*, 1998. 160: 1028.  
<https://www.ncbi.nlm.nih.gov/pubmed/9719271>
756. Shaikh, N., *et al.* Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. *JAMA Pediatr*, 2014. 168: 893.  
<https://www.ncbi.nlm.nih.gov/pubmed/25089634>
757. Hansson, S., *et al.* Dimercapto-succinic acid scintigraphy instead of voiding cystourethrography for infants with urinary tract infection. *J Urol*, 2004. 172: 1071.  
<https://www.ncbi.nlm.nih.gov/pubmed/15311040>
758. Herz, D., *et al.* 5-year prospective results of dimercapto-succinic acid imaging in children with febrile urinary tract infection: proof that the top-down approach works. *J Urol*, 2010. 184: 1703.  
<https://www.ncbi.nlm.nih.gov/pubmed/20728131>
759. Preda, I., *et al.* Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrography unnecessary after urinary tract infection. *J Pediatr*, 2007. 151: 581.  
<https://www.ncbi.nlm.nih.gov/pubmed/18035134>
760. Colen, J., *et al.* Dysfunctional elimination syndrome is a negative predictor for vesicoureteral reflux. *J Pediatr Urol*, 2006. 2: 312.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947628>
761. Shaikh, N., *et al.* Recurrent Urinary Tract Infections in Children With Bladder and Bowel Dysfunction. *Pediatrics*, 2016. 137.  
<https://www.ncbi.nlm.nih.gov/pubmed/26647376>
762. Elder, J.S., *et al.* Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. *J Urol*, 1997. 157: 1846.  
<https://www.ncbi.nlm.nih.gov/pubmed/9112544>
763. Dias, C.S., *et al.* Risk factors for recurrent urinary tract infections in a cohort of patients with primary vesicoureteral reflux. *Pediatr Infect Dis J*, 2010. 29: 139.  
<https://www.ncbi.nlm.nih.gov/pubmed/20135833>
764. Wheeler, D.M., *et al.* Interventions for primary vesicoureteric reflux. *Cochrane Database Syst Rev*, 2004: CD001532.  
<https://www.ncbi.nlm.nih.gov/pubmed/15266449>
765. Williams, G.J., *et al.* Long-term antibiotics for preventing recurrent urinary tract infection in children. *Cochrane Database Syst Rev*, 2006: CD001534.  
<https://www.ncbi.nlm.nih.gov/pubmed/16855971>
766. Singh-Grewal, D., *et al.* Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. *Arch Dis Child*, 2005. 90: 853.  
<https://www.ncbi.nlm.nih.gov/pubmed/15890696>
767. Greenfield, S.P. Antibiotic prophylaxis in pediatric urology: an update. *Curr Urol Rep*, 2011. 12: 126.  
<https://www.ncbi.nlm.nih.gov/pubmed/21229337>
768. Greenfield, S.P., *et al.* Vesicoureteral reflux: the RIVUR study and the way forward. *J Urol*, 2008. 179: 405.  
<https://www.ncbi.nlm.nih.gov/pubmed/18076937>
769. Brandstrom, P., *et al.* The Swedish reflux trial in children: IV. Renal damage. *J Urol*, 2010. 184: 292.  
<https://www.ncbi.nlm.nih.gov/pubmed/20488494>
770. Hoberman, A., *et al.* Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med*, 2014. 370: 2367.  
<https://www.ncbi.nlm.nih.gov/pubmed/24795142>
771. de Bessa, J., Jr., *et al.* Antibiotic prophylaxis for prevention of febrile urinary tract infections in children with vesicoureteral reflux: a meta-analysis of randomized, controlled trials comparing dilated to nondilated vesicoureteral reflux. *J Urol*, 2015. 193: 1772.  
<https://www.ncbi.nlm.nih.gov/pubmed/25817142>
772. Hidas, G., *et al.* Predicting the Risk of Breakthrough Urinary Tract Infections: Primary Vesicoureteral Reflux. *J Urol*, 2015. 194: 1396.  
<https://www.ncbi.nlm.nih.gov/pubmed/26066405>
773. Mathews, R., *et al.* The role of antimicrobial prophylaxis in the management of children with vesicoureteral reflux--the RIVUR study outcomes. *Adv Chronic Kidney Dis*, 2015. 22: 325.  
<https://www.ncbi.nlm.nih.gov/pubmed/26088078>



774. Wang, Z.T., *et al.* A Reanalysis of the RIVUR Trial Using a Risk Classification System. *J Urol*, 2018. 199: 1608.  
<https://www.ncbi.nlm.nih.gov/pubmed/29198997>
775. Dogan, H.S., *et al.* Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: does bulking substance matter? *J Pediatr Urol*, 2015. 11: 90.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25791422>
776. Kocherov, S., *et al.* Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (Vantris). *Urology*, 2014. 84: 689.  
<https://www.ncbi.nlm.nih.gov/pubmed/25168553>
777. Puri, P., *et al.* Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene. *J Urol*, 1998. 160: 1007.  
<https://www.ncbi.nlm.nih.gov/pubmed/9719265>
778. Steyaert, H., *et al.* Migration of PTFE paste particles to the kidney after treatment for vesico-ureteric reflux. *BJU Int*, 2000. 85: 168.  
<https://www.ncbi.nlm.nih.gov/pubmed/10619969>
779. Lightner, D.J. Review of the available urethral bulking agents. *Curr Opin Urol*, 2002. 12: 333.  
<https://www.ncbi.nlm.nih.gov/pubmed/12072655>
780. Elder, J.S., *et al.* Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. *J Urol*, 2006. 175: 716.  
<https://www.ncbi.nlm.nih.gov/pubmed/16407037>
781. Ben-Meir, D., *et al.* Late-onset Uretero-vesical Junction Obstruction Following Endoscopic Injection of Bulking Material for the Treatment of Vesico-ureteral Reflux. *Urology*, 2017. 101: 60.  
<https://www.ncbi.nlm.nih.gov/pubmed/27993711>
782. Warchol, S., *et al.* Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up. *Cent European J Urol*, 2017. 70: 314.  
<https://www.ncbi.nlm.nih.gov/pubmed/29104797>
783. Okawada, M., *et al.* Incidence of ureterovesical obstruction and Cohen antireflux surgery after Deflux(R) treatment for vesicoureteric reflux. *J Pediatr Surg*, 2018. 53: 310.  
<https://www.ncbi.nlm.nih.gov/pubmed/29217322>
784. Holmdahl, G., *et al.* The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. *J Urol*, 2010. 184: 280.  
<https://www.ncbi.nlm.nih.gov/pubmed/20488469>
785. Duckett, J.W., *et al.* Surgical results: International Reflux Study in Children--United States branch. *J Urol*, 1992. 148: 1674.  
<https://www.ncbi.nlm.nih.gov/pubmed/1433586>
786. Lipski, B.A., *et al.* Voiding dysfunction after bilateral extravesical ureteral reimplantation. *J Urol*, 1998. 159: 1019.  
<https://www.ncbi.nlm.nih.gov/pubmed/9474222>
787. Kurtz, M.P., *et al.* Robotic versus open pediatric ureteral reimplantation: Costs and complications from a nationwide sample. *J Pediatr Urol*, 2016. 12: 408.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/27593917>
788. Esposito, C., *et al.* Robot-assisted extravesical ureteral reimplantation (revur) for unilateral vesicoureteral reflux in children: results of a multicentric international survey. *World J Urol*, 2018. 36: 481.  
<https://www.ncbi.nlm.nih.gov/pubmed/29248949>
789. Deng, T., *et al.* Robot-assisted laparoscopic versus open ureteral reimplantation for pediatric vesicoureteral reflux: a systematic review and meta-analysis. *World J Urol*, 2018. 36: 819.  
<https://www.ncbi.nlm.nih.gov/pubmed/29374841>
790. Boysen, W.R., *et al.* Prospective multicenter study on robot-assisted laparoscopic extravesical ureteral reimplantation (RALUR-EV): Outcomes and complications. *J Pediatr Urol*, 2018. 14: 262.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/29503220>
791. Austin, J.C., *et al.* Vesicoureteral reflux: who benefits from correction. *Urol Clin North Am*, 2010. 37: 243.  
<https://www.ncbi.nlm.nih.gov/pubmed/20569802>
792. Canon, S.J., *et al.* Vesicoscopic cross-trigonal ureteral reimplantation: a minimally invasive option for repair of vesicoureteral reflux. *J Urol*, 2007. 178: 269.  
<https://www.ncbi.nlm.nih.gov/pubmed/17499791>
793. Chung, P.H., *et al.* Comparing open and pneumovesical approach for ureteric reimplantation in pediatric patients--a preliminary review. *J Pediatr Surg*, 2008. 43: 2246.  
<https://www.ncbi.nlm.nih.gov/pubmed/19040945>

794. El-Ghoneimi, A. Paediatric laparoscopic surgery. *Curr Opin Urol*, 2003. 13: 329.  
<https://www.ncbi.nlm.nih.gov/pubmed/12811298>
795. Grimsby, G.M., *et al.* Multi-institutional review of outcomes of robot-assisted laparoscopic extravesical ureteral reimplantation. *J Urol*, 2015. 193: 1791.  
<https://www.ncbi.nlm.nih.gov/pubmed/25301094>
796. Janetschek, G., *et al.* Laparoscopic ureteral anti-reflux plasty reimplantation. First clinical experience. *Ann Urol (Paris)*, 1995. 29: 101.  
<https://www.ncbi.nlm.nih.gov/pubmed/7645993>
797. Jayanthi, V., *et al.* Vesicoscopic ureteral reimplantation: a minimally invasive technique for the definitive repair of vesicoureteral reflux. *Adv Urol*, 2008: 973616.  
<https://www.ncbi.nlm.nih.gov/pubmed/19009038>
798. Marchini, G.S., *et al.* Robotic assisted laparoscopic ureteral reimplantation in children: case matched comparative study with open surgical approach. *J Urol*, 2011. 185: 1870.  
<https://www.ncbi.nlm.nih.gov/pubmed/21421223>
799. Riquelme, M., *et al.* Laparoscopic extravesical transperitoneal approach for vesicoureteral reflux. *J Laparoendosc Adv Surg Tech A*, 2006. 16: 312.  
<https://www.ncbi.nlm.nih.gov/pubmed/16796449>
800. Straub, M., *et al.* Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. *World J Urol*, 2005. 23: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/16315051>
801. Metcalfe, P.D., *et al.* What is the need for additional bladder surgery after bladder augmentation in childhood? *J Urol*, 2006. 176: 1801.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945653>
802. Bush, N.C., *et al.* Hospitalizations for pediatric stone disease in United States, 2002-2007. *J Urol*, 2010. 183: 1151.  
<https://www.ncbi.nlm.nih.gov/pubmed/20096871>
803. Novak, T.E., *et al.* Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. *Urology*, 2009. 74: 104.  
<https://www.ncbi.nlm.nih.gov/pubmed/19428065>
804. Tasian, G.E., *et al.* Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012. *Clin J Am Soc Nephrol*, 2016. 11: 488.  
<https://www.ncbi.nlm.nih.gov/pubmed/26769765>
805. Sas, D.J., *et al.* Increasing incidence of kidney stones in children evaluated in the emergency department. *J Pediatr*, 2010. 157: 132.  
<https://www.ncbi.nlm.nih.gov/pubmed/20362300>
806. Kirejczyk, J.K., *et al.* An association between kidney stone composition and urinary metabolic disturbances in children. *J Pediatr Urol*, 2014. 10: 130.  
<https://www.ncbi.nlm.nih.gov/pubmed/23953243>
807. Kruse, K., *et al.* Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. *Eur J Pediatr*, 1984. 143: 25.  
<https://www.ncbi.nlm.nih.gov/pubmed/6510426>
808. Sargent, J.D., *et al.* Normal values for random urinary calcium to creatinine ratios in infancy. *J Pediatr*, 1993. 123: 393.  
<https://www.ncbi.nlm.nih.gov/pubmed/8355114>
809. Stapleton, F.B., *et al.* Urinary excretion of calcium following an oral calcium loading test in healthy children. *Pediatrics*, 1982. 69: 594.  
<https://www.ncbi.nlm.nih.gov/pubmed/7079015>
810. Borghi, L., *et al.* Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med*, 2002. 346: 77.  
<https://www.ncbi.nlm.nih.gov/pubmed/11784873>
811. Curhan, G.C., *et al.* A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*, 1993. 328: 833.  
<https://www.ncbi.nlm.nih.gov/pubmed/8441427>
812. Bartosh, S.M. Medical management of pediatric stone disease. *Urol Clin North Am*, 2004. 31: 575.  
<https://www.ncbi.nlm.nih.gov/pubmed/15313066>
813. Choi, J.N., *et al.* Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. *Acta Paediatr*, 2011. 100: e71.  
<https://www.ncbi.nlm.nih.gov/pubmed/21284722>

814. Naseri, M., *et al.* Role of high-dose hydrochlorothiazide in idiopathic hypercalciuric urolithiasis of childhood. *Iran J Kidney Dis*, 2011. 5: 162.  
<https://www.ncbi.nlm.nih.gov/pubmed/21525575>
815. Preminger, G.M., *et al.* Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. *J Urol*, 1987. 137: 1104.  
<https://www.ncbi.nlm.nih.gov/pubmed/3586136>
816. Tekin, A., *et al.* Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. *J Urol*, 2002. 168: 2572.  
<https://www.ncbi.nlm.nih.gov/pubmed/12441986>
817. Hoppe, B., *et al.* Urinary calcium oxalate saturation in healthy infants and children. *J Urol*, 1997. 158: 557.  
<https://www.ncbi.nlm.nih.gov/pubmed/9224359>
818. Neuhaus, T.J., *et al.* Urinary oxalate excretion in urolithiasis and nephrocalcinosis. *Arch Dis Child*, 2000. 82: 322.  
<https://www.ncbi.nlm.nih.gov/pubmed/10735843>
819. Turudic, D., *et al.* Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios. *Eur J Pediatr*, 2016. 175: 1959.  
<https://www.ncbi.nlm.nih.gov/pubmed/27730307>
820. Morgenstern, B.Z., *et al.* Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. *J Pediatr*, 1993. 123: 248.  
<https://www.ncbi.nlm.nih.gov/pubmed/8345420>
821. Defoor, W., *et al.* Results of a prospective trial to compare normal urine supersaturation in children and adults. *J Urol*, 2005. 174: 1708.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148687>
822. Kovacevic, L., *et al.* From hypercalciuria to hypocitraturia--a shifting trend in pediatric urolithiasis? *J Urol*, 2012. 188: 1623.  
<https://www.ncbi.nlm.nih.gov/pubmed/22910255>
823. Tekin, A., *et al.* A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. *J Urol*, 2000. 164: 162.  
<https://www.ncbi.nlm.nih.gov/pubmed/10840454>
824. Celiksoy, M.H., *et al.* Metabolic disorders in Turkish children with urolithiasis. *Urology*, 2015. 85: 909.  
<https://www.ncbi.nlm.nih.gov/pubmed/25817115>
825. Tekin, A., *et al.* Cystine calculi in children: the results of a metabolic evaluation and response to medical therapy. *J Urol*, 2001. 165: 2328.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371943>
826. Gabrielsen, J.S., *et al.* Pediatric urinary stone composition in the United States. *J Urol*, 2012. 187: 2182.  
<https://www.ncbi.nlm.nih.gov/pubmed/22503021>
827. Rellum, D.M., *et al.* Pediatric urolithiasis in a non-endemic country: a single center experience from The Netherlands. *J Pediatr Urol*, 2014. 10: 155.  
<https://www.ncbi.nlm.nih.gov/pubmed/23981680>
828. Bove, P., *et al.* Reexamining the value of hematuria testing in patients with acute flank pain. *J Urol*, 1999. 162: 685.  
<https://www.ncbi.nlm.nih.gov/pubmed/10458342>
829. Sternberg, K., *et al.* Pediatric stone disease: an evolving experience. *J Urol*, 2005. 174: 1711.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148688>
830. Memarsadeghi, M., *et al.* Unenhanced multi-detector row CT in patients suspected of having urinary stone disease: effect of section width on diagnosis. *Radiology*, 2005. 235: 530.  
<https://www.ncbi.nlm.nih.gov/pubmed/15758192>
831. Oner, S., *et al.* Comparison of spiral CT and US in the evaluation of pediatric urolithiasis. *Jbr-btr*, 2004. 87: 219.  
<https://www.ncbi.nlm.nih.gov/pubmed/15587558>
832. Strouse, P.J., *et al.* Non-contrast thin-section helical CT of urinary tract calculi in children. *Pediatr Radiol*, 2002. 32: 326.  
<https://www.ncbi.nlm.nih.gov/pubmed/11956719>
833. Kwon, J.K., *et al.* Usefulness of low-dose nonenhanced computed tomography with iterative reconstruction for evaluation of urolithiasis: diagnostic performance and agreement between the urologist and the radiologist. *Urology*, 2015. 85: 531.  
<https://www.ncbi.nlm.nih.gov/pubmed/25733262>

834. Alpay, H., *et al.* Clinical and metabolic features of urolithiasis and microlithiasis in children. *Pediatr Nephrol*, 2009. 24: 2203.  
<https://www.ncbi.nlm.nih.gov/pubmed/19603196>
835. Skolarikos, A., *et al.* Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. *Eur Urol*, 2015. 67: 750.  
<https://www.ncbi.nlm.nih.gov/pubmed/25454613>
836. Raza, A., *et al.* Pediatric urolithiasis: 15 years of local experience with minimally invasive endourological management of pediatric calculi. *J Urol*, 2005. 174: 682.  
<https://www.ncbi.nlm.nih.gov/pubmed/16006948>
837. Rizvi, S.A., *et al.* Pediatric urolithiasis: developing nation perspectives. *J Urol*, 2002. 168: 1522.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352448>
838. Shahat, A., *et al.* Is Tamsulosin Effective after Shock Wave Lithotripsy for Pediatric Renal Stones? A Randomized, Controlled Study. *J Urol*, 2016. 195: 1284.  
<https://www.ncbi.nlm.nih.gov/pubmed/26926538>
839. Velazquez, N., *et al.* Medical expulsive therapy for pediatric urolithiasis: Systematic review and meta-analysis. *J Pediatr Urol*, 2015. 11: 321.  
<https://www.ncbi.nlm.nih.gov/pubmed/26165192>
840. Dincel, N., *et al.* Are small residual stone fragments really insignificant in children? *J Pediatr Surg*, 2013. 48: 840.  
<https://www.ncbi.nlm.nih.gov/pubmed/23583144>
841. El-Assmy, A., *et al.* Clinically Insignificant Residual Fragments: Is It an Appropriate Term in Children? *Urology*, 2015. 86: 593.  
<https://www.ncbi.nlm.nih.gov/pubmed/26126693>
842. Akin, Y., *et al.* Long-term effects of pediatric extracorporeal shockwave lithotripsy on renal function. *Res Rep Urol*, 2014. 6: 21.  
<https://www.ncbi.nlm.nih.gov/pubmed/24892029>
843. Aksoy, Y., *et al.* Extracorporeal shock wave lithotripsy in children: experience using a mpl-9000 lithotripter. *World J Urol*, 2004. 22: 115.  
<https://www.ncbi.nlm.nih.gov/pubmed/14740160>
844. Aldridge, R.D., *et al.* Anesthesia for pediatric lithotripsy. *Paediatr Anaesth*, 2006. 16: 236.  
<https://www.ncbi.nlm.nih.gov/pubmed/16490086>
845. McLorie, G.A., *et al.* Safety and efficacy of extracorporeal shock wave lithotripsy in infants. *Can J Urol*, 2003. 10: 2051.  
<https://www.ncbi.nlm.nih.gov/pubmed/14704109>
846. Reisiger, K., *et al.* Pediatric nephrolithiasis: does treatment affect renal growth? *Urology*, 2007. 69: 1190.  
<https://www.ncbi.nlm.nih.gov/pubmed/17572213>
847. Villanyi, K.K., *et al.* Short-term changes in renal function after extracorporeal shock wave lithotripsy in children. *J Urol*, 2001. 166: 222.  
<https://www.ncbi.nlm.nih.gov/pubmed/11435873>
848. Vlajkovic, M., *et al.* Long-term functional outcome of kidneys in children with urolithiasis after ESWL treatment. *Eur J Pediatr Surg*, 2002. 12: 118.  
<https://www.ncbi.nlm.nih.gov/pubmed/12015657>
849. Willis, L.R., *et al.* Relationship between kidney size, renal injury, and renal impairment induced by shock wave lithotripsy. *J Am Soc Nephrol*, 1999. 10: 1753.  
<https://www.ncbi.nlm.nih.gov/pubmed/10446943>
850. Ather, M.H., *et al.* Does size and site matter for renal stones up to 30-mm in size in children treated by extracorporeal lithotripsy? *Urology*, 2003. 61: 212.  
<https://www.ncbi.nlm.nih.gov/pubmed/12559298>
851. Muslumanoglu, A.Y., *et al.* Extracorporeal shock wave lithotripsy as first line treatment alternative for urinary tract stones in children: a large scale retrospective analysis. *J Urol*, 2003. 170: 2405.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634438>
852. Ugur, G., *et al.* Anaesthetic/analgesic management of extracorporeal shock wave lithotripsy in paediatric patients. *Paediatr Anaesth*, 2003. 13: 85.  
<https://www.ncbi.nlm.nih.gov/pubmed/12535048>
853. Afshar, K., *et al.* Outcome of small residual stone fragments following shock wave lithotripsy in children. *J Urol*, 2004. 172: 1600.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371769>
854. Al-Busaidy, S.S., *et al.* Pediatric staghorn calculi: the role of extracorporeal shock wave lithotripsy monotherapy with special reference to ureteral stenting. *J Urol*, 2003. 169: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544330>

855. Lottmann, H.B., *et al.* Monotherapy extracorporeal shock wave lithotripsy for the treatment of staghorn calculi in children. *J Urol*, 2001. 165: 2324.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371942>
856. Rodrigues Netto, N., Jr., *et al.* Extracorporeal shock wave lithotripsy in children. *J Urol*, 2002. 167: 2164.  
<https://www.ncbi.nlm.nih.gov/pubmed/11956471>
857. Tan, A.H., *et al.* Results of shockwave lithotripsy for pediatric urolithiasis. *J Endourol*, 2004. 18: 527.  
<https://www.ncbi.nlm.nih.gov/pubmed/15333214>
858. Demirkesen, O., *et al.* Efficacy of extracorporeal shock wave lithotripsy for isolated lower caliceal stones in children compared with stones in other renal locations. *Urology*, 2006. 67: 170.  
<https://www.ncbi.nlm.nih.gov/pubmed/16413356>
859. Onal, B., *et al.* The impact of caliceal pelvic anatomy on stone clearance after shock wave lithotripsy for pediatric lower pole stones. *J Urol*, 2004. 172: 1082.  
<https://www.ncbi.nlm.nih.gov/pubmed/15311043>
860. Ozgur Tan, M., *et al.* The impact of radiological anatomy in clearance of lower calyceal stones after shock wave lithotripsy in paediatric patients. *Eur Urol*, 2003. 43: 188.  
<https://www.ncbi.nlm.nih.gov/pubmed/12565778>
861. Hochreiter, W.W., *et al.* Extracorporeal shock wave lithotripsy for distal ureteral calculi: what a powerful machine can achieve. *J Urol*, 2003. 169: 878.  
<https://www.ncbi.nlm.nih.gov/pubmed/12576804>
862. Landau, E.H., *et al.* Extracorporeal shock wave lithotripsy is highly effective for ureteral calculi in children. *J Urol*, 2001. 165: 2316.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371970>
863. McAdams, S., *et al.* Preoperative Stone Attenuation Value Predicts Success After Shock Wave Lithotripsy in Children. *J Urol*, 2010. 184: 1804.  
<https://www.ncbi.nlm.nih.gov/pubmed/20728112>
864. Dogan, H.S., *et al.* A new nomogram for prediction of outcome of pediatric shock-wave lithotripsy. *J Pediatr Urol*, 2015. 11: 84 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25812469>
865. Onal, B., *et al.* Nomogram and scoring system for predicting stone-free status after extracorporeal shock wave lithotripsy in children with urolithiasis. *BJU Int*, 2013. 111: 344.  
<https://www.ncbi.nlm.nih.gov/pubmed/22672514>
866. Wu, H.Y., *et al.* Surgical management of children with urolithiasis. *Urol Clin North Am*, 2004. 31: 589.  
<https://www.ncbi.nlm.nih.gov/pubmed/15313067>
867. Bassiri, A., *et al.* Transureteral lithotripsy in pediatric practice. *J Endourol*, 2002. 16: 257.  
<https://www.ncbi.nlm.nih.gov/pubmed/12042111>
868. Caione, P., *et al.* Endoscopic manipulation of ureteral calculi in children by rigid operative ureterorenoscopy. *J Urol*, 1990. 144: 484.  
<https://www.ncbi.nlm.nih.gov/pubmed/2374225>
869. De Dominicis, M., *et al.* Retrograde ureteroscopy for distal ureteric stone removal in children. *BJU Int*, 2005. 95: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/15839930>
870. Desai, M.R., *et al.* Percutaneous nephrolithotomy for complex pediatric renal calculus disease. *J Endourol*, 2004. 18: 23.  
<https://www.ncbi.nlm.nih.gov/pubmed/15006048>
871. Dogan, H.S., *et al.* Use of the holmium:YAG laser for ureterolithotripsy in children. *BJU Int*, 2004. 94: 131.  
<https://www.ncbi.nlm.nih.gov/pubmed/15217447>
872. Raza, A., *et al.* Ureteroscopy in the management of pediatric urinary tract calculi. *J Endourol*, 2005. 19: 151.  
<https://www.ncbi.nlm.nih.gov/pubmed/15798409>
873. Satar, N., *et al.* Rigid ureteroscopy for the treatment of ureteral calculi in children. *J Urol*, 2004. 172: 298.  
<https://www.ncbi.nlm.nih.gov/pubmed/15201799>
874. Soygur, T., *et al.* Hydrodilation of the ureteral orifice in children renders ureteroscopic access possible without any further active dilation. *J Urol*, 2006. 176: 285.  
<https://www.ncbi.nlm.nih.gov/pubmed/16753421>
875. Thomas, J.C., *et al.* Pediatric ureteroscopic stone management. *J Urol*, 2005. 174: 1072.  
<https://www.ncbi.nlm.nih.gov/pubmed/16094060>

876. Van Savage, J.G., *et al.* Treatment of distal ureteral stones in children: similarities to the american urological association guidelines in adults. *J Urol*, 2000. 164: 1089.  
<https://www.ncbi.nlm.nih.gov/pubmed/10958749>
877. ElSheemy, M.S., *et al.* Lower calyceal and renal pelvic stones in preschool children: A comparative study of mini-percutaneous nephrolithotomy versus extracorporeal shockwave lithotripsy. *Int J Urol*, 2016. 23: 564.  
<https://www.ncbi.nlm.nih.gov/pubmed/27173126>
878. Jackman, S.V., *et al.* Percutaneous nephrolithotomy in infants and preschool age children: experience with a new technique. *Urology*, 1998. 52: 697.  
<https://www.ncbi.nlm.nih.gov/pubmed/9763096>
879. Badawy, H., *et al.* Percutaneous management of renal calculi: experience with percutaneous nephrolithotomy in 60 children. *J Urol*, 1999. 162: 1710.  
<https://www.ncbi.nlm.nih.gov/pubmed/10524919>
880. Boormans, J.L., *et al.* Percutaneous nephrolithotomy for treating renal calculi in children. *BJU Int*, 2005. 95: 631.  
<https://www.ncbi.nlm.nih.gov/pubmed/15705093>
881. Dawaba, M.S., *et al.* Percutaneous nephrolithotomy in children: early and late anatomical and functional results. *J Urol*, 2004. 172: 1078.  
<https://www.ncbi.nlm.nih.gov/pubmed/15311042>
882. Sahin, A., *et al.* Percutaneous nephrolithotomy in older children. *J Pediatr Surg*, 2000. 35: 1336.  
<https://www.ncbi.nlm.nih.gov/pubmed/10999692>
883. Shokeir, A.A., *et al.* Percutaneous nephrolithotomy in treatment of large stones within horseshoe kidneys. *Urology*, 2004. 64: 426.  
<https://www.ncbi.nlm.nih.gov/pubmed/15351557>
884. Dogan, H.S., *et al.* Percutaneous nephrolithotomy in children: does age matter? *World J Urol*, 2011. 29: 725.  
<https://www.ncbi.nlm.nih.gov/pubmed/21590468>
885. Guven, S., *et al.* Successful percutaneous nephrolithotomy in children: multicenter study on current status of its use, efficacy and complications using Clavien classification. *J Urol*, 2011. 185: 1419.  
<https://www.ncbi.nlm.nih.gov/pubmed/21334653>
886. Khairy Salem, H., *et al.* Tubeless percutaneous nephrolithotomy in children. *J Pediatr Urol*, 2007. 3: 235.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947742>
887. Nouralizadeh, A., *et al.* Experience of percutaneous nephrolithotomy using adult-size instruments in children less than 5 years old. *J Pediatr Urol*, 2009. 5: 351.  
<https://www.ncbi.nlm.nih.gov/pubmed/19230776>
888. Ozden, E., *et al.* Modified Clavien classification in percutaneous nephrolithotomy: assessment of complications in children. *J Urol*, 2011. 185: 264.  
<https://www.ncbi.nlm.nih.gov/pubmed/21074805>
889. Unsal, A., *et al.* Safety and efficacy of percutaneous nephrolithotomy in infants, preschool age, and older children with different sizes of instruments. *Urology*, 2010. 76: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/20022089>
890. Onal, B., *et al.* Factors affecting complication rates of percutaneous nephrolithotomy in children: results of a multi-institutional retrospective analysis by the Turkish pediatric urology society. *J Urol*, 2014. 191: 777.  
<https://www.ncbi.nlm.nih.gov/pubmed/24095906>
891. Ozden, E., *et al.* Percutaneous renal surgery in children with complex stones. *J Pediatr Urol*, 2008. 4: 295.  
<https://www.ncbi.nlm.nih.gov/pubmed/18644533>
892. Bilen, C.Y., *et al.* Tubeless mini percutaneous nephrolithotomy in infants and preschool children: a preliminary report. *J Urol*, 2010. 184: 2498.  
<https://www.ncbi.nlm.nih.gov/pubmed/20961572>
893. Bilen, C.Y., *et al.* Percutaneous nephrolithotomy in children: lessons learned in 5 years at a single institution. *J Urol*, 2007. 177: 1867.  
<https://www.ncbi.nlm.nih.gov/pubmed/17437838>
894. Jackman, S.V., *et al.* The "mini-perc" technique: a less invasive alternative to percutaneous nephrolithotomy. *World J Urol*, 1998. 16: 371.  
<https://www.ncbi.nlm.nih.gov/pubmed/9870281>
895. Dede, O., *et al.* Ultra-mini-percutaneous nephrolithotomy in pediatric nephrolithiasis: Both low pressure and high efficiency. *J Pediatr Urol*, 2015. 11: 253 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25964199>

896. Desai, M.R., *et al.* Single-step percutaneous nephrolithotomy (microperc): the initial clinical report. *J Urol*, 2011. 186: 140.  
<https://www.ncbi.nlm.nih.gov/pubmed/21575966>
897. Hatipoglu, N.K., *et al.* Comparison of shockwave lithotripsy and microperc for treatment of kidney stones in children. *J Endourol*, 2013. 27: 1141.  
<https://www.ncbi.nlm.nih.gov/pubmed/23713511>
898. Karatag, T., *et al.* A Comparison of 2 Percutaneous Nephrolithotomy Techniques for the Treatment of Pediatric Kidney Stones of Sizes 10-20 mm: Microperc vs Miniperc. *Urology*, 2015. 85: 1015.  
<https://www.ncbi.nlm.nih.gov/pubmed/25917724>
899. Aghamir, S.M., *et al.* Feasibility of totally tubeless percutaneous nephrolithotomy under the age of 14 years: a randomized clinical trial. *J Endourol*, 2012. 26: 621.  
<https://www.ncbi.nlm.nih.gov/pubmed/22192104>
900. Bodakci, M.N., *et al.* Ultrasound-guided micropercutaneous nephrolithotomy in pediatric patients with kidney stones. *Int J Urol*, 2015. 22: 773.  
<https://www.ncbi.nlm.nih.gov/pubmed/25975519>
901. Gamal, W., *et al.* Supine pediatric percutaneous nephrolithotomy (PCNL). *J Pediatr Urol*, 2015. 11: 78 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25819602>
902. al Busaidy, S.S., *et al.* Paediatric ureteroscopy for ureteric calculi: a 4-year experience. *Br J Urol*, 1997. 80: 797.  
<https://www.ncbi.nlm.nih.gov/pubmed/9393306>
903. Hill, D.E., *et al.* Ureteroscopy in children. *J Urol*, 1990. 144: 481.  
<https://www.ncbi.nlm.nih.gov/pubmed/2374224>
904. Richter, S., *et al.* Early post-ureteroscopy vesicoureteral reflux--a temporary and infrequent complication: prospective study. *J Endourol*, 1999. 13: 365.  
<https://www.ncbi.nlm.nih.gov/pubmed/10446797>
905. Schuster, T.G., *et al.* Ureteroscopy for the treatment of urolithiasis in children. *J Urol*, 2002. 167: 1813.  
<https://www.ncbi.nlm.nih.gov/pubmed/11912438>
906. Gokce, M.I., *et al.* Evaluation of Postoperative Hydronephrosis Following Ureteroscopy in Pediatric Population: Incidence and Predictors. *Urology*, 2016. 93: 164.  
<https://www.ncbi.nlm.nih.gov/pubmed/26972147>
907. Dogan, H.S., *et al.* Factors affecting complication rates of ureteroscopic lithotripsy in children: results of multi-institutional retrospective analysis by Pediatric Stone Disease Study Group of Turkish Pediatric Urology Society. *J Urol*, 2011. 186: 1035.  
<https://www.ncbi.nlm.nih.gov/pubmed/21784482>
908. Abu Ghazaleh, L.A., *et al.* Retrograde intrarenal lithotripsy for small renal stones in prepubertal children. *Saudi J Kidney Dis Transpl*, 2011. 22: 492.  
<https://www.ncbi.nlm.nih.gov/pubmed/21566306>
909. Corcoran, A.T., *et al.* When is prior ureteral stent placement necessary to access the upper urinary tract in prepubertal children? *J Urol*, 2008. 180: 1861.  
<https://www.ncbi.nlm.nih.gov/pubmed/18721946>
910. Dave, S., *et al.* Single-institutional study on role of ureteroscopy and retrograde intrarenal surgery in treatment of pediatric renal calculi. *Urology*, 2008. 72: 1018.  
<https://www.ncbi.nlm.nih.gov/pubmed/18585764>
911. Kim, S.S., *et al.* Pediatric flexible ureteroscopic lithotripsy: the children's hospital of Philadelphia experience. *J Urol*, 2008. 180: 2616.  
<https://www.ncbi.nlm.nih.gov/pubmed/18950810>
912. Tanaka, S.T., *et al.* Pediatric ureteroscopic management of intrarenal calculi. *J Urol*, 2008. 180: 2150.  
<https://www.ncbi.nlm.nih.gov/pubmed/18804225>
913. Erkurt, B., *et al.* Treatment of renal stones with flexible ureteroscopy in preschool age children. *Urolithiasis*, 2014. 42: 241.  
<https://www.ncbi.nlm.nih.gov/pubmed/24374900>
914. Makhless, I.A., *et al.* Retrograde intrarenal surgery monotherapy versus shock wave lithotripsy for stones 10 to 20 mm in preschool children: a prospective, randomized study. *J Urol*, 2014. 191: 1496.  
<https://www.ncbi.nlm.nih.gov/pubmed/24679882>
915. Saad, K.S., *et al.* Percutaneous Nephrolithotomy vs Retrograde Intrarenal Surgery for Large Renal Stones in Pediatric Patients: A Randomized Controlled Trial. *J Urol*, 2015. 194: 1716.  
<https://www.ncbi.nlm.nih.gov/pubmed/26165587>

916. Bas, O., *et al.* Comparison of Retrograde Intrarenal Surgery and Micro-Percutaneous Nephrolithotomy in Moderately Sized Pediatric Kidney Stones. *J Endourol*, 2016. 30: 765.  
<https://www.ncbi.nlm.nih.gov/pubmed/26983791>
917. Chen, Y., *et al.* Percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric patients with upper urinary stones: a systematic review and meta-analysis. *Urolithiasis*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29368009>
918. Lu, P., *et al.* Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: A PRISMA-compliant article. *Medicine (Baltimore)*, 2017. 96: e8346.  
<https://www.ncbi.nlm.nih.gov/pubmed/29069011>
919. Casale, P., *et al.* Transperitoneal laparoscopic pyelolithotomy after failed percutaneous access in the pediatric patient. *J Urol*, 2004. 172: 680.  
<https://www.ncbi.nlm.nih.gov/pubmed/15247760>
920. Ghani, K.R., *et al.* Robotic nephrolithotomy and pyelolithotomy with utilization of the robotic ultrasound probe. *Int Braz J Urol*, 2014. 40: 125.  
<https://www.ncbi.nlm.nih.gov/pubmed/24642160>
921. Lee, R.S., *et al.* Early results of robot assisted laparoscopic lithotomy in adolescents. *J Urol*, 2007. 177: 2306.  
<https://www.ncbi.nlm.nih.gov/pubmed/17509345>
922. Srivastava, A., *et al.* Laparoscopic Ureterolithotomy in Children: With and Without Stent - Initial Tertiary Care Center Experience with More Than 1-Year Follow-Up. *Eur J Pediatr Surg*, 2016.  
<https://www.ncbi.nlm.nih.gov/pubmed/26878339>
923. Uson, A.C., *et al.* Ureteroceles in infants and children: a report based on 44 cases. *Pediatrics*, 1961. 27: 971.  
<https://www.ncbi.nlm.nih.gov/pubmed/13779382>
924. Prewitt, L.H., Jr., *et al.* The single ectopic ureter. *AJR Am J Roentgenol*, 1976. 127: 941.  
<https://www.ncbi.nlm.nih.gov/pubmed/998831>
925. Ahmed, S., *et al.* Single-system ectopic ureters: a review of 12 cases. *J Pediatr Surg*, 1992. 27: 491.  
<https://www.ncbi.nlm.nih.gov/pubmed/1522464>
926. Chwalla, R. The process of formation of cystic dilatation of the vesical end of the ureter and of diverticula at the ureteral ostium. *Urol Cutan Ren* 1927. 31: 499. [No abstract available].
927. Stephens, D. Caecoureterocele and concepts on the embryology and aetiology of ureteroceles. *Aust N Z J Surg*, 1971. 40: 239.  
<https://www.ncbi.nlm.nih.gov/pubmed/5279434>
928. Tokunaka, S., *et al.* Muscle dysplasia in megaureters. *J Urol*, 1984. 131: 383.  
<https://www.ncbi.nlm.nih.gov/pubmed/6699978>
929. Zerin, J.M., *et al.* Single-system ureteroceles in infants and children: imaging features. *Pediatr Radiol*, 2000. 30: 139.  
<https://www.ncbi.nlm.nih.gov/pubmed/10755749>
930. Monfort, G., *et al.* Surgical management of duplex ureteroceles. *J Pediatr Surg*, 1992. 27: 634.  
<https://www.ncbi.nlm.nih.gov/pubmed/1625138>
931. Bolduc, S., *et al.* Histology of upper pole is unaffected by prenatal diagnosis in duplex system ureteroceles. *J Urol*, 2002. 168: 1123.  
<https://www.ncbi.nlm.nih.gov/pubmed/12187250>
932. Upadhyay, J., *et al.* Impact of prenatal diagnosis on the morbidity associated with ureterocele management. *J Urol*, 2002. 167: 2560.  
<https://www.ncbi.nlm.nih.gov/pubmed/11992089>
933. Ellerker, A.G. The extravescical ectopic ureter. *Br J Surg*, 1958. 45: 344.  
<https://www.ncbi.nlm.nih.gov/pubmed/13536326>
934. Pfister, C., *et al.* The value of endoscopic treatment for ureteroceles during the neonatal period. *J Urol*, 1998. 159: 1006.  
<https://www.ncbi.nlm.nih.gov/pubmed/9474217>
935. Kwatra, N., *et al.* Scintigraphic features of duplex kidneys on DMSA renal cortical scans. *Pediatr Radiol*, 2013. 43: 1204.  
<https://www.ncbi.nlm.nih.gov/pubmed/23385361>
936. Meneghesso, D., *et al.* Clinico-pathological correlation in duplex system ectopic ureters and ureteroceles: can preoperative work-up predict renal histology? *Pediatr Surg Int*, 2012. 28: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/22127487>
937. Kocyigit, A., *et al.* Efficacy of magnetic resonance urography in detecting renal scars in children with vesicoureteral reflux. *Pediatr Nephrol*, 2014. 29: 1215.  
<https://www.ncbi.nlm.nih.gov/pubmed/24500707>



938. Khrichenko, D., *et al.*, Intra- and inter-observer variability of functional MR urography (fMRU) assessment in children. *Pediatr Radiol*, 2016. 46: 666.  
<https://www.ncbi.nlm.nih.gov/pubmed/26795619>
939. Bellah, R.D., *et al.* Ureterocele eversion with vesicoureteral reflux in duplex kidneys: findings at voiding cystourethrography. *AJR Am J Roentgenol*, 1995. 165: 409.  
<https://www.ncbi.nlm.nih.gov/pubmed/7618568>
940. Carrico, C., *et al.* Incontinence due to an infraspincteric ectopic ureter: why the delay in diagnosis and what the radiologist can do about it. *Pediatr Radiol*, 1998. 28: 942.  
<https://www.ncbi.nlm.nih.gov/pubmed/9880638>
941. Ehammer, T., *et al.* High resolution MR for evaluation of lower urogenital tract malformations in infants and children: feasibility and preliminary experiences. *Eur J Radiol*, 2011. 78: 388.  
<https://www.ncbi.nlm.nih.gov/pubmed/20138451>
942. Sumfest, J.M., *et al.* Pseudoureterocele: potential for misdiagnosis of an ectopic ureter as a ureterocele. *Br J Urol*, 1995. 75: 401.  
<https://www.ncbi.nlm.nih.gov/pubmed/7735809>
943. Figueroa, V.H., *et al.* Utility of MR urography in children suspected of having ectopic ureter. *Pediatr Radiol*, 2014. 44: 956.  
<https://www.ncbi.nlm.nih.gov/pubmed/24535117>
944. Beganovic, A., *et al.* Ectopic ureterocele: long-term results of open surgical therapy in 54 patients. *J Urol*, 2007. 178: 251.  
<https://www.ncbi.nlm.nih.gov/pubmed/17499769>
945. Byun, E., *et al.* A meta-analysis of surgical practice patterns in the endoscopic management of ureteroceles. *J Urol*, 2006. 176: 1871.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945677>
946. Chertin, B., *et al.* Endoscopic treatment of vesicoureteral reflux associated with ureterocele. *J Urol*, 2007. 178: 1594.  
<https://www.ncbi.nlm.nih.gov/pubmed/17707044>
947. Decter, R.M., *et al.* Individualized treatment of ureteroceles. *J Urol*, 1989. 142: 535.  
<https://www.ncbi.nlm.nih.gov/pubmed/2746775>
948. Husmann, D., *et al.* Management of ectopic ureterocele associated with renal duplication: a comparison of partial nephrectomy and endoscopic decompression. *J Urol*, 1999. 162: 1406.  
<https://www.ncbi.nlm.nih.gov/pubmed/10492225>
949. Castagnetti, M., *et al.* Management of duplex system ureteroceles in neonates and infants. *Nat Rev Urol*, 2009. 6: 307.  
<https://www.ncbi.nlm.nih.gov/pubmed/19498409>
950. Monfort, G., *et al.* [Simplified treatment of ureteroceles]. *Chir Pediatr*, 1985. 26: 26.  
<https://www.ncbi.nlm.nih.gov/pubmed/3995671>
951. Sander, J.C., *et al.* Outcomes of endoscopic incision for the treatment of ureterocele in children at a single institution. *J Urol*, 2015. 193: 662.  
<https://www.ncbi.nlm.nih.gov/pubmed/25167992>
952. Han, M.Y., *et al.* Indications for nonoperative management of ureteroceles. *J Urol*, 2005. 174: 1652.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148674>
953. Mariyappa, B., *et al.* Management of duplex-system ureterocele. *J Paediatr Child Health*, 2014. 50: 96.  
<https://www.ncbi.nlm.nih.gov/pubmed/24372828>
954. Adorisio, O., *et al.* Effectiveness of primary endoscopic incision in treatment of ectopic ureterocele associated with duplex system. *Urology*, 2011. 77: 191.  
<https://www.ncbi.nlm.nih.gov/pubmed/21168903>
955. DeFoor, W., *et al.* Ectopic ureterocele: clinical application of classification based on renal unit jeopardy. *J Urol*, 2003. 169: 1092.  
<https://www.ncbi.nlm.nih.gov/pubmed/12576859>
956. Jesus, L.E., *et al.* Clinical evolution of vesicoureteral reflux following endoscopic puncture in children with duplex system ureteroceles. *J Urol*, 2011. 186: 1455.  
<https://www.ncbi.nlm.nih.gov/pubmed/21862045>
957. Husmann, D.A., *et al.* Ureterocele associated with ureteral duplication and a nonfunctioning upper pole segment: management by partial nephroureterectomy alone. *J Urol*, 1995. 154: 723.  
<https://www.ncbi.nlm.nih.gov/pubmed/7609163>
958. Gran, C.D., *et al.* Primary lower urinary tract reconstruction for nonfunctioning renal moieties associated with obstructing ureteroceles. *J Urol*, 2005. 173: 198.  
<https://www.ncbi.nlm.nih.gov/pubmed/15592074>

959. Gander, R., *et al.* Evaluation of the Initial Treatment of Ureteroceles. *Urology*, 2016. 89: 113.  
<https://www.ncbi.nlm.nih.gov/pubmed/26674749>
960. Pohl, H.G. Recent advances in the management of ureteroceles in infants and children: Why less may be more. *Current Opinion in Urology*, 2011. 21: 322.  
<https://www.ncbi.nlm.nih.gov/pubmed/21519275>
961. Biles, M.J., *et al.* Innovation in Robotics and Pediatric Urology: Robotic Ureteroureterostomy for Duplex Systems with Ureteral Ectopia. *J Endourol*, 2016. 30: 1041.  
<https://www.ncbi.nlm.nih.gov/pubmed/27542552>
962. Castagnetti, M., *et al.* Dismembered extravesical reimplantation of dilated upper pole ectopic ureters in duplex systems. *J Pediatr Surg*, 2013. 48: 459.  
<https://www.ncbi.nlm.nih.gov/pubmed/23414887>
963. Esposito, C., *et al.* A comparison between laparoscopic and retroperitoneoscopic approach for partial nephrectomy in children with duplex kidney: a multicentric survey. *World J Urol*, 2016. 34: 939.  
<https://www.ncbi.nlm.nih.gov/pubmed/26577623>
964. Herz, D., *et al.* Robot-assisted laparoscopic management of duplex renal anomaly: Comparison of surgical outcomes to traditional pure laparoscopic and open surgery. *J Pediatr Urol*, 2016. 12: 44.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26443241>
965. Cohen, S.A., *et al.* Examining trends in the treatment of ureterocele yields no definitive solution. *J Pediatr Urol*, 2015. 11: 29.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/25459387>
966. Roy Choudhury, S., *et al.* Spectrum of ectopic ureters in children. *Pediatr Surg Int*, 2008. 24: 819.  
<https://www.ncbi.nlm.nih.gov/pubmed/18463883>
967. Houk, C.P., *et al.* Summary of consensus statement on intersex disorders and their management. International Intersex Consensus Conference. *Pediatrics*, 2006. 118: 753.  
<https://www.ncbi.nlm.nih.gov/pubmed/16882833>
968. Lee, P.A., *et al.* Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. *Pediatrics*, 2006. 118: e488.  
<https://www.ncbi.nlm.nih.gov/pubmed/16882788>
969. Parliamentary Assembly, Council of Europe. Promoting the human rights of and eliminating discrimination against intersex people. 2017.  
<http://assembly.coe.int/nw/xml/XRef/Xref-DocDetails-en.asp?FileId=24027>
970. Wolffbuttel, K.P., *et al.* Gonadal dysgenesis in disorders of sex development: Diagnosis and surgical management. *J Pediatr Urol*, 2016. 12: 411.  
<https://www.ncbi.nlm.nih.gov/pubmed/27769830>
971. Maggi, M., *et al.* Standard operating procedures: pubertas tarda/delayed puberty--male. *J Sex Med*, 2013. 10: 285.  
<https://www.ncbi.nlm.nih.gov/pubmed/22376050>
972. Wales, J.K. Disordered pubertal development. *Arch Dis Child Educ Pract Ed*, 2012. 97: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/21278425>
973. Lee, P.A., *et al.* Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. *Horm Res Paediatr*, 2016. 85: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/26820577>
974. Feldman, K.W., *et al.* Fetal phallic growth and penile standards for newborn male infants. *J Pediatr*, 1975. 86: 395.  
<https://www.ncbi.nlm.nih.gov/pubmed/1113226>
975. Creighton, S., *et al.* Medical photography: ethics, consent and the intersex patient. *BJU Int*, 2002. 89: 67.  
<https://www.ncbi.nlm.nih.gov/pubmed/11849163>
976. Biswas, K., *et al.* Imaging in intersex disorders. *J Pediatr Endocrinol Metab*, 2004. 17: 841.  
<https://www.ncbi.nlm.nih.gov/pubmed/15270401>
977. Wright, N.B., *et al.* Imaging children with ambiguous genitalia and intersex states. *Clin Radiol*, 1995. 50: 823.  
<https://www.ncbi.nlm.nih.gov/pubmed/8536391>
978. Chertin, B., *et al.* The use of laparoscopy in intersex patients. *Pediatr Surg Int*, 2006. 22: 405.  
<https://www.ncbi.nlm.nih.gov/pubmed/16521001>
979. Denes, F.T., *et al.* Laparoscopic management of intersexual states. *Urol Clin North Am*, 2001. 28: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/11277066>

980. American Academy of Pediatrics. Timing of elective surgery on the genitalia of male children with particular reference to the risks, benefits, and psychological effects of surgery and anesthesia. *Pediatrics*, 1996. 97: 590.  
<http://pediatrics.aappublications.org/content/97/4/590>
981. Mouriouand, P., *et al.* The ESPU/SPU standpoint on the surgical management of Disorders of Sex Development (DSD). *J Pediatr Urol*, 2014. 10: 8.  
<https://www.ncbi.nlm.nih.gov/pubmed/24528671>
982. Wolffenbuttel K.P. *et al.* Open letter to the Council of Europe. *J Pediatr Urol*, 2018. 14: 4/  
[https://www.jpuro.com/article/S1477-5131\(18\)30060-3/abstract](https://www.jpuro.com/article/S1477-5131(18)30060-3/abstract)
983. van der Zwan, Y.G., *et al.* Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. *Eur Urol*, 2015. 67: 692.  
<https://www.ncbi.nlm.nih.gov/pubmed/25240975>
984. Cools, M., *et al.* Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. *Endocr Rev*, 2006. 27: 468.  
<https://www.ncbi.nlm.nih.gov/pubmed/16735607>
985. Hennis, P.M., *et al.* A systematic review on the accuracy of diagnostic procedures for infravesical obstruction in boys. *PLoS One*, 2014. 9: e85474.  
<https://www.ncbi.nlm.nih.gov/pubmed/24586242>
986. Hodges, S.J., *et al.* Posterior urethral valves. *ScientificWorldJournal*, 2009. 9: 1119.  
<https://www.ncbi.nlm.nih.gov/pubmed/19838598>
987. Thakkar, D., *et al.* Epidemiology and demography of recently diagnosed cases of posterior urethral valves. *Pediatr Res*, 2014. 76: 560.  
<https://www.ncbi.nlm.nih.gov/pubmed/25198372>
988. Malin, G., *et al.* Congenital lower urinary tract obstruction: a population-based epidemiological study. *BJOG*, 2012. 119: 1455.  
<https://www.ncbi.nlm.nih.gov/pubmed/22925164>
989. Dewan, P.A., *et al.* Endoscopic reappraisal of the morphology of congenital obstruction of the posterior urethra. *Br J Urol*, 1992. 70: 439.  
<https://www.ncbi.nlm.nih.gov/pubmed/1450856>
990. Young, H.H., *et al.* Congenital obstruction of the posterior urethra. *J Urol*, 3: 289-365, 1919. *J Urol*, 2002. 167: 265.  
<https://www.ncbi.nlm.nih.gov/pubmed/11743334>
991. Rosenfeld, B., *et al.* Type III posterior urethral valves: presentation and management. *J Pediatr Surg*, 1994. 29: 81.  
<https://www.ncbi.nlm.nih.gov/pubmed/8120770>
992. Stephens, F.D., *et al.* Pathogenesis of the prune belly syndrome. *J Urol*, 1994. 152: 2328.  
<https://www.ncbi.nlm.nih.gov/pubmed/7966734>
993. Roy, S., *et al.* [Contribution of ultrasound signs for the prenatal diagnosis of posterior urethral valves: Experience of 3years at the maternity of the Bicetre Hospital]. *J Gynecol Obstet Biol Reprod (Paris)*, 2016. 45: 478.  
<https://www.ncbi.nlm.nih.gov/pubmed/25980903>
994. Churchill, B.M., *et al.* Emergency treatment and long-term follow-up of posterior urethral valves. *Urol Clin North Am*, 1990. 17: 343.  
<https://www.ncbi.nlm.nih.gov/pubmed/2186540>
995. Hoover, D.L., *et al.* Posterior urethral valves, unilateral reflux and renal dysplasia: a syndrome. *J Urol*, 1982. 128: 994.  
<https://www.ncbi.nlm.nih.gov/pubmed/7176067>
996. Rittenberg, M.H., *et al.* Protective factors in posterior urethral valves. *J Urol*, 1988. 140: 993.  
<https://www.ncbi.nlm.nih.gov/pubmed/3139895>
997. Cuckow, P.M., *et al.* Long-term renal function in the posterior urethral valves, unilateral reflux and renal dysplasia syndrome. *J Urol*, 1997. 158: 1004.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258130>
998. Kleppe, S., *et al.* Impact of prenatal urinomas in patients with posterior urethral valves and postnatal renal function. *J Perinat Med*, 2006. 34: 425.  
<https://www.ncbi.nlm.nih.gov/pubmed/16965232>
999. Heikkila, J., *et al.* Posterior Urethral Valves are Often Associated With Cryptorchidism and Inguinal Hernias. *J Urol*, 2008. 180: 715.  
<https://www.ncbi.nlm.nih.gov/pubmed/18554641>
1000. Wong, J., *et al.* Why do undescended testes and posterior urethral valve occur together? *Pediatr Surg Int*, 2016. 32: 509.  
<https://www.ncbi.nlm.nih.gov/pubmed/27072813>

1001. Dinneen, M.D., *et al.* Antenatal diagnosis of posterior urethral valves. *Br J Urol*, 1993. 72: 364.  
<https://www.ncbi.nlm.nih.gov/pubmed/8220998>
1002. Freedman, A.L., *et al.* Fetal therapy for obstructive uropathy: past, present.future? *Pediatr Nephrol*, 2000. 14: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/10684370>
1003. Abdennadher, W., *et al.* Fetal urine biochemistry at 13-23 weeks of gestation in lower urinary tract obstruction: criteria for in-utero treatment. *Ultrasound Obstet Gynecol*, 2015. 46: 306.  
<https://www.ncbi.nlm.nih.gov/pubmed/25412852>
1004. McLorie, G., *et al.* Outcome analysis of vesicoamniotic shunting in a comprehensive population. *J Urol*, 2001. 166: 1036.  
<https://www.ncbi.nlm.nih.gov/pubmed/11490292>
1005. Salam, M.A. Posterior urethral valve: Outcome of antenatal intervention. *Int J Urol*, 2006. 13: 1317.  
<https://www.ncbi.nlm.nih.gov/pubmed/17010011>
1006. Nassr, A.A., *et al.* Effectiveness of vesicoamniotic shunt in fetuses with congenital lower urinary tract obstruction: an updated systematic review and meta-analysis. *Ultrasound Obstet Gynecol*, 2017. 49: 696.  
<https://www.ncbi.nlm.nih.gov/pubmed/27270578>
1007. Morris, R.K., *et al.* Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. *Lancet*, 2013. 382: 1496.  
<https://www.ncbi.nlm.nih.gov/pubmed/23953766>
1008. Sananes, N., *et al.* Urological fistulas after fetal cystoscopic laser ablation of posterior urethral valves: surgical technical aspects. *Ultrasound Obstet Gynecol*, 2015. 45: 183.  
<https://www.ncbi.nlm.nih.gov/pubmed/24817027>
1009. Morris, R.K., *et al.* Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review. *Ultrasound Obstet Gynecol*, 2011. 37: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/21374748>
1010. Babu, R., *et al.* Early outcome following diathermy versus cold knife ablation of posterior urethral valves. *J Pediatr Urol*, 2013. 9: 7.  
<https://www.ncbi.nlm.nih.gov/pubmed/22417679>
1011. Sarhan, O., *et al.* Surgical complications of posterior urethral valve ablation: 20 years experience. *J Pediatr Surg*, 2010. 45: 2222.  
<https://www.ncbi.nlm.nih.gov/pubmed/21034948>
1012. Shirazi, M., *et al.* Which patients are at higher risk for residual valves after posterior urethral valve ablation? *Korean J Urol*, 2014. 55: 64.  
<https://www.ncbi.nlm.nih.gov/pubmed/24466400>
1013. Nawaz, G., *et al.* Justification For Re-Look Cystoscopy After Posterior Urethral Valve Fulguration. *J Ayub Med Col, Abbottabad : JAMC*, 2017. 29: 30.  
<https://www.ncbi.nlm.nih.gov/pubmed/28712168>
1014. Smeulders, N., *et al.* The predictive value of a repeat micturating cystourethrogram for remnant leaflets after primary endoscopic ablation of posterior urethral valves. *J Pediatr Urol*, 2011. 7: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/20537589>
1015. Krahn, C.G., *et al.* Cutaneous vesicostomy in the young child: indications and results. *Urology*, 1993. 41: 558.  
<https://www.ncbi.nlm.nih.gov/pubmed/8516992>
1016. Kim, Y.H., *et al.* Comparative urodynamic findings after primary valve ablation, vesicostomy or proximal diversion. *J Urol*, 1996. 156: 673.  
<https://www.ncbi.nlm.nih.gov/pubmed/8683757>
1017. Podesta, M., *et al.* Bladder function associated with posterior urethral valves after primary valve ablation or proximal urinary diversion in children and adolescents. *J Urol*, 2002. 168: 1830.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352370>
1018. Chua, M.E., *et al.* Impact of Adjuvant Urinary Diversion versus Valve Ablation Alone on Progression from Chronic to End Stage Renal Disease in Posterior Urethral Valves: A Single Institution 15-Year Time-to-Event Analysis. *J Urol*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29061539>
1019. Novak, M.E., *et al.* Single-stage reconstruction of urinary tract after loop cutaneous ureterostomy. *Urology*, 1978. 11: 134.  
<https://www.ncbi.nlm.nih.gov/pubmed/628990>
1020. Sober, I. Pelvioureterostomy-en-Y. *J Urol*, 1972. 107: 473.  
<https://www.ncbi.nlm.nih.gov/pubmed/5010719>
1021. Williams, D.I., *et al.* Ring ureterostomy. *Br J Urol*, 1975. 47: 789.  
<https://www.ncbi.nlm.nih.gov/pubmed/1222345>

1022. Scott, J.E. Management of congenital posterior urethral valves. *Br J Urol*, 1985. 57: 71.  
<https://www.ncbi.nlm.nih.gov/pubmed/3971107>
1023. Mukherjee, S., *et al.* What is the effect of circumcision on risk of urinary tract infection in boys with posterior urethral valves? *J Pediatr Surg*, 2009. 44: 417.  
<https://www.ncbi.nlm.nih.gov/pubmed/19231547>
1024. Casey, J.T., *et al.* Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. *J Urol*, 2012. 188: 1516.  
<https://www.ncbi.nlm.nih.gov/pubmed/22910256>
1025. Cozzi, D.A., *et al.* Posterior urethral valves: relationship between vesicoureteral reflux and renal function. *Urology*, 2011. 77: 1209.  
<https://www.ncbi.nlm.nih.gov/pubmed/21109298>
1026. Heikkila, J., *et al.* Long-term risk of end stage renal disease in patients with posterior urethral valves. *J Urol*, 2011. 186: 2392.  
<https://www.ncbi.nlm.nih.gov/pubmed/22014822>
1027. Bellinger, M.F. Ureterocystoplasty: a unique method for vesical augmentation in children. *J Urol*, 1993. 149: 811.  
<https://www.ncbi.nlm.nih.gov/pubmed/8455246>
1028. Koff, S.A., *et al.* The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. *J Urol*, 2002. 167: 291.  
<https://www.ncbi.nlm.nih.gov/pubmed/11743343>
1029. Nguyen, M.T., *et al.* Overnight catheter drainage in children with poorly compliant bladders improves post-obstructive diuresis and urinary incontinence. *J Urol*, 2005. 174: 1633.  
<https://www.ncbi.nlm.nih.gov/pubmed/16148670>
1030. Holmdahl, G. Bladder dysfunction in boys with posterior urethral valves. *Scand J Urol Nephrol Suppl*, 1997. 188: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/9458522>
1031. Neel, K.F. Feasibility and outcome of clean intermittent catheterization for children with sensate urethra. *Can Urol Ass*, 2010. 4: 403.  
<https://www.ncbi.nlm.nih.gov/pubmed/21191500>
1032. King, T., *et al.* Mitrofanoff for valve bladder syndrome: Effect on urinary tract and renal function. *J Urol*, 2014. 191: 1517.  
<https://www.ncbi.nlm.nih.gov/pubmed/24679888>
1033. Coleman, R., *et al.* Nadir creatinine in posterior urethral valves: How high is low enough? *J Pediatr Urol*, 2015. 11: 356.  
<https://www.ncbi.nlm.nih.gov/pubmed/26292912>
1034. Sarhan, O., *et al.* Prognostic value of serum creatinine levels in children with posterior urethral valves treated by primary valve ablation. *Urology*, 2009. 74: S267.  
<https://www.ncbi.nlm.nih.gov/pubmed/19581129>
1035. Akdogan, B., *et al.* Significance of age-specific creatinine levels at presentation in posterior urethral valve patients. *J Pediatr Urol*, 2006. 2: 446.  
<https://www.ncbi.nlm.nih.gov/pubmed/18947654>
1036. Lemmens, A.S., *et al.* Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome. *J Matern Fetal Neonatal Med*, 2015. 28: 1026.  
<https://www.ncbi.nlm.nih.gov/pubmed/25000449>
1037. Odeh, R., *et al.* Predicting Risk of Chronic Kidney Disease in Infants and Young Children at Diagnosis of Posterior Urethral Valves: Initial Ultrasound Kidney Characteristics and Validation of Parenchymal Area as Forecasters of Renal Reserve. *J Urol*, 2016. 196: 862.  
<https://www.ncbi.nlm.nih.gov/pubmed/27017936>
1038. Jalkanen, J., *et al.* Controlled Outcomes for Achievement of Urinary Continence among Boys Treated for Posterior Urethral Valves. *J Urol*, 2016. 196: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/26964916>
1039. Smith, G.H., *et al.* The long-term outcome of posterior urethral valves treated with primary valve ablation and observation. *J Urol*, 1996. 155: 1730.  
<https://www.ncbi.nlm.nih.gov/pubmed/8627873>
1040. Concodora, C.W., *et al.* The Role of Video Urodynamics in the Management of the Valve Bladder. *Curr Urol Rep*, 2017. 18: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/28233231>
1041. Capitanucci, M.L., *et al.* Long-term bladder function followup in boys with posterior urethral valves: Comparison of noninvasive vs invasive urodynamic studies. *J Urol*, 2012. 188: 953.  
<https://www.ncbi.nlm.nih.gov/pubmed/22819111>

1042. Kim, Y.H., *et al.* Management of posterior urethral valves on the basis of urodynamic findings. *J Urol*, 1997. 158: 1011.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258132>
1043. Misseri, R., *et al.* Myogenic failure in posterior urethral valve disease: real or imagined? *J Urol*, 2002. 168: 1844.  
<https://www.ncbi.nlm.nih.gov/pubmed/12352373>
1044. Abraham, M.K., *et al.* Role of alpha adrenergic blocker in the management of posterior urethral valves. *Pediatr Surg Int*, 2009. 25: 1113.  
<https://www.ncbi.nlm.nih.gov/pubmed/19727771>
1045. Skenazy, J., *et al.* 1618 Alpha adrenergic blockade in neonates with posterior urethral valves. *J Urol*, 2012. 187: e654.  
<https://www.sciencedirect.com/science/article/pii/S0022534712017752>
1046. DeFoor, W., *et al.* Risk Factors for End Stage Renal Disease in Children With Posterior Urethral Valves. *J Urol*, 2008. 180: 1705.  
<https://www.ncbi.nlm.nih.gov/pubmed/18708224>
1047. Ansari, M.S., *et al.* Risk factors for progression to end-stage renal disease in children with posterior urethral valves. *J Pediatr Urol*, 2010. 6: 261.  
<https://www.ncbi.nlm.nih.gov/pubmed/19833558>
1048. Fine, M.S., *et al.* Posterior urethral valve treatments and outcomes in children receiving kidney transplants. *J Urol*, 2011. 185: 2507.  
<https://www.ncbi.nlm.nih.gov/pubmed/21527196>
1049. Kamal, M.M., *et al.* Impact of posterior urethral valves on pediatric renal transplantation: a single-center comparative study of 297 cases. *Pediatr Transplant*, 2011. 15: 482.  
<https://www.ncbi.nlm.nih.gov/pubmed/21599816>
1050. Lopez Pereira, P., *et al.* Long-term bladder function, fertility and sexual function in patients with posterior urethral valves treated in infancy. *J Pediatr Urol*, 2013. 9: 38.  
<https://www.ncbi.nlm.nih.gov/pubmed/22154080>
1051. Woodhouse, C.R., *et al.* Sexual function and fertility in patients treated for posterior urethral valves. *J Urol*, 1989. 142: 586.  
<https://www.ncbi.nlm.nih.gov/pubmed/2746783>
1052. Taskinen, S., *et al.* Effects of posterior urethral valves on long-term bladder and sexual function. *Nat Rev Urol*, 2012. 9: 699.  
<https://www.ncbi.nlm.nih.gov/pubmed/23147930>
1053. McAninch, J.W., *et al.* Renal reconstruction after injury. *J Urol*, 1991. 145: 932.  
<https://www.ncbi.nlm.nih.gov/pubmed/2016804>
1054. McAleer, I.M., *et al.* Genitourinary trauma in the pediatric patient. *Urology*, 1993. 42: 563.  
<https://www.ncbi.nlm.nih.gov/pubmed/8236601>
1055. Miller, R.C., *et al.* The incidental discovery of occult abdominal tumors in children following blunt abdominal trauma. *J Trauma*, 1966. 6: 99.  
<https://www.ncbi.nlm.nih.gov/pubmed/5901856>
1056. Moore, E.E., *et al.* Organ injury scaling: spleen, liver, and kidney. *J Trauma*, 1989. 29: 1664.  
<https://www.ncbi.nlm.nih.gov/pubmed/2593197>
1057. Stalker, H.P., *et al.* The significance of hematuria in children after blunt abdominal trauma. *AJR Am J Roentgenol*, 1990. 154: 569.  
<https://www.ncbi.nlm.nih.gov/pubmed/2106223>
1058. Mee, S.L., *et al.* Radiographic assessment of renal trauma: a 10-year prospective study of patient selection. *J Urol*, 1989. 141: 1095.  
<https://www.ncbi.nlm.nih.gov/pubmed/2709493>
1059. Stein, J.P., *et al.* Blunt renal trauma in the pediatric population: indications for radiographic evaluation. *Urology*, 1994. 44: 406.  
<https://www.ncbi.nlm.nih.gov/pubmed/8073555>
1060. Carpio, F., *et al.* Radiographic staging of renal injuries. *World J Urol*, 1999. 17: 66.  
<https://www.ncbi.nlm.nih.gov/pubmed/10367363>
1061. Radmayr, C., *et al.* Blunt renal trauma in children: 26 years clinical experience in an alpine region. *Eur Urol*, 2002. 42: 297.  
<https://www.ncbi.nlm.nih.gov/pubmed/12234516>
1062. Presti, J.C., Jr., *et al.* Ureteral and renal pelvic injuries from external trauma: diagnosis and management. *J Trauma*, 1989. 29: 370.  
<https://www.ncbi.nlm.nih.gov/pubmed/2926851>

1063. Mulligan, J.M., *et al.* Ureteropelvic junction disruption secondary to blunt trauma: excretory phase imaging (delayed films) should help prevent a missed diagnosis. *J Urol*, 1998. 159: 67.  
<https://www.ncbi.nlm.nih.gov/pubmed/9400439>
1064. al-Ali, M., *et al.* The late treatment of 63 overlooked or complicated ureteral missile injuries: the promise of nephrostomy and role of autotransplantation. *J Urol*, 1996. 156: 1918.  
<https://www.ncbi.nlm.nih.gov/pubmed/8911355>
1065. Fernandez Fernandez, A., *et al.* Blunt traumatic rupture of the high right ureter, repaired with appendix interposition. *Urol Int*, 1994. 53: 97.  
<https://www.ncbi.nlm.nih.gov/pubmed/7801425>
1066. Sivit, C.J., *et al.* CT diagnosis and localization of rupture of the bladder in children with blunt abdominal trauma: significance of contrast material extravasation in the pelvis. *AJR Am J Roentgenol*, 1995. 164: 1243.  
<https://www.ncbi.nlm.nih.gov/pubmed/7717239>
1067. Hochberg, E., *et al.* Bladder rupture associated with pelvic fracture due to blunt trauma. *Urology*, 1993. 41: 531.  
<https://www.ncbi.nlm.nih.gov/pubmed/8516988>
1068. Haas, C.A., *et al.* Limitations of routine spiral computerized tomography in the evaluation of bladder trauma. *J Urol*, 1999. 162: 51.  
<https://www.ncbi.nlm.nih.gov/pubmed/10379738>
1069. Volpe, M.A., *et al.* Is there a difference in outcome when treating traumatic intraperitoneal bladder rupture with or without a suprapubic tube? *J Urol*, 1999. 161: 1103.  
<https://www.ncbi.nlm.nih.gov/pubmed/10081847>
1070. Richardson, J.R., Jr., *et al.* Non-operative treatment of the ruptured bladder. *J Urol*, 1975. 114: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/1159910>
1071. Cass, A.S., *et al.* Urethral injury due to external trauma. *Urology*, 1978. 11: 607.  
<https://www.ncbi.nlm.nih.gov/pubmed/675928>
1072. Pokorny, M., *et al.* Urological injuries associated with pelvic trauma. *J Urol*, 1979. 121: 455.  
<https://www.ncbi.nlm.nih.gov/pubmed/439217>
1073. Elliott, D.S., *et al.* Long-term followup and evaluation of primary realignment of posterior urethral disruptions. *J Urol*, 1997. 157: 814.  
<https://www.ncbi.nlm.nih.gov/pubmed/9072573>
1074. Boone, T.B., *et al.* Postpubertal genitourinary function following posterior urethral disruptions in children. *J Urol*, 1992. 148: 1232.  
<https://www.ncbi.nlm.nih.gov/pubmed/1404642>
1075. Koraitim, M.M. Posttraumatic posterior urethral strictures in children: a 20-year experience. *J Urol*, 1997. 157: 641.  
<https://www.ncbi.nlm.nih.gov/pubmed/8996388>
1076. Avanoğlu, A., *et al.* Posterior urethral injuries in children. *Br J Urol*, 1996. 77: 597.  
<https://www.ncbi.nlm.nih.gov/pubmed/8777627>
1077. Nair, S.G., *et al.* Perioperative fluid and electrolyte management in pediatric patients. *Indian J Anaesth*, 2004. 48: 355.  
<http://medind.nic.in/iad/t04/i5/iadt04i5p355.pdf>
1078. Imura, K., *et al.* Perioperative nutrition and metabolism in pediatric patients. *World J Surg*, 2000. 24: 1498.  
<https://www.ncbi.nlm.nih.gov/pubmed/11193714>
1079. Ward Platt, M.P., *et al.* The effects of anesthesia and surgery on metabolic homeostasis in infancy and childhood. *J Pediatr Surg*, 1990. 25: 472.  
<https://www.ncbi.nlm.nih.gov/pubmed/2191106>
1080. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: a report by the American Society of Anesthesiologist Task Force on Preoperative Fasting. *Anesthesiology*, 1999. 90: 896.  
<https://www.ncbi.nlm.nih.gov/pubmed/10078693>
1081. Murat, I., *et al.* Perioperative fluid therapy in pediatrics. *Paediatr Anaesth*, 2008. 18: 363.  
<https://www.ncbi.nlm.nih.gov/pubmed/18312509>
1082. Redfern, N., *et al.* Blood glucose in anaesthetised children. Comparison of blood glucose concentrations in children fasted for morning and afternoon surgery. *Anaesthesia*, 1986. 41: 272.  
<https://www.ncbi.nlm.nih.gov/pubmed/3963330>
1083. Leelanukrom, R., *et al.* Intraoperative fluid and glucose management in children. *Paediatr Anaesth*, 2000. 10: 353.  
<https://www.ncbi.nlm.nih.gov/pubmed/10886690>

1084. Holliday, M.A., *et al.* The maintenance need for water in parenteral fluid therapy. *Pediatrics*, 1957. 19: 823.  
<https://www.ncbi.nlm.nih.gov/pubmed/13431307>
1085. Lindahl, S.G. Energy expenditure and fluid and electrolyte requirements in anesthetized infants and children. *Anesthesiology*, 1988. 69: 377.  
<https://www.ncbi.nlm.nih.gov/pubmed/3415017>
1086. Bailey, A.G., *et al.* Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? *Anesth Analg*, 2010. 110: 375.  
<https://www.ncbi.nlm.nih.gov/pubmed/19955503>
1087. Furman, E.B., *et al.* Specific therapy in water, electrolyte and blood-volume replacement during pediatric surgery. *Anesthesiology*, 1975. 42: 187.  
<https://www.ncbi.nlm.nih.gov/pubmed/1115368>
1088. Berry, F., Practical aspects of fluid and electrolyte therapy, In: *Anesthetic Management of Difficult and Routine Pediatric Patients*, F. Berry, Editor. 1986, Churchill Livingstone: New York.
1089. Kearney, R., *et al.* Withholding oral fluids from children undergoing day surgery reduces vomiting. *Paediatr Anaesth*, 1998. 8: 331.  
<https://www.ncbi.nlm.nih.gov/pubmed/9672932>
1090. Goodarzi, M., *et al.* A prospective randomized blinded study of the effect of intravenous fluid therapy on postoperative nausea and vomiting in children undergoing strabismus surgery. *Paediatr Anaesth*, 2006. 16: 49.  
<https://www.ncbi.nlm.nih.gov/pubmed/16409529>
1091. Moritz, M.L., *et al.* Intravenous fluid management for the acutely ill child. *Curr Opin Pediatr*, 2011. 23: 186.  
<https://www.ncbi.nlm.nih.gov/pubmed/21415832>
1092. Yung, M., *et al.* Randomised controlled trial of intravenous maintenance fluids. *J Paediatr Child Health*, 2009. 45: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/18036144>
1093. Duke, T., *et al.* Intravenous fluids for seriously ill children: time to reconsider. *Lancet*, 2003. 362: 1320.  
<https://www.ncbi.nlm.nih.gov/pubmed/14575980>
1094. Greenbaum, L., The pathophysiology of body fluids and fluid therapy, In: *Kliegman: Nelson textbook of pediatrics*, R. Kliegman, R. Behrman, H. Jenson & B. Stanton, Editors. 2007, Saunders Elsevier: Philadelphia, PA.
1095. Holliday, M.A., *et al.* Fluid therapy for children: facts, fashions and questions. *Arch Dis Child*, 2007. 92: 546.  
<https://www.ncbi.nlm.nih.gov/pubmed/17175577>
1096. Moritz, M.L., *et al.* Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. *Pediatrics*, 2003. 111: 227.  
<https://www.ncbi.nlm.nih.gov/pubmed/12563043>
1097. Messner, A.H., *et al.* Oral fluid intake following tonsillectomy. *Int J Pediatr Otorhinolaryngol*, 1997. 39: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/9051436>
1098. Schreiner, M.S., *et al.* Should children drink before discharge from day surgery? *Anesthesiology*, 1992. 76: 528.  
<https://www.ncbi.nlm.nih.gov/pubmed/1550277>
1099. Radke, O.C., *et al.* The effect of postoperative fasting on vomiting in children and their assessment of pain. *Paediatr Anaesth*, 2009. 19: 494.  
<https://www.ncbi.nlm.nih.gov/pubmed/19453581>
1100. Cheng, W., *et al.* Electrogastrographic changes in children who undergo day-surgery anesthesia. *J Pediatr Surg*, 1999. 34: 1336.  
<https://www.ncbi.nlm.nih.gov/pubmed/10507424>
1101. Mercan, A., *et al.* The effect of timing and temperature of oral fluids ingested after minor surgery in preschool children on vomiting: a prospective, randomized, clinical study. *Paediatr Anaesth*, 2011. 21: 1066.  
<https://www.ncbi.nlm.nih.gov/pubmed/21668799>
1102. Ivani, G., *et al.* Postoperative analgesia in infants and children: new developments. *Minerva Anestesiol*, 2004. 70: 399.  
<https://www.ncbi.nlm.nih.gov/pubmed/15181422>
1103. Karling, M., *et al.* Acute and postoperative pain in children: a Swedish nationwide survey. *Acta Paediatr*, 2002. 91: 660.  
<https://www.ncbi.nlm.nih.gov/pubmed/12162598>



1104. Stamer, U.M., *et al.* Postoperative analgesia in children--current practice in Germany. *Eur J Pain*, 2005. 9: 555.  
<https://www.ncbi.nlm.nih.gov/pubmed/16139184>
1105. Prevention and management of pain and stress in the neonate. American Academy of Pediatrics. Committee on Fetus and Newborn. Committee on Drugs. Section on Anesthesiology. Section on Surgery. Canadian Paediatric Society. Fetus and Newborn Committee. *Pediatrics*, 2000. 105: 454.  
<https://www.ncbi.nlm.nih.gov/pubmed/10654977>
1106. Anand, K.J. Consensus statement for the prevention and management of pain in the newborn. *Arch Pediatr Adolesc Med*, 2001. 155: 173.  
<https://www.ncbi.nlm.nih.gov/pubmed/11177093>
1107. Everett, L.L. Pain management for pediatric ambulatory anesthesia. *Curr Opin Anaesthesiol*, 2002. 15: 609.  
<https://www.ncbi.nlm.nih.gov/pubmed/17019260>
1108. Simons, S.H., *et al.* Do we still hurt newborn babies? A prospective study of procedural pain and analgesia in neonates. *Arch Pediatr Adolesc Med*, 2003. 157: 1058.  
<https://www.ncbi.nlm.nih.gov/pubmed/14609893>
1109. Taylor, B.J., *et al.* Assessing postoperative pain in neonates: a multicenter observational study. *Pediatrics*, 2006. 118: e992.  
<https://www.ncbi.nlm.nih.gov/pubmed/17015519>
1110. Bozkurt, P. The analgesic efficacy and neuroendocrine response in paediatric patients treated with two analgesic techniques: using morphine-epidural and patient-controlled analgesia. *Paediatr Anaesth*, 2002. 12: 248.  
<https://www.ncbi.nlm.nih.gov/pubmed/11903939>
1111. Grunau, R.E., *et al.* Demographic and therapeutic determinants of pain reactivity in very low birth weight neonates at 32 Weeks' postconceptional Age. *Pediatrics*, 2001. 107: 105.  
<https://www.ncbi.nlm.nih.gov/pubmed/11134442>
1112. Kain, Z.N., *et al.* Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. *Pediatrics*, 2006. 118: 651.  
<https://www.ncbi.nlm.nih.gov/pubmed/16882820>
1113. Taddio, A., *et al.* Effect of neonatal circumcision on pain response during subsequent routine vaccination. *Lancet*, 1997. 349: 599.  
<https://www.ncbi.nlm.nih.gov/pubmed/9057731>
1114. Ghai, B., *et al.* Postoperative pain assessment in preverbal children and children with cognitive impairment. *Paediatr Anaesth*, 2008. 18: 462.  
<https://www.ncbi.nlm.nih.gov/pubmed/18363630>
1115. Young, K.D. Pediatric procedural pain. *Ann Emerg Med*, 2005. 45: 160.  
<https://www.ncbi.nlm.nih.gov/pubmed/15671974>
1116. Birmingham, P.K., *et al.* Patient-controlled epidural analgesia in children: can they do it? *Anesth Analg*, 2003. 96: 686.  
<https://www.ncbi.nlm.nih.gov/pubmed/12598244>
1117. Ellis, J.A., *et al.* Evaluation of a continuous epidural analgesia program for postoperative pain in children. *Pain Manag Nurs*, 2007. 8: 146.  
<https://www.ncbi.nlm.nih.gov/pubmed/18036502>
1118. Gehdoo, R.P. Postoperative pain management in pediatric patients. *Indian J Anesth* 2004. 48: 406.  
<http://medind.nic.in/iad/t04/i5/iadt04i5p406.pdf>
1119. Jonas, D.A. Parent's management of their child's pain in the home following day surgery. *J Child Health Care*, 2003. 7: 150.  
<https://www.ncbi.nlm.nih.gov/pubmed/14516009>
1120. Kankkunen, P., *et al.* Families' and children's postoperative pain--literature review. *J Pediatr Nurs*, 2004. 19: 133.  
<https://www.ncbi.nlm.nih.gov/pubmed/15077212>
1121. Schechter, W.P., *et al.* Special considerations in perioperative pain management: audiovisual distraction, geriatrics, pediatrics, and pregnancy. *J Am Coll Surg*, 2005. 201: 612.  
<https://www.ncbi.nlm.nih.gov/pubmed/16183502>
1122. Woolf, C.J., *et al.* Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization. *Anesth Analg*, 1993. 77: 362.  
<https://www.ncbi.nlm.nih.gov/pubmed/8346839>
1123. Kehlet, H., *et al.* The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. *Anesth Analg*, 1993. 77: 1048.  
<https://www.ncbi.nlm.nih.gov/pubmed/8105724>

1124. World Health Organization, Cancer Pain Relief and Palliative Care in Children. 1998, World Health Organization: Geneva.  
<http://apps.who.int/iris/bitstream/10665/42001/1/9241545127.pdf>
1125. Anand, K.J., *et al.* Analgesia and local anesthesia during invasive procedures in the neonate. *Clin Ther*, 2005. 27: 844.  
<https://www.ncbi.nlm.nih.gov/pubmed/16117989>
1126. Yawman, D., *et al.* Pain relief for neonatal circumcision: a follow-up of residency training practices. *Ambul Pediatr*, 2006. 6: 210.  
<https://www.ncbi.nlm.nih.gov/pubmed/16843252>
1127. Choi, W.Y., *et al.* EMLA cream versus dorsal penile nerve block for postcircumcision analgesia in children. *Anesth Analg*, 2003. 96: 396.  
<https://www.ncbi.nlm.nih.gov/pubmed/12538184>
1128. Lehr, V.T., *et al.* Lidocaine 4% cream compared with lidocaine 2.5% and prilocaine 2.5% or dorsal penile block for circumcision. *Am J Perinatol*, 2005. 22: 231.  
<https://www.ncbi.nlm.nih.gov/pubmed/16041631>
1129. Matsota, P., *et al.* Intraoperative and postoperative analgesia with subcutaneous ring block of the penis with levobupivacaine for circumcision in children. *Eur J Pediatr Surg*, 2004. 14: 198.  
<https://www.ncbi.nlm.nih.gov/pubmed/15211412>
1130. Smith, D.P., *et al.* The efficacy of LMX versus EMLA for pain relief in boys undergoing office meatotomy. *J Urol*, 2004. 172: 1760.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371808>
1131. Taddio, A., *et al.* A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. *Pediatrics*, 1998. 101: E1.  
<https://www.ncbi.nlm.nih.gov/pubmed/9445511>
1132. Brady-Fryer, B., *et al.* Pain relief for neonatal circumcision. *Cochrane Database Syst Rev*, 2004: CD004217.  
<https://www.ncbi.nlm.nih.gov/pubmed/15495086>
1133. Faraoni, D., *et al.* Does ultrasound guidance improve the efficacy of dorsal penile nerve block in children? *Paediatr Anaesth*, 2010. 20: 931.  
<https://www.ncbi.nlm.nih.gov/pubmed/20849498>
1134. Sandeman, D.J., *et al.* A retrospective audit of three different regional anaesthetic techniques for circumcision in children. *Anaesth Intensive Care*, 2010. 38: 519.  
<https://www.ncbi.nlm.nih.gov/pubmed/20514962>
1135. Beyaz, S.G. Comparison of Postoperative Analgesic Efficacy of Caudal Block versus Dorsal Penile Nerve Block with Levobupivacaine for Circumcision in Children. *Korean J Pain*, 2011. 24: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/21390176>
1136. Gauntlett, I. A comparison between local anaesthetic dorsal nerve block and caudal bupivacaine with ketamine for paediatric circumcision. *Paediatr Anaesth*, 2003. 13: 38.  
<https://www.ncbi.nlm.nih.gov/pubmed/12535037>
1137. Sharpe, P., *et al.* Analgesia for circumcision in a paediatric population: comparison of caudal bupivacaine alone with bupivacaine plus two doses of clonidine. *Paediatr Anaesth*, 2001. 11: 695.  
<https://www.ncbi.nlm.nih.gov/pubmed/11696146>
1138. Cyna, A.M., *et al.* Caudal epidural block versus other methods of postoperative pain relief for circumcision in boys. *Cochrane Database Syst Rev*, 2008: CD003005.  
<https://www.ncbi.nlm.nih.gov/pubmed/18843636>
1139. Margetts, L., *et al.* A comparison of caudal bupivacaine and ketamine with penile block for paediatric circumcision. *Eur J Anaesthesiol*, 2008. 25: 1009.  
<https://www.ncbi.nlm.nih.gov/pubmed/18652709>
1140. Weksler, N., *et al.* Is penile block better than caudal epidural block for postcircumcision analgesia? *J Anesth*, 2005. 19: 36.  
<https://www.ncbi.nlm.nih.gov/pubmed/15674514>
1141. Al-Zaben, K.R., *et al.* Intraoperative administration of dexmedetomidine reduces the analgesic requirements for children undergoing hypospadias surgery. *Eur J Anaesthesiol*, 2010. 27: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/19952754>
1142. Apiliogullari, S., *et al.* Efficacy of a low-dose spinal morphine with bupivacaine for postoperative analgesia in children undergoing hypospadias repair. *Paediatr Anaesth*, 2009. 19: 1078.  
<https://www.ncbi.nlm.nih.gov/pubmed/19708911>
1143. Cho, J.E., *et al.* The addition of fentanyl to 1.5 mg/ml ropivacaine has no advantage for paediatric epidural analgesia. *Acta Anaesthesiol Scand*, 2009. 53: 1084.  
<https://www.ncbi.nlm.nih.gov/pubmed/19572930>

1144. Gunduz, M., *et al.* Comparison of caudal ketamine with lidocaine or tramadol administration for postoperative analgesia of hypospadias surgery in children. *Paediatr Anaesth*, 2006. 16: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/16430412>
1145. Gunes, Y., *et al.* Comparison of caudal vs intravenous tramadol administered either preoperatively or postoperatively for pain relief in boys. *Paediatr Anaesth*, 2004. 14: 324.  
<https://www.ncbi.nlm.nih.gov/pubmed/15078378>
1146. Hansen, T.G., *et al.* Caudal bupivacaine supplemented with caudal or intravenous clonidine in children undergoing hypospadias repair: a double-blind study. *Br J Anaesth*, 2004. 92: 223.  
<https://www.ncbi.nlm.nih.gov/pubmed/14722172>
1147. Laiq, N., *et al.* Comparison of caudal bupivacaine and bupivacaine-tramadol for postoperative analgesia in children undergoing hypospadias surgery. *J Coll Physicians Surg Pak*, 2009. 19: 678.  
<https://www.ncbi.nlm.nih.gov/pubmed/19889260>
1148. Silvani, P., *et al.* Caudal anesthesia in pediatrics: an update. *Minerva Anestesiol*, 2006. 72: 453.  
<https://www.ncbi.nlm.nih.gov/pubmed/16682915>
1149. Abdulatif, M., *et al.* Caudal neostigmine, bupivacaine, and their combination for postoperative pain management after hypospadias surgery in children. *Anesth Analg*, 2002. 95: 1215.  
<https://www.ncbi.nlm.nih.gov/pubmed/12401596>
1150. Bhardwaj, N., *et al.* Neostigmine does not prolong the duration of analgesia produced by caudal bupivacaine in children undergoing urethroplasty. *J Postgrad Med*, 2007. 53: 161.  
<https://www.ncbi.nlm.nih.gov/pubmed/17699988>
1151. De Negri, P., *et al.* A comparison of epidural bupivacaine, levobupivacaine, and ropivacaine on postoperative analgesia and motor blockade. *Anesth Analg*, 2004. 99: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/15281501>
1152. Ozbek, H., *et al.* The comparison of caudal ketamine, alfentanil and ketamine plus alfentanil administration for postoperative analgesia in children. *Paediatr Anaesth*, 2002. 12: 610.  
<https://www.ncbi.nlm.nih.gov/pubmed/12358657>
1153. Ozyuvaci, E., *et al.* Evaluation of adding preoperative or postoperative rectal paracetamol to caudal bupivacaine for postoperative analgesia in children. *Paediatr Anaesth*, 2004. 14: 661.  
<https://www.ncbi.nlm.nih.gov/pubmed/15283825>
1154. Samuel, M., *et al.* Prospective to a randomized double-blind controlled trial to assess efficacy of double caudal analgesia in hypospadias repair. *J Pediatr Surg*, 2002. 37: 168.  
<https://www.ncbi.nlm.nih.gov/pubmed/11819193>
1155. Thies, K.C., *et al.* Longer than expected-duration of caudal analgesia with two different doses of levobupivacaine in children undergoing hypospadias repair. *J Pediatr Urol*, 2010. 6: 585.  
<https://www.ncbi.nlm.nih.gov/pubmed/20171143>
1156. Metzelder, M.L., *et al.* Penile block is associated with less urinary retention than caudal anesthesia in distal hypospadias repair in children. *World J Urol*, 2010. 28: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/19466428>
1157. Chhibber, A.K., *et al.* Penile block timing for postoperative analgesia of hypospadias repair in children. *J Urol*, 1997. 158: 1156.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258161>
1158. Breschan, C., *et al.* A prospective study comparing the analgesic efficacy of levobupivacaine, ropivacaine and bupivacaine in pediatric patients undergoing caudal blockade. *Paediatr Anaesth*, 2005. 15: 301.  
<https://www.ncbi.nlm.nih.gov/pubmed/15787921>
1159. Hong, J.Y., *et al.* Effect of dexamethasone in combination with caudal analgesia on postoperative pain control in day-case paediatric orchiopey. *Br J Anaesth*, 2010. 105: 506.  
<https://www.ncbi.nlm.nih.gov/pubmed/20659915>
1160. Taheri, R., *et al.* Efficacy of bupivacaine-neostigmine and bupivacaine-tramadol in caudal block in pediatric inguinal herniorrhaphy. *Paediatr Anaesth*, 2010. 20: 866.  
<https://www.ncbi.nlm.nih.gov/pubmed/20716080>
1161. Fredrickson, M.J., *et al.* Improved analgesia with the ilioinguinal block compared to the transversus abdominis plane block after pediatric inguinal surgery: a prospective randomized trial. *Paediatr Anaesth*, 2010. 20: 1022.  
<https://www.ncbi.nlm.nih.gov/pubmed/20964768>
1162. Jagannathan, N., *et al.* Unilateral groin surgery in children: will the addition of an ultrasound-guided ilioinguinal nerve block enhance the duration of analgesia of a single-shot caudal block? *Paediatr Anaesth*, 2009. 19: 892.  
<https://www.ncbi.nlm.nih.gov/pubmed/19627532>

1163. Demiraran, Y., *et al.* Does tramadol wound infiltration offer an advantage over bupivacaine for postoperative analgesia in children following herniotomy? *Paediatr Anaesth*, 2006. 16: 1047.  
<https://www.ncbi.nlm.nih.gov/pubmed/16972834>
1164. Machotta, A., *et al.* Comparison between instillation of bupivacaine versus caudal analgesia for postoperative analgesia following inguinal herniotomy in children. *Paediatr Anaesth*, 2003. 13: 397.  
<https://www.ncbi.nlm.nih.gov/pubmed/12791112>
1165. Shenfeld, O., *et al.* Intraoperative irrigation with bupivacaine for analgesia after orchiopey and herniorrhaphy in children. *J Urol*, 1995. 153: 185.  
<https://www.ncbi.nlm.nih.gov/pubmed/7966769>
1166. Saeed, A., *et al.* Pain management for unilateral orchidopexy in children: an effective regimen. *World J Surg*, 2009. 33: 603.  
<https://www.ncbi.nlm.nih.gov/pubmed/19115030>
1167. Arana, A., *et al.* Treatment with paracetamol in infants. *Acta Anaesthesiol Scand*, 2001. 45: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/11152028>
1168. Messerer, B., *et al.* Implementation of a standardized pain management in a pediatric surgery unit. *Pediatr Surg Int*, 2010. 26: 879.  
<https://www.ncbi.nlm.nih.gov/pubmed/20625751>
1169. Verghese, S.T., *et al.* Acute pain management in children. *J Pain Res*, 2010. 3: 105.  
<https://www.ncbi.nlm.nih.gov/pubmed/21197314>
1170. Cain, M.P., *et al.* Continuous epidural anesthesia after ureteroneocystostomy in children. *J Urol*, 1995. 154: 791.  
<https://www.ncbi.nlm.nih.gov/pubmed/7609181>
1171. Merguerian, P.A., *et al.* Efficacy of continuous epidural analgesia versus single dose caudal analgesia in children after intravesical ureteroneocystostomy. *J Urol*, 2004. 172: 1621.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371775>
1172. Tripi, P.A., *et al.* Clonidine increases duration of bupivacaine caudal analgesia for ureteroneocystostomy: a double-blind prospective trial. *J Urol*, 2005. 174: 1081.  
<https://www.ncbi.nlm.nih.gov/pubmed/16094063>
1173. Hong, J.Y., *et al.* Fentanyl-sparing effect of acetaminophen as a mixture of fentanyl in intravenous parent-/nurse-controlled analgesia after pediatric ureteroneocystostomy. *Anesthesiology*, 2010. 113: 672.  
<https://www.ncbi.nlm.nih.gov/pubmed/20693884>
1174. Jo, Y.Y., *et al.* Ketorolac or fentanyl continuous infusion for post-operative analgesia in children undergoing ureteroneocystostomy. *Acta Anaesthesiol Scand*, 2011. 55: 54.  
<https://www.ncbi.nlm.nih.gov/pubmed/21083540>
1175. Miller, O.F., *et al.* Early hospital discharge for intravesical ureteroneocystostomy. *J Urol*, 2002. 167: 2556.  
<https://www.ncbi.nlm.nih.gov/pubmed/11992088>
1176. Park, J.M., *et al.* Ketorolac suppresses postoperative bladder spasms after pediatric ureteral reimplantation. *Anesth Analg*, 2000. 91: 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/10866879>
1177. Routh, J.C., *et al.* Ketorolac is underutilized after ureteral reimplantation despite reduced hospital cost and reduced length of stay. *Urology*, 2010. 76: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/20138342>
1178. Kumar, R., *et al.* Dorsal lumbotomy incision for pediatric pyeloplasty--a good alternative. *Pediatr Surg Int*, 1999. 15: 562.  
<https://www.ncbi.nlm.nih.gov/pubmed/10631734>
1179. Piedrahita, Y.K., *et al.* Is one-day hospitalization after open pyeloplasty possible and safe? *Urology*, 2006. 67: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/16413360>
1180. Berta, E., *et al.* Single injection paravertebral block for renal surgery in children. *Paediatr Anaesth*, 2008. 18: 593.  
<https://www.ncbi.nlm.nih.gov/pubmed/18482238>
1181. Lonnqvist, P.A., *et al.* Paravertebral vs epidural block in children. Effects on postoperative morphine requirement after renal surgery. *Acta Anaesthesiol Scand*, 1994. 38: 346.  
<https://www.ncbi.nlm.nih.gov/pubmed/8067221>
1182. Ben-Meir, D., *et al.* Continuous epidural versus nonepidural analgesia for post-pyeloplasty pain in children. *J Urol*, 2009. 182: 1841.  
<https://www.ncbi.nlm.nih.gov/pubmed/19692062>

1183. Dingemann, J., *et al.* Perioperative analgesia strategies in fast-track pediatric surgery of the kidney and renal pelvis: lessons learned. *World J Urol*, 2010. 28: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/19565247>
1184. Freilich, D.A., *et al.* The effectiveness of aerosolized intraperitoneal bupivacaine in reducing postoperative pain in children undergoing robotic-assisted laparoscopic pyeloplasty. *J Pediatr Urol*, 2008. 4: 337.  
<https://www.ncbi.nlm.nih.gov/pubmed/18790415>

## 5. CONFLICT OF INTEREST

All members of the Paediatric Urology Guidelines Panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/>. This Guidelines document was developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 6. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-02.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*

